A N N U A L
R E P O R T
2018MARCH 2019
To Our
Shareholders
Alex Gorsky
Chairman and Chief Executive Officer
IIII hhhhaaaavvvveeee tttthhhheeee pppprrrriiiivvvviiiilllleeeeggggeeee ooooffff bbbbeeeeiiiinnnngggg tttthhhheeee CCCCEEEEOOOO ooooffff aaaannnndddd mmmmaaaarrrrkkkkeeeetttt sssshhhhaaaarrrreeee nnnnuuuummmmbbbbeeeerrrrssss.... TTTThhhhiiiissss pppphhhhiiiilllloooossssoooopppphhhhyyyy
JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn dddduuuurrrriiiinnnngggg aaaa rrrreeeemmmmaaaarrrrkkkkaaaabbbblllleeee ttttiiiimmmmeeee aaaalllllllloooowwwwssss uuuussss ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy eeeevvvveeeennnn iiiinnnn tttthhhheeee
iiiinnnn hhhhiiiissssttttoooorrrryyyy.... TTTThhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy sssseeeevvvveeeennnn yyyyeeeeaaaarrrrssss iiiinnnn tttthhhhiiiissss mmmmoooosssstttt cccchhhhaaaalllllllleeeennnnggggiiiinnnngggg ttttiiiimmmmeeeessss,,,, ttttoooo ddddrrrriiiivvvveeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee
rrrroooolllleeee,,,, tttthhhheeeerrrreeee hhhhaaaavvvveeee bbbbeeeeeeeennnn mmmmaaaannnnyyyy ddddrrrraaaammmmaaaattttiiiicccc cccchhhhaaaannnnggggeeeessss aaaannnndddd ppppuuuurrrrppppoooosssseeee wwwwiiiitttthhhh eeeeqqqquuuuaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt,,,, aaaannnndddd
iiiinnnn gggglllloooobbbbaaaallll ppppoooolllliiiittttiiiiccccssss,,,, tttthhhheeee wwwwoooorrrrlllldddd eeeeccccoooonnnnoooommmmyyyy,,,, sssscccciiiieeeennnncccceeee,,,, eeeennnnaaaabbbblllleeeessss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa lllleeeeaaaaddddiiiinnnngggg rrrroooolllleeee iiiinnnn
tttteeeecccchhhhnnnnoooollllooooggggyyyy aaaannnndddd ccccuuuullllttttuuuurrrreeee.... AAAAtttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee,,,, tttthhhheeeerrrreeee ddddeeeefifififinnnniiiinnnngggg tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee wwwwoooorrrrllllddddwwwwiiiiddddeeee....
hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ppppaaaacccceeee ooooffff pppprrrrooooggggrrrreeeessssssss
iiiinnnn hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh:::: uuuunnnnlllloooocccckkkkiiiinnnngggg tttthhhheeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ooooffff
tttthhhheeee hhhhuuuummmmaaaannnn ggggeeeennnnoooommmmeeee,,,, eeeevvvvoooollllvvvviiiinnnngggg aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg tttthhhheeee It is an honor to lead an innovation-driven
uuuusssseeee ooooffff rrrroooobbbboooottttiiiiccccssss aaaannnndddd mmmmiiiiccccrrrroooo ssssuuuurrrrggggeeeerrrryyyy,,,, eeeexxxxtttteeeennnnddddiiiinnnngggg culture that continues to demonstrate the
tttthhhheeee lllliiiiffffeeee eeeexxxxppppeeeeccccttttaaaannnnccccyyyy ffffoooorrrr ppppeeeeoooopppplllleeee wwwwiiiitttthhhh HHHHIIIIVVVV,,,, aaaannnndddd
energy, drive and passion of a “start-up.”
ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo wwwwaaaaggggeeee aaaannnndddd wwwwiiiinnnn tttthhhheeee fifififigggghhhhtttt aaaaggggaaaaiiiinnnnsssstttt
ccccaaaannnncccceeeerrrr aaaannnndddd ooootttthhhheeeerrrr ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeeessss tttthhhhaaaatttt
IIIInnnn tttthhhhiiiissss lllleeeetttttttteeeerrrr,,,, IIII sssshhhhaaaarrrreeee tttthhhheeee hhhhiiiigggghhhhlllliiiigggghhhhttttssss ooooffff oooouuuurrrr
hhhhaaaavvvveeee rrrreeeessssiiiisssstttteeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss....
ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee,,,, oooouuuurrrr nnnnoooottttaaaabbbblllleeee aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnnttttssss aaaannnndddd oooouuuurrrr
aaaassssppppiiiirrrraaaattttiiiioooonnnnssss ffffoooorrrr tttthhhheeee yyyyeeeeaaaarrrrssss ttttoooo ccccoooommmmeeee.... MMMMyyyy ggggooooaaaallll iiiissss ttttoooo
WWWWhhhhaaaatttt’’’’ssss mmmmoooosssstttt eeeexxxxcccciiiittttiiiinnnngggg aaaabbbboooouuuutttt tttthhhhiiiissss pppprrrrooooggggrrrreeeessssssss
pppprrrroooovvvviiiiddddeeee aaaannnn aaaaeeeerrrriiiiaaaallll vvvviiiieeeewwww ooooffff JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn
iiiissss tttthhhhaaaatttt JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn hhhhaaaassss bbbbeeeeeeeennnn aaaatttt tttthhhheeee
ttttooooddddaaaayyyy————aaaa CCCCoooommmmppppaaaannnnyyyy tttthhhhaaaatttt ssssppppaaaannnnssss ssssiiiixxxx ccccoooonnnnttttiiiinnnneeeennnnttttssss
vvvveeeerrrryyyy ffffoooorrrreeeeffffrrrroooonnnntttt ooooffff mmmmaaaannnnyyyy ooooffff tttthhhheeeesssseeee rrrreeeevvvvoooolllluuuuttttiiiioooonnnnaaaarrrryyyy
aaaannnndddd 66660000 ccccoooouuuunnnnttttrrrriiiieeeessss,,,, ddddeeeevvvveeeellllooooppppssss nnnnuuuummmmeeeerrrroooouuuussss iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeee
cccchhhhaaaannnnggggeeeessss aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg hhhhoooorrrriiiizzzzoooonnnnssss————ttttiiiimmmmeeee
pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss aaaannnndddd ttttoooouuuucccchhhheeeessss tttthhhheeee lllliiiivvvveeeessss
aaaannnndddd ttttiiiimmmmeeee aaaaggggaaaaiiiinnnn,,,, ddddeeeelllliiiivvvveeeerrrriiiinnnngggg lllliiiiffffeeee---- ssssaaaavvvviiiinnnngggg
ooooffff ppppeeeeoooopppplllleeee aaaallllllll aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy ddddaaaayyyy....
mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd lllliiiiffffeeee----cccchhhhaaaannnnggggiiiinnnngggg ssssoooolllluuuuttttiiiioooonnnnssss....
MMMMoooosssstttt iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy,,,, IIII wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee mmmmyyyy
IIIItttt iiiissss aaaannnn hhhhoooonnnnoooorrrr ttttoooo lllleeeeaaaadddd aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn----ddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee
ccccoooonnnnfifififiddddeeeennnncccceeee iiiinnnn oooouuuurrrr eeeexxxxppppaaaannnnssssiiiivvvveeee ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss,,,, eeeexxxxpppprrrreeeessssssss
tttthhhhaaaatttt ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeee tttthhhheeee eeeennnneeeerrrrggggyyyy,,,, ddddrrrriiiivvvveeee
mmmmyyyy rrrreeeeaaaalllliiiissssttttiiiicccc ooooppppttttiiiimmmmiiiissssmmmm aaaabbbboooouuuutttt oooouuuurrrr ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss aaaannnndddd
aaaannnndddd ppppaaaassssssssiiiioooonnnn ooooffff aaaa ““““ssssttttaaaarrrrtttt----uuuupppp....”””” HHHHoooowwwweeeevvvveeeerrrr,,,, wwwweeee aaaallllssssoooo
cccchhhhaaaalllllllleeeennnnggggeeeessss,,,, aaaannnndddd ooooffffffffeeeerrrr mmmmyyyy iiiinnnnssssiiiigggghhhhttttssss oooonnnn hhhhoooowwww wwwweeee wwwwiiiillllllll
hhhhaaaavvvveeee tttthhhheeee ddddiiiissssttttiiiinnnncccctttt aaaaddddvvvvaaaannnnttttaaaaggggeeee ooooffff oooouuuurrrr ttttiiiimmmmeeeelllleeeessssssss
ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo sssshhhhaaaappppeeee tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ttttooooddddaaaayyyy....
vvvvaaaalllluuuueeeessss,,,, ssssuuuucccchhhh aaaassss tttthhhheeee ssssttttrrrroooonnnngggg iiiinnnnflflflfluuuueeeennnncccceeee ooooffff oooouuuurrrr
lllloooonnnngggg----tttteeeerrrrmmmm ssssttttrrrraaaatttteeeeggggiiiicccc vvvviiiieeeewwww,,,, tttthhhheeee uuuunnnnwwwwaaaavvvveeeerrrriiiinnnngggg CCCCeeeelllleeeebbbbrrrraaaattttiiiinnnngggg OOOOuuuurrrr CCCCrrrreeeeddddoooo
gggguuuuiiiiddddaaaannnncccceeee ooooffff OOOOuuuurrrr CCCCrrrreeeeddddoooo aaaannnndddd tttthhhheeee pppprrrrooooffffoooouuuunnnndddd wwwwaaaayyyy IIIInnnn 2222000011118888,,,, wwwweeee cccceeeelllleeeebbbbrrrraaaatttteeeedddd tttthhhheeee 77775555tttthhhh aaaannnnnnnniiiivvvveeeerrrrssssaaaarrrryyyy
iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee mmmmeeeeaaaassssuuuurrrreeee pppprrrrooooggggrrrreeeessssssss aaaannnndddd ssssuuuucccccccceeeessssssss.... ooooffff OOOOuuuurrrr CCCCrrrreeeeddddoooo.... WWWWrrrriiiitttttttteeeennnn aaaannnndddd iiiinnnnttttrrrroooodddduuuucccceeeedddd iiiinnnn 1111999944443333
OOOOuuuurrrr CCCCrrrreeeeddddoooo cccchhhhaaaalllllllleeeennnnggggeeeessss uuuussss ttttoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg bbbbyyyy GGGGeeeennnneeeerrrraaaallll RRRRoooobbbbeeeerrrrtttt WWWWoooooooodddd JJJJoooohhhhnnnnssssoooonnnn,,,, OOOOuuuurrrr CCCCrrrreeeeddddoooo
oooouuuuttttccccoooommmmeeeessss ffffoooorrrr ppppaaaattttiiiieeeennnnttttssss aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy,,,, hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee bbbblllluuuueeeepppprrrriiiinnnntttt ffffoooorrrr sssshhhhaaaappppiiiinnnngggg tttthhhheeee rrrroooolllleeee
wwwwhhhhiiiilllleeee wwwweeee aaaallllssssoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg rrrreeeevvvveeeennnnuuuueeee tttthhhhaaaatttt JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn ppppllllaaaayyyyssss iiiinnnn ssssoooocccciiiieeeettttyyyy....
(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)(cid:3)(cid:373)(cid:3)(cid:44)AAAAlllltttthhhhoooouuuugggghhhh OOOOuuuurrrr CCCCrrrreeeeddddoooo iiiissss lllliiiitttteeeerrrraaaallllllllyyyy eeeettttcccchhhheeeedddd iiiinnnn ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss,,,, eeeexxxxppppeeeerrrriiiieeeennnncccceeeessss,,,, ooooppppiiiinnnniiiioooonnnnssss aaaannnndddd
ssssttttoooonnnneeee,,,, iiiitttt iiiissss aaaa lllliiiivvvviiiinnnngggg ddddooooccccuuuummmmeeeennnntttt tttthhhhaaaatttt,,,, oooonnnn aaaa vvvveeeerrrryyyy aaaapppppppprrrrooooaaaacccchhhheeeessss,,,, eeeennnnrrrriiiicccchhhheeeessss oooouuuurrrr ccccoooollllllllaaaabbbboooorrrraaaattttiiiivvvveeee
ffffeeeewwww sssseeeelllleeeecccctttt ooooccccccccaaaassssiiiioooonnnnssss,,,, wwwweeee hhhhaaaavvvveeee eeeevvvvoooollllvvvveeeedddd ttttoooo iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn pppprrrroooocccceeeessssssss.... AAAAnnnndddd tttthhhhiiiissss ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn
kkkkeeeeeeeepppp ppppaaaacccceeee wwwwiiiitttthhhh tttthhhheeee wwwwoooorrrrlllldddd iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee lllliiiivvvveeee.... rrrreeeeaaaacccchhhheeeessss ffffaaaarrrr bbbbeeeeyyyyoooonnnndddd tttthhhheeee wwwwaaaallllllllssss ooooffff JJJJoooohhhhnnnnssssoooonnnn &&&&
JJJJoooohhhhnnnnssssoooonnnn.... FFFFoooorrrr iiiinnnnssssttttaaaannnncccceeee,,,, wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh
IIIInnnn ffffaaaacccctttt,,,, llllaaaatttteeee llllaaaasssstttt yyyyeeeeaaaarrrr wwwweeee ddddiiiidddd eeeexxxxaaaaccccttttllllyyyy tttthhhhiiiissss bbbbyyyy
ssssoooommmmeeee ooooffff tttthhhheeee wwwwoooorrrrlllldddd’’’’ssss mmmmoooosssstttt rrrreeeessssppppeeeecccctttteeeedddd uuuunnnniiiivvvveeeerrrrssssiiiittttiiiieeeessss,,,,
iiiinnnnttttrrrroooodddduuuucccciiiinnnngggg ssssoooommmmeeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss ttttoooo OOOOuuuurrrr
rrrreeeesssseeeeaaaarrrrcccchhhh iiiinnnnssssttttiiiittttuuuuttttiiiioooonnnnssss,,,, tttteeeecccchhhhnnnnoooollllooooggggyyyy ggggiiiiaaaannnnttttssss aaaannnndddd
CCCCrrrreeeeddddoooo rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt wwwweeeerrrreeee iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy
ttttrrrraaaaddddiiiittttiiiioooonnnnaaaallll ssssttttaaaarrrrtttt----uuuuppppssss aaaassss wwwweeee ssssuuuuppppppppoooorrrrtttt tttthhhhoooosssseeee wwwwhhhhoooo
ffffeeeeeeeeddddbbbbaaaacccckkkk ffffrrrroooommmm mmmmoooorrrreeee tttthhhhaaaannnn 2222,,,,000000000000 ooooffff oooouuuurrrr ddddiiiivvvveeeerrrrsssseeee
(cid:72)(cid:72)(cid:72)(cid:72)(cid:91)(cid:91)(cid:91)(cid:91)(cid:83)(cid:83)(cid:83)(cid:83)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:90)(cid:90)(cid:90)(cid:90)(cid:612)(cid:612)(cid:612)(cid:612)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:71)(cid:71)(cid:71)(cid:71)(cid:86)(cid:86)(cid:86)(cid:86)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:70)(cid:70)(cid:70)(cid:70)(cid:75)(cid:75)(cid:75)(cid:75)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:45)(cid:45)(cid:45)(cid:45)(cid:47)(cid:47)(cid:47)(cid:47)(cid:36)(cid:36)(cid:36)(cid:36)(cid:37)(cid:37)(cid:37)(cid:37)(cid:54)(cid:54)(cid:54)(cid:54)(cid:15)(cid:15)(cid:15)(cid:15)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)
JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn eeeemmmmppppllllooooyyyyeeeeeeeessss,,,, rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg
JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn IIIInnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiinnnnccccuuuubbbbaaaattttoooorrrrssss....
aaaallllllll rrrreeeeggggiiiioooonnnnssss,,,, sssseeeeggggmmmmeeeennnnttttssss aaaannnndddd ffffuuuunnnnccccttttiiiioooonnnnssss....
AAAA kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee iiiissss hhhhoooowwww wwwweeee aaaarrrreeee hhhhaaaarrrrnnnneeeessssssssiiiinnnngggg tttthhhheeee
TTTThhhheeeesssseeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss::::
ssssttttrrrreeeennnnggggtttthhhh ooooffff aaaallllllll tttthhhhrrrreeeeeeee ooooffff oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:3)(cid:3)(cid:40)(cid:40)(cid:40)(cid:40)(cid:91)(cid:91)(cid:91)(cid:91)(cid:83)(cid:83)(cid:83)(cid:83)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:70)(cid:70)(cid:70)(cid:70)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:83)(cid:83)(cid:83)(cid:83)(cid:88)(cid:88)(cid:88)(cid:88)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:83)(cid:83)(cid:83)(cid:83)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:612)(cid:612)(cid:612)(cid:612)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71) (cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:68)(cid:68)(cid:68)(cid:68)(cid:69)(cid:69)(cid:69)(cid:69)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:90)(cid:90)(cid:90)(cid:90)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:37)(cid:37)(cid:37)(cid:37)(cid:82)(cid:82)(cid:82)(cid:82)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:56)(cid:56)(cid:56)(cid:56)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:92)(cid:92)(cid:92)(cid:92)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:70)(cid:70)(cid:70)(cid:70)(cid:75)(cid:75)(cid:75)(cid:75)
aaaatttt tttthhhheeee cccceeeennnntttteeeerrrr ooooffff oooouuuurrrr ffffooooccccuuuussss;;;; sssscccciiiieeeennnnttttiiiissssttttssss ttttoooo iiiiddddeeeennnnttttiiiiffffyyyy wwwwaaaayyyyssss ttttoooo bbbbeeeetttttttteeeerrrr ddddeeeetttteeeecccctttt
aaaannnndddd ttttrrrreeeeaaaatttt tttthhhheeee eeeennnnttttiiiirrrreeee ccccyyyycccclllleeee ooooffff lllluuuunnnngggg ccccaaaannnncccceeeerrrr.... TTTThhhhiiiissss
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:3)(cid:53)(cid:53)(cid:53)(cid:53)(cid:72)(cid:72)(cid:72)(cid:72)(cid:613)(cid:613)(cid:613)(cid:613)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:86)(cid:86)(cid:86)(cid:86)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:68)(cid:68)(cid:68)(cid:68)(cid:70)(cid:70)(cid:70)(cid:70)(cid:75)(cid:75)(cid:75)(cid:75)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:90)(cid:90)(cid:90)(cid:90)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:79)(cid:79)(cid:79)(cid:79)(cid:71)(cid:71)(cid:71)(cid:71)
aaaannnndddd aaaa nnnneeeewwww ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff eeeemmmmppppllllooooyyyyeeeeeeeessss;;;; ddddiiiisssseeeeaaaasssseeee iiiissss tttthhhheeee lllleeeeaaaaddddiiiinnnngggg ccccaaaauuuusssseeee ooooffff ccccaaaannnncccceeeerrrr mmmmoooorrrrttttaaaalllliiiittttyyyy
aaaarrrroooouuuunnnndddd tttthhhheeee gggglllloooobbbbeeee————wwwweeee rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee nnnneeeeeeeedddd
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:56)(cid:56)(cid:56)(cid:56)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:80)(cid:80)(cid:80)(cid:80)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)
aaaannnndddd uuuurrrrggggeeeennnnccccyyyy,,,, aaaannnndddd wwwweeee aaaarrrreeee rrrreeeessssppppoooonnnnddddiiiinnnngggg ttttoooo tttthhhhiiiissss
ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn;;;; aaaannnndddd
ccccaaaallllllll ttttoooo aaaaccccttttiiiioooonnnn wwwwiiiitttthhhh tttthhhhiiiissss eeeexxxxcccciiiittttiiiinnnngggg ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp....
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:3)(cid:3)(cid:54)(cid:54)(cid:54)(cid:54)(cid:82)(cid:82)(cid:82)(cid:82)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:73)(cid:73)(cid:73)(cid:73)(cid:92)(cid:92)(cid:92)(cid:92)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:80)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:80)(cid:80)(cid:80)(cid:80)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:76)(cid:76)(cid:76)(cid:76)(cid:80)(cid:80)(cid:80)(cid:80)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:89)(cid:89)(cid:89)(cid:89)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)
tttthhhheeee hhhheeeeaaaalllltttthhhh ooooffff hhhhuuuummmmaaaannnniiiittttyyyy.... PPPPoooowwwweeeerrrrffffuuuullll iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn mmmmaaaaddddeeee ppppoooossssssssiiiibbbblllleeee
bbbbyyyy tttthhhheeee fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh wwwweeee’’’’vvvveeee bbbbuuuuiiiilllltttt oooovvvveeeerrrr tttthhhheeee
OOOOuuuurrrr CCCCrrrreeeeddddoooo rrrreeeemmmmaaaaiiiinnnnssss aaaassss rrrreeeelllleeeevvvvaaaannnntttt ttttooooddddaaaayyyy aaaassss wwwwhhhheeeennnn
(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:68)(cid:68)(cid:68)(cid:68)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:88)(cid:88)(cid:88)(cid:88)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:80)(cid:80)(cid:80)(cid:80)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:89)(cid:89)(cid:89)(cid:89)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)
iiiitttt wwwwaaaassss fifififirrrrsssstttt iiiinnnnttttrrrroooodddduuuucccceeeedddd 77775555 yyyyeeeeaaaarrrrssss aaaaggggoooo,,,, aaaannnndddd IIII’’’’mmmm
iiiissss cccceeeennnnttttrrrraaaallll ttttoooo oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo ccccrrrreeeeaaaatttteeee mmmmeeeeaaaannnniiiinnnnggggffffuuuullll
ccccoooonnnnfifififiddddeeeennnntttt tttthhhhaaaatttt iiiitttt wwwwiiiillllllll pppprrrrooooppppeeeellll JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn
cccchhhhaaaannnnggggeeee aaaannnndddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee ddddiiiiffffffffeeeerrrreeeennnnttttiiiiaaaattttiiiioooonnnn.... IIIInnnn 2222000011118888,,,,
ffffoooorrrrwwwwaaaarrrrdddd ffffoooorrrr tttthhhheeee nnnneeeexxxxtttt 77775555 yyyyeeeeaaaarrrrssss aaaannnndddd bbbbeeeeyyyyoooonnnndddd....
wwwweeee aaaacccchhhhiiiieeeevvvveeeedddd aaaa rrrreeeeccccoooorrrrdddd----lllleeeevvvveeeellll ooooffff RRRReeeesssseeeeaaaarrrrcccchhhh aaaannnndddd
IIIInnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss OOOOuuuurrrr CCCCaaaalllllllliiiinnnngggg CCCCaaaarrrrdddd DDDDeeeevvvveeeellllooooppppmmmmeeeennnntttt ((((RRRR&&&&DDDD)))) iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ooooffff aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy
WWWWhhhheeeennnn wwwweeee hhhheeeeaaaarrrr tttthhhheeee tttteeeerrrrmmmm ““““ssssttttaaaarrrrtttt----uuuupppp,,,,”””” wwwweeee tttthhhhiiiinnnnkkkk ooooffff aaaannnn $$$$11110000....8888 bbbbiiiilllllllliiiioooonnnn.... IIIInnnn ffffaaaacccctttt,,,, aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss,,,, wwwweeee
oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn wwwwiiiitttthhhh hhhhiiiigggghhhh eeeennnneeeerrrrggggyyyy aaaannnndddd ccccrrrreeeeaaaattttiiiivvvviiiittttyyyy,,,, oooonnnneeee aaaarrrreeee oooonnnneeee ooooffff tttthhhheeee ttttoooopppp 11110000 ccccoooommmmppppaaaannnniiiieeeessss tttthhhhaaaatttt iiiinnnnvvvveeeesssstttteeeedddd
tttthhhhaaaatttt vvvvaaaalllluuuueeeessss aaaaggggiiiilllliiiittttyyyy aaaannnndddd hhhhaaaassss aaaa bbbboooolllldddd vvvviiiissssiiiioooonnnn ttttoooo cccchhhhaaaannnnggggeeee aaaatttt tttthhhheeee hhhhiiiigggghhhheeeesssstttt lllleeeevvvveeeellllssss iiiinnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaannnndddd RRRR&&&&DDDD....
tttthhhheeee wwwwoooorrrrlllldddd.... AAAAssss IIII llllooooooookkkk aaaatttt tttthhhheeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss wwwweeee aaaarrrreeee
LLLLaaaasssstttt yyyyeeeeaaaarrrr,,,, tttthhhheeee JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn FFFFaaaammmmiiiillllyyyy ooooffff
iiiinnnnvvvveeeessssttttiiiinnnngggg iiiinnnn,,,, tttthhhheeee ccccoooommmmppppaaaannnniiiieeeessss wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh
CCCCoooommmmppppaaaannnniiiieeeessss iiiinnnnvvvveeeesssstttteeeedddd iiiinnnn aaaa nnnnuuuummmmbbbbeeeerrrr ooooffff vvvvaaaalllluuuueeee----ccccrrrreeeeaaaattttiiiinnnngggg
aaaannnndddd tttthhhheeee ppppeeeeoooopppplllleeee wwwwhhhhoooo ccccoooommmmeeee ttttoooo wwwwoooorrrrkkkk ffffoooorrrr uuuussss eeeevvvveeeerrrryyyy
aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnnssss,,,, wwwwhhhhiiiicccchhhh iiiinnnncccclllluuuuddddeeeedddd
ddddaaaayyyy,,,, IIII bbbbeeeelllliiiieeeevvvveeee tttthhhhoooosssseeee ssssttttaaaarrrrtttt----uuuupppp aaaattttttttrrrriiiibbbbuuuutttteeeessss ddddeeeefifififinnnneeee oooouuuurrrr
ZZZZaaaarrrrbbbbeeeeeeee’’’’ssss,,,, IIIInnnncccc....,,,, aaaa lllleeeeaaaaddddeeeerrrr iiiinnnn nnnnaaaattttuuuurrrraaaallllllllyyyy bbbbaaaasssseeeedddd oooovvvveeeerrrr----tttthhhheeee----
CCCCoooommmmppppaaaannnnyyyy ttttoooooooo————ddddrrrriiiivvvviiiinnnngggg aaaa vvvviiiissssiiiioooonnnn ooooffff cccchhhhaaaannnnggggeeee tttthhhhaaaatttt wwwwiiiillllllll
ccccoooouuuunnnntttteeeerrrr ((((OOOOTTTTCCCC)))) rrrreeeemmmmeeeeddddiiiieeeessss,,,, OOOOrrrrtttthhhhoooottttaaaaxxxxyyyy,,,, aaaa ddddeeeevvvveeeellllooooppppeeeerrrr
hhhhaaaavvvveeee lllloooonnnngggg----llllaaaassssttttiiiinnnngggg iiiimmmmppppaaaacccctttt ffffoooorrrr ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee....
ooooffff ssssooooffffttttwwwwaaaarrrreeee----eeeennnnaaaabbbblllleeeedddd oooorrrrtttthhhhooooppppaaaaeeeeddddiiiicccc ssssuuuurrrrggggeeeerrrryyyy
tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss aaaannnndddd AAAArrrrrrrroooowwwwhhhheeeeaaaadddd PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallllssss,,,,
IIIInnnncccc....,,,, wwwwhhhheeeerrrreeee wwwweeee aaaarrrreeee wwwwoooorrrrkkkkiiiinnnngggg ttttoooo bbbbrrrriiiinnnngggg aaaa ffffuuuunnnnccccttttiiiioooonnnnaaaallll
Sustaining our investment in innovation is
ccccuuuurrrreeee ttttoooo ppppaaaattttiiiieeeennnnttttssss wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeppppaaaattttiiiittttiiiissss BBBB.... IIIInnnn
central to our ability to create meaningful
ttttoooottttaaaallll,,,, wwwweeee eeeexxxxeeeeccccuuuutttteeeedddd 11112222 aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnsssseeeessss
change and competitive differentiation. ooooffff vvvvaaaarrrriiiioooouuuussss ssssiiiizzzzeeeessss,,,, iiiinnnncccclllluuuuddddiiiinnnngggg oooouuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff tttthhhheeee
ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt mmmmaaaarrrrkkkkeeeettttssss tttthhhheeee DDDDRRRR CCCCIIII LLLLAAAABBBBOOOO lllliiiinnnneeee ooooffff
HHHHoooowwwweeeevvvveeeerrrr,,,, tttthhhheeee ttttiiiimmmmeeeelllleeeessssssss vvvvaaaalllluuuueeeessss tttthhhhaaaatttt ssssuuuuppppppppoooorrrrtttt sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuuccccttttssss,,,, wwwwhhhhiiiicccchhhh ooooffiffiffifficccciiiiaaaallllllllyyyy cccclllloooosssseeeedddd iiiinnnn 2222000011119999....
tttthhhheeeesssseeee ssssttttrrrraaaatttteeeeggggiiiieeeessss aaaallllssssoooo mmmmaaaakkkkeeee uuuussss ddddiiiiffffffffeeeerrrreeeennnntttt AAAAddddddddiiiittttiiiioooonnnnaaaallllllllyyyy,,,, wwwweeee ssssiiiiggggnnnneeeedddd 77774444 iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ddddeeeeaaaallllssss aaaassss wwwweeeellllllll
ffffrrrroooommmm tttthhhheeee ttttyyyyppppiiiiccccaaaallll ssssttttaaaarrrrtttt----uuuupppp.... OOOOuuuurrrr 111133333333 yyyyeeeeaaaarrrrssss ooooffff aaaassss 22229999 nnnneeeewwww ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt ddddeeeeaaaallllssss,,,, aaaannnndddd wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee
ssssuuuucccccccceeeessssssss aaaannnndddd aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnntttt mmmmoooottttiiiivvvvaaaatttteeee uuuussss eeeevvvveeeennnn ttttoooo mmmmaaaakkkkeeee iiiinnnnvvvveeeessssttttmmmmeeeennnnttttssss aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss tttthhhhrrrroooouuuugggghhhh
mmmmoooorrrreeee ttttoooo bbbbrrrriiiinnnngggg nnnneeeewwww iiiiddddeeeeaaaassss aaaannnndddd aaaapppppppprrrrooooaaaacccchhhheeeessss ttttoooo JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn IIIInnnnnnnnoooovvvvaaaattttiiiioooonnnn----JJJJJJJJDDDDCCCC,,,, IIIInnnncccc.... ((((JJJJJJJJDDDDCCCC))))....
mmmmaaaarrrrkkkkeeeetttt ttttooooddddaaaayyyy aaaannnndddd wwwweeeellllllll iiiinnnnttttoooo tttthhhheeee ffffuuuuttttuuuurrrreeee....
AAAAssss IIII jjjjuuuusssstttt mmmmeeeennnnttttiiiioooonnnneeeedddd,,,, wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo iiiinnnnnnnnoooovvvvaaaatttteeee
TTTThhhheeee ddddiiiivvvveeeerrrrssssiiiittttyyyy ooooffff oooouuuurrrr oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn,,,, wwwwhhhhiiiicccchhhh iiiinnnn ssssuuuurrrrggggeeeerrrryyyy.... OOOOvvvveeeerrrr 111100000000 yyyyeeeeaaaarrrrssss aaaaggggoooo,,,, wwwweeee wwwweeeerrrreeee tttthhhheeee
ccccoooommmmpppprrrriiiisssseeeessss aaaa wwwwiiiiddddeeee aaaarrrrrrrraaaayyyy ooooffff bbbbaaaacccckkkkggggrrrroooouuuunnnnddddssss,,,, ppppiiiioooonnnneeeeeeeerrrrssss ooooffff sssstttteeeerrrriiiilllleeee ssssuuuurrrrggggeeeerrrryyyy,,,, eeeessssttttaaaabbbblllliiiisssshhhhiiiinnnngggg aaaannnn
(cid:44)(cid:44)(cid:3)(cid:373)(cid:3)(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)iiiinnnnccccrrrreeeeddddiiiibbbblllleeee hhhheeeerrrriiiittttaaaaggggeeee tttthhhhaaaatttt ttttooooddddaaaayyyy iiiinnnncccclllluuuuddddeeeessss oooouuuurrrr DDDDrrrriiiivvvviiiinnnngggg LLLLoooonnnngggg----tttteeeerrrrmmmm SSSShhhhaaaarrrreeeehhhhoooollllddddeeeerrrr VVVVaaaalllluuuueeee
lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp iiiinnnn mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy aaaannnndddd OOOOuuuurrrr ffffrrrreeeeeeee ccccaaaasssshhhh flflflfloooowwww**** ffffoooorrrr 2222000011118888 iiiimmmmpppprrrroooovvvveeeedddd ttttoooo $$$$11118888....5555
iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeeellllyyyy ccccoooonnnnttttrrrroooolllllllliiiinnnngggg ssssuuuurrrrggggiiiiccccaaaallll bbbblllleeeeeeeeddddiiiinnnngggg aaaannnndddd bbbbiiiilllllllliiiioooonnnn,,,, aaaannnndddd eeeemmmmppppllllooooyyyyiiiinnnngggg oooouuuurrrr pppprrrroooovvvveeeennnn ccccaaaappppiiiittttaaaallll
iiiinnnnffffeeeeccccttttiiiioooonnnn gggglllloooobbbbaaaallllllllyyyy.... OOOOuuuurrrr ggggooooaaaallll aaaannnndddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt iiiissss aaaallllllllooooccccaaaattttiiiioooonnnn ssssttttrrrraaaatttteeeeggggyyyy,,,, wwwweeee aaaarrrreeee aaaabbbblllleeee ttttoooo eeeeffffffffeeeeccccttttiiiivvvveeeellllyyyy
ttttoooo nnnnoooowwww ccccrrrreeeeaaaatttteeee tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ssssuuuurrrrggggeeeerrrryyyy.... TTTThhhhaaaatttt’’’’ssss iiiinnnnvvvveeeesssstttt iiiinnnn oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo ddddrrrriiiivvvveeee
wwwwhhhhyyyy IIII’’’’mmmm eeeexxxxcccciiiitttteeeedddd tttthhhhaaaatttt wwwweeee eeeennnntttteeeerrrreeeedddd iiiinnnnttttoooo aaaa ddddeeeefifififinnnniiiittttiiiivvvveeee ggggrrrroooowwwwtttthhhh ffffoooorrrr lllloooonnnngggg----tttteeeerrrrmmmm vvvvaaaalllluuuueeee,,,, wwwwhhhhiiiilllleeee aaaallllssssoooo rrrreeeettttuuuurrrrnnnniiiinnnngggg
aaaaggggrrrreeeeeeeemmmmeeeennnntttt ttttoooo aaaaccccqqqquuuuiiiirrrreeee AAAAuuuurrrriiiissss HHHHeeeeaaaalllltttthhhh,,,, IIIInnnncccc.... AAAAuuuurrrriiiissss vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss.... OOOOuuuurrrr ccccaaaappppiiiittttaaaallll aaaallllllllooooccccaaaattttiiiioooonnnn
HHHHeeeeaaaalllltttthhhh iiiissss aaaa ddddeeeevvvveeeellllooooppppeeeerrrr ooooffff rrrroooobbbboooottttiiiicccc tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss ssssttttrrrraaaatttteeeeggggyyyy iiiinnnncccclllluuuuddddeeeessss ffffoooouuuurrrr kkkkeeeeyyyy pppprrrriiiioooorrrriiiittttiiiieeeessss::::
tttthhhhaaaatttt ccccuuuurrrrrrrreeeennnnttttllllyyyy ffffooooccccuuuusssseeeessss oooonnnn lllluuuunnnngggg ccccaaaannnncccceeeerrrr.... TTTThhhhiiiissss
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:50)(cid:50)(cid:50)(cid:50)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:612)(cid:612)(cid:612)(cid:612)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:92)(cid:92)(cid:92)(cid:92)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:88)(cid:88)(cid:88)(cid:88)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:81)(cid:81)(cid:81)(cid:81)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:74)(cid:74)(cid:74)(cid:74)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:90)(cid:90)(cid:90)(cid:90)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)
aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn wwwwiiiillllllll aaaacccccccceeeelllleeeerrrraaaatttteeee oooouuuurrrr eeeennnnttttrrrryyyy iiiinnnnttttoooo ddddiiiiggggiiiittttaaaallllllllyyyy
(cid:82)(cid:82)(cid:82)(cid:82)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:87)(cid:87)(cid:87)(cid:87)(cid:88)(cid:88)(cid:88)(cid:88)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:89)(cid:89)(cid:89)(cid:89)(cid:76)(cid:76)(cid:76)(cid:76)(cid:68)(cid:68)(cid:68)(cid:68)(cid:53)(cid:53)(cid:53)(cid:53)(cid:9)(cid:9)(cid:9)(cid:9)(cid:39)(cid:39)(cid:39)(cid:39)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:54)(cid:54)(cid:54)(cid:54)(cid:48)(cid:48)(cid:48)(cid:48)(cid:9)(cid:9)(cid:9)(cid:9)(cid:36)(cid:36)(cid:36)(cid:36)(cid:11)(cid:11)(cid:11)(cid:11)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:15)(cid:15)(cid:15)(cid:15)
eeeennnnaaaabbbblllleeeedddd rrrroooobbbboooottttiiiiccccssss pppprrrroooocccceeeedddduuuurrrreeeessss wwwwiiiitttthhhh tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll
mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd aaaaddddmmmmiiiinnnniiiissssttttrrrraaaattttiiiivvvveeee)))) iiiinnnniiiittttiiiiaaaattttiiiivvvveeeessss....
ffffoooorrrr ggggrrrroooowwwwtttthhhh aaaannnndddd eeeexxxxppppaaaannnnssssiiiioooonnnn iiiinnnnttttoooo ooootttthhhheeeerrrr iiiinnnntttteeeerrrrvvvveeeennnnttttiiiioooonnnnaaaallll
aaaapppppppplllliiiiccccaaaattttiiiioooonnnnssss.... IIIInnnn tttthhhhiiiissss nnnneeeewwww eeeerrrraaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee,,,, wwwweeee (cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:55)(cid:55)(cid:55)(cid:55)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:91)(cid:91)(cid:91)(cid:91)(cid:87)(cid:87)(cid:87)(cid:87)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:92)(cid:92)(cid:92)(cid:92)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:83)(cid:83)(cid:83)(cid:83)(cid:72)(cid:72)(cid:72)(cid:72)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)
aaaarrrreeee aaaaiiiimmmmiiiinnnngggg ttttoooo ssssiiiimmmmpppplllliiiiffffyyyy ssssuuuurrrrggggeeeerrrryyyy,,,, ddddrrrriiiivvvveeee eeeeffiffiffifficccciiiieeeennnnccccyyyy,,,, ddddiiiivvvviiiiddddeeeennnndddd ttttoooo oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss,,,, aaaannnndddd iiiinnnn 2222000011118888
rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss,,,, iiiimmmmpppprrrroooovvvveeee oooouuuuttttccccoooommmmeeeessss ffffoooorrrr wwwweeee ppppaaaaiiiidddd $$$$9999....5555 bbbbiiiilllllllliiiioooonnnn iiiinnnn ddddiiiivvvviiiiddddeeeennnnddddssss.... WWWWeeee aaaarrrreeee
ppppaaaattttiiiieeeennnnttttssss aaaannnndddd mmmmaaaakkkkeeee ssssuuuurrrrggggeeeerrrryyyy eeeevvvveeeennnn ssssaaaaffffeeeerrrr.... TTTThhhhiiiissss vvvveeeerrrryyyy pppprrrroooouuuudddd tttthhhhaaaatttt oooouuuurrrr ddddiiiivvvviiiiddddeeeennnndddd hhhhaaaassss iiiinnnnccccrrrreeeeaaaasssseeeedddd
ccccoooonnnnttttiiiinnnnuuuueeeessss oooouuuurrrr ssssuuuurrrrggggiiiiccccaaaallll lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttthhhhaaaatttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr tttthhhheeee llllaaaasssstttt 55556666 ccccoooonnnnsssseeeeccccuuuuttttiiiivvvveeee yyyyeeeeaaaarrrrssss....
iiiinnnn mmmmoooottttiiiioooonnnn ssssiiiinnnncccceeee tttthhhheeee bbbbeeeeggggiiiinnnnnnnniiiinnnngggg ooooffff oooouuuurrrr CCCCoooommmmppppaaaannnnyyyy....
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:50)(cid:50)(cid:50)(cid:50)(cid:81)(cid:81)(cid:81)(cid:81)(cid:70)(cid:70)(cid:70)(cid:70)(cid:72)(cid:72)(cid:72)(cid:72)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)(cid:366)(cid:366)(cid:366)(cid:366)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:80)(cid:80)(cid:80)(cid:80)(cid:72)(cid:72)(cid:72)(cid:72)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:89)(cid:89)(cid:89)(cid:89)(cid:76)(cid:76)(cid:76)(cid:76)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:74)(cid:74)(cid:74)(cid:74)(cid:82)(cid:82)(cid:82)(cid:82)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:86)(cid:86)(cid:86)(cid:86)(cid:15)(cid:15)(cid:15)(cid:15)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)
ttttaaaarrrrggggeeeetttt mmmmeeeerrrrggggeeeerrrrssss,,,, aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnssssiiiinnnngggg
LLLLooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd,,,, IIII aaaammmm aaaallllssssoooo vvvveeeerrrryyyy eeeexxxxcccciiiitttteeeedddd aaaabbbboooouuuutttt oooouuuurrrr
aaaaggggrrrreeeeeeeemmmmeeeennnnttttssss tttthhhhaaaatttt wwwweeee bbbbeeeelllliiiieeeevvvveeee wwwwiiiillllllll aaaadddddddd
ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn wwwwiiiitttthhhh AAAApppppppplllleeee,,,, IIIInnnncccc.... tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd
ssssiiiiggggnnnniiiifififificcccaaaannnntttt lllloooonnnngggg----tttteeeerrrrmmmm vvvvaaaalllluuuueeee ccccrrrreeeeaaaattttiiiioooonnnn ffffoooorrrr oooouuuurrrr
eeeeaaaarrrrllllyyyy iiiinnnn 2222000011119999.... TTTTooooggggeeeetttthhhheeeerrrr,,,, wwwweeee wwwwiiiillllllll bbbbeeee ccccoooonnnndddduuuuccccttttiiiinnnngggg aaaa
sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss aaaannnndddd aaaallllllll ooootttthhhheeeerrrr ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss....
rrrreeeesssseeeeaaaarrrrcccchhhh ssssttttuuuuddddyyyy tttthhhhaaaatttt aaaannnnaaaallllyyyyzzzzeeeessss wwwwhhhheeeetttthhhheeeerrrr aaaa nnnneeeewwww hhhheeeeaaaarrrrtttt
hhhheeeeaaaalllltttthhhh pppprrrrooooggggrrrraaaammmm uuuussssiiiinnnngggg aaaannnn aaaapppppppp ffffrrrroooommmm tttthhhheeee JJJJoooohhhhnnnnssssoooonnnn (cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:36)(cid:36)(cid:36)(cid:36)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:612)(cid:612)(cid:612)(cid:612)(cid:81)(cid:81)(cid:81)(cid:81)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:15)(cid:15)(cid:15)(cid:15)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:76)(cid:76)(cid:76)(cid:76)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:88)(cid:88)(cid:88)(cid:88)(cid:71)(cid:71)(cid:71)(cid:71)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:90)(cid:90)(cid:90)(cid:90)(cid:68)(cid:68)(cid:68)(cid:68)(cid:92)(cid:92)(cid:92)(cid:92)(cid:86)(cid:86)(cid:86)(cid:86)
&&&& JJJJoooohhhhnnnnssssoooonnnn FFFFaaaammmmiiiillllyyyy ooooffff CCCCoooommmmppppaaaannnniiiieeeessss,,,, iiiinnnn ccccoooommmmbbbbiiiinnnnaaaattttiiiioooonnnn ttttoooo rrrreeeettttuuuurrrrnnnn vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss,,,, ssssuuuucccchhhh aaaassss sssshhhhaaaarrrreeee
wwwiiiittthhhh AAApppppplllleee WWWaaatttccchhhh’’’’sss iiiirrrrrreeeggguuullllaaarrr rrrhhhhyyyttthhhhmmm nnnoootttiiiifififificccaaatttiiiiooonnnsss rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee pppprrrrooooggggrrrraaaammmmssss;;;; aaaannnndddd wwwweeee aaaarrrreeee ccccuuuurrrrrrrreeeennnnttttllllyyyy
aaaannnndddd EEEElllleeeeccccttttrrrroooo CCCCaaaarrrrddddiiiiooooggggrrrraaaammmm ((((EEEECCCCGGGG)))) aaaapppppppp,,,, ccccaaaannnn eeeexxxxeeeeccccuuuuttttiiiinnnngggg aaaaggggaaaaiiiinnnnsssstttt aaaa $$$$5555 bbbbiiiilllllllliiiioooonnnn sssshhhhaaaarrrreeee rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee
aaaacccccccceeeelllleeeerrrraaaatttteeee aaaattttrrrriiiiaaaallll fifififibbbbrrrriiiillllllllaaaattttiiiioooonnnn ((((AAAAFFFFiiiibbbb)))) ddddiiiiaaaaggggnnnnoooossssiiiissss,,,, aaaannnndddd tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd llllaaaasssstttt DDDDeeeecccceeeemmmmbbbbeeeerrrr....
iiiimmmmpppprrrroooovvvveeee hhhheeeeaaaalllltttthhhh oooouuuuttttccccoooommmmeeeessss iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeee pppprrrreeeevvvveeeennnnttttiiiioooonnnn
GGGGiiiivvvveeeennnn oooouuuurrrr fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh,,,, wwwweeee ccccaaaannnn ppppuuuurrrrssssuuuueeee aaaallllllll
ooooffff ssssttttrrrrooookkkkeeee ffffoooorrrr tttthhhheeee 33333333 mmmmiiiilllllllliiiioooonnnn ppppeeeeoooopppplllleeee wwwwoooorrrrllllddddwwwwiiiiddddeeee
ooooffff tttthhhheeeesssseeee pppprrrriiiioooorrrriiiittttiiiieeeessss ssssiiiimmmmuuuullllttttaaaannnneeeeoooouuuussssllllyyyy,,,, aaaassss wwwweeee ddddiiiidddd iiiinnnn
lllliiiivvvviiiinnnngggg wwwwiiiitttthhhh AAAAFFFFiiiibbbb.... TTTThhhhiiiissss iiiissss aaaa ccccoooonnnnddddiiiittttiiiioooonnnn tttthhhhaaaatttt ccccaaaannnn
2222000011118888.... TTTThhhhrrrroooouuuugggghhhhoooouuuutttt JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn’’’’ssss hhhhiiiissssttttoooorrrryyyy,,,,
lllleeeeaaaadddd ttttoooo ssssttttrrrrooookkkkeeee aaaannnndddd ooootttthhhheeeerrrr ppppooootttteeeennnnttttiiiiaaaallllllllyyyy ddddeeeevvvvaaaassssttttaaaattttiiiinnnngggg
wwwweeee hhhhaaaavvvveeee mmmmaaaaiiiinnnnttttaaaaiiiinnnneeeedddd aaaa ssssttttrrrroooonnnngggg,,,, ccccoooonnnnssssiiiisssstttteeeennnntttt aaaannnndddd
(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:83)(cid:83)(cid:83)(cid:83)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:70)(cid:70)(cid:70)(cid:70)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:17)(cid:17)(cid:17)(cid:17)(cid:44)(cid:44)(cid:44)(cid:44)(cid:81)(cid:81)(cid:81)(cid:81)(cid:73)(cid:73)(cid:73)(cid:73)(cid:68)(cid:68)(cid:68)(cid:68)(cid:70)(cid:70)(cid:70)(cid:70)(cid:87)(cid:87)(cid:87)(cid:87)(cid:15)(cid:15)(cid:15)(cid:15)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:17)(cid:17)(cid:17)(cid:17)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:15)(cid:15)(cid:15)(cid:15)(cid:36)(cid:36)(cid:36)(cid:36)(cid:41)(cid:41)(cid:41)(cid:41)(cid:76)(cid:76)(cid:76)(cid:76)(cid:69)(cid:69)(cid:69)(cid:69)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)
ssssuuuussssttttaaaaiiiinnnnaaaabbbblllleeee bbbbuuuussssiiiinnnneeeessssssss.... TTTThhhhiiiissss iiiissss iiiilllllllluuuussssttttrrrraaaatttteeeedddd bbbbyyyy::::
rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ffffoooorrrr aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy 111133330000,,,,000000000000 ddddeeeeaaaatttthhhhssss
aaaannnndddd 777755550000,,,,000000000000 hhhhoooossssppppiiiittttaaaalllliiiizzzzaaaattttiiiioooonnnnssss eeeevvvveeeerrrryyyy yyyyeeeeaaaarrrr....
(cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:22)(cid:22)(cid:22)(cid:22)(cid:24)(cid:24)(cid:24)(cid:24)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:88)(cid:88)(cid:88)(cid:88)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:92)(cid:92)(cid:92)(cid:92)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:68)(cid:68)(cid:68)(cid:68)(cid:71)(cid:71)(cid:71)(cid:71)(cid:77)(cid:77)(cid:77)(cid:77)(cid:88)(cid:88)(cid:88)(cid:88)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)
ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll eeeeaaaarrrrnnnniiiinnnnggggssss ggggrrrroooowwwwtttthhhh****
WWWWeeee aaaarrrreeee vvvveeeerrrryyyy ooooppppttttiiiimmmmiiiissssttttiiiicccc aaaabbbboooouuuutttt tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll
ooooffff tttthhhhiiiissss wwwweeeeaaaarrrraaaabbbblllleeee tttteeeecccchhhhnnnnoooollllooooggggyyyy.... AAAAnnnndddd,,,, bbbbaaaasssseeeedddd oooonnnn (cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:3)(cid:3)(cid:37)(cid:37)(cid:37)(cid:37)(cid:72)(cid:72)(cid:72)(cid:72)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:87)(cid:87)(cid:87)(cid:87)(cid:90)(cid:90)(cid:90)(cid:90)(cid:82)(cid:82)(cid:82)(cid:82)(cid:70)(cid:70)(cid:70)(cid:70)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:83)(cid:83)(cid:83)(cid:83)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)
tttthhhheeee iiiinnnnssssiiiigggghhhhttttssss ggggeeeennnneeeerrrraaaatttteeeedddd tttthhhhrrrroooouuuugggghhhh tttthhhhiiiissss rrrreeeesssseeeeaaaarrrrcccchhhh hhhhoooolllldddd aaaa TTTTrrrriiiipppplllleeee AAAA ccccrrrreeeeddddiiiitttt rrrraaaattttiiiinnnngggg;;;; aaaannnndddd
pppprrrrooooggggrrrraaaammmm,,,, iiiinnnn tttthhhheeee ffffuuuuttttuuuurrrreeee wwwweeee mmmmaaaayyyy aaaallllssssoooo bbbbeeee aaaabbbblllleeee (cid:373)(cid:373)(cid:373)(cid:373)(cid:3)(cid:3)(cid:50)(cid:50)(cid:50)(cid:50)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:68)(cid:68)(cid:68)(cid:68)(cid:80)(cid:80)(cid:80)(cid:80)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:54)(cid:54)(cid:54)(cid:54)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:71)(cid:71)(cid:71)(cid:71)(cid:9)(cid:9)(cid:9)(cid:9)(cid:51)(cid:51)(cid:51)(cid:51)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:366)(cid:366)(cid:366)(cid:366)(cid:86)(cid:86)(cid:86)(cid:86)
ttttoooo ddddeeeevvvveeeelllloooopppp nnnneeeewwww wwwwaaaayyyyssss ttttoooo ddddeeeetttteeeecccctttt ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhh TTTToooopppp 11110000 MMMMaaaarrrrkkkkeeeetttt CCCCaaaapppp ccccoooommmmppppaaaannnniiiieeeessss....
ccccoooonnnnddddiiiittttiiiioooonnnnssss ssssoooooooonnnneeeerrrr.... EEEEaaaarrrrllllyyyy ddddiiiiaaaaggggnnnnoooossssiiiissss nnnnooootttt oooonnnnllllyyyy
TTTThhhheeee SSSSttttrrrraaaatttteeeeggggiiiiccccAAAAddddvvvvaaaannnnttttaaaaggggeeee ooooffff OOOOuuuurrrr BBBBrrrrooooaaaadddd BBBBaaaasssseeee
hhhhaaaassss tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll ttttoooo ssssaaaavvvveeee lllliiiivvvveeeessss,,,, bbbbuuuutttt iiiitttt mmmmaaaayyyy aaaallllssssoooo
PPPPoooossssiiiittttiiiioooonnnneeeedddd aaaaccccrrrroooossssssss tttthhhhrrrreeeeeeee vvvviiiittttaaaallll aaaassssppppeeeeccccttttssss ooooffff
lllloooowwwweeeerrrr ccccoooossssttttssss aaaaccccrrrroooossssssss tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssyyyysssstttteeeemmmm....
hhhheeeeaaaalllltttthhhhccccaaaarrrreeee————PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll,,,, CCCCoooonnnnssssuuuummmmeeeerrrr aaaannnndddd
IIIInnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss oooouuuurrrr ccccaaaalllllllliiiinnnngggg ccccaaaarrrrdddd ttttoooo tttthhhheeee wwwwoooorrrrlllldddd ooooffff MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss————wwwweeee hhhhaaaavvvveeee uuuunnnniiiiqqqquuuueeee iiiinnnnssssiiiigggghhhhtttt iiiinnnnttttoooo
sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy.... WWWWeeee rrrreeeemmmmaaaaiiiinnnn ooooppppeeeennnn ttttoooo tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss wwwwhhhheeeennnneeeevvvveeeerrrr aaaannnndddd
bbbbeeeesssstttt iiiiddddeeeeaaaassss,,,, nnnnoooo mmmmaaaatttttttteeeerrrr wwwwhhhheeeerrrreeee tttthhhheeeeyyyy ccccoooommmmeeee ffffrrrroooommmm,,,, wwwwhhhheeeerrrreeeevvvveeeerrrr tttthhhheeeeyyyy eeeemmmmeeeerrrrggggeeee.... WWWWeeee aaaarrrreeee ssssttttrrrruuuuccccttttuuuurrrreeeedddd ttttoooo
aaaassss wwwweeee rrrreeeelllleeeennnnttttlllleeeessssssssllllyyyy ppppuuuurrrrssssuuuueeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll mmmmeeeeeeeetttt tttthhhheeee ccccuuuurrrrrrrreeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee nnnneeeeeeeeddddssss ooooffff ppppaaaattttiiiieeeennnnttttssss
iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo bbbbeeeennnneeeefifififitttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh,,,, iiiinnnntttteeeerrrrnnnnaaaallllllllyyyy aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy,,,, aaaannnndddd ttttoooo aaaaddddddddrrrreeeessssssss tttthhhheeee
aaaannnndddd tttthhhhrrrroooouuuugggghhhhoooouuuutttt oooouuuurrrr iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn eeeeccccoooossssyyyysssstttteeeemmmm,,,, cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss tttthhhhaaaatttt tttthhhheeee wwwwoooorrrrlllldddd
aaaaccccrrrroooossssssss oooouuuurrrr IIIInnnnnnnnoooovvvvaaaattttiiiioooonnnn CCCCeeeennnntttteeeerrrrssss,,,, JJJJLLLLAAAABBBBssss,,,, ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrreeeesssseeeennnnttttssss.... WWWWeeee rrrreeeemmmmaaaaiiiinnnn ffffooooccccuuuusssseeeedddd oooonnnn
JJJJJJJJDDDDCCCC aaaannnndddd mmmmaaaannnnyyyy ssssttttrrrraaaatttteeeeggggiiiicccc ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiippppssss.... lllleeeevvvveeeerrrraaaaggggiiiinnnngggg oooouuuurrrr bbbbrrrrooooaaaadddd----bbbbaaaasssseeeedddd ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss ttttoooo
(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)(cid:3)(cid:373)(cid:3)(cid:44)(cid:44)(cid:44)ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddrrrriiiivvvveeee tttthhhheeee nnnneeeexxxxtttt ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff ggggrrrroooowwwwtttthhhh BBBBuuuussssiiiinnnneeeessssssss PPPPeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd 2222000011119999 OOOOuuuuttttllllooooooookkkk
aaaaccccrrrroooossssssss oooouuuurrrr eeeennnnttttiiiirrrreeee ppppoooorrrrttttffffoooolllliiiioooo,,,, bbbbooootttthhhh iiiinnnn mmmmaaaarrrrkkkkeeeettttssss
PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll
wwwwhhhheeeerrrreeee wwwweeee hhhhaaaavvvveeee ggggrrrreeeeaaaatttteeeerrrr ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo ccccoooommmmppppeeeetttteeee,,,,
WWWiiiittthhhh aaannn iiiinnndddduuussstttrrryyy---lllleeeaaaddddiiiinnnggg pppiiiipppeeelllliiiinnneee aaannndddd eeessstttaaabbbblllliiiissshhhheeedddd
aaaassss wwwweeeellllllll aaaassss iiiinnnn tttthhhheeee mmmmaaaarrrrkkkkeeeettttssss wwwwhhhheeeerrrreeee wwwweeee lllleeeeaaaadddd,,,, wwwwhhhhiiiicccchhhh
ccccoooommmmmmmmeeeerrrrcccciiiiaaaallll eeeexxxxcccceeeelllllllleeeennnncccceeee,,,, oooouuuurrrr PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll
iiiinnnncccclllluuuuddddeeee oooouuuurrrr 22226666 ppppllllaaaattttffffoooorrrrmmmmssss tttthhhhaaaatttt eeeeaaaacccchhhh ddddeeeelllliiiivvvveeeerrrreeeedddd
bbbbuuusssiiiinnneeessssss hhhhaaasss ddddeeelllliiiivvveeerrreeedddd ooouuutttssstttaaannnddddiiiinnnggg pppeeerrrffffooorrrmmmaaannnccceee
aaaa bbbbiiiilllllllliiiioooonnnn ddddoooollllllllaaaarrrrssss oooorrrr mmmmoooorrrreeee iiiinnnn ssssaaaalllleeeessss llllaaaasssstttt yyyyeeeeaaaarrrr....
(cid:73)(cid:73)(cid:73)(cid:73)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:83)(cid:83)(cid:83)(cid:83)(cid:68)(cid:68)(cid:68)(cid:68)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:86)(cid:86)(cid:86)(cid:86)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:88)(cid:88)(cid:88)(cid:88)(cid:70)(cid:70)(cid:70)(cid:70)(cid:70)(cid:70)(cid:70)(cid:70)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:73)(cid:73)(cid:73)(cid:73)(cid:88)(cid:88)(cid:88)(cid:88)(cid:79)(cid:79)(cid:79)(cid:79)
OOOOuuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee iiiissss nnnnooootttt jjjjuuuusssstttt oooouuuurrrr hhhheeeerrrriiiittttaaaaggggeeee,,,, iiiitttt llllaaaauuuunnnncccchhhheeeessss aaaannnndddd ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh iiiinnnn sssseeeevvvveeeerrrraaaallll ooooffff
iiiissss aaaa ssssttttrrrraaaatttteeeeggggiiiicccc cccchhhhooooiiiicccceeee,,,, ggggrrrroooouuuunnnnddddeeeedddd aaaannnndddd pppprrrroooovvvveeeennnn oooouuuurrrr bbbblllloooocccckkkkbbbbuuuusssstttteeeerrrr mmmmeeeeddddiiiicccciiiinnnneeeessss ccccrrrreeeeaaaatttteeeedddd 11111111....8888%%%%
iiiinnnn lllloooonnnngggg----tttteeeerrrrmmmm ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd oooouuuurrrr bbbbrrrrooooaaaadddd ooopppeeerrraaatttiiiiooonnnaaallll gggrrrooowwwttthhhh***,,, aaannndddd ooouuurrr PPPhhhhaaarrrmmmaaaccceeeuuutttiiiicccaaallll
aaaannnndddd ddddeeeeeeeepppp uuuunnnnddddeeeerrrrssssttttaaaannnnddddiiiinnnngggg ooooffff tttthhhheeee iiiinnnndddduuuussssttttrrrryyyy’’’’ssss bbbbuuuussssiiiinnnneeeessssssss ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo bbbbeeee aaaannnn iiiinnnndddduuuussssttttrrrryyyy lllleeeeaaaaddddeeeerrrr iiiinnnn
pppprrrreeeesssseeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee.... WWWWeeee cccclllleeeeaaaarrrrllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee aaaallllllll ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee mmmmeeeeaaaassssuuuurrrreeeessss,,,, iiiinnnncccclllluuuuddddiiiinnnngggg RRRR&&&&DDDD....
iiiimmmmppppoooorrrrttttaaaannnntttt rrrroooolllleeee wwwweeee ppppllllaaaayyyy iiiinnnn lllleeeeaaaaddddiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy
aaaannnndddd rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg oooouuuurrrr iiiinnnndddduuuussssttttrrrryyyy wwwwiiiitttthhhh iiiinnnntttteeeeggggrrrriiiittttyyyy.... AAAAssss wwwweeee llllooooooookkkk ttttoooowwwwaaaarrrrdddd 2222000011119999 aaaannnndddd bbbbeeeeyyyyoooonnnndddd,,,, wwwweeee rrrreeeemmmmaaaaiiiinnnn
fffooocccuuussseeeddd ooonnn bbbrrriiinnnggggiiinnngggg iiinnnnnnooovvvaaatttiiivvveee sssooollluuutttiiiooonnnsss tttooo
OOOOuuuurrrr ““““HHHHeeeeaaaalllltttthhhh ffffoooorrrr HHHHuuuummmmaaaannnniiiittttyyyy RRRReeeeppppoooorrrrtttt”””” uuuunnnnddddeeeerrrrssssccccoooorrrreeeessss
ppppaaaattttiiiieeeennnnttttssss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy,,,,
oooouuuurrrr ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo hhhheeeellllpppp eeeennnnssssuuuurrrreeee tttthhhhaaaatttt eeeeaaaacccchhhh nnnneeeewwww
wwwwhhhhiiiilllleeee ddddrrrriiiivvvviiiinnnngggg ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg
ggggeeeennnneeeerrrraaaattttiiiioooonnnn iiiissss hhhheeeeaaaalllltttthhhhiiiieeeerrrr tttthhhhaaaannnn tttthhhheeee llllaaaasssstttt.... WWWWeeee bbbbeeeelllliiiieeeevvvveeee
ttttoooo aaaaddddvvvvaaaannnncccceeee oooouuuurrrr ppppiiiippppeeeelllliiiinnnneeee.... PPPPaaaatttteeeennnntttt pppprrrreeeessssssssuuuurrrreeee iiiissss aaaa
oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee hhhheeeellllppppssss uuuussss bbbbeeeetttttttteeeerrrr uuuunnnnddddeeeerrrrssssttttaaaannnndddd aaaannnndddd
fffeeeaaatttuuurrreee ooofff tttooodddaaayyyy’’’sss pppphhhaaarrrmmmaaaccceeeuuutttiiicccaaalll iiinnnddduuussstttrrryyyy,,, aaannnddd
ppppoooossssiiiittttiiiivvvveeeellllyyyy iiiimmmmppppaaaacccctttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaatttt eeeevvvveeeerrrryyyy aaaaggggeeee aaaannnndddd
wwweee hhhhaaavvveee ddddeeelllliiiibbbbeeerrraaattteeellllyyy aaannndddd aaaccctttiiiivvveeellllyyy mmmaaannnaaagggeeedddd ooouuurrr
aaaatttt eeeevvvveeeerrrryyyy ssssttttaaaaggggeeee.... IIIInnnn 2222000011118888 wwwweeee wwwweeeerrrreeee rrrreeeeccccooooggggnnnniiiizzzzeeeedddd aaaassss oooonnnneeee
ppppoooorrrrttttffffoooolllliiiioooo oooovvvveeeerrrr tttthhhheeee llllaaaasssstttt ffffeeeewwww yyyyeeeeaaaarrrrssss ttttoooo eeeennnnaaaabbbblllleeee uuuussss
ooooffff tttthhhheeee ttttoooopppp tttteeeennnn ccccoooorrrrppppoooorrrraaaattttiiiioooonnnnssss ffffoooorrrr oooouuuurrrr eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll,,,,
tttooo mmmaaakkkeee ttthhheee iiinnnvvveeessstttmmmeeennntttsss nnneeeccceeessssssaaarrryyyy tttooo nnnooottt ooonnnlllyyyy
ssssoooocccciiiiaaaallll aaaannnndddd ggggoooovvvveeeerrrrnnnnaaaannnncccceeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee bbbbyyyy
wwwiiiittthhhhssstttaaannndddd ttthhhhiiiisss iiiimmmpppaaacccttt,,, bbbbuuuttt tttooo gggrrrooowww aaattt cccooommmpppeeetttiiiitttiiiivvveee
CCCCoooorrrrppppoooorrrraaaatttteeee RRRReeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy MMMMaaaaggggaaaazzzziiiinnnneeee....
rrraaattteeesss iiiinnn 222000111999... WWWeee rrreeemmmaaaiiiinnn ffffooocccuuussseeedddd ooonnn ddddeeevvveeellllooopppiiiinnnggg
mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt ddddeeeelllliiiivvvveeeerrrr ggggrrrreeeeaaaatttt vvvvaaaalllluuuueeee
tttooo ttthhheee ppppaaatttiiieeennntttsss aaannnddd cccooonnnsssuuummmeeerrrsss wwwhhhooo dddeeeppppeeennnddd
Our broad base is not just our heritage,
oooonnnn oooouuuurrrr pppprrrroooodddduuuuccccttttssss ttttoooo mmmmaaaakkkkeeee tttthhhheeeeiiiirrrr lllliiiivvvveeeessss bbbbeeeetttttttteeeerrrr.... OOOOuuuurrrr
it is a strategic choice, grounded and
ggggooooaaaallll aaaannnndddd eeeexxxxppppeeeeccccttttaaaattttiiiioooonnnn ffffoooorrrr 2222000022220000 aaaannnndddd bbbbeeeeyyyyoooonnnndddd iiiissss
proven in long-term performance and ssssuuuussssttttaaaaiiiinnnneeeedddd,,,, lllloooonnnngggg----tttteeeerrrrmmmm,,,, aaaabbbboooovvvveeee----mmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh....
our broad and deep understanding of
WWWeee kkkknnnooowww ttthhhhaaattt iiiinnnnnnooovvvaaatttiiiiooonnn ddddrrriiiivvveeesss ooouuurrr
the industry’s present and future.
PPPhhhaaarrrmmmaaaccceeeuuutttiiicccaaalll bbbuuusssiiinnneeessssss’’’sss sssuuucccccceeessssss,,,, aaannnddd wwweee
(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:92)(cid:92)(cid:92)(cid:92)(cid:72)(cid:72)(cid:72)(cid:72)(cid:91)(cid:91)(cid:91)(cid:91)(cid:70)(cid:70)(cid:70)(cid:70)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:69)(cid:69)(cid:69)(cid:69)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:17)(cid:17)(cid:17)(cid:17)(cid:41)(cid:41)(cid:41)(cid:41)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:39)(cid:39)(cid:39)(cid:85)(cid:85)(cid:85)(cid:88)(cid:88)(cid:88)(cid:74)(cid:74)(cid:74)(cid:74)
CCCCoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn iiiissss ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll ttttoooo tttthhhheeee wwwwoooorrrrkkkk wwwweeee ddddoooo
(cid:36)(cid:36)(cid:36)(cid:36)(cid:71)(cid:71)(cid:71)(cid:71)(cid:80)(cid:80)(cid:80)(cid:80)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:11)(cid:11)(cid:11)(cid:11)(cid:41)(cid:41)(cid:41)(cid:41)(cid:39)(cid:39)(cid:39)(cid:39)(cid:36)(cid:36)(cid:36)(cid:36)(cid:12)(cid:12)(cid:12)(cid:12)(cid:68)(cid:68)(cid:68)(cid:68)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:89)(cid:89)(cid:89)(cid:89)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:54)(cid:54)(cid:54)(cid:54)(cid:51)(cid:51)(cid:51)(cid:51)(cid:53)(cid:53)(cid:53)(cid:53)(cid:36)(cid:36)(cid:36)(cid:36)(cid:57)(cid:57)(cid:57)(cid:57)(cid:36)(cid:36)(cid:36)(cid:36)(cid:55)(cid:55)(cid:55)(cid:55)(cid:50)(cid:50)(cid:50)(cid:50)(cid:400)(cid:400)(cid:400)(cid:400)
eeeevvvveeeerrrryyyy ddddaaaayyyy aaaannnndddd oooouuuurrrr pppprrrreeeesssseeeennnncccceeee iiiinnnn jjjjuuuusssstttt aaaabbbboooouuuutttt eeeevvvveeeerrrryyyy
(cid:11)(cid:11)(cid:11)(cid:11)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:78)(cid:78)(cid:78)(cid:78)(cid:72)(cid:72)(cid:72)(cid:72)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:80)(cid:80)(cid:80)(cid:80)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:12)(cid:12)(cid:12)(cid:12)(cid:38)(cid:38)(cid:38)(cid:38)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:44)(cid:49)(cid:49)(cid:49)(cid:49)(cid:68)(cid:68)(cid:68)(cid:68)(cid:86)(cid:86)(cid:86)(cid:86)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:54)(cid:54)(cid:54)(cid:54)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:92)(cid:92)(cid:92)(cid:92)(cid:73)(cid:73)(cid:73)(cid:73)(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:71)(cid:71)(cid:71)(cid:71)(cid:88)(cid:88)(cid:88)(cid:88)(cid:79)(cid:79)(cid:79)(cid:79)(cid:87)(cid:87)(cid:87)(cid:87)(cid:86)(cid:86)(cid:86)(cid:86)(cid:90)(cid:90)(cid:90)(cid:90)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)
aaaarrrreeeeaaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee.... TTTThhhhiiiissss lllleeeevvvveeeellll ooooffff eeeennnnggggaaaaggggeeeemmmmeeeennnntttt
TTTTrrrreeeeaaaattttmmmmeeeennnntttt RRRReeeessssiiiissssttttaaaannnntttt DDDDeeeepppprrrreeeessssssssiiiioooonnnn ((((TTTTRRRRDDDD)))),,,, wwwwhhhhoooo
aaaalllllllloooowwwwssss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ccccoooonnnnttttiiiinnnnuuuuoooouuuussss ddddiiiiaaaalllloooogggguuuueeee
hhhhaaaavvvveeee ccccyyyycccclllleeeedddd tttthhhhrrrroooouuuugggghhhh mmmmuuuullllttttiiiipppplllleeee ttttrrrreeeeaaaattttmmmmeeeennnnttttssss
wwwwiiiitttthhhh hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss,,,, bbbbuuuussssiiiinnnneeeessssssss lllleeeeaaaaddddeeeerrrrssss,,,,
wwwwiiiitttthhhhoooouuuutttt rrrreeeelllliiiieeeeffff.... TTTTRRRRDDDD iiiissss aaaa ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeee tttthhhhaaaatttt
aaaaccccaaaaddddeeeemmmmiiiiccccssss,,,, ggggoooovvvveeeerrrrnnnnmmmmeeeennnntttt ooooffiffiffifficccciiiiaaaallllssss,,,, sssscccciiiieeeennnnttttiiiissssttttssss,,,,
iiiissss aaaassssssssoooocccciiiiaaaatttteeeedddd wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeaaaalllltttthhhh pppprrrroooobbbblllleeeemmmmssss,,,, aaaannnndddd
pppprrrroooovvvviiiiddddeeeerrrr ssssyyyysssstttteeeemmmmssss,,,, ccccuuuussssttttoooommmmeeeerrrrssss,,,, ppppaaaattttiiiieeeennnnttttssss aaaannnndddd
qqqquuuuiiiitttteeee ttttrrrraaaaggggiiiiccccaaaallllllllyyyy,,,, ccccaaaannnn lllleeeeaaaadddd ttttoooo ssssuuuuiiiicccciiiiddddeeee iiiiffff nnnnooootttt ttttrrrreeeeaaaatttteeeedddd
ccccoooonnnnssssuuuummmmeeeerrrrssss.... WWWWeeee rrrreeeemmmmaaaaiiiinnnn ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo bbbbeeeeiiiinnnngggg aaaa
(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:83)(cid:83)(cid:83)(cid:83)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:51)(cid:51)(cid:51)(cid:51)(cid:53)(cid:53)(cid:53)(cid:53)(cid:36)(cid:36)(cid:36)(cid:36)(cid:57)(cid:57)(cid:57)(cid:57)(cid:36)(cid:36)(cid:36)(cid:36)(cid:55)(cid:55)(cid:55)(cid:55)(cid:50)(cid:50)(cid:50)(cid:50)(cid:400)(cid:400)(cid:400)(cid:400)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:86)(cid:86)(cid:86)(cid:86)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:90)(cid:90)(cid:90)(cid:90)
lllleeeeaaaaddddeeeerrrr iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssppppaaaacccceeee,,,, ttttoooo hhhheeeellllpppp ddddrrrriiiivvvveeee
bbbbrrrreeeeaaaakkkktttthhhhrrrroooouuuugggghhhh mmmmeeeeddddiiiicccciiiinnnneeee iiiinnnn oooouuuurrrr pppprrrroooodddduuuucccctttt ppppoooorrrrttttffffoooolllliiiioooo,,,,
tttthhhheeee cccchhhhaaaannnnggggeeee tttthhhhaaaatttt ppppeeeeoooopppplllleeee aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd wwwwaaaannnntttt
bbbbuuuutttt aaaallllssssoooo aaaa nnnneeeewwww hhhhooooppppeeee ffffoooorrrr aaaadddduuuullllttttssss wwwwhhhhoooo ssssuuuuffffffffeeeerrrr ffffrrrroooommmm
aaaannnndddd nnnneeeeeeeedddd ttttoooo sssseeeeeeee....
TTTTRRRRDDDD.... IIIItttt aaaallllssssoooo ooooffffffffeeeerrrrssss tttthhhheeee fifififirrrrsssstttt nnnneeeewwww mmmmeeeecccchhhhaaaannnniiiissssmmmm
WWWWeeee sssseeeeeeee aaaa vvvviiiittttaaaallll aaaannnndddd vvvviiiibbbbrrrraaaannnntttt ffffuuuuttttuuuurrrreeee ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ooooffff aaaaccccttttiiiioooonnnn ttttoooo aaaaddddddddrrrreeeessssssss TTTTRRRRDDDD.... AAAAnnnndddd iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy,,,, iiiinnnn
aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd tttthhhhaaaatttt iiiissss bbbbeeeeiiiinnnngggg ddddrrrriiiivvvveeeennnn bbbbyyyy tttthhhheeee aaaaccccccccoooorrrrddddaaaannnncccceeee wwwwiiiitttthhhh rrrriiiisssskkkk mmmmiiiittttiiiiggggaaaattttiiiioooonnnn gggguuuuiiiiddddaaaannnncccceeee ffffrrrroooommmm
ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg eeeexxxxppppaaaannnnssssiiiioooonnnn ooooffff tttthhhheeee gggglllloooobbbbaaaallll mmmmiiiiddddddddlllleeee (cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:41)(cid:41)(cid:41)(cid:41)(cid:39)(cid:39)(cid:39)(cid:39)(cid:36)(cid:36)(cid:36)(cid:36)(cid:15)(cid:15)(cid:15)(cid:15)(cid:54)(cid:54)(cid:54)(cid:54)(cid:51)(cid:51)(cid:51)(cid:51)(cid:53)(cid:53)(cid:53)(cid:53)(cid:36)(cid:36)(cid:36)(cid:36)(cid:57)(cid:57)(cid:57)(cid:57)(cid:36)(cid:36)(cid:36)(cid:36)(cid:55)(cid:55)(cid:55)(cid:55)(cid:50)(cid:50)(cid:50)(cid:50)(cid:400)(cid:400)(cid:400)(cid:400)(cid:70)(cid:70)(cid:70)(cid:70)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:69)(cid:69)(cid:69)(cid:69)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:71)(cid:71)(cid:71)(cid:71)(cid:80)(cid:80)(cid:80)(cid:80)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)
ccccllllaaaassssssss.... IIIItttt iiiissss tttthhhheeee mmmmiiiiddddddddlllleeee ccccllllaaaassssssss tttthhhhaaaatttt ddddrrrriiiivvvveeeessss gggglllloooobbbbaaaallll bbbbyyyy cccceeeerrrrttttiiiififififieeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt cccceeeennnntttteeeerrrrssss aaaannnndddd wwwwiiiillllllll nnnnooootttt bbbbeeee
eeeeccccoooonnnnoooommmmiiiicccc ggggrrrroooowwwwtttthhhh aaaannnndddd wwwwiiiitttthhhh iiiitttt,,,, tttthhhheeee ddddeeeemmmmaaaannnndddd ffffoooorrrr ddddiiiissssppppeeeennnnsssseeeedddd ddddiiiirrrreeeeccccttttllllyyyy ttttoooo ppppaaaattttiiiieeeennnnttttssss ttttoooo ttttaaaakkkkeeee aaaatttt hhhhoooommmmeeee....
ggggrrrreeeeaaaatttteeeerrrr aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee.... IIII bbbbeeeelllliiiieeeevvvveeee
tttthhhhaaaatttt nnnnoooo ccccoooommmmppppaaaannnnyyyy oooonnnn EEEEaaaarrrrtttthhhh iiiissss bbbbeeeetttttttteeeerrrr ppppoooossssiiiittttiiiioooonnnneeeedddd WWWWeeee hhhhaaaavvvveeee lllliiiisssstttteeeennnneeeedddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttt iiiinnnntttteeeennnntttt ttttoooo tttthhhheeee ccccoooonnnncccceeeerrrrnnnnssss
tttthhhhaaaannnn JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn ttttoooo ccccaaaappppttttuuuurrrreeee tttthhhhiiiissss vvvvooooiiiicccceeeedddd bbbbyyyy mmmmaaaannnnyyyy ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss oooovvvveeeerrrr tttthhhheeee pppprrrriiiicccciiiinnnngggg aaaannnndddd
ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd lllleeeeaaaadddd tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy.... ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ooooffff pppprrrroooodddduuuuccccttttssss aaaannnndddd oooouuuurrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee
(cid:44)(cid:57)(cid:3)(cid:373)(cid:3)(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)(cid:86)(cid:86)(cid:86)(cid:86)(cid:92)(cid:92)(cid:92)(cid:92)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:80)(cid:80)(cid:80)(cid:80)(cid:86)(cid:86)(cid:86)(cid:86)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:54)(cid:54)(cid:54)(cid:54)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72) ffffrrrraaaaggggrrrraaaannnncccceeee iiiinnnnggggrrrreeeeddddiiiieeeennnnttttssss aaaabbbboooovvvveeee 111100000000 ppppaaaarrrrttttssss ppppeeeerrrr mmmmiiiilllllllliiiioooonnnn
wwwwoooorrrrlllldddd.... WWWWeeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ttttaaaakkkkiiiinnnngggg tttthhhheeee lllleeeeaaaadddd,,,, ((((ppppppppmmmm)))) iiiinnnn oooouuuurrrr sssshhhhaaaammmmppppoooooooossss,,,, wwwwaaaasssshhhheeeessss aaaannnndddd lllloooottttiiiioooonnnnssss....
bbbbeeeeiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ppppaaaarrrrttttnnnneeeerrrrssss aaaannnndddd ddddooooiiiinnnngggg oooouuuurrrr ppppaaaarrrrtttt ttttoooo AAAAnnnndddd wwwweeee’’’’vvvveeee bbbbeeeeeeeennnn rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr tttthhhhiiiissss ggggrrrreeeeaaaatttteeeerrrr
nnnnooootttt oooonnnnllllyyyy ttttrrrreeeeaaaatttt ppppaaaattttiiiieeeennnnttttssss,,,, bbbbuuuutttt aaaallllssssoooo eeeennnnssssuuuurrrreeee tttthhhheeeeyyyy ccccaaaannnn ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy bbbbyyyy TTTThhhheeee EEEEnnnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll WWWWoooorrrrkkkkiiiinnnngggg
ggggeeeetttt aaaacccccccceeeessssssss iiiinnnn aaaannnn ooooppppeeeennnn aaaannnndddd aaaaffffffffoooorrrrddddaaaabbbblllleeee mmmmaaaannnnnnnneeeerrrr.... GGGGrrrroooouuuupppp.... OOOOuuuurrrr rrrreeeellllaaaauuuunnnncccchhhh aaaallllssssoooo iiiinnnncccclllluuuuddddeeeessss nnnneeeewwww ppppaaaacccckkkkaaaaggggiiiinnnngggg
aaaannnndddd iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll ssssoooocccciiiiaaaallll mmmmeeeeddddiiiiaaaa ccccoooommmmmmmmuuuunnnniiiiccccaaaattttiiiioooonnnnssss
AAAAssss aaaa rrrreeeessssuuuulllltttt ooooffff ddddiiiirrrreeeecccctttt iiiinnnntttteeeerrrraaaaccccttttiiiioooonnnn wwwwiiiitttthhhh ppppaaaattttiiiieeeennnnttttssss,,,, ttttaaaaiiiilllloooorrrreeeedddd ttttoooo tttthhhheeee nnnneeeeeeeeddddssss aaaannnndddd wwwwaaaannnnttttssss ooooffff mmmmiiiilllllllleeeennnnnnnniiiiaaaallll
tttthhhheeeeiiiirrrr ffffaaaammmmiiiilllliiiieeeessss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss (cid:80)(cid:80)(cid:80)(cid:80)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:86)(cid:86)(cid:86)(cid:86)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:71)(cid:71)(cid:71)(cid:71)(cid:86)(cid:86)(cid:86)(cid:86)(cid:17)(cid:17)(cid:17)(cid:17)(cid:50)(cid:50)(cid:50)(cid:50)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:74)(cid:74)(cid:74)(cid:74)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:69)(cid:69)(cid:69)(cid:69)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:45)(cid:45)(cid:45)(cid:45)(cid:50)(cid:50)(cid:50)(cid:50)(cid:43)(cid:43)(cid:43)(cid:43)(cid:49)(cid:49)(cid:49)(cid:49)(cid:54)(cid:54)(cid:54)(cid:54)(cid:50)(cid:50)(cid:50)(cid:50)(cid:49)(cid:49)(cid:49)(cid:49)(cid:366)(cid:366)(cid:366)(cid:366)(cid:86)(cid:86)(cid:86)(cid:86)(cid:37)(cid:37)(cid:37)(cid:37)(cid:68)(cid:68)(cid:68)(cid:68)(cid:69)(cid:69)(cid:69)(cid:69)(cid:92)(cid:92)(cid:92)(cid:92)
(cid:68)(cid:68)(cid:68)(cid:68)(cid:70)(cid:70)(cid:70)(cid:70)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:81)(cid:81)(cid:81)(cid:81)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:54)(cid:54)(cid:54)(cid:54)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:15)(cid:15)(cid:15)(cid:15)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:69)(cid:69)(cid:69)(cid:69)(cid:88)(cid:88)(cid:88)(cid:88)(cid:76)(cid:76)(cid:76)(cid:76)(cid:79)(cid:79)(cid:79)(cid:79)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:88)(cid:88)(cid:88)(cid:88)(cid:83)(cid:83)(cid:83)(cid:83)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72) rrrreeeellllaaaauuuunnnncccchhhh iiiissss ooooffffffff ttttoooo aaaa ssssoooolllliiiidddd ssssttttaaaarrrrtttt aaaannnndddd wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee
(cid:82)(cid:82)(cid:82)(cid:82)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:74)(cid:74)(cid:74)(cid:74)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:83)(cid:83)(cid:83)(cid:83)(cid:82)(cid:82)(cid:82)(cid:82)(cid:86)(cid:86)(cid:86)(cid:86)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:73)(cid:73)(cid:73)(cid:73)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:80)(cid:80)(cid:80)(cid:80)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:17)(cid:17)(cid:17)(cid:17)(cid:39)(cid:39)(cid:39)(cid:39)(cid:72)(cid:72)(cid:72)(cid:72)(cid:83)(cid:83)(cid:83)(cid:83)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:87)(cid:87)(cid:87)(cid:87)(cid:80)(cid:80)(cid:80)(cid:80)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73) ttttoooo llllaaaauuuunnnncccchhhh aaaaccccrrrroooossssssss gggglllloooobbbbaaaallll mmmmaaaarrrrkkkkeeeettttssss tttthhhhrrrroooouuuugggghhhhoooouuuutttt 2222000011119999....
(cid:43)(cid:43)(cid:43)(cid:43)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:43)(cid:43)(cid:43)(cid:43)(cid:88)(cid:88)(cid:88)(cid:88)(cid:80)(cid:80)(cid:80)(cid:80)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:54)(cid:54)(cid:54)(cid:54)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:89)(cid:89)(cid:89)(cid:89)(cid:76)(cid:76)(cid:76)(cid:76)(cid:70)(cid:70)(cid:70)(cid:70)(cid:72)(cid:72)(cid:72)(cid:72)(cid:86)(cid:86)(cid:86)(cid:86)(cid:15)(cid:15)(cid:15)(cid:15)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)(cid:89)(cid:89)(cid:89)(cid:89)(cid:82)(cid:82)(cid:82)(cid:82)(cid:79)(cid:79)(cid:79)(cid:79)(cid:88)(cid:88)(cid:88)(cid:88)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:76)(cid:76)(cid:76)(cid:76)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:87)(cid:87)(cid:87)(cid:87)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:82)(cid:78)(cid:78)(cid:78)(cid:78)
aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt mmmmeeeeaaaassssuuuurrrreeee ttttoooo hhhheeeellllpppp ccccoooonnnnssssuuuummmmeeeerrrrssss ggggaaaaiiiinnnn aaaa AAAAddddddddiiiittttiiiioooonnnnaaaallllllllyyyy,,,, iiiinnnn rrrreeeessssppppoooonnnnsssseeee ttttoooo oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss aaaasssskkkkiiiinnnngggg
bbbbeeeetttttttteeeerrrr ppppiiiiccccttttuuuurrrreeee ooooffff wwwwhhhhaaaatttt tttthhhheeeeyyyy sssshhhhoooouuuulllldddd eeeexxxxppppeeeecccctttt ttttoooo ppppaaaayyyy ffffoooorrrr ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt aaaaddddddddrrrreeeessssssss
ffffoooorrrr tttthhhheeeeiiiirrrr mmmmeeeeddddiiiicccciiiinnnneeeessss.... WWWWeeee hhhhaaaavvvveeee pppprrrrooooppppoooosssseeeedddd iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeeeiiiirrrr sssskkkkiiiinnnn’’’’ssss uuuunnnniiiiqqqquuuueeee nnnneeeeeeeeddddssss,,,, wwwweeee aaaarrrreeee ddddeeeevvvveeeellllooooppppiiiinnnngggg
lllliiiisssstttt----pppprrrriiiicccceeee iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnn iiiinnnn ddddiiiirrrreeeecccctttt----ttttoooo----ccccoooonnnnssssuuuummmmeeeerrrr TTTTVVVV oooouuuurrrr mmmmoooosssstttt ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuucccctttt ttttoooo
aaaaddddssss,,,, ssssttttaaaarrrrttttiiiinnnngggg wwwwiiiitttthhhh oooouuuurrrr mmmmoooosssstttt----pppprrrreeeessssccccrrrriiiibbbbeeeedddd mmmmeeeeddddiiiicccciiiinnnneeee,,,, (cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:15)(cid:15)(cid:15)(cid:15)(cid:70)(cid:70)(cid:70)(cid:70)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:49)(cid:49)(cid:49)(cid:49)(cid:40)(cid:40)(cid:40)(cid:40)(cid:56)(cid:56)(cid:56)(cid:56)(cid:55)(cid:55)(cid:55)(cid:55)(cid:53)(cid:53)(cid:53)(cid:53)(cid:50)(cid:50)(cid:50)(cid:50)(cid:42)(cid:42)(cid:42)(cid:42)(cid:40)(cid:40)(cid:40)(cid:40)(cid:49)(cid:49)(cid:49)(cid:49)(cid:36)(cid:36)(cid:36)(cid:36)(cid:48)(cid:48)(cid:48)(cid:48)(cid:68)(cid:68)(cid:68)(cid:68)(cid:86)(cid:86)(cid:86)(cid:86)(cid:78)(cid:78)(cid:78)(cid:78)(cid:76)(cid:76)(cid:76)(cid:76)(cid:39)(cid:39)(cid:39)(cid:39)(cid:17)(cid:17)(cid:17)(cid:17)(cid:55)(cid:55)(cid:55)(cid:55)(cid:75)(cid:75)(cid:75)(cid:75)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)
XXXXAAAARRRREEEELLLLTTTTOOOO ((((rrrriiiivvvvaaaarrrrooooxxxxaaaabbbbaaaannnn)))),,,, aaaannnn oooorrrraaaallll aaaannnnttttiiii----ccccooooaaaagggguuuullllaaaannnntttt.... 3333DDDD----pppprrrriiiinnnntttteeeedddd sssshhhheeeeeeeetttt mmmmaaaasssskkkk iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy uuuusssseeeerrrr ddddaaaattttaaaa
TTTToooo eeeennnnssssuuuurrrreeee ppppaaaattttiiiieeeennnnttttssss hhhhaaaavvvveeee ccccllllaaaarrrriiiittttyyyy,,,, wwwweeee ppppllllaaaannnn ttttoooo aaaannnndddd wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr tttthhhheeee cccclllliiiinnnniiiiccccaaaallll eeeeffiffiffifficcccaaaaccccyyyy eeeexxxxppppeeeecccctttteeeedddd
iiiinnnncccclllluuuuddddeeee bbbbooootttthhhh tttthhhheeee lllliiiisssstttt pppprrrriiiicccceeee aaaannnndddd ppppooootttteeeennnnttttiiiiaaaallll ppppaaaattttiiiieeeennnntttt ffffrrrroooommmm tttthhhheeee ####1111 ddddeeeerrrrmmmmaaaattttoooollllooooggggiiiisssstttt----rrrreeeeccccoooommmmmmmmeeeennnnddddeeeedddd
oooouuuutttt----ooooffff----ppppoooocccckkkkeeeetttt ccccoooossssttttssss.... WWWWeeee bbbbeeeelllliiiieeeevvvveeee ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy iiiissss (cid:69)(cid:69)(cid:69)(cid:69)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:56)(cid:56)(cid:56)(cid:56)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:17)(cid:17)(cid:17)(cid:17)(cid:50)(cid:50)(cid:50)(cid:50)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:49)(cid:49)(cid:49)(cid:49)(cid:40)(cid:40)(cid:40)(cid:40)(cid:56)(cid:56)(cid:56)(cid:56)(cid:55)(cid:55)(cid:55)(cid:55)(cid:53)(cid:53)(cid:53)(cid:53)(cid:50)(cid:50)(cid:50)(cid:50)(cid:42)(cid:42)(cid:42)(cid:42)(cid:40)(cid:40)(cid:40)(cid:40)(cid:49)(cid:49)(cid:49)(cid:49)(cid:36)(cid:36)(cid:36)(cid:36)(cid:69)(cid:69)(cid:69)(cid:69)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)
aaaa ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy ooooffff tttthhhhiiiissss CCCCoooommmmppppaaaannnnyyyy.... iiiissss aaaallllrrrreeeeaaaaddddyyyy gggglllloooobbbbaaaallllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg
IIIItttt’’’’ssss aaaallllssssoooo aaaannnnooootttthhhheeeerrrr ssssttttrrrroooonnnngggg ddddeeeemmmmoooonnnnssssttttrrrraaaattttiiiioooonnnn tttthhhhaaaatttt ttttooooppppiiiiccccaaaallll sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss aaaatttt tttthhhheeee iiiinnnntttteeeerrrrsssseeeeccccttttiiiioooonnnn
oooouuuurrrr ppppuuuurrrrppppoooosssseeee,,,, ffffooooccccuuuusssseeeedddd oooonnnn hhhheeeellllppppiiiinnnngggg ppppaaaattttiiiieeeennnnttttssss,,,, iiiissss ooooffff sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy.... TTTThhhhiiiissss nnnneeeewwww pppprrrroooodddduuuucccctttt
ddddrrrriiiivvvviiiinnnngggg oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss –––– jjjjuuuusssstttt aaaassss iiiitttt sssshhhhoooouuuulllldddd bbbbeeee.... wwwwiiiillllllll rrrreeeepppprrrreeeesssseeeennnntttt oooonnnneeee ffffuuuurrrrtttthhhheeeerrrr sssstttteeeepppp ttttoooowwwwaaaarrrrdddd aaaa nnnneeeewwww
mmmmooooddddeeeellll ooooffff pppprrrroooodddduuuucccctttt ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt wwwwhhhheeeerrrreeee wwwweeee fifififinnnndddd
OOOOuuuurrrr PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss hhhhaaaassss ttttaaaakkkkeeeennnn aaaa ssssttttrrrroooonnnngggg ccccrrrreeeeaaaattttiiiivvvveeee uuuusssseeeessss ffffoooorrrr tttthhhheeee llllaaaatttteeeesssstttt tttteeeecccchhhhnnnnoooollllooooggggyyyy,,,, ssssuuuucccchhhh aaaassss
lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp ssssttttaaaannnncccceeee oooonnnn iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ddddiiiiggggiiiittttaaaallll iiiimmmmaaaaggggiiiinnnngggg,,,, sssskkkkiiiinnnn aaaannnnaaaallllyyyyssssiiiissss aaaannnndddd 3333DDDD pppprrrriiiinnnnttttiiiinnnngggg,,,,
iiiinnnn tttthhhheeee iiiinnnndddduuuussssttttrrrryyyy.... IIII aaaammmm pppplllleeeeaaaasssseeeedddd ttttoooo sssshhhhaaaarrrreeee wwwweeee ttttoooo ggggiiiivvvveeee ccccoooonnnnssssuuuummmmeeeerrrrssss nnnneeeewwww wwwwaaaayyyyssss ttttoooo aaaacccchhhhiiiieeeevvvveeee tttthhhheeeeiiiirrrr
(cid:90)(cid:90)(cid:90)(cid:90)(cid:76)(cid:76)(cid:76)(cid:76)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:76)(cid:76)(cid:76)(cid:76)(cid:85)(cid:85)(cid:85)(cid:85)(cid:71)(cid:71)(cid:71)(cid:71)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:81)(cid:88)(cid:88)(cid:88)(cid:88)(cid:68)(cid:68)(cid:68)(cid:68)(cid:79)(cid:79)(cid:79)(cid:79)(cid:45)(cid:45)(cid:45)(cid:45)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:86)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:56)(cid:56)(cid:56)(cid:56)(cid:17)(cid:17)(cid:17)(cid:17)(cid:54)(cid:54)(cid:54)(cid:54)(cid:17)(cid:17)(cid:17)(cid:17) bbbbeeeesssstttt sssskkkkiiiinnnnccccaaaarrrreeee ppppoooossssssssiiiibbbblllleeee.... IIIItttt iiiissss aaaallllssssoooo aaaa ggggrrrreeeeaaaatttt eeeexxxxaaaammmmpppplllleeee
TTTTrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy RRRReeeeppppoooorrrrtttt iiiinnnn llllaaaatttteeee MMMMaaaarrrrcccchhhh.... TTTThhhhiiiissss rrrreeeeppppoooorrrrtttt,,,, ooooffff hhhhoooowwww wwwweeee aaaarrrreeee lllleeeevvvveeeerrrraaaaggggiiiinnnngggg iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaaccccrrrroooossssssss
rrrreeeeflflflfleeeeccccttttiiiivvvveeee ooooffff oooouuuurrrr aaaaccccttttiiiioooonnnnssss iiiinnnn 2222000011118888,,,, sssshhhhoooowwwwssss tttthhhhaaaatttt oooouuuurrrr oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss,,,, aaaassss oooouuuurrrr 3333DDDD pppprrrriiiinnnnttttiiiinnnngggg
nnnneeeetttt pppprrrriiiicccceeeessss hhhhaaaavvvveeee ddddeeeeccccrrrreeeeaaaasssseeeedddd aaaaggggaaaaiiiinnnn,,,, bbbbyyyy 6666....8888%%%%.... ccccaaaappppaaaabbbbiiiilllliiiittttyyyy oooorrrriiiiggggiiiinnnnaaaatttteeeedddd wwwwiiiitttthhhhiiiinnnn MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss....
CCCCoooonnnnssssuuuummmmeeeerrrr
MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss
IIIInnnn 2222000011118888,,,, ffffuuuueeeelllleeeedddd bbbbyyyy oooouuuurrrr iiiiccccoooonnnniiiicccc bbbbrrrraaaannnnddddssss aaaannnndddd ddddeeeeeeeepppp
OOOOuuuurrrr MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaarrrreeee aaaammmmoooonnnngggg tttthhhheeee
ccccoooonnnnssssuuuummmmeeeerrrr iiiinnnnssssiiiigggghhhhttttssss,,,, oooouuuurrrr CCCCoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss
mmmmoooosssstttt ddddiiiivvvveeeerrrrsssseeee aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll iiiinnnn tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee
aaaacccchhhhiiiieeeevvvveeeedddd aaaabbbboooovvvveeee----mmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh.... AAAAssss wwwweeee llllooooooookkkk
iiiinnnndddduuuussssttttrrrryyyy.... AAAAtttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee,,,, wwwweeee ffffuuuullllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee
aaaahhhheeeeaaaadddd,,,, wwwweeee wwwwiiiillllllll wwwwoooorrrrkkkk ttttoooo eeeennnnhhhhaaaannnncccceeee oooouuuurrrr lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp
tttthhhhaaaatttt oooouuuurrrr pppprrrrooooggggrrrreeeessssssss hhhhaaaassss nnnnooootttt bbbbeeeeeeeennnn uuuunnnniiiiffffoooorrrrmmmm aaaaccccrrrroooossssssss
iiiinnnn pppprrrriiiioooorrrriiiittttyyyy ccccaaaatttteeeeggggoooorrrriiiieeeessss bbbbyyyy ffffooooccccuuuussssiiiinnnngggg oooonnnn ccccrrrriiiittttiiiiccccaaaallll
tttthhhheeee MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss ppppoooorrrrttttffffoooolllliiiioooo.... WWWWeeee hhhhaaaavvvveeee mmmmaaaannnnyyyy
ggggeeeeooooggggrrrraaaapppphhhhiiiieeeessss aaaannnndddd oooouuuurrrr mmmmeeeeggggaaaa----bbbbrrrraaaannnnddddssss,,,, wwwwhhhhiiiilllleeee aaaallllssssoooo
aaaarrrreeeeaaaassss ooooffff ppppaaaarrrrttttiiiiccccuuuullllaaaarrrrllllyyyy ssssttttrrrroooonnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ssssuuuucccchhhh
ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo eeeexxxxppppaaaannnndddd iiiinnnnttttoooo tttthhhheeee ffffaaaasssstttt----ggggrrrroooowwwwiiiinnnngggg
aaaassss EEEElllleeeeccccttttrrrroooopppphhhhyyyyssssiiiioooollllooooggggyyyy,,,, VVVViiiissssiiiioooonnnn CCCCaaaarrrreeee,,,, WWWWoooouuuunnnndddd
nnnnaaaattttuuuurrrraaaallllssss ccccaaaatttteeeeggggoooorrrryyyy.... OOOOuuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff ZZZZaaaarrrrbbbbeeeeeeee’’’’ssss,,,, IIIInnnncccc....
(cid:38)(cid:38)(cid:38)(cid:38)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:86)(cid:86)(cid:86)(cid:86)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:15)(cid:15)(cid:15)(cid:15)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:71)(cid:71)(cid:71)(cid:71)(cid:37)(cid:37)(cid:37)(cid:37)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:16)(cid:16)(cid:16)(cid:16)(cid:54)(cid:54)(cid:54)(cid:54)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:74)(cid:74)(cid:74)(cid:74)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:92)(cid:92)(cid:92)(cid:92)(cid:17)(cid:17)(cid:17)(cid:17)(cid:43)(cid:43)(cid:43)(cid:43)(cid:82)(cid:82)(cid:82)(cid:82)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)(cid:89)(cid:89)(cid:89)(cid:89)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:15)(cid:15)(cid:15)(cid:15)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:68)(cid:68)(cid:68)(cid:68)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)
iiiinnnn OOOOTTTTCCCC iiiissss aaaa kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee ooooffff tttthhhhiiiissss eeeexxxxppppaaaannnnddddiiiinnnngggg ffffooooccccuuuussss....
aaaallllssssoooo aaaarrrreeeeaaaassss wwwwhhhheeeerrrreeee wwwweeee mmmmuuuusssstttt iiiimmmmpppprrrroooovvvveeee,,,, ssssppppeeeecccciiiifififificcccaaaallllllllyyyy
wwwwiiiitttthhhhiiiinnnn OOOOrrrrtttthhhhooooppppaaaaeeeeddddiiiiccccssss.... WWWWeeee ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd pppprrrrooooggggrrrreeeessssssss
WWWWeeee hhhhaaaavvvveeee tttthhhheeee ssssttttrrrraaaatttteeeeggggiiiieeeessss iiiinnnn ppppllllaaaacccceeee ttttoooo mmmmoooovvvveeee wwwwiiiitttthhhh tttthhhheeee
tttthhhhrrrroooouuuugggghhhhoooouuuutttt 2222000011118888 wwwwiiiitttthhhh tttthhhheeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ooooffff oooouuuurrrr
aaaaggggiiiilllliiiittttyyyy rrrreeeeqqqquuuuiiiirrrreeeedddd ttttoooo aaaaddddddddrrrreeeessssssss eeeevvvvoooollllvvvviiiinnnngggg mmmmaaaarrrrkkkkeeeetttt nnnneeeeeeeeddddssss....
kkkknnnneeeeeeee aaaannnndddd ssssppppiiiinnnneeee bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaannnndddd wwwweeee bbbbeeeelllliiiieeeevvvveeee
WWWWeeee hhhhaaaavvvveeee aaaaddddoooopppptttteeeedddd aaaa mmmmuuuullllttttiiiicccchhhhaaaannnnnnnneeeellll aaaapppppppprrrrooooaaaacccchhhh,,,,
tttthhhhiiiissss ppppoooossssiiiittttiiiioooonnnnssss uuuussss wwwweeeellllllll ffffoooorrrr 2222000011119999 aaaannnndddd bbbbeeeeyyyyoooonnnndddd....
ffffrrrroooommmm tttthhhheeee bbbbiiiigggg----bbbbooooxxxx rrrreeeettttaaaaiiiilllleeeerrrrssss ttttoooo eeee----ccccoooommmmmmmmeeeerrrrcccceeee
cccchhhhaaaannnnnnnneeeellllssss,,,, ttttoooo bbbbeeeetttttttteeeerrrr sssseeeerrrrvvvveeee oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss....
IIIInnnn 2222000011118888 wwwweeee iiiimmmmpppprrrroooovvvveeeedddd ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll ggggrrrroooowwwwtttthhhh
TTTThhhheeee rrrreeeessssuuuullllttttssss ooooffff oooouuuurrrr ccccoooonnnnttttiiiinnnnuuuuaaaallll ccccoooonnnnnnnneeeeccccttttiiiioooonnnn wwwwiiiitttthhhh eeeexxxxcccclllluuuuddddiiiinnnngggg aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ddddiiiivvvveeeessssttttiiiittttuuuurrrreeeessss bbbbyyyy
ccccoooonnnnssssuuuummmmeeeerrrrssss ccccaaaannnn bbbbeeee sssseeeeeeeennnn iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll rrrreeeellllaaaauuuunnnncccchhhh ooooffff 1111....1111%%%%****,,,, aaaassss ccccoooommmmppppaaaarrrreeeedddd ttttoooo 2222000011117777.... AAAAddddddddiiiittttiiiioooonnnnaaaallllllllyyyy,,,,
(cid:82)(cid:82)(cid:82)(cid:82)(cid:88)(cid:88)(cid:88)(cid:88)(cid:85)(cid:85)(cid:85)(cid:85)(cid:45)(cid:45)(cid:45)(cid:45)(cid:50)(cid:50)(cid:50)(cid:50)(cid:43)(cid:43)(cid:43)(cid:43)(cid:49)(cid:49)(cid:49)(cid:49)(cid:54)(cid:54)(cid:54)(cid:54)(cid:50)(cid:50)(cid:50)(cid:50)(cid:49)(cid:49)(cid:49)(cid:49)(cid:366)(cid:366)(cid:366)(cid:366)(cid:86)(cid:86)(cid:86)(cid:86)(cid:37)(cid:37)(cid:37)(cid:37)(cid:68)(cid:68)(cid:68)(cid:68)(cid:69)(cid:69)(cid:69)(cid:69)(cid:92)(cid:92)(cid:92)(cid:92)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:82)(cid:82)(cid:82)(cid:82)(cid:73)(cid:73)(cid:73)(cid:73)(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:71)(cid:71)(cid:71)(cid:71)(cid:88)(cid:88)(cid:88)(cid:88)(cid:70)(cid:70)(cid:70)(cid:70)(cid:87)(cid:87)(cid:87)(cid:87)(cid:86)(cid:86)(cid:86)(cid:86)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:21)(cid:21)(cid:21)(cid:21)(cid:19)(cid:19)(cid:19)(cid:19)(cid:20)(cid:20)(cid:20)(cid:20)(cid:27)(cid:27)(cid:27)(cid:27)(cid:17)(cid:17)(cid:17)(cid:17) wwwweeee iiiimmmmpppprrrroooovvvveeeedddd oooouuuurrrr ccccaaaaddddeeeennnncccceeee ooooffff iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn bbbbyyyy
WWWWeeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ddddiiiisssscccclllloooossssiiiinnnngggg 111100000000%%%% ooooffff oooouuuurrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg 22221111 mmmmaaaajjjjoooorrrr pppprrrroooodddduuuucccctttt llllaaaauuuunnnncccchhhheeeessss iiiinnnn 2222000011118888....
(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)(cid:3)(cid:373)(cid:3)(cid:57)OOOOnnnneeee eeeexxxxaaaammmmpppplllleeee iiiissss tttthhhheeee llllaaaauuuunnnncccchhhh ooooffff tttthhhheeee EEEEMMMMBBBBOOOOTTTTRRRRAAAAPPPP nnnnaaaammmmeeee jjjjuuuusssstttt aaaa ffffeeeewwww.... AAAAnnnndddd lllliiiittttiiiiggggaaaattttiiiioooonnnn,,,, uuuunnnnffffoooorrrrttttuuuunnnnaaaatttteeeellllyyyy,,,, iiiissss
IIIIIIII RRRReeeevvvvaaaassssccccuuuullllaaaarrrriiiizzzzaaaattttiiiioooonnnn DDDDeeeevvvviiiicccceeee,,,, aaaa nnnneeeexxxxtttt----ggggeeeennnneeeerrrraaaattttiiiioooonnnn pppprrrreeeevvvvaaaalllleeeennnntttt tttthhhhrrrroooouuuugggghhhhoooouuuutttt tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy....
sssstttteeeennnntttt rrrreeeettttrrrriiiieeeevvvveeeerrrr uuuusssseeeedddd ttttoooo ccccaaaappppttttuuuurrrreeee aaaannnndddd rrrreeeemmmmoooovvvveeee
TTTThhhheeeesssseeee kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll ffffaaaaccccttttoooorrrrssss ccccaaaannnn iiiimmmmppppaaaacccctttt aaaannnnyyyy
lllliiiiffffeeee----tttthhhhrrrreeeeaaaatttteeeennnniiiinnnngggg bbbblllloooooooodddd cccclllloooottttssss ffffrrrroooommmm tttthhhheeee bbbbrrrraaaaiiiinnnn
bbbbuuuussssiiiinnnneeeessssssss’’’’ bbbbrrrraaaannnndddd,,,, rrrreeeeppppuuuuttttaaaattttiiiioooonnnn,,,, aaaannnndddd bbbbuuuussssiiiinnnneeeessssssss mmmmooooddddeeeellll,,,,
ffffoooolllllllloooowwwwiiiinnnngggg aaaannnn iiiisssscccchhhheeeemmmmiiiicccc ssssttttrrrrooookkkkeeee.... WWWWeeee rrrreeeecccceeeeiiiivvvveeeedddd
ssssoooo iiiinnnn ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr BBBBooooaaaarrrrdddd ooooffff DDDDiiiirrrreeeeccccttttoooorrrrssss,,,,
FFFFDDDDAAAA cccclllleeeeaaaarrrraaaannnncccceeee ttttoooo mmmmaaaarrrrkkkkeeeetttt tttthhhheeee mmmmeeeecccchhhhaaaannnniiiiccccaaaallll ccccllllooootttt
eeeexxxxeeeeccccuuuuttttiiiivvvveeee ccccoooommmmmmmmiiiitttttttteeeeeeee,,,, aaaannnndddd lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttteeeeaaaammmmssss
rrrreeeemmmmoooovvvvaaaallll,,,, oooorrrr tttthhhhrrrroooommmmbbbbeeeeccccttttoooommmmyyyy ddddeeeevvvviiiicccceeee,,,, llllaaaasssstttt MMMMaaaayyyy....
aaaaccccrrrroooossssssss tttthhhheeee CCCCoooommmmppppaaaannnnyyyy,,,, wwwweeee llllooooooookkkk ttttoooo mmmmiiiittttiiiiggggaaaatttteeee tttthhhheeeesssseeee
IIIInnnn 2222000011119999,,,, wwwweeee ppppllllaaaannnn ttttoooo llllaaaauuuunnnncccchhhh 22220000 ttttoooo 22225555 mmmmaaaajjjjoooorrrr
kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll rrrriiiisssskkkk ffffaaaaccccttttoooorrrrssss wwwwhhhheeeerrrreeeevvvveeeerrrr ppppoooossssssssiiiibbbblllleeee....
(cid:83)(cid:83)(cid:83)(cid:83)(cid:85)(cid:85)(cid:85)(cid:85)(cid:82)(cid:82)(cid:82)(cid:82)(cid:71)(cid:71)(cid:71)(cid:71)(cid:88)(cid:88)(cid:88)(cid:88)(cid:70)(cid:70)(cid:70)(cid:70)(cid:87)(cid:87)(cid:87)(cid:87)(cid:86)(cid:86)(cid:86)(cid:86)(cid:15)(cid:15)(cid:15)(cid:15)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:70)(cid:70)(cid:70)(cid:70)(cid:79)(cid:79)(cid:79)(cid:79)(cid:88)(cid:88)(cid:88)(cid:88)(cid:71)(cid:71)(cid:71)(cid:71)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:74)(cid:74)(cid:74)(cid:74)(cid:36)(cid:36)(cid:36)(cid:36)(cid:38)(cid:38)(cid:38)(cid:38)(cid:56)(cid:56)(cid:56)(cid:56)(cid:57)(cid:57)(cid:57)(cid:57)(cid:56)(cid:56)(cid:56)(cid:56)(cid:40)(cid:40)(cid:40)(cid:40)(cid:50)(cid:50)(cid:50)(cid:50)(cid:36)(cid:36)(cid:36)(cid:36)(cid:54)(cid:54)(cid:54)(cid:54)(cid:60)(cid:60)(cid:60)(cid:60)(cid:54)(cid:54)(cid:54)(cid:54)(cid:90)(cid:90)(cid:90)(cid:90)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)
(cid:55)(cid:55)(cid:55)(cid:55)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:76)(cid:76)(cid:76)(cid:76)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:86)(cid:86)(cid:86)(cid:86)(cid:400)(cid:400)(cid:400)(cid:400)(cid:47)(cid:47)(cid:47)(cid:47)(cid:76)(cid:76)(cid:76)(cid:76)(cid:74)(cid:74)(cid:74)(cid:74)(cid:75)(cid:75)(cid:75)(cid:75)(cid:87)(cid:87)(cid:87)(cid:87)(cid:44)(cid:44)(cid:44)(cid:44)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:79)(cid:76)(cid:76)(cid:76)(cid:76)(cid:74)(cid:74)(cid:74)(cid:74)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:55)(cid:55)(cid:55)(cid:55)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:75)(cid:75)(cid:75)(cid:75)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:74)(cid:74)(cid:74)(cid:74)(cid:92)(cid:92)(cid:92)(cid:92)(cid:400)(cid:400)(cid:400)(cid:400)(cid:15)(cid:15)(cid:15)(cid:15) AAAAddddddddiiiittttiiiioooonnnnaaaallllllllyyyy,,,, IIII wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee tttthhhhaaaatttt pppprrrroooodddduuuucccctttt
aaaa fifififirrrrsssstttt----ooooffff----iiiittttssss----kkkkiiiinnnndddd ccccoooonnnnttttaaaacccctttt lllleeeennnnssss tttthhhhaaaatttt wwwwaaaassss nnnnaaaammmmeeeedddd qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeeettttyyyy aaaarrrreeee nnnnooootttt oooonnnnllllyyyy ttttoooopppp bbbbuuuussssiiiinnnneeeessssssss
oooonnnneeee ooooffff TTTTIIIIMMMMEEEE MMMMaaaaggggaaaazzzziiiinnnneeee’’’’ssss BBBBeeeesssstttt IIIInnnnvvvveeeennnnttttiiiioooonnnnssss ooooffff 2222000011118888.... pppprrrriiiioooorrrriiiittttiiiieeeessss ffffoooorrrr JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn,,,, tttthhhheeeeyyyy aaaarrrreeee
(cid:36)(cid:36)(cid:36)(cid:36)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:91)(cid:91)(cid:91)(cid:91)(cid:68)(cid:68)(cid:68)(cid:68)(cid:80)(cid:80)(cid:80)(cid:80)(cid:83)(cid:83)(cid:83)(cid:83)(cid:79)(cid:79)(cid:79)(cid:79)(cid:72)(cid:72)(cid:72)(cid:72)(cid:76)(cid:76)(cid:76)(cid:76)(cid:86)(cid:86)(cid:86)(cid:86)(cid:87)(cid:87)(cid:87)(cid:87)(cid:75)(cid:75)(cid:75)(cid:75)(cid:72)(cid:72)(cid:72)(cid:72)(cid:40)(cid:40)(cid:40)(cid:40)(cid:38)(cid:38)(cid:38)(cid:38)(cid:43)(cid:43)(cid:43)(cid:43)(cid:40)(cid:40)(cid:40)(cid:40)(cid:47)(cid:47)(cid:47)(cid:47)(cid:50)(cid:50)(cid:50)(cid:50)(cid:49)(cid:49)(cid:49)(cid:49)(cid:38)(cid:38)(cid:38)(cid:38)(cid:44)(cid:44)(cid:44)(cid:44)(cid:53)(cid:53)(cid:53)(cid:53)(cid:38)(cid:38)(cid:38)(cid:38)(cid:56)(cid:56)(cid:56)(cid:56)(cid:47)(cid:47)(cid:47)(cid:47)(cid:36)(cid:36)(cid:36)(cid:36)(cid:53)(cid:53)(cid:53)(cid:53) aaaallllssssoooo ccccoooorrrreeee oooobbbblllliiiiggggaaaattttiiiioooonnnnssss eeeemmmmbbbbooooddddiiiieeeedddd iiiinnnn OOOOuuuurrrr CCCCrrrreeeeddddoooo....
(cid:51)(cid:51)(cid:51)(cid:51)(cid:82)(cid:82)(cid:82)(cid:82)(cid:90)(cid:90)(cid:90)(cid:90)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:71)(cid:71)(cid:71)(cid:71)(cid:54)(cid:54)(cid:54)(cid:54)(cid:87)(cid:87)(cid:87)(cid:87)(cid:68)(cid:68)(cid:68)(cid:68)(cid:83)(cid:83)(cid:83)(cid:83)(cid:79)(cid:79)(cid:79)(cid:79)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:15)(cid:15)(cid:15)(cid:15)(cid:68)(cid:68)(cid:68)(cid:68)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:91)(cid:91)(cid:91)(cid:91)(cid:87)(cid:87)(cid:87)(cid:87)(cid:74)(cid:74)(cid:74)(cid:74)(cid:72)(cid:72)(cid:72)(cid:72)(cid:81)(cid:81)(cid:81)(cid:81)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:68)(cid:68)(cid:68)(cid:68)(cid:87)(cid:87)(cid:87)(cid:87)(cid:76)(cid:76)(cid:76)(cid:76)(cid:82)(cid:82)(cid:82)(cid:82)(cid:81)(cid:81)(cid:81)(cid:81)(cid:87)(cid:87)(cid:87)(cid:87)(cid:72)(cid:72)(cid:72)(cid:72)(cid:70)(cid:70)(cid:70)(cid:70)(cid:75)(cid:75)(cid:75)(cid:75)(cid:81)(cid:81)(cid:81)(cid:81)(cid:82)(cid:82)(cid:82)(cid:82)(cid:79)(cid:79)(cid:79)(cid:79)(cid:82)(cid:82)(cid:82)(cid:82)(cid:74)(cid:74)(cid:74)(cid:74)(cid:92)(cid:92)(cid:92)(cid:92) AAAAccccrrrroooossssssss eeeevvvveeeerrrryyyy JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn bbbbuuuussssiiiinnnneeeessssssss,,,, wwwweeee
ttttoooo rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss iiiinnnn ccccoooolllloooorrrreeeeccccttttaaaallll,,,, ggggaaaassssttttrrrriiiicccc aaaappppppppllllyyyy aaaa sssscccciiiieeeennnnttttiiiifififificccc,,,, eeeevvvviiiiddddeeeennnncccceeee----bbbbaaaasssseeeedddd aaaapppppppprrrrooooaaaacccchhhh iiiinnnn
aaaannnndddd tttthhhhoooorrrraaaacccciiiicccc ccccaaaannnncccceeeerrrr ssssuuuurrrrggggeeeerrrriiiieeeessss.... CCCClllleeeeaaaarrrrllllyyyy,,,, ddddeeeecccciiiissssiiiioooonnnnssss aaaabbbboooouuuutttt tttthhhheeee rrrreeeesssseeeeaaaarrrrcccchhhh,,,, mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd
aaaaddddvvvvaaaannnncccciiiinnnngggg oooouuuurrrr ssssttttrrrraaaatttteeeeggggyyyy iiiinnnn ddddiiiiggggiiiittttaaaallll ssssuuuurrrrggggeeeerrrryyyy iiiissss aaaa uuuusssseeee ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss.... MMMMaaaannnnyyyy ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss aaaannnndddd
mmmmaaaajjjjoooorrrr iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ffffoooorrrr oooouuuurrrr ffffuuuuttttuuuurrrreeee.... OOOOuuuurrrr ddddiiiiggggiiiittttaaaallll pppprrrroooodddduuuuccccttttssss hhhhaaaavvvveeee bbbbeeeeeeeennnn ttttrrrruuuusssstttteeeedddd bbbbyyyy ccccoooonnnnssssuuuummmmeeeerrrrssss ffffoooorrrr
ssssuuuurrrrggggeeeerrrryyyy ppppllllaaaattttffffoooorrrrmmmm iiiissss bbbbeeeeiiiinnnngggg ddddeeeessssiiiiggggnnnneeeedddd ttttoooo ccccoooommmmbbbbiiiinnnneeee ddddeeeeccccaaaaddddeeeessss,,,, aaaannnndddd wwwwhhhheeeennnn tttthhhheeee ssssaaaaffffeeeettttyyyy ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss
rrrroooobbbboooottttiiiiccccssss,,,, aaaaddddvvvvaaaannnncccceeeedddd iiiinnnnssssttttrrrruuuummmmeeeennnnttttaaaattttiiiioooonnnn aaaannnndddd ddddaaaattttaaaa iiiissss cccchhhhaaaalllllllleeeennnnggggeeeedddd,,,, wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddeeeeffffeeeennnndddd tttthhhheeeemmmm....
aaaannnnaaaallllyyyyttttiiiiccccssss ttttoooo eeeennnnaaaabbbblllleeee bbbbeeeetttttttteeeerrrr ppppaaaattttiiiieeeennnntttt oooouuuuttttccccoooommmmeeeessss bbbbyyyy WWWWeeee hhhhaaaavvvveeee aaaa lllleeeeggggaaaaccccyyyy ooooffff wwwwoooorrrrkkkkiiiinnnngggg hhhhaaaarrrrdddd ttttoooo eeeeaaaarrrrnnnn oooouuuurrrr
iiiimmmmpppprrrroooovvvviiiinnnngggg aaaacccccccceeeessssssss ttttoooo mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy ccccuuuussssttttoooommmmeeeerrrrssss’’’’ ttttrrrruuuusssstttt aaaannnndddd wwwwoooorrrrkkkkiiiinnnngggg eeeeqqqquuuuaaaallllllllyyyy hhhhaaaarrrrdddd ttttoooo kkkkeeeeeeeepppp
aaaannnndddd hhhheeeellllppppiiiinnnngggg ttttoooo rrrreeeedddduuuucccceeee tttthhhheeee ccccoooosssstttt ooooffff ccccaaaarrrreeee.... iiiitttt————tttthhhhiiiissss ccccoooommmmmmmmiiiittttmmmmeeeennnntttt wwwwiiiillllllll aaaallllwwwwaaaayyyyssss rrrreeeemmmmaaaaiiiinnnn iiiinnnnttttaaaacccctttt....
AAAAssss wwwweeee ccccaaaappppiiiittttaaaalllliiiizzzzeeee oooonnnn oooouuuurrrr ccccoooommmmpppprrrreeeehhhheeeennnnssssiiiivvvveeee WWWWeeee aaaarrrreeee ccccoooonnnnfifififiddddeeeennnntttt iiiinnnn oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh
ppppoooorrrrttttffffoooolllliiiioooo aaaannnndddd aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ggggrrrroooowwwwtttthhhh ssssttttrrrraaaatttteeeeggggyyyy,,,, cccceeeerrrrttttaaaaiiiinnnnttttyyyy aaaannnndddd ttttoooo rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy nnnnaaaavvvviiiiggggaaaatttteeee oooouuuurrrr wwwwaaaayyyy
wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo iiiimmmmpppprrrroooovvvviiiinnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee tttthhhhrrrroooouuuugggghhhh tttthhhheeeesssseeee ppppooootttteeeennnnttttiiiiaaaallll cccchhhhaaaalllllllleeeennnnggggeeeessss.... AAAAnnnndddd bbbbeeeeccccaaaauuuusssseeee
aaaaccccrrrroooossssssss oooouuuurrrr MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss.... wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo tttthhhhrrrriiiivvvviiiinnnngggg iiiinnnn tttthhhhiiiissss cccchhhhaaaannnnggggeeee
eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnntttt,,,, oooouuuurrrr ggggooooaaaallll iiiissss nnnnooootttt mmmmeeeerrrreeeellllyyyy ttttoooo aaaaddddaaaapppptttt
WWWWhhhhiiiilllleeee wwwweeee aaaarrrreeee pppplllleeeeaaaasssseeeedddd wwwwiiiitttthhhh oooouuuurrrr 2222000011118888 ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee,,,,
ttttoooo cccchhhhaaaannnnggggeeee,,,, bbbbuuuutttt ttttoooo bbbbeeee tttthhhheeee ccccaaaattttaaaallllyyyysssstttt ffffoooorrrr nnnneeeeeeeeddddeeeedddd
wwwweeee aaaarrrreeee nnnneeeevvvveeeerrrr ssssaaaattttiiiissssfifififieeeedddd.... LLLLooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd,,,, wwwweeee aaaarrrreeee
cccchhhhaaaannnnggggeeee.... WWWWeeee aaaallllssssoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy bbbbeeeeccccaaaauuuusssseeee
ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ppppiiiippppeeeelllliiiinnnneeee
wwwweeee aaaarrrreeee iiiinnnn tttthhhheeee bbbbuuuussssiiiinnnneeeessssssss ooooffff ccccaaaarrrriiiinnnngggg ffffoooorrrr tttthhhheeee wwwwoooorrrrlllldddd aaaallllllll
iiiinnnn oooouuuurrrr PPPPhhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss,,,, bbbbrrrrooooaaaaddddeeeennnniiiinnnngggg tttthhhheeee
ddddaaaayyyy,,,, eeeevvvveeeerrrryyyy ddddaaaayyyy.... GGGGuuuuiiiiddddeeeedddd bbbbyyyy OOOOuuuurrrr CCCCrrrreeeeddddoooo,,,, wwwweeee hhhhaaaavvvveeee
rrrreeeeaaaacccchhhh ooooffff oooouuuurrrr CCCCoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd mmmmeeeeeeeettttiiiinnnngggg tttthhhheeee
aaaa ssssoooolllliiiidddd fifififinnnnaaaannnncccciiiiaaaallll ffffoooouuuunnnnddddaaaattttiiiioooonnnn,,,, aaaa ssssttttrrrroooonnnngggg ssssttttrrrraaaatttteeeeggggiiiicccc
ffffuuuullllllll ppppooootttteeeennnnttttiiiiaaaallll ooooffff oooouuuurrrr MMMMeeeeddddiiiiccccaaaallll DDDDeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss....
ffffrrrraaaammmmeeeewwwwoooorrrrkkkk,,,, aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn mmmmiiiinnnnddddsssseeeetttt,,,, aaaa ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee
ddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee aaaannnndddd aaaa vvvveeeerrrryyyy bbbbrrrriiiigggghhhhtttt ffffuuuuttttuuuurrrreeee ffffooooccccuuuusssseeeedddd
oooonnnn aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee hhhheeeeaaaalllltttthhhh aaaannnndddd wwwweeeellllllll----bbbbeeeeiiiinnnngggg ooooffff aaaallllllll oooouuuurrrr
I want to emphasize that product quality
ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss————ttttooooddddaaaayyyy aaaannnndddd ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss ttttoooo ccccoooommmmeeee....
and safety are not only top business priorities
OOOOuuuurrrr PPPPeeeeoooopppplllleeee,,,, PPPPaaaassssssssiiiioooonnnn aaaannnndddd PPPPuuuurrrrppppoooosssseeee
for Johnson & Johnson, they are also core
IIII’’’’vvvveeee oooofffftttteeeennnn nnnnooootttteeeedddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss aaaannnn iiiinnnndddduuuussssttttrrrryyyy tttthhhhaaaatttt
obligations embodied in Our Credo.
aaaattttttttrrrraaaaccccttttssss vvvveeeerrrryyyy ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee.... WWWWhhhhiiiilllleeee tttthhhheeeeyyyy wwwwaaaannnntttt
tttthhhheeee ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo bbbbuuuuiiiilllldddd aaaa mmmmeeeeaaaannnniiiinnnnggggffffuuuullll ccccaaaarrrreeeeeeeerrrr,,,,
LLLLeeeeaaaaddddiiiinnnngggg WWWWiiiitttthhhh CCCCeeeerrrrttttaaaaiiiinnnnttttyyyy
tttthhhheeeeyyyy aaaallllssssoooo wwwwaaaannnntttt ttttoooo bbbbeeee aaaa ppppaaaarrrrtttt ooooffff ssssoooommmmeeeetttthhhhiiiinnnngggg ttttrrrruuuullllyyyy
TTTThhhheeee vvvvoooolllluuuummmmeeee aaaannnndddd ssssppppeeeeeeeedddd ooooffff cccchhhhaaaannnnggggeeee aaaarrrroooouuuunnnndddd tttthhhheeee
ssssiiiiggggnnnniiiifififificcccaaaannnntttt tttthhhhaaaatttt mmmmaaaakkkkeeeessss aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt ddddiiiiffffffffeeeerrrreeeennnncccceeee iiiinnnn
wwwwoooorrrrlllldddd aaaannnndddd aaaaccccrrrroooossssssss aaaallllllll bbbbuuuussssiiiinnnneeeessssssss iiiinnnndddduuuussssttttrrrriiiieeeessss iiiissss
ppppeeeeoooopppplllleeee’’’’ssss lllliiiivvvveeeessss.... FFFFoooorrrrttttuuuunnnnaaaatttteeeellllyyyy,,,, wwwweeee hhhhaaaavvvveeee tttthhhheeee vvvveeeerrrryyyy bbbbeeeesssstttt
tttthhhheeee nnnneeeewwww nnnnoooorrrrmmmmaaaallll.... TTTThhhheeee vvvveeeelllloooocccciiiittttyyyy ooooffff tttthhhhiiiissss cccchhhhaaaannnnggggeeee
ooooffff tttthhhheeeesssseeee ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee aaaatttt tttthhhheeee JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn
iiiissss aaaappppppppaaaarrrreeeennnntttt wwwwiiiitttthhhh cccciiiirrrrccccuuuummmmssssttttaaaannnncccceeeessss lllliiiikkkkeeee tttthhhheeee
FFFFaaaammmmiiiillllyyyy ooooffff CCCCoooommmmppppaaaannnniiiieeeessss.... AAAAnnnndddd IIII bbbbeeeelllliiiieeeevvvveeee oooouuuurrrr ccccuuuullllttttuuuurrrreeee
eeeevvvvoooollllvvvviiiinnnngggg ggggeeeeooooppppoooolllliiiittttiiiiccccaaaallll llllaaaannnnddddssssccccaaaappppeeee,,,, oooonnnnggggooooiiiinnnngggg
ooooffff ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn bbbbrrrriiiinnnnggggssss oooouuuutttt tttthhhheeee bbbbeeeesssstttt tttthhhhaaaatttt
mmmmaaaarrrrkkkkeeeetttt vvvvoooollllaaaattttiiiilllliiiittttyyyy,,,, rrrriiiissssiiiinnnngggg pppprrrreeeessssssssuuuurrrreeee ttttoooo rrrreeeedddduuuucccceeee
oooouuuurrrr JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss hhhhaaaavvvveeee ttttoooo ooooffffffffeeeerrrr....
pppprrrriiiicccciiiinnnngggg,,,, rrrraaaappppiiiidddd eeeennnnttttrrrryyyy ooooffff ddddiiiissssrrrruuuuppppttttiiiivvvveeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss,,,,
aaaa ccccrrrroooowwwwddddeeeedddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee mmmmaaaarrrrkkkkeeeettttppppllllaaaacccceeee,,,, aaaannnndddd aaaannnn TTTTooooddddaaaayyyy,,,, wwwweeee hhhhaaaavvvveeee aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy 111133335555,,,,000000000000 gggglllloooobbbbaaaallll
eeeexxxxppppaaaannnnddddiiiinnnngggg rrrraaaannnnggggeeee ooooffff ccccuuuussssttttoooommmmeeeerrrr pppprrrreeeeffffeeeerrrreeeennnncccceeeessss,,,, ttttoooo eeeemmmmppppllllooooyyyyeeeeeeeessss,,,, uuuunnnniiiitttteeeedddd bbbbyyyy aaaa sssshhhhaaaarrrreeeedddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt
(cid:57)(cid:44)(cid:3)(cid:373)(cid:3)(cid:38)(cid:43)(cid:36)(cid:44)(cid:53)(cid:48)(cid:36)(cid:49)(cid:366)(cid:54)(cid:3)(cid:47)(cid:40)(cid:55)(cid:55)(cid:40)(cid:53)aaaannnndddd aaaa ccccoooommmmmmmmoooonnnn ppppuuuurrrrppppoooosssseeee tttthhhhaaaatttt aaaassssppppiiiirrrreeeessss ttttoooo ccccrrrreeeeaaaatttteeee gggguuuuiiiiddddiiiinnnngggg ssssuuuuppppppppoooorrrrtttt ooooffff oooouuuurrrr hhhhiiiigggghhhhllllyyyy aaaaccccccccoooommmmpppplllliiiisssshhhheeeedddd
aaaa wwwwoooorrrrlllldddd wwwwiiiitttthhhhoooouuuutttt ddddiiiisssseeeeaaaasssseeee aaaannnndddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttteeeerrrr BBBBooooaaaarrrrdddd ooooffff DDDDiiiirrrreeeeccccttttoooorrrrssss aaaannnndddd ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo bbbbeeee pppprrrroooouuuudddd aaaannnndddd
aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee————lllliiiiffffeeee----ssssaaaavvvviiiinnnngggg hhhhuuuummmmbbbblllleeeedddd aaaassss IIII wwwwoooorrrrkkkk ssssiiiiddddeeee bbbbyyyy ssssiiiiddddeeee wwwwiiiitttthhhh tttthhhhiiiissss tttteeeeaaaammmm ooooffff
mmmmeeeeddddiiiicccciiiinnnneeeessss,,,, lllliiiiffffeeee----cccchhhhaaaannnnggggiiiinnnngggg mmmmeeeeddddiiiiccccaaaallll ssssoooolllluuuuttttiiiioooonnnnssss aaaannnndddd iiiimmmmpppprrrreeeessssssssiiiivvvveeee eeeexxxxeeeeccccuuuuttttiiiivvvveeee lllleeeeaaaaddddeeeerrrrssss,,,, wwwwhhhhoooosssseeee ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp
lllliiiiffffeeee----eeeennnnhhhhaaaannnncccciiiinnnngggg ccccoooonnnnssssuuuummmmeeeerrrr pppprrrroooodddduuuuccccttttssss.... AAAAllllllll ooooffff uuuussss aaaannnndddd eeeexxxxppppeeeerrrrttttiiiisssseeee mmmmoooottttiiiivvvvaaaatttteeee mmmmeeee aaaannnndddd aaaallllllll oooouuuurrrr JJJJoooohhhhnnnnssssoooonnnn
mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ppppeeeerrrrssssiiiisssstttteeeennnntttt ffffooooccccuuuussss oooonnnn ddddeeeevvvveeeellllooooppppiiiinnnngggg aaaannnndddd &&&& JJJJoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss eeeevvvveeeerrrryyyy ddddaaaayyyy iiiinnnn oooouuuurrrr sssshhhhaaaarrrreeeedddd
ddddeeeelllliiiivvvveeeerrrriiiinnnngggg qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeee pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss.... ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo aaaaddddvvvvaaaannnncccceeee hhhheeeeaaaalllltttthhhh ffffoooorrrr hhhhuuuummmmaaaannnniiiittttyyyy....
DDDDeeeelllliiiivvvveeeerrrriiiinnnngggg oooonnnn tttthhhheeee pppprrrroooommmmiiiisssseeeessss ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss iiiissss bbbbooootttthhhh
aaaa ppppeeeerrrrssssoooonnnnaaaallll aaaannnndddd pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt....
We have approximately 135,000 global
TTTThhhhiiiissss iiiissss ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd iiiinnnn tttthhhheeee ttttiiiirrrreeeelllleeeessssssss eeeeffffffffoooorrrrttttssss
employees, united by a shared commitment
aaaannnndddd rrrreeeelllleeeennnnttttlllleeeessssssss ppppaaaassssssssiiiioooonnnn tttthhhhaaaatttt ddddrrrriiiivvvveeee oooouuuurrrr aaaammmmbbbbiiiittttiiiioooonnnn
and a common purpose that aspires to
ttttoooo rrrreeeeaaaacccchhhh tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ccccaaaannnncccceeeerrrr ccccaaaarrrreeee,,,,
ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ccccoooommmmbbbbaaaatttt EEEEbbbboooollllaaaa aaaannnndddd HHHHIIIIVVVV,,,, bbbbrrrriiiinnnngggg hhhheeeeaaaalllltttthhhhyyyy create a world without disease and with
vvvviiiissssiiiioooonnnn ttttoooo ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee,,,, ccccrrrreeeeaaaatttteeee aaaa wwwwoooorrrrlllldddd greater access to quality healthcare.
ffffrrrreeeeeeee ffffrrrroooommmm ttttuuuubbbbeeeerrrrccccuuuulllloooossssiiiissss,,,, rrrreeeedddduuuucccceeee oooouuuurrrr ccccaaaarrrrbbbboooonnnn
ffffoooooooottttpppprrrriiiinnnntttt,,,, iiiimmmmpppprrrroooovvvveeee oooouuuurrrr pppprrrroooodddduuuucccctttt ssssuuuussssttttaaaaiiiinnnnaaaabbbbiiiilllliiiittttyyyy MMMMyyyy ooooppppttttiiiimmmmiiiissssmmmm ffffoooorrrr tttthhhheeee ffffuuuuttttuuuurrrreeee iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy tttthhhheeee
aaaannnndddd rrrreeeeiiiimmmmaaaaggggiiiinnnneeee tttthhhheeee wwwwaaaayyyy tttthhhhaaaatttt ccccaaaarrrreeee iiiissss ddddeeeelllliiiivvvveeeerrrreeeedddd,,,, rrrraaaappppiiiidddd aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuoooouuuussss iiiimmmmpppprrrroooovvvveeeemmmmeeeennnnttttssss iiiinnnn tttthhhheeee
wwwwhhhhiiiilllleeee aaaallllssssoooo eeeexxxxppppaaaannnnddddiiiinnnngggg aaaacccccccceeeessssssss ffffoooorrrr tttthhhheeee wwwwoooorrrrlllldddd’’’’ssss mmmmoooosssstttt ccccoooonnnnddddiiiittttiiiioooonnnn ooooffff hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaannnndddd tttthhhheeee iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg
vvvvuuuullllnnnneeeerrrraaaabbbblllleeee ppppooooppppuuuullllaaaattttiiiioooonnnnssss.... JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnn tttthhhheeee wwwwoooorrrrlllldddd.... MMMMoooosssstttt
mmmmaaaaddddeeee FFFFoooorrrrttttuuuunnnneeee’’’’ssss ““““CCCChhhhaaaannnnggggeeee tttthhhheeee WWWWoooorrrrlllldddd LLLLiiiisssstttt”””” aaaaggggaaaaiiiinnnn iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy,,,, wwwweeee hhhhaaaavvvveeee tttthhhheeee aaaammmmaaaazzzziiiinnnngggg pppprrrriiiivvvviiiilllleeeeggggeeee
iiiinnnn 2222000011118888,,,, iiiinnnn rrrreeeeccccooooggggnnnniiiittttiiiioooonnnn ooooffff oooouuuurrrr eeeeffffffffoooorrrrttttssss ttttoooo hhhheeeellllpppp ttttrrrraaaaiiiinnnn ooooffff ttttoooouuuucccchhhhiiiinnnngggg lllliiiivvvveeeessss aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy
ssssuuuurrrrggggeeeeoooonnnnssss,,,, ppppaaaarrrraaaammmmeeeeddddiiiiccccssss aaaannnndddd ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ddddaaaayyyy————ffffrrrroooommmm bbbbaaaabbbbiiiieeeessss ttttaaaakkkkiiiinnnngggg tttthhhheeeeiiiirrrr fifififirrrrsssstttt bbbbrrrreeeeaaaatttthhhh ttttoooo
pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy tttthhhhrrrroooouuuugggghhhh oooouuuurrrr JJJJoooohhhhnnnnssssoooonnnn &&&& bbbbaaaabbbbyyyy bbbboooooooommmmeeeerrrrssss ttttaaaakkkkiiiinnnngggg aaaa bbbbrrrreeeeaaaatttthhhh aaaafffftttteeeerrrr ddddooooiiiinnnngggg tttthhhheeee
JJJJoooohhhhnnnnssssoooonnnn IIIInnnnssssttttiiiittttuuuutttteeee aaaannnndddd ooootttthhhheeeerrrr ccccaaaarrrreeee pppprrrrooooggggrrrraaaammmmssss.... JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn OOOOffiffiffifficccciiiiaaaallll 7777 MMMMiiiinnnnuuuutttteeee WWWWoooorrrrkkkkoooouuuutttt....
OOOOuuuurrrr ggggooooaaaallll iiiissss ttttoooo lllleeeeaaaadddd bbbbyyyy eeeexxxxaaaammmmpppplllleeee,,,, bbbbyyyy ccccuuuullllttttiiiivvvvaaaattttiiiinnnngggg WWWWeeee aaaallllssssoooo hhhhaaaavvvveeee tttthhhheeee pppplllleeeeaaaassssuuuurrrreeee ooooffff sssseeeerrrrvvvviiiinnnngggg ppppaaaattttiiiieeeennnnttttssss
tttthhhheeee wwwwoooorrrrlllldddd’’’’ssss hhhheeeeaaaalllltttthhhhiiiieeeesssstttt,,,, mmmmoooosssstttt pppprrrroooodddduuuuccccttttiiiivvvveeee aaaannnndddd mmmmoooosssstttt aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee oooonnnn EEEEaaaarrrrtttthhhh————ppppeeeeoooopppplllleeee
eeeennnnggggaaaaggggeeeedddd wwwwoooorrrrkkkkffffoooorrrrcccceeee.... IIII bbbbeeeelllliiiieeeevvvveeee tttthhhhiiiissss iiiissss ccccrrrriiiittttiiiiccccaaaallll ffffoooorrrr wwwwhhhhoooo ppppuuuutttt tttthhhheeeeiiiirrrr ttttrrrruuuusssstttt iiiinnnn oooouuuurrrr JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn
ooooppppeeeerrrraaaattttiiiinnnngggg aaaa hhhheeeeaaaalllltttthhhhyyyy aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll bbbbuuuussssiiiinnnneeeessssssss.... AAAAnnnndddd bbbbrrrraaaannnnddddssss.... WWWWeeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy tttthhhhaaaatttt
tttthhhhiiiissss iiiissss hhhhoooowwww wwwweeee wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr aaaannnndddd eeeennnnssssuuuurrrreeee tttthhhhaaaatttt aaaannnnooootttthhhheeeerrrr ccccoooommmmeeeessss wwwwiiiitttthhhh tttthhhhiiiissss ttttrrrruuuusssstttt.... AAAAnnnndddd wwwweeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt oooouuuurrrr
111133333333 yyyyeeeeaaaarrrrssss ooooffff qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss wwwwiiiitttthhhhiiiinnnn rrrreeeeaaaacccchhhh ooooffff eeeesssssssseeeennnnttttiiiiaaaallll ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss
eeeevvvveeeerrrryyyyoooonnnneeee,,,, eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee.... wwwwhhhhoooo ssssuuuuppppppppoooorrrrtttt oooouuuurrrr mmmmiiiissssssssiiiioooonnnn aaaannnndddd hhhheeeellllpppp uuuussss ppppuuuurrrrssssuuuueeee
aaaa nnnnoooobbbblllleeee ppppuuuurrrrppppoooosssseeee.... WWWWhhhhiiiilllleeee tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaarrrreeee
AAAAnnnn EEEEdddduuuuccccaaaattttiiiioooonnnn iiiinnnnHHHHuuuummmmaaaannnn HHHHeeeeaaaalllltttthhhh
ggggrrrreeeeaaaatttt,,,, tttthhhheeee rrrreeeewwwwaaaarrrrddddssss aaaarrrreeee eeeevvvveeeennnn ggggrrrreeeeaaaatttteeeerrrr.... IIII ccccaaaannnn’’’’tttt
IIII aaaammmm aaaassss eeeexxxxcccciiiitttteeeedddd aaaannnndddd eeeennnnccccoooouuuurrrraaaaggggeeeedddd ttttooooddddaaaayyyy,,,, aaaassss IIII wwwwaaaassss
iiiimmmmaaaaggggiiiinnnneeee aaaa bbbbeeeetttttttteeeerrrr oooorrrr mmmmoooorrrreeee ffffuuuullllfifififilllllllliiiinnnngggg ccccaaaalllllllliiiinnnngggg!!!!
oooonnnn tttthhhheeee ddddaaaayyyy IIII ssssttttaaaarrrrtttteeeedddd aaaassss CCCCEEEEOOOO ooooffff tttthhhhiiiissss CCCCoooommmmppppaaaannnnyyyy aaaannnndddd
aaaacccccccceeeepppptttteeeedddd tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt ccccoooommmmeeee wwwwiiiitttthhhh iiiitttt.... IIII ooooffffffffeeeerrrr mmmmyyyy ssssiiiinnnncccceeeerrrreeee tttthhhhaaaannnnkkkkssss ttttoooo aaaallllllll ooooffff yyyyoooouuuu ffffoooorrrr tttthhhhiiiissss
ggggrrrreeeeaaaatttt pppprrrriiiivvvviiiilllleeeeggggeeee,,,, ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd eeeexxxxppppeeeerrrriiiieeeennnncccceeee....
TTTThhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy ccccaaaarrrreeeeeeeerrrr aaaatttt JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn,,,, IIII
hhhhaaaavvvveeee bbbbeeeeeeeennnn vvvveeeerrrryyyy ffffoooorrrrttttuuuunnnnaaaatttteeee ttttoooo lllleeeeaaaarrrrnnnn tttthhhhiiiissss bbbbuuuussssiiiinnnneeeessssssss
(cid:54)(cid:54)(cid:54)(cid:54)(cid:76)(cid:76)(cid:76)(cid:76)(cid:81)(cid:81)(cid:81)(cid:81)(cid:70)(cid:70)(cid:70)(cid:70)(cid:72)(cid:72)(cid:72)(cid:72)(cid:85)(cid:85)(cid:85)(cid:85)(cid:72)(cid:72)(cid:72)(cid:72)(cid:79)(cid:79)(cid:79)(cid:79)(cid:92)(cid:92)(cid:92)(cid:92)(cid:15)(cid:15)(cid:15)(cid:15)
ffffrrrroooommmm tttthhhheeee ppppeeeerrrrssssppppeeeeccccttttiiiivvvveeee ooooffff aaaa ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt iiiissss bbbbuuuuiiiilllltttt
oooonnnn tttthhhheeee bbbbeeeelllliiiieeeeffff iiiinnnn tttthhhheeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiivvvveeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss
ooooffff hhhhuuuummmmaaaannnn iiiinnnnggggeeeennnnuuuuiiiittttyyyy aaaannnndddd ppppeeeerrrrssssoooonnnnaaaallll ccccaaaarrrriiiinnnngggg.... TTTThhhheeee
wwwwoooorrrrlllldddd hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee ccccaaaammmmppppuuuussss ffffoooorrrr mmmmyyyy eeeedddduuuuccccaaaattttiiiioooonnnn iiiinnnn AAAAlllleeeexxxx GGGGoooorrrrsssskkkkyyyy
hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh,,,, aaaassss iiiitttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr mmmmyyyy JJJJoooohhhhnnnnssssoooonnnn &&&& CCCChhhhaaaaiiiirrrrmmmmaaaannnn aaaannnndddd CCCChhhhiiiieeeeffff EEEExxxxeeeeccccuuuuttttiiiivvvveeee OOOOffiffiffifficccceeeerrrr
JJJJoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss.... IIII ddddeeeeeeeeppppllllyyyy aaaapppppppprrrreeeecccciiiiaaaatttteeee tttthhhheeee JJJJoooohhhhnnnnssssoooonnnn &&&& JJJJoooohhhhnnnnssssoooonnnn
*Non-GAAP measures: Free cash flow is defined as operating cash flow less capital spending. Adjusted operational earnings growth excludes special items, intangible
(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:68)(cid:81)(cid:71)(cid:87)(cid:75)(cid:72)(cid:72)(cid:609)(cid:72)(cid:70)(cid:87)(cid:82)(cid:73)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:17)(cid:50)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)(cid:72)(cid:91)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:86)(cid:87)(cid:75)(cid:72)(cid:72)(cid:609)(cid:72)(cid:70)(cid:87)(cid:82)(cid:73)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:17)(cid:54)(cid:72)(cid:72)(cid:49)(cid:82)(cid:81)(cid:16)(cid:42)(cid:36)(cid:36)(cid:51)(cid:53)(cid:72)(cid:70)(cid:82)(cid:81)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)-
tions of Free cash flow and Operational sales growth excluding acquisitions and divestitures for the Medical Devices segment in this Annual Report.
(cid:49)(cid:50)(cid:55)(cid:40)(cid:3)(cid:53)(cid:40)(cid:42)(cid:36)(cid:53)(cid:39)(cid:44)(cid:49)(cid:42)(cid:41)(cid:50)(cid:53)(cid:58)(cid:36)(cid:53)(cid:39)(cid:569)(cid:47)(cid:50)(cid:50)(cid:46)(cid:44)(cid:49)(cid:42)(cid:54)(cid:55)(cid:36)(cid:55)(cid:40)(cid:48)(cid:40)(cid:49)(cid:55)(cid:54)(cid:3)
This letter contains forward-looking statements relating to, among other things, future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information
about these statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and
projections expressed in any forward-looking statements, the readers should review the enclosed Annual Report on Form 10-K for the fiscal year ended December 30,
(cid:21)(cid:19)(cid:20)(cid:27)(cid:15)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:76)(cid:81)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:70)(cid:68)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:72)(cid:71)(cid:368)(cid:38)(cid:68)(cid:88)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:85)(cid:92)(cid:49)(cid:82)(cid:87)(cid:72)(cid:53)(cid:72)(cid:74)(cid:68)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:41)(cid:82)(cid:85)(cid:90)(cid:68)(cid:85)(cid:71)(cid:16)(cid:47)(cid:82)(cid:82)(cid:78)(cid:76)(cid:81)(cid:74)(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:369)(cid:68)(cid:81)(cid:71)(cid:368)(cid:44)(cid:87)(cid:72)(cid:80)(cid:20)(cid:36)(cid:17)(cid:53)(cid:76)(cid:86)(cid:78)(cid:41)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:17)(cid:369)(cid:45)(cid:82)(cid:75)(cid:81)(cid:86)(cid:82)(cid:81)(cid:9)(cid:45)(cid:82)(cid:75)(cid:81)(cid:86)(cid:82)(cid:81)(cid:71)(cid:82)(cid:72)(cid:86)(cid:81)(cid:82)(cid:87)(cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:87)(cid:68)(cid:78)(cid:72)
to update any forward-looking statement as a result of new information or future events or developments.UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
ForthefiscalyearendedDecember30,2018 Commissionfilenumber1-3215
JOHNSON & JOHNSON
(Exactnameofregistrantasspecifiedinitscharter)
NewJersey 22-1024240
(Stateofincorporation) (I.R.S.EmployerIdentificationNo.)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey 08933
(Addressofprincipalexecutiveoffices) (ZipCode)
Registrant’stelephonenumber,includingareacode:(732)524-0400
SECURITIESREGISTEREDPURSUANTTOSECTION12(b)OFTHEACT
Titleofeachclass Nameofeachexchangeonwhichregistered
CommonStock,ParValue$1.00 NewYorkStockExchange
4.75%NotesDueNovember2019 NewYorkStockExchange
0.250%NotesDueJanuary2022 NewYorkStockExchange
0.650%NotesDueMay2024 NewYorkStockExchange
5.50%NotesDueNovember2024 NewYorkStockExchange
1.150%NotesDueNovember2028 NewYorkStockExchange
1.650%NotesDueMay2035 NewYorkStockExchange
Indicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecurities
Act. Yes Í No ‘
IndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13orSection15(d)oftheExchange
Act. Yes ‘ No Í
Indicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)ofthe
ExchangeActduringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuch
reports),and(2)hasbeensubjecttosuchfilingrequirementsforthepast90days. Yes Í No ‘
IndicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmitted
pursuanttoRule405ofRegulationS-Tduringthepreceding12months(orforsuchshorterperiodthattheregistrantwas
requiredtosubmitsuchfiles). Yes Í No ‘
IndicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoItem405ofRegulationS-Kisnotcontainedherein,and
willnotbecontained,tothebestofregistrant’sknowledge,indefinitiveproxyorinformationstatementsincorporatedby
referenceinPartIIIofthisForm10-KoranyamendmenttothisForm10-K. ‘
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,asmaller
reportingcompany,oremerginggrowthcompany.Seethedefinitionsof“largeacceleratedfiler,”“acceleratedfiler”,“smaller
reportingcompany,”and“emerginggrowthcompany”inRule12b-2oftheExchangeAct.
Largeacceleratedfiler Í Acceleratedfiler ‘ Non-acceleratedfiler ‘ Smallerreportingcompany ‘
Emerginggrowthcompany ‘
Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod
forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection13(a)oftheExchange
Act. ‘
Indicatebycheckmarkwhethertheregistrantisashellcompany(asdefinedinRule12b-2oftheExchange
Act). Yes ‘ No Í
TheaggregatemarketvalueoftheCommonStockheldbynon-affiliatescomputedbyreferencetothepriceatwhichthe
CommonStockwaslastsoldasofthelastbusinessdayoftheregistrant’smostrecentlycompletedsecondfiscalquarter
wasapproximately$325billion.
OnFebruary15,2019,therewere2,663,138,579sharesofCommonStockoutstanding.
DOCUMENTSINCORPORATEDBYREFERENCE
PartsIandIII: Portionsofregistrant’sproxystatementforits2019annualmeetingofshareholdersfiledwithin
120daysafterthecloseoftheregistrant’sfiscalyear(the“ProxyStatement”),areincorporatedby
referencetothisreportonForm10-K(this“Report”).Item Page
PARTI
1 Business 1
General 1
SegmentsofBusiness 1
GeographicAreas 2
RawMaterials 2
Patents 2
Trademarks 3
Seasonality 3
Competition 3
Environment 3
Regulation 3
AvailableInformation 4
1A. RiskFactors 4
1B. UnresolvedStaffComments 9
2 Properties 9
3 LegalProceedings 10
4 MineSafetyDisclosures 10
ExecutiveOfficersoftheRegistrant 11
PARTII
5 MarketforRegistrant’sCommonEquity,RelatedStockholderMattersandIssuerPurchasesof
EquitySecurities 13
6 SelectedFinancialData 14
7 Management’sDiscussionandAnalysisofResultsofOperationsandFinancialCondition 15
7A. QuantitativeandQualitativeDisclosuresAboutMarketRisk 35
8 FinancialStatementsandSupplementaryData 35
9 ChangesinandDisagreementsWithAccountantsonAccountingandFinancialDisclosure 102
9A. ControlsandProcedures 102
9B. OtherInformation 102
PARTIII
10 Directors,ExecutiveOfficersandCorporateGovernance 103
11 ExecutiveCompensation 103
12 SecurityOwnershipofCertainBeneficialOwnersandManagementandRelatedStockholder
Matters 103
13 CertainRelationshipsandRelatedTransactions,andDirectorIndependence 104
14 PrincipalAccountantFeesandServices 104
PARTIV
15 ExhibitsandFinancialStatementSchedules 105
16 Form10-KSummary 105
Signatures 106
ExhibitIndex 107CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
ThisAnnualReportonForm10-KandJohnson&Johnson’sotherpubliclyavailabledocumentscontain“forward-looking
statements”withinthemeaningofthesafeharborprovisionsoftheU.S.PrivateSecuritiesLitigationReformActof
1995.ManagementandrepresentativesofJohnson&Johnsonanditssubsidiaries(the“Company”)alsomayfromtimeto
timemakeforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand
reflectmanagement’sassumptions,views,plans,objectivesandprojectionsaboutthefuture.Forward-lookingstatements
maybeidentifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andotherwordsof
similarmeaninginconjunctionwith,amongotherthings:discussionsoffutureoperations;expectedoperatingresultsand
financialperformance;impactofplannedacquisitionsanddispositions;theCompany’sstrategyforgrowth;product
development;regulatoryapprovals;marketpositionandexpenditures.
Becauseforward-lookingstatementsarebasedoncurrentbeliefs,expectationsandassumptionsregardingfutureevents,
theyaresubjecttouncertainties,risksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurate,orknownorunknownrisksor
uncertaintiesmaterialize,theCompany’sactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand
projectionsexpressedorimpliedinitsforward-lookingstatements.Investorsarethereforecautionednottorelyonthese
forward-lookingstatements.Risksanduncertaintiesinclude,butarenotlimitedto:
RisksRelatedtoProductDevelopment,MarketSuccessandCompetition
• Challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies
onwhichtheCompany’scontinuedgrowthandsuccessdepend,includinguncertaintyofclinicaloutcomes,additional
analysisofexistingclinicaldata,obtainingregulatoryapprovals,healthplancoverageandcustomeraccess,andinitial
andcontinuedcommercialsuccess;
• ChallengestotheCompany’sabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew
andexistingproductsandtechnologiesintheUnitedStatesandotherimportantmarkets;
• Theimpactofpatentexpirations,typicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand
resultingrevenueandmarketsharelosses;
• IncreasinglyaggressiveandfrequentchallengestotheCompany’spatentsbycompetitorsandothersseekingtolaunch
competinggeneric,biosimilarorotherproductsandincreasedreceptivityofcourts,theUnitedStatesPatentand
TrademarkOfficeandotherdecisionmakerstosuchchallenges,potentiallyresultinginlossofmarketexclusivityand
rapiddeclineinsalesfortherelevantproductsoonerthanexpected;
• Competitioninresearchanddevelopmentofnewandimprovedproducts,processesandtechnologies,whichcanresult
inproductandprocessobsolescence;
• Competitiontoreachagreementwiththirdpartiesforcollaboration,licensing,developmentandmarketingagreements
forproductsandtechnologies;
• Competitionbasedoncost-effectiveness,productperformance,technologicaladvancesandpatentsattainedby
competitors;and
• AllegationsthattheCompany’sproductsinfringethepatentsandotherintellectualpropertyrightsofthirdparties,which
couldadverselyaffecttheCompany’sabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages
andfutureroyalties.
RisksRelatedtoProductLiability,LitigationandRegulatoryActivity
• Productefficacyorsafetyconcerns,whetherornotbasedonscientificevidence,potentiallyresultinginproduct
withdrawals,recalls,regulatoryactiononthepartoftheUnitedStatesFoodandDrugAdministration(orinternational
counterparts),decliningsales,reputationaldamage,increasedlitigationexpenseandsharepriceimpact;
• Impact,includingdecliningsalesandreputationaldamage,ofsignificantlitigationorgovernmentactionadversetothe
Company,includingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand
contractingstrategies;
• Impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedings,including
patentlitigation,productliability,personalinjuryclaims,securitiesclassactions,governmentinvestigations,employment
andotherlegalproceedings;
• Increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin
investigationsandprosecutions,whichcarrytheriskofsignificantcivilandcriminalpenalties,including,butnotlimited
to,debarmentfromgovernmentbusiness;
Johnson&Johnson2018AnnualReport •• FailuretomeetcomplianceobligationsintheMcNEIL-PPC,Inc.ConsentDecreeoranyothercomplianceagreements
withgovernmentsorgovernmentagencies,whichcouldresultinsignificantsanctions;
• PotentialchangestoapplicablelawsandregulationsaffectingUnitedStatesandinternationaloperations,including
relatingto:approvalofnewproducts;licensingandpatentrights;salesandpromotionofhealthcareproducts;access
to,andreimbursementandpricingfor,healthcareproductsandservices;environmentalprotectionandsourcingofraw
materials;
• CompliancewithlocalregulationsandlawsthatmayrestricttheCompany’sabilitytomanufactureorsellitsproductsin
relevantmarketsincluding,requirementstocomplywithmedicaldevicereportingregulationsandotherrequirements
suchastheEuropeanUnion’sMedicalDevicesRegulation;
• Changesindomesticandinternationaltaxlawsandregulations,includingchangesrelatedtoTheTaxCutsandJobs
ActintheUnitedStates,theFederalActonTaxReformandAHVFinancinginSwitzerland,increasingauditscrutinyby
taxauthoritiesaroundtheworldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreserves;and
• IssuanceofneworrevisedaccountingstandardsbytheFinancialAccountingStandardsBoardandregulationsbythe
SecuritiesandExchangeCommission.
RisksRelatedtotheCompany’sStrategicInitiativesandHealthcareMarketTrends
• Pricingpressuresresultingfromtrendstowardhealthcarecostcontainment,includingthecontinuedconsolidation
amonghealthcareprovidersandothermarketparticipants,trendstowardmanagedcare,theshifttowardgovernments
increasinglybecomingtheprimarypayersofhealthcareexpenses,significantnewentrantstothehealthcaremarkets
seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases;
• Restrictedspendingpatternsofindividual,institutionalandgovernmentalpurchasersofhealthcareproductsand
servicesduetoeconomichardshipandbudgetaryconstraints;
• ChallengestotheCompany’sabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations,
suchasdevelopmentcollaborations,strategicacquisitions,licensingandmarketingagreements,andthepotential
heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures;
• Thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor
divestiturebytheCompanymaynotberealizedormaytakelongertorealizethanexpected;and
• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe
realizedormaytakelongertorealizethanexpected.
RisksRelatedtoEconomicConditions,FinancialMarketsandOperatingInternationally
• MarketconditionsandthepossibilitythattheCompany’ssharerepurchaseprogrammaybedelayed,suspendedor
discontinued;
• Impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch
fluctuationsonrevenues,expensesandresultingmargins;
• Potentialchangesinexport/importandtradelaws,regulationsandpoliciesoftheUnitedStatesandothercountries,
includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation;
• Theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomies,sovereignrisk,possible
impositionofgovernmentalcontrolsandrestrictiveeconomicpolicies,andunstableinternationalgovernmentsandlegal
systems;
• Changestoglobalclimate,extremeweatherandnaturaldisastersthatcouldaffectdemandfortheCompany’sproducts
andservices,causedisruptionsinmanufacturinganddistributionnetworks,altertheavailabilityofgoodsandservices
withinthesupplychain,andaffecttheoveralldesignandintegrityoftheCompany’sproductsandoperations;and
• TheimpactofarmedconflictsandterroristattacksintheUnitedStatesandotherpartsoftheworldincludingsocialand
economicdisruptionsandinstabilityoffinancialandothermarkets.
RisksRelatedtoSupplyChainandOperations
• Difficultiesanddelaysinmanufacturing,internallythroughthirdpartyprovidersorotherwisewithinthesupplychain,that
mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdowns,productshortages,withdrawalsor
suspensionsofproductsfromthemarket,andpotentialregulatoryaction;
• InterruptionsandbreachesoftheCompany’sinformationtechnologysystemsorthoseoftheCompany’svendors
which,couldresultinreputational,competitive,operationalorotherbusinessharmaswellasfinancialcostsand
regulatoryaction;
• Relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing
regulatoryrequirementsthatmayadverselyaffectsupply,sourcingandpricingofmaterialsusedintheCompany’s
products;and
• Johnson&Johnson2018AnnualReport• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal
supplychainmaynotberealizedormaytakelongertorealizethanexpected,includingduetoanyrequiredapprovals
fromapplicableregulatoryauthorities.Disruptionsassociatedwiththeannouncedglobalsupplychainactionsmay
adverselyaffectsupplyandsourcingofmaterialsusedintheCompany’sproducts.
InvestorsalsoshouldcarefullyreadtheRiskFactorsdescribedinItem1AofthisAnnualReportonForm10-Kfora
descriptionofcertainrisksthatcould,amongotherthings,causetheCompany’sactualresultstodiffermateriallyfrom
thoseexpressedinitsforward-lookingstatements.Investorsshouldunderstandthatitisnotpossibletopredictoridentify
allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinItem1Atobeacompletestatementofall
potentialrisksanduncertainties.TheCompanydoesnotundertaketopubliclyupdateanyforward-lookingstatementthat
maybemadefromtimetotime,whetherasaresultofnewinformationorfutureeventsordevelopments.
Johnson&Johnson2018AnnualReport •PART I
Item 1. BUSINESS
General
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately135,100employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.Johnson&Johnson
isaholdingcompany,whichhasmorethan260operatingcompaniesconductingbusinessinvirtuallyallcountriesofthe
world.TheCompany’sprimaryfocusisproductsrelatedtohumanhealthandwell-being.Johnson&Johnsonwas
incorporatedintheStateofNewJerseyin1887.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Company’sthreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.Withinthestrategicparameters
providedbytheCommittee,seniormanagementgroupsatU.S.andinternationaloperatingcompaniesareeach
responsiblefortheirownstrategicplansandtheday-to-dayoperationsofthosecompanies.Eachsubsidiarywithinthe
businesssegmentsis,withlimitedexceptions,managedbyresidentsofthecountrywherelocated.
Segments of Business
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.Additional
informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments
andoperatingresultsunder:Item7.“Management’sDiscussionandAnalysisofResultsofOperationsandFinancial
Condition”ofthisReport;andNote18“SegmentsofBusinessandGeographicAreas”oftheNotestoConsolidated
FinancialStatementsincludedinItem8ofthisReport.
Consumer
TheConsumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty,over-the-counter
pharmaceutical,women’shealthandwoundcaremarkets.BabyCareincludestheJOHNSON’S®lineofproducts.Oral
CareincludestheLISTERINE®productline.MajorbrandsinBeautyincludetheAVEENO®;CLEAN&CLEAR®;
DABAO™;JOHNSON’S®Adult;LEPETITEMARSEILLAIS®;NEUTROGENA®andOGX®productlines.
Over-the-countermedicinesincludethebroadfamilyofTYLENOL®acetaminophenproducts;SUDAFED®cold,fluand
allergyproducts;BENADRYL®andZYRTEC®allergyproducts;MOTRIN®IBibuprofenproducts;andthePEPCID®line
ofacidrefluxproducts.MajorbrandsinWomen’sHealthoutsideofNorthAmericaareSTAYFREE®andCAREFREE®
sanitarypadsando.b.®tamponbrands.WoundCarebrandsincludetheBAND-AID®BrandAdhesiveBandagesand
NEOSPORIN®FirstAidproductlines.Theseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutlets
anddistributorsthroughouttheworld.
Pharmaceutical
ThePharmaceuticalsegmentisfocusedonsixtherapeuticareas:Immunology(e.g.,rheumatoidarthritis,inflammatory
boweldiseaseandpsoriasis),InfectiousDiseasesandVaccines(e.g.,HIV/AIDS),Neuroscience(e.g.,mooddisorders,
neurodegenerativedisordersandschizophrenia),Oncology(e.g.,prostatecancerandhematologicmalignancies),
CardiovascularandMetabolism(e.g.,thrombosisanddiabetes)andPulmonaryHypertension(e.g.,PulmonaryArterial
Hypertension).Medicinesinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealthcare
professionalsforprescriptionuse.KeyproductsinthePharmaceuticalsegmentinclude:REMICADE®(infliximab),a
treatmentforanumberofimmune-mediatedinflammatorydiseases;SIMPONI®(golimumab),asubcutaneoustreatment
foradultswithmoderatetosevererheumatoidarthritis,activepsoriaticarthritis,activeankylosingspondylitisand
moderatelyactivetoseverelyactiveulcerativecolitis;SIMPONIARIA®(golimumab),anintravenoustreatmentforadults
withmoderatetosevererheumatoidarthritis,activepsoriaticarthritisandactiveankylosingspondylitis;STELARA®
(ustekinumab),atreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasis,foradultswithactivepsoriatic
arthritis,andforadultswithmoderatelytoseverelyactiveCrohn’sdisease;TREMFYA®(guselkumab),atreatmentfor
adultswithmoderatetosevereplaquepsoriasis;EDURANT®(rilpivirine),INTELENCE®(etravirine),PREZISTA®
Johnson&Johnson2018AnnualReport • 1(darunavir)andPREZCOBIX®/REZOLSTA®(darunavir/cobicistat),antiretroviralmedicinesforthetreatmentofhuman
immunodeficiencyvirus(HIV-1)incombinationwithotherantiretroviralproductsandSYMTUZA®(darunavir/cobicistat/
emtricitabine/tenofoviralafenamide),aonce-dailysingletabletregimenforthetreatmentofHIV;CONCERTA®
(methylphenidateHCl)extended-releasetabletsCII,atreatmentforattentiondeficithyperactivitydisorder;INVEGA
SUSTENNA®/XEPLION®(paliperidonepalmitate),forthetreatmentofschizophreniaandschizoaffectivedisorderin
adults;INVEGATRINZA®/TREVICTA®(paliperidonepalmitate),forthetreatmentofschizophreniainpatientsafterthey
havebeenadequatelytreatedwithINVEGASUSTENNA®foratleastfourmonths;RISPERDALCONSTA®(risperidone
long-actinginjection),forthetreatmentofschizophreniaandthemaintenancetreatmentofBipolar1Disorderinadults;
ZYTIGA®(abirateroneacetate),atreatmentformetastaticcastration-resistantprostatecancer(CRPC)andmetastatic
high-riskcastration-sensitiveprostatecancer;IMBRUVICA®(ibrutinib),atreatmentforcertainB-cellmalignancies,or
bloodcancers,chronicgraftversushostdiseaseandWaldenström’sMacroglobulinemia;DARZALEX®(daratumumab),a
treatmentforrelapsed/refractorymultiplemyeloma;VELCADE®(bortezomib),atreatmentformultiplemyelomamantlecell
lymphoma;PROCRIT®/EPREX®(epoetinalfa),atreatmentforchemotherapy-inducedanemiaandpatientswithchronic
kidneydisease;XARELTO®(rivaroxaban),anoralanticoagulantforthepreventionofdeepveinthrombosis(DVT),which
mayleadtopulmonaryembolism(PE)inpatientsundergoinghiporkneereplacementsurgery,toreducetheriskofstroke
andsystemicembolisminpatientswithnonvalvularatrialfibrillation,andforthetreatmentandreductionofriskof
recurrenceofDVTandPE;INVOKANA®(canagliflozin),forthetreatmentofadultswithtype2diabetes;INVOKAMET®
/VOKANAMET®(canagliflozin/metforminHCl),acombinationtherapyoffixeddosesofcanagliflozinandmetformin
hydrochlorideforthetreatmentofadultswithtype2diabetes;andINVOKAMET®XR(canagliflozin/metformin
hydrochlorideextended-release),aonce-daily,fixed-dosecombinationtherapyofcanagliflozinandmetformin
hydrochlorideextended-release,forthetreatmentofadultswithtype2diabetes;OPSUMIT®(macitentan),as
monotherapyorincombination,indicatedforthelong-termtreatmentofpulmonaryarterialhypertension(PAH);UPTRAVI®
(selexipag),theonlyapprovedoral,selectiveIPreceptoragonisttargetingaprostacyclinpathwayinPAH.Manyofthese
medicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintain
activelifecycledevelopmentprograms.
MedicalDevices
TheMedicalDevicessegmentincludesabroadrangeofproductsusedintheorthopaedic,surgery,interventional
solutions(cardiovascularandneurovascular),diabetescare(divestedinthefiscalfourthquarterof2018)andeyehealth
fields.Theseproductsaredistributedtowholesalers,hospitalsandretailers,andusedprincipallyintheprofessionalfields
byphysicians,nurses,hospitals,eyecareprofessionalsandclinics.Theyincludeorthopaedicproducts;generalsurgery,
biosurgical,endomechanicalandenergyproducts;electrophysiologyproductstotreatcardiovasculardisease;sterilization
anddisinfectionproductstoreducesurgicalinfection;andvisionproductssuchasdisposablecontactlensesand
ophthalmicproductsrelatedtocataractandlaserrefractivesurgery.
Geographic Areas
ThebusinessofJohnson&Johnsonisconductedbymorethan260operatingcompanieslocatedinmorethan
60countries,includingtheU.S.,whichsellproductsinvirtuallyallcountriesthroughouttheworld.Theproductsmadeand
soldintheinternationalbusinessincludemanyofthosedescribedaboveunder“—SegmentsofBusiness—Consumer,”
“—Pharmaceutical”and“—MedicalDevices.”However,theprincipalmarkets,productsandmethodsofdistributionin
theinternationalbusinessvarywiththecountryandtheculture.Theproductssoldininternationalbusinessincludethose
developedintheU.S.andbysubsidiariesabroad.
InvestmentsandactivitiesinsomecountriesoutsidetheU.S.aresubjecttohigherrisksthancomparableU.S.activities
becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies,
restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties.
Raw Materials
RawmaterialsessentialtotheCompany’sbusinessaregenerallyreadilyavailablefrommultiplesources.Wherethereare
exceptions,thetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe
financialresultsoftheCompany.
Patents
TheCompany’ssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere
possible.Theyown,orarelicensedunder,asignificantnumberofpatentsintheU.S.andothercountriesrelatingtotheir
2 • Johnson&Johnson2018AnnualReportproducts,productuses,formulationsandmanufacturingprocesses,whichintheaggregatearebelievedtobeofmaterial
importancetotheCompanyintheoperationofitsbusinesses.TheCompany’ssubsidiariesfacepatentchallengesfrom
thirdparties,includingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsoftheCompany’s
keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Significantlegal
proceedingsandclaimsinvolvingtheCompany’spatentandotherintellectualpropertyaredescribedinNote21,“Legal
Proceedings—IntellectualProperty”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
SalesoftheCompany’s2ndlargestproduct,STELARA®(ustekinumab),accountedforapproximately6.3%ofthe
Company’stotalrevenuesforfiscal2018.Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialto
theCompany.
ThereisonesetofgrantedpatentsrelatedspecificallytoSTELARA®.ThissetofpatentsisownedbyJanssenBiotech,
Inc.,awholly-ownedsubsidiaryofJohnson&Johnson.ThesepatentsareinforceintheU.S.andmanycountriesoutside
theUnitedStates.IntheU.S.,thelatestprojectedexpirationdateforpatentsinthissetis2023duetoapatentterm
extension.InEurope,thelatestprojectedexpirationdateforpatentsinthissetis2024duetoaSupplementalPatent
Certificate(patenttermextension).Inmostothercountries,thelatestprojectedexpirationdateis2021.
InadditiontocompetingintheimmunologymarketwithSTELARA®,theCompanyiscurrentlymarketingSIMPONI®
(golimumab)andSIMPONIARIA®(golimumab),nextgenerationimmunologyproductswithremainingpatentlivesofupto
sixyears.TheCompanyalsomarketsREMICADE®(infliximab)intheimmunologymarketwhichistheCompany’slargest
product.PatentsonthisproducthaveexpiredandtheFoodandDrugAdministrationapprovedthefirstinfliximabbiosimilar
forsaleintheU.S.in2016,andanumberofsuchproductshavebeenlaunchedsincethen.Foramoreextensive
descriptionoflegalmattersregardingthepatentsrelatedtoREMICADE®,seeNote21“LegalProceedings—Intellectual
Property—Pharmaceutical—REMICADE®RelatedCases”oftheNotestoConsolidatedFinancialStatementsincluded
inItem8ofthisReport.
Trademarks
TheCompany’ssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection
forthesetrademarksbyallavailablemeans.ThesetrademarksareprotectedbyregistrationintheU.S.andothercountries
wheresuchproductsaremarketed.TheCompanyconsidersthesetrademarksintheaggregatetobeofmaterial
importanceintheoperationofitsbusinesses.
Seasonality
Worldwidesalesdonotreflectanysignificantdegreeofseasonality;however,spendinghasbeenheavierinthefourth
quarterofeachyearthaninotherquarters.Thisreflectsincreasedspendingdecisions,principallyforadvertisingand
researchanddevelopmentactivity.
Competition
Inalloftheirproductlines,theCompany’ssubsidiariescompetewithcompaniesbothlocallyandglobally.Competition
existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.Competitionin
research,bothinternallyandexternallysourced,involvingthedevelopmentandtheimprovementofnewandexisting
productsandprocesses,isparticularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotecting
theunderlyingintellectualpropertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareas
ofitsbusiness.Thecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,the
developmentandmaintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvesignificant
expendituresforadvertisingandpromotion.
Environment
TheCompanyissubjecttoavarietyofU.S.andinternationalenvironmentalprotectionmeasures.TheCompanybelieves
thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulations.TheCompany’s
compliancewiththeserequirementsdidnotchangeduringthepastyear,andisnotexpectedtohaveamaterialeffect
uponitscapitalexpenditures,cashflows,earningsorcompetitiveposition.
Regulation
TheCompany’sbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations
areconducted,andthegeneraltrendistowardincreasinglystringentregulation.IntheU.S.,thedrug,deviceandcosmetic
Johnson&Johnson2018AnnualReport • 3industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagencies,primarilyastoproductsafety,
efficacy,manufacturing,advertising,labelingandsafetyreporting.TheexerciseofbroadregulatorypowersbytheU.S.
FoodandDrugAdministration(theFDA)continuestoresultinincreasesintheamountsoftestinganddocumentation
requiredforFDAapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction.
SimilartrendsarealsoevidentinmajormarketsoutsideoftheU.S.Thenewmedicaldeviceregulatoryframeworkandthe
newprivacyregulationsinEuropeareexamplesofsuchincreasedregulation.
Thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudy,investigationandregulationby
governmentalagenciesandlegislativebodiesaroundtheworld.IntheU.S.,attentionhasbeenfocusedondrugprices
andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugs,ortorecommend,useor
purchaseparticularmedicaldevices.Payershavebecomeamorepotentforceinthemarketplaceandincreasedattention
isbeingpaidtodrugandmedicaldevicepricing,appropriatedrugandmedicaldeviceutilizationandthequalityandcosts
ofhealthcaregenerally.
U.S.governmentagenciescontinuetoimplementtheextensiverequirementsofthePatientProtectionandAffordableCare
Act(theACA).ThesehavebothpositiveandnegativeimpactsontheU.S.healthcareindustrywithmuchremaining
uncertainastohowvariousprovisionsoftheACA,andpotentialmodificationorrepealofACAprovisions,willultimately
affecttheindustry.
TheregulatoryagenciesunderwhosepurviewtheCompanyoperateshaveadministrativepowersthatmaysubjectitto
actionssuchasproductwithdrawals,recalls,seizureofproductsandothercivilandcriminalsanctions.Insomecases,the
Company’ssubsidiariesmaydeemitadvisabletoinitiateproductrecalls.
Inaddition,businesspracticesinthehealthcareindustryhavecomeunderincreasedscrutiny,particularlyintheU.S.,by
governmentagenciesandstateattorneysgeneral,andresultinginvestigationsandprosecutionscarrytheriskofsignificant
civilandcriminalpenalties.
Further,theCompanyreliesonglobalsupplychains,andproductionanddistributionprocesses,thatarecomplex,are
subjecttoincreasingregulatoryrequirements,andmaybefacedwithunexpectedchangessuchasthoseresultingfrom
Brexit,thatmayaffectsourcing,supplyandpricingofmaterialsusedintheCompany’sproducts.Theseprocessesalso
aresubjecttolengthyregulatoryapprovals.
Available Information
TheCompany’smaincorporatewebsiteaddressiswww.jnj.com.AlloftheCompany’sSECfilingsarealsoavailableonthe
Company’swebsiteatwww.investor.jnj.com/sec.cfm,assoonasreasonablypracticableafterhavingbeenelectronically
filedorfurnishedtotheSEC.AllSECfilingsarealsoavailableattheSEC’swebsiteatwww.sec.gov.Inaddition,the
writtenchartersoftheAuditCommittee,theCompensation&BenefitsCommittee,theNominating&Corporate
GovernanceCommittee,theRegulatoryComplianceCommitteeandtheScience,Technology&SustainabilityCommittee
oftheBoardofDirectorsandtheCompany’sPrinciplesofCorporateGovernance,CodeofBusinessConduct(for
employees),CodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers,andother
corporategovernancematerials,areavailableatwww.investor.jnj.com/gov.cfmontheCompany’swebsiteandwillbe
providedwithoutchargetoanyshareholdersubmittingawrittenrequest,asprovidedabove.Theinformationonthe
Company’swebsiteisnot,andwillnotbedeemed,apartofthisReportorincorporatedintoanyotherfilingstheCompany
makeswiththeSEC.
Item 1A. RISK FACTORS
TheCompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.InadditiontotheotherinformationinthisreportandtheCompany’sotherfilingswiththeSEC,
investorsshouldconsidercarefullythefactorssetforthbelow.Investorsshouldbeawarethatitisnotpossibletopredict
oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor
uncertainties.Ifknownorunknownrisksoruncertaintiesmaterialize,theCompany’sbusiness,resultsofoperationsor
financialconditioncouldbeadverselyaffected,potentiallyinamaterialway.
GlobalsalesintheCompany’sPharmaceuticalandMedicalDevicesSegmentsmaybenegativelyimpacted
byhealthcarereformsandincreasingpricingpressures.
SalesoftheCompany’spharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby
third-partypayerssuchasgovernmenthealthcareprograms,privateinsuranceplansandmanagedcareorganizations.As
4 • Johnson&Johnson2018AnnualReportpartofvariouseffortstocontainhealthcarecosts,thesepayersareputtingdownwardpressureonpricesatwhich
productswillbereimbursed.IntheU.S.,increasedpurchasingpowerofentitiesthatnegotiateonbehalfofMedicare,
Medicaid,andprivatesectorbeneficiaries,inpartduetocontinuedconsolidationamonghealthcareproviders,could
resultinfurtherpricingpressures.Inaddition,increasedpoliticalscrutinycouldresultinadditionalpricingpressures.
OutsidetheU.S.,numerousmajormarkets,includingtheEUandJapan,havepervasivegovernmentinvolvementinfunding
healthcareand,inthatregard,directlyorindirectlyimposepricecontrols,limitaccessto,orreimbursementfor,the
Company’sproducts,orreducethevalueofitsintellectualpropertyprotection.
TheCompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpenses,finesand
reputationaldamage.
Intheordinarycourseofbusiness,Johnson&Johnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits
involvingvariousissuessuchaspatentdisputes,productliabilityandclaimsthattheirproductsales,marketingandpricing
practicesviolatevariousantitrust,unfairtradepracticesand/orconsumerprotectionlaws.Themostsignificantofthese
proceedingsaredescribedinNote21,“LegalProceedings”underNotestotheConsolidatedFinancialStatements
includedinItem8ofthisReport.WhiletheCompanybelievesithassubstantialdefensesinthesematters,itisnot
feasibletopredicttheultimateoutcomeoflitigation.TheCompanycouldinthefutureberequiredtopaysignificant
amountsasaresultofsettlementsorjudgmentsinthesematters,potentiallyinexcessofaccruals,includingmatterswhere
theCompanycouldbeheldjointlyandseverallyliableamongotherdefendants.Theresolutionof,orincreaseinaccruals
for,oneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.Furthermore,asaresultofcostandavailabilityfactors,effectiveNovember1,
2005,theCompanyceasedpurchasingthird-partyproductliabilityinsurance.
Productreliability,safetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand
resultsofoperations,leadtolitigationandcausereputationaldamage.
Concernsaboutproductsafety,whetherraisedinternallyorbylitigants,regulatorsorconsumeradvocates,andwhetheror
notbasedonscientificevidence,canresultinsafetyalerts,productrecalls,governmentalinvestigations,regulatoryaction
onthepartoftheFDA(oritscounterpartinothercountries),privateclaimsandlawsuits,paymentoffinesandsettlements,
decliningsalesandreputationaldamage.Thesecircumstancescanalsoresultindamagetobrandimage,brandequity
andconsumertrustintheCompany’sproducts.Productrecallshaveinthepast,andcouldinthefuture,prompt
governmentinvestigationsandinspections,theshutdownofmanufacturingfacilities,continuedproductshortagesand
relatedsalesdeclines,significantremediationcosts,reputationaldamage,possiblecivilpenaltiesandcriminalprosecution.
ChangesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpacttheCompany’s
operatingresults.
ChangesintaxlawsorregulationsaroundtheworldcouldnegativelyimpacttheCompany’seffectivetaxrateandresults
ofoperations.AchangeinstatutorytaxrateinanycountrywouldresultintherevaluationoftheCompany’sdeferredtax
assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenacted.Thischange
wouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidatedStatementofEarnings.TheCompany
closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.Changestothestatutorytaxratemay
occuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe
lawchangeisenacted.
OnDecember22,2017,theU.S.enactedTheTaxCutsandJobsAct(theTCJA),whichintroducedsignificantchangesto
U.S.corporateincometaxlawthatwillhaveameaningfulimpactontheCompany’sprovisionforincometaxes.Accounting
fortheincometaxeffectsoftheTCJArequiressignificantjudgmentstobemadeininterpretingitsprovisions.Anticipated
guidancefromtheU.S.TreasuryaboutimplementingtheTCJA,whichshouldbefinalbyJune22,2019(18monthsafter
enactment),mayresultinadjustmentsthatcouldmateriallyaffecttheCompany’sfinancialpositionandresultsof
operationsaswellastheeffectivetaxrateintheperiodinwhichtheadjustmentsaremade.
OnSeptember28,2018,theSwissParliamentapprovedtheFederalActonTaxReformandAHVFinancing(SwissTax
Reform).However,areferendumhasbeencalledand,asaresult,apublicvoteontheSwissTaxReformwilltakeplaceon
May19th,2019.IftheSwissTaxReformpasses,thenthemeasuresareexpectedtocomeintoforceineitherJanuary
2020orJanuary2021.Priortoapprovalinthereferendumanditssubsequentcantonalimplementation,theproposed
SwissTaxReformisnotenactedandthereforetheCompanyhasnotreflectedanyofthepotentialimpactsinitsfiscal
results.TheCompanyiscurrentlyassessingtheimpactoftheproposedSwissTaxReform,andwhenenacted,thelaw
mayhaveamaterialimpactontheCompany’soperatingresults.
TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes
withmanytaxauthorities.InconnectionwiththeOrganizationforEconomicCooperationandDevelopmentBaseErosion
Johnson&Johnson2018AnnualReport • 5andProfitShifting(BEPS)project,companiesarerequiredtodisclosemoreinformationtotaxauthoritiesonoperations
aroundtheworld,whichmayleadtogreaterauditscrutinyofprofitsearnedinothercountries.TheCompanyregularly
assessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserves.However,
anytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytotheCompany’sexpectations,whichcouldresult
intaxliabilitiesinexcessofreserves.
TheCompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto
theCompany’sbusinesses.
TheCompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrights,determinedbypatentoffices,
courtsandlawmakersinvariouscountries,relatingtoitsproductsandmanufacturingprocesses.Theserightsareessential
totheCompany’sbusinessesandmateriallyimportanttotheCompany’sresultsofoperations.Publicpolicy,bothwithin
andoutsidetheU.S.,hasbecomeincreasinglyunfavorabletowardintellectualpropertyrights.TheCompanycannotbe
certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheU.S.andotherimportant
marketsorthatsuchprotections,oncegranted,willlastaslongasoriginallyanticipated.
CompetitorsroutinelychallengethevalidityorextentoftheCompany’sownedorlicensedpatentsandproprietaryrights
throughlitigation,interferences,oppositionsandotherproceedings.Theseproceedingsabsorbresourcesandcanbe
protractedaswellasunpredictable.Inaddition,challengesthattheCompany’sproductsinfringethepatentsofthird
partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand
salesoftheproductsinquestion.
TheCompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand
biosimilarversionsoftheCompany’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering
thoseproducts.IntheU.S.,manufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay
challengethevalidity,orclaimnon-infringement,ofinnovatorproductsthroughtheAbbreviatedNewDrugApplication,or
ANDA,processwiththeFDA.TheBiologicsPriceCompetitionandInnovationAct(BPCIA),enactedin2010,which
createdanewregulatorypathwayfortheapprovalbytheFDAofbiosimilaralternativestoinnovator-developedbiological
products,alsocreatedmechanismsforbiosimilarapplicantstochallengethepatentsontheinnovatorbiologics.Theinter
partesreview(IPR)processwiththeUSPTO,createdunderthe2011AmericaInventsAct,isalsobeingusedby
competitorstochallengepatentsheldbytheCompany’ssubsidiaries.
IntheeventtheCompanyisnotsuccessfulindefendingitspatentsagainstsuchchallenges,oruponthe“at-risk”launch
(despitependingpatentinfringementlitigation)bythegenericorbiosimilarfirmofitsproduct,theCompanycanlosea
majorportionofrevenuesforthereferencedproductinaveryshortperiodoftime.Currentlegalproceedingsinvolvingthe
Company’spatentsandotherintellectualpropertyrightsaredescribedinNote21,“LegalProceedings—Intellectual
Property”oftheNotestotheConsolidatedFinancialStatementsincludedinItem8ofthisReport.
TheCompany’sbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould
adverselyaffecttheCompany’searnings.
TheCompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarkets.TheCompany’s
businessescompetewithcompaniesofallsizesonthebasisofcost-effectiveness,technologicalinnovations,intellectual
propertyrights,productperformance,realorperceivedproductadvantages,pricingandavailabilityandrateof
reimbursement.TheCompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions,
collaborationsandlicensingagreementswiththirdparties.Competitionforrightstoproductcandidatesandtechnologies
mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsfortheCompany.Competitors’
developmentofmoreeffectiveorlesscostlyproducts,and/ortheirabilitytosecurepatentandotherintellectualproperty
rightsandsuccessfullymarketproductsaheadoftheCompany,couldnegativelyimpactsalesoftheCompany’sexisting
productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct
development.
FortheCompany’spharmaceuticalbusinesses,lossofpatentexclusivityforaproductoftenisfollowedbyasubstantial
reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket.
Similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproduct.FortheCompany’smedicaldevice
businesses,technologicalinnovation,productquality,reputationandcustomerserviceareespeciallyimportantto
competitiveness.Developmentbyothercompaniesofneworimprovedproducts,processesandtechnologiescould
threatentomaketheCompany’sproductsortechnologieslessdesirable,lesseconomicalorobsolete.TheCompany’s
consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailers’private-labelbrands.Ifthe
Companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproducts,thiscouldadverselyaffect
revenuesandprofitabilityofthoseproducts.
6 • Johnson&Johnson2018AnnualReportSignificantchallengesordelaysintheCompany’sinnovationanddevelopmentofnewproducts,
technologiesandindicationscouldhaveanadverseimpactontheCompany’slong-termsuccess.
TheCompany’scontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated
productsandservicesthataddresstheevolvinghealthcareneedsofpatients,providersandconsumers.Developmentof
successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhentheCompany’sexistingproducts
losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivity.Newproductsintroduced
withinthepastfiveyearsaccountedforapproximately25%of2018sales.TheCompanycannotbecertainwhenor
whetheritwillbeabletodevelop,licenseorotherwiseacquirecompanies,productsandtechnologies,whetherparticular
productcandidateswillbegrantedregulatoryapproval,and,ifapproved,whethertheproductswillbecommercially
successful.
TheCompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations,
acquisitions,jointventuresandlicensingorotherarrangementswiththirdparties.Inallofthesecontexts,developingnew
products,particularlypharmaceuticalandbiotechnologyproductsandmedicaldevices,requiressignificantinvestmentof
resourcesovermanyyears.Onlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially
viableproducts.Theprocessdependsonmanyfactorsincludingtheabilitytodiscernpatients’andhealthcareproviders’
futureneeds;developpromisingnewcompounds,strategiesandtechnologies;achievesuccessfulclinicaltrialresults;
secureeffectiveintellectualpropertyprotection;obtainregulatoryapprovalsonatimelybasis;and,ifandwhentheyreach
themarket,successfullydifferentiatetheCompany’sproductsfromcompetingproductsandapproachestotreatment.
Newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue
toproductandpricecompetition,changesincustomerpreferencesorhealthcarepurchasingpatterns,resistanceby
healthcareprovidersoruncertaintyoverthird-partyreimbursement.Evenfollowinginitialregulatoryapproval,thesuccess
ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulations,aswellas
marketentryofcompetitiveproducts.
TheCompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexposes
theCompanytogovernmentinvestigations,legalactionsandpenalties.
Likeothercompaniesinthehealthcareindustry,theCompanyissubjecttoextensiveregulation,investigationsandlegal
action,bynational,stateandlocalgovernmentagenciesintheU.S.andothercountriesinwhichtheyoperate.Regulatory
issuesregardingcompliancewithGoodManufacturingPractices(cGMP)(andcomparablequalityregulationsinforeign
countries)bymanufacturersofdrugs,devicesandconsumerproductscanleadtofinesandpenalties,productrecalls,
productshortages,interruptionsinproduction,delaysinnewproductapprovalsandlitigation.Inaddition,themarketing,
pricingandsaleoftheCompany’sproductsaresubjecttoregulation,investigationsandlegalactionsincludingunderthe
FederalFood,Drug,andCosmeticAct,theMedicaidRebateProgram,federalandstatefalseclaimsacts,stateunfair
tradepracticesactsandconsumerprotectionlaws.Increasedscrutinyofhealthcareindustrybusinesspracticesinrecent
yearsbygovernmentagenciesandstateattorneysgeneralintheU.S.,andanyresultinginvestigationsandprosecutions,
carryriskofsignificantcivilandcriminalpenaltiesincluding,butnotlimitedto,debarmentfromparticipationingovernment
healthcareprograms.AnysuchdebarmentcouldhaveamaterialadverseeffectontheCompany’sbusinessandresultsof
operations.Themostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin
Note21,“LegalProceedings-GovernmentProceedings”underNotestotheConsolidatedFinancialStatementsincluded
inItem8ofthisReport.
TheCompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally.
TheCompany’sextensiveoperationsandbusinessactivityoutsidetheU.S.areaccompaniedbycertainfinancial,
economicandpoliticalrisks,includingthoselistedbelow.
ForeignCurrencyExchange:Infiscal2018,approximately49%oftheCompany’ssalesoccurredoutsideoftheU.S.,with
approximately23%inEurope,8%intheWesternHemisphere,excludingtheU.S.,and18%intheAsia-PacificandAfrica
region.Changesinnon-U.S.currenciesrelativetotheU.S.dollarimpacttheCompany’srevenuesandexpenses.While
theCompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows,
unhedgedexposurescontinuetobesubjecttocurrencyfluctuations.Inaddition,theweakeningorstrengtheningofthe
U.S.dollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe
Company’snon-U.S.businessactivityaretranslatedintoU.S.dollars.
InflationandCurrencyDevaluationRisks:TheCompanyfaceschallengesinmaintainingprofitabilityofoperationsin
economiesexperiencinghighinflationrates.TheCompanyhasaccountedforoperationsinArgentina(beginninginthe
fiscalthirdquarterof2018)andVenezuelaashighlyinflationary,asthepriorthree-yearcumulativeinflationratesurpassed
100%.WhiletheCompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprograms,productivity
Johnson&Johnson2018AnnualReport • 7improvementsandperiodicpriceincreases,itmightexperienceoperatinglossesasaresultofcontinuedinflation.In
addition,theimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange
fluctuationscouldnegativelyimpacttheCompany’soperatingresults.
IllegalImportationofPharmaceuticalProducts:Theillegalimportationofpharmaceuticalproductsfromcountrieswhere
governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffecttheCompany’ssalesand
profitabilityintheU.S.andothercountriesinwhichtheCompanyoperates.Withtheexceptionoflimitedquantitiesof
prescriptiondrugsforpersonaluse,foreignimportsofpharmaceuticalproductsareillegalundercurrentU.S.law.
However,thevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower-
pricedimportshasgrownsignificantly.
Anti-BriberyandOtherRegulations:TheCompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational
businesspracticeswithrespecttopaymentstogovernmentofficials.ThoselawsincludetheU.S.ForeignCorrupt
PracticesAct(FCPA),whichprohibitsU.S.publiclytradedcompaniesfrompromising,offering,orgivinganythingofvalue
toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingtheCompanyobtain
orretainbusinessorgainanyimproperadvantage.TheCompany’sbusinessisheavilyregulatedandthereforeinvolves
significantinteractionwithforeignofficials.Also,inmanycountriesoutsidetheU.S.,thehealthcareproviderswho
prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare
governmententities;therefore,theCompany’sinteractionswiththeseprescribersandpurchasersaresubjecttoregulation
undertheFCPA.InadditiontotheU.S.applicationandenforcementoftheFCPA,variousjurisdictionsinwhichthe
Companyoperateshavelawsandregulations,includingtheU.KBriberyAct2010,aimedatpreventingandpenalizing
corruptandanticompetitivebehavior.EnforcementactivitiesundertheselawscouldsubjecttheCompanytoadditional
administrativeandlegalproceedingsandactions,whichcouldincludeclaimsforcivilpenalties,criminalsanctions,and
administrativeremedies,includingexclusionfromhealthcareprograms.
OtherLegal,SocialandPoliticalRisks.Otherrisksinherentinconductingbusinessgloballyinclude:
• protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimport/exportlicensing
requirements;
• compliancewithlocalregulationsandlawsincluding,insomecountries,regulatoryrequirementsrestrictingthe
Company’sabilitytomanufactureorsellitsproductsintherelevantmarket;
• diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions;
• potentialnationalizationorexpropriationoftheCompany’sforeignassets;and
• disruptionstomarketsduetowar,armedconflict,terrorism,socialupheavalsorpandemics.
InterruptionsanddelaysinmanufacturingoperationscouldadverselyaffecttheCompany’sbusiness,sales
andreputation.
TheCompany’smanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplex,high-quality
componentsandmaterials.TheCompany’ssubsidiariesoperate111manufacturingfacilitiesaswellassourcingfrom
hundredsofsuppliersaroundtheworld.TheCompanyhasinthepast,andmayinthefuture,faceunanticipated
interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychain.Manufacturingdisruptionscanoccur
formanyreasonsincludingregulatoryaction,productionqualitydeviationsorsafetyissues,labordisputes,site-specific
incidents(suchasfires),naturaldisasterssuchashurricanesandothersevereweatherevents,rawmaterialshortages,
politicalunrestandterroristattacks.Suchdelaysanddifficultiesinmanufacturingcanresultinproductshortages,declines
insalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociatedwithaddressingthe
shortage.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Anyfailurebyorlossofathird
partymanufacturercouldresultindelaysandincreasedcosts,whichmayadverselyaffectourbusiness.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Wedependonthesethirdparty
manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneeds,toproduceproducts
ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat
acceptableprices.However,wecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournear-term
orlong-termmanufacturingrequirements,whichcouldresultinlostsalesandhaveanadverseeffectonourbusiness.
Otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsinclude,relianceonthethirdparty
forregulatorycomplianceandqualityassurance,misappropriationoftheCompany’sintellectualproperty,limitedabilityto
manageourinventory,possiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor
nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforus.Moreover,if
8 • Johnson&Johnson2018AnnualReportanyofourthirdpartymanufacturerssufferanydamagetofacilities,losebenefitsundermaterialagreements,experience
poweroutages,encounterfinancialdifficulties,areunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsuffer
anyotherreductioninefficiency,theCompanymayexperiencesignificantbusinessdisruption.Intheeventofanysuch
disruption,theCompanywouldneedtoseekandsourceotherqualifiedthirdpartymanufacturers,likelyresultinginfurther
delaysandincreasedcostswhichcouldaffectourbusinessadversely.
Aninformationsecurityincident,includingacybersecuritybreach,couldhaveanegativeimpacttothe
Company’sbusinessorreputation.
Tomeetbusinessobjectives,theCompanyreliesonbothinternalinformationtechnology(IT)systemsandnetworks,and
thoseofthirdpartiesandtheirvendors,toprocessandstoresensitivedata,includingconfidentialresearch,business
plans,financialinformation,intellectualproperty,andpersonaldatathatmaybesubjecttolegalprotection.Theextensive
informationsecurityandcybersecuritythreats,whichaffectcompaniesglobally,posearisktothesecurityandavailability
oftheseITsystemsandnetworks,andtheconfidentiality,integrity,andavailabilityoftheCompany’ssensitivedata.The
Companycontinuallyassessesthesethreatsandmakesinvestmentstoincreaseinternalprotection,detection,and
responsecapabilities,aswellasensuretheCompany’sthirdpartyprovidershaverequiredcapabilitiesandcontrols,to
addressthisrisk.Todate,theCompanyhasnotexperiencedanymaterialimpacttothebusinessoroperationsresulting
frominformationorcybersecurityattacks;however,becauseofthefrequentlychangingattacktechniques,alongwiththe
increasedvolumeandsophisticationoftheattacks,thereisthepotentialfortheCompanytobeadverselyimpacted.This
impactcouldresultinreputational,competitive,operationalorotherbusinessharmaswellasfinancialcostsand
regulatoryaction.TheCompanymaintainscybersecurityinsuranceintheeventofaninformationsecurityorcyberincident,
however,thecoveragemaynotbesufficienttocoverallfinanciallosses.
Item 1B. UNRESOLVED STAFF COMMENTS
Notapplicable.
Item 2. PROPERTIES
TheCompany’ssubsidiariesoperate111manufacturingfacilitiesoccupyingapproximately20.5millionsquarefeetoffloor
space.ThemanufacturingfacilitiesareusedbytheindustrysegmentsoftheCompany’sbusinessapproximatelyas
follows:
SquareFeet
Segment (inthousands)
Consumer 6,503
Pharmaceutical 6,819
MedicalDevices 7,183
WorldwideTotal 20,505
WithintheU.S.,fivefacilitiesareusedbytheConsumersegment,fivebythePharmaceuticalsegmentand27bythe
MedicalDevicessegment.OutsideoftheU.S.,25facilitiesareusedbytheConsumersegment,14bythePharmaceutical
segmentand35bytheMedicalDevicessegment.
Thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows:
SquareFeet
GeographicArea NumberofFacilities (inthousands)
UnitedStates 37 5,855
Europe 34 7,587
WesternHemisphere,excludingU.S. 12 2,800
Africa,AsiaandPacific 28 4,263
WorldwideTotal 111 20,505
Inadditiontothemanufacturingfacilitiesdiscussedabove,theCompanymaintainsnumerousofficeandwarehouse
facilitiesthroughouttheworld.ResearchfacilitiesarealsodiscussedinItem7.“Management’sDiscussionandAnalysisof
ResultsofOperationsandFinancialCondition”ofthisReport.
Johnson&Johnson2018AnnualReport • 9TheCompany’ssubsidiariesgenerallyseektoown,ratherthanlease,theirmanufacturingfacilities,althoughsome,
principallyinnon-U.S.locations,areleased.Officeandwarehousefacilitiesareoftenleased.TheCompanyalsoengages
contractmanufacturers.
TheCompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition.
McNEIL-PPC,Inc.(nowJohnson&JohnsonConsumerInc.)(McNEIL-PPC)continuestooperateunderaconsentdecree,
signedin2011withtheFDA,whichgovernscertainMcNeilConsumerHealthcaremanufacturingoperations,andrequires
McNEIL-PPCtoremediatethefacilitiesitoperatesinLancaster,Pennsylvania,FortWashington,Pennsylvania,andLas
Piedras,PuertoRico(the“ConsentDecree”).FollowingFDAinspectionsin2015,McNEIL-PPCreceivednotifications
fromtheFDAthatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulations,andcommercial
productionhasrestarted.
UndertheConsentDecree,afterreceivingnoticefromtheFDAofbeingincompliancewithapplicablelawsand
regulations,eachofthethreefacilitiesissubjecttoafive-yearauditperiodbyathird-partycGMPexpert.Thus,athird-
partyexpertwillcontinuetoreassessthesitesatvarioustimesuntilatleast2020.
Forinformationregardingleaseobligations,seeNote16“RentalExpenseandLeaseCommitments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.Segmentinformationonadditionstoproperty,plant
andequipmentiscontainedinNote18“SegmentsofBusinessandGeographicAreas”oftheNotestoConsolidated
FinancialStatementsincludedinItem8ofthisReport.
Item 3. LEGAL PROCEEDINGS
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinNote21“Legal
Proceedings”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Inaddition,Johnson&Johnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe
ComprehensiveEnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,and
comparablestate,localorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
Item 4. MINE SAFETY DISCLOSURES
Notapplicable.
10 • Johnson&Johnson2018AnnualReportEXECUTIVE OFFICERS OF THE REGISTRANT
ListedbelowaretheexecutiveofficersoftheCompany.Therearenofamilyrelationshipsbetweenanyoftheexecutive
officers,andthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto
whichtheexecutiveofficerwasselected.AttheannualmeetingoftheBoardofDirectors,theexecutiveofficersare
electedbytheBoardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualified,oruntil
earlierresignationorremoval.
InformationwithregardtothedirectorsoftheCompany,includinginformationforAlexGorsky,whoisalsoanexecutive
officer,isincorporatedhereinbyreferencetothematerialcaptioned“Item1.ElectionofDirectors”intheProxyStatement.
Name Age Position
JoaquinDuato 56 ViceChairman,ExecutiveCommittee(a)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefHuman
PeterM.Fasolo 56
ResourcesOfficer(b)
Chairman,BoardofDirectors;Chairman,ExecutiveCommittee;ChiefExecutive
AlexGorsky 58
Officer
Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
AshleyMcEvoy 48
MedicalDevices(c)
Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
JorgeMesquita 57
Consumer(d)
Appointee,Member,ExecutiveCommittee,ExecutiveVicePresident,Worldwide
ThibautMongon 49
Chairman,Consumer(e)
Member,ExecutiveCommittee;ExecutiveVicePresident,GlobalCorporate
MichaelE.Sneed 59
AffairsandChiefCommunicationOfficer(f)
PaulusStoffels 56 ViceChairman,ExecutiveCommittee;ChiefScientificOfficer(g)
Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
JenniferL.Taubert 55
Pharmaceuticals(h)
MichaelH.Ullmann 60 Member,ExecutiveCommittee;ExecutiveVicePresident,GeneralCounsel(i)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefGlobalSupply
KathrynE.Wengel 53
ChainOfficer(j)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefFinancial
JosephJ.Wolk 52
Officer(k)
(a) Mr.J.DuatojoinedtheCompanyin1989withJanssen-FarmaceuticaS.A.(Spain),asubsidiaryoftheCompany,andheldexecutive
positionsofincreasingresponsibilityinthePharmaceuticalsector.In2009,hewasnamedCompanyGroupChairman,
Pharmaceuticals,andin2011,hewasnamedWorldwideChairman,Pharmaceuticals.In2016,Mr.Duatobecameamemberofthe
ExecutiveCommitteeandwasnamedExecutiveVicePresident,WorldwideChairman,Pharmaceuticals.InJuly2018,Mr.Duatowas
promotedtoViceChairmanoftheExecutiveCommittee,withresponsibilityforthecompany’sPharmaceuticalandConsumersectors,
supplychain,informationtechnology,globalservicesandtheHealth&Wellnessgroups.
(b) Dr.P.M.FasolojoinedtheCompanyin2004asVicePresident,WorldwideHumanResourcesforCordisCorporation,asubsidiary
oftheCompany,andwassubsequentlynamedVicePresident,GlobalTalentManagementfortheCompany.Heleft
Johnson&Johnsonin2007tojoinKohlbergKravisRoberts&Co.asChiefTalentOfficer.Dr.FasoloreturnedtotheCompanyin
2010astheVicePresident,GlobalHumanResources,andin2011,hebecameamemberoftheExecutiveCommittee.InApril
2016,hewasnamedExecutiveVicePresident,ChiefHumanResourcesOfficer.Dr.Fasolohasresponsibilityforglobaltalent,
recruiting,diversity,compensation,benefits,employeerelationsandallaspectsofthehumanresourcesagendafortheCompany.
(c) Ms.A.McEvoyjoinedtheCompanyin1997asAssistantBrandManagerofMcNeilConsumerHealth,asubsidiaryoftheCompany,
advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedCompanyGroupChairman,VisionCarein2012,
followedbyCompanyGroupChairman,ConsumerMedicalDevicesin2014.InJuly2018,Ms.McEvoywaspromotedtoExecutive
VicePresident,WorldwideChairman,MedicalDevices,andbecameamemberoftheExecutiveCommittee.Shehasresponsibilityfor
thesurgery,orthopaedics,interventionalsolutionsandeyehealthbusinessesacrossEthicon,DePuySynthes,BiosenseWebsterand
Johnson&JohnsonVision.
(d) Mr.J.MesquitajoinedtheCompanyin2014asWorldwideChairman,Consumer.PriortojoiningtheCompany,heservedinvarious
marketingandleadershipcapacitiesacrossLatinAmerica,includingrolesinOralCareandBeautyatTheProcter&Gamble
Johnson&Johnson2018AnnualReport • 11Companyfrom1984to2013.InApril2016,Mr.MesquitabecameamemberoftheExecutiveCommitteeandwaspromotedto
ExecutiveVicePresident,WorldwideChairman,Consumer.Mr.MesquitaplanstoretirefromtheCompanyinMarch2019.
(e) Mr.T.MongonjoinedtheCompanyin2000asDirectorofMarketingfortheVisionCaregroupinFranceandsubsequentlyheld
generalmanagementpositionsasCountryManagerFrance,BelgiumandNorthAfrica,ManagingDirectorLatinAmerica,and
PresidentAsia-Pacific.Mr.MongontransitionedtothePharmaceuticalsectorin2012astheGlobalCommercialStrategyLeaderfor
theNeurosciencetherapeuticarea,beforejoiningtheconsumersectorasCompanyGroupChairmanAsia-Pacific.TheCompanyhas
announcedthatMr.MongonwillbenamedExecutiveVicePresidentandWorldwideChairman,Consumer,andamemberofthe
ExecutiveCommittee,upontheretirementofhispredecessor,Mr.Mesquita,effectiveMarch1,2019.Inadditiontoleadingthe
Consumerbusiness,Mr.MongonwillhaveresponsibilityforJohnson&JohnsonSoutheastAsia.
(f) Mr.M.E.SneedjoinedtheCompanyin1986asProductDirectorforPersonalProducts,asubsidiaryoftheCompany,andgained
increasedresponsibilitiesinexecutivepositionsacrosstheglobalenterprise.In2004,Mr.SneedwasappointedCompanyGroup
Chairman,ConsumerNorthAmerica,followedbyCompanyGroupChairman,VisionCareFranchisein2007.In2012,hebecame
theVicePresident,GlobalCorporateAffairsandChiefCommunicationsOfficer.Mr.SneedwasappointedExecutiveVicePresident,
GlobalCorporateAffairsandChiefCommunicationsOfficerinJanuary2018,andbecameamemberoftheExecutiveCommitteein
July2018,leadingthecorporation’sglobalmarketing,communication,designandphilanthropyfunctions.
(g) Dr.P.StoffelsjoinedtheCompanyin2002withtheacquisitionofTibotecVircoNV,wherehewasChiefExecutiveOfficerofVirco
NVandChairmanofTibotecNV.In2005,hewasappointedCompanyGroupChairman,GlobalVirology.In2006,heassumedthe
roleofCompanyGroupChairman,Pharmaceuticals.Dr.StoffelswasappointedGlobalHead,Research&Development,
Pharmaceuticalsin2009,andin2011,becameWorldwideChairman,Pharmaceuticals.In2012,Dr.StoffelswasappointedChief
ScientificOfficer,andbecameamemberoftheExecutiveCommittee.In2016,Dr.StoffelswasnamedExecutiveVicePresident,
ChiefScientificOfficer.In2018,Dr.StoffelswaspromotedtoViceChairmanoftheExecutiveCommittee,ChiefScientificOfficer.He
isresponsiblefortheCompany’sinnovationagendaacrossthePharmaceutical,MedicalDevicesandConsumersectors,product
safetystrategy,andtheCompany’sglobalpublichealthstrategy.
(h) Ms.J.L.TaubertjoinedtheCompanyin2005asWorldwideVicePresidentatJohnson&JohnsonPharmaceuticalServices,a
subsidiaryoftheCompany.SheheldseveralexecutivepositionsinthePharmaceuticalsectoruntil2012whenshewasappointed
CompanyGroupChairman,NorthAmericaPharmaceuticals,andin2015becameCompanyGroupChairman,TheAmericas,
Pharmaceuticals.InJuly2018,Ms.TaubertwaspromotedtoExecutiveVicePresident,WorldwideChairman,Pharmaceuticals,and
becameamemberoftheExecutiveCommittee.
(i) Mr.M.H.UllmannjoinedtheCompanyin1989asacorporateattorneyintheLawDepartment.HewasappointedCorporate
Secretaryin1999andservedinthatroleuntil2006.Duringthattime,healsoheldvariousmanagementpositionsintheLaw
Department.In2006,hewasnamedGeneralCounsel,MedicalDevicesandDiagnosticsandwasappointedVicePresident,General
CounselandbecameamemberoftheExecutiveCommitteein2012.InApril2016,Mr.UllmannwasnamedExecutiveVice
President,GeneralCounsel.Mr.Ullmannhasworldwideresponsibilityforlegal,governmentaffairs&policy,globalsecurity,aviation
andhealthcarecompliance&privacy.
(j) Ms.K.E.WengeljoinedtheCompanyin1988asProjectEngineerandEngineeringSupervisoratJanssen,asubsidiaryofthe
Company.DuringhertenurewiththeCompany,shehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe
globalenterprise,inroleswithinoperations,quality,engineering,newproducts,informationtechnology,andothertechnicaland
businessfunctions.In2010,Ms.WengelbecamethefirstChiefQualityOfficeroftheCompany.In2014,shewaspromotedtoVice
President,Johnson&JohnsonSupplyChain.InJuly2018,shewaspromotedtoExecutiveVicePresident,ChiefGlobalSupplyChain
Officer,andbecameamemberoftheExecutiveCommittee.
(k) Mr.J.J.WolkjoinedtheCompanyin1998asFinanceManager,BusinessDevelopmentforOrtho-McNeil,asubsidiaryofthe
Company,andthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrosstheCompany’s
subsidiaries,inPharmaceuticals,MedicalDevicesandSupplyChain.From2014to2016,heservedasVicePresident,Financeand
ChiefFinancialOfficeroftheJanssenPharmaceuticalCompaniesofJohnson&Johnson.In2016,Mr.WolkbecametheVice
President,InvestorRelations.InJuly2018,hewasappointedExecutiveVicePresident,ChiefFinancialOfficerandbecameamember
oftheExecutiveCommittee.Mr.WolkisresponsibleforleadingthedevelopmentandexecutionoftheCompany’sgloballong-term
financialstrategy.
12 • Johnson&Johnson2018AnnualReportPART II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES
AsofFebruary15,2019,therewere142,029recordholdersofcommonstockoftheCompany.Additionalinformation
calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisReport:Note17“Common
Stock,StockOptionPlansandStockCompensationAgreements”oftheNotestoConsolidatedFinancialStatements
includedinItem8;andItem12“SecurityOwnershipofCertainBeneficialOwnersandManagementandRelated
StockholderMatters—EquityCompensationPlanInformation”.
Issuer Purchases of Equity Securities
OnDecember17,2018,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’sCommonStock.Sharerepurchasestakeplace
fromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactions.Therepurchaseprogramhasnotime
limitandmaybesuspendedforperiodsordiscontinuedatanytime.
ThefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbytheCompanyduringthefiscalfourth
quarterof2018.Commonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds
oftheCompany’scompensationprograms.Therepurchasesbelowalsoincludethestock-for-stockoptionexercisesthat
settledinthefiscalfourthquarter.
TotalNumberof MaximumNumber(or
Shares(orUnits) ApproximateDollar
PurchasedasPart Value)ofShares(orUnits)
TotalNumber ofPublicly thatMayYetBe
ofShares Avg.Price AnnouncedPlans PurchasedUnderthe
Period Purchased(1) PaidPerShare orPrograms(2) PlansorPrograms(3)
October1,2018throughOctober28,
2018 2,192,500 $138.74 — —
October29,2018throughNovember25,
2018 6,849,298 143.27 — —
November26,2018through
December30,2018 18,130,189 139.10 7,073,136 32,131,870
Total 27,171,987
(1) Duringthefiscalfourthquarterof2018,theCompanyrepurchasedanaggregateof27,171,987sharesofJohnson&Johnson
CommonStockinopen-markettransactions,ofwhich7,073,136shareswerepurchasedpursuanttotherepurchaseprogramthat
waspubliclyannouncedonDecember17,2018,andofwhich20,098,851shareswerepurchasedinopen-markettransactionsas
partofasystematicplantomeettheneedsoftheCompany’scompensationprograms.
(2) AsofDecember30,2018,anaggregateof7,073,136shareswerepurchasedforatotalof$0.9billionsincetheinceptionofthe
repurchaseprogramannouncedonDecember17,2018.
(3) AsofDecember30,2018,themaximumnumberofsharesthatmayyetbepurchasedundertheplanis32,131,870basedonthe
closingpriceofJohnson&JohnsonCommonStockontheNewYorkStockExchangeonDecember28,2018of$127.27pershare.
Johnson&Johnson2018AnnualReport • 13Item 6. SELECTED FINANCIAL DATA
Summary of Operations and Statistical Data 2008-2018*
(DollarsinMillionsExcept
PerShareAmounts) 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Salestocustomers—U.S. $41,884 39,863 37,811 35,687 34,782 31,910 29,830 28,908 29,450 30,889 32,309
Salestocustomers—
International 39,697 36,587 34,079 34,387 39,549 39,402 37,394 36,122 32,137 31,008 31,438
Totalsales 81,581 76,450 71,890 70,074 74,331 71,312 67,224 65,030 61,587 61,897 63,747
Costofproductssold 27,091 25,439 21,789 21,426 22,684 22,181 21,515 20,219 18,688 18,380 18,463
Selling,marketingand
administrativeexpenses 22,540 21,520 20,067 21,079 21,887 21,650 20,697 20,800 19,296 19,712 21,431
Researchanddevelopment
expense 10,775 10,594 9,143 8,999 8,471 8,119 7,602 7,486 6,796 6,949 7,554
In-processresearchand
development 1,126 408 29 224 178 580 1,163 — — — 181
Interestincome (611) (385) (368) (128) (67) (74) (64) (91) (107) (90) (361)
Interestexpense,netof
portioncapitalized 1,005 934 726 552 533 482 532 571 455 451 435
Other(income)expense,
net 1,405 (42) 210 (1,783) 82 2,903 2,004 3,115 (488) (333) (885)
Restructuring 251 309 491 509 — — — 569 — 1,073 —
63,582 58,777 52,087 50,878 53,768 55,841 53,449 52,669 44,640 46,142 46,818
Earningsbeforeprovision
fortaxesonincome $17,999 17,673 19,803 19,196 20,563 15,471 13,775 12,361 16,947 15,755 16,929
Provisionfortaxeson
income 2,702 16,373 3,263 3,787 4,240 1,640 3,261 2,689 3,613 3,489 3,980
Netearnings 15,297 1,300 16,540 15,409 16,323 13,831 10,514 9,672 13,334 12,266 12,949
Add:Netlossattributable
tononcontrollinginterest — — — — — — 339 — — — —
Netearnings
attributableto
Johnson&Johnson 15,297 1,300 16,540 15,409 16,323 13,831 10,853 9,672 13,334 12,266 12,949
Percentofsalesto
customers 18.8% 1.7 23.0 22.0 22.0 19.4 16.1 14.9 21.7 19.8 20.3
Dilutednetearningsper
shareofcommonstock(1) $5.61 0.47 5.93 5.48 5.70 4.81 3.86 3.49 4.78 4.40 4.57
Percentreturnonaverage
shareholders’equity 25.5% 2.0 23.4 21.9 22.7 19.9 17.8 17.0 24.9 26.4 30.2
Percentincrease
(decrease)over
previousyear:
Salestocustomers 6.7% 6.3 2.6 (5.7) 4.2 6.1 3.4 5.6 (0.5) (2.9) 4.3
Dilutednetearningsper
share N/M (92.1)% 8.2 (3.9) 18.5 24.6 10.6 (27.0) 8.6 (3.7) 25.9
Supplementarybalance
sheetdata:
Property,plantand
equipment,net 17,035 17,005 15,912 15,905 16,126 16,710 16,097 14,739 14,553 14,759 14,365
Additionstoproperty,plant
andequipment 3,670 3,279 3,226 3,463 3,714 3,595 2,934 2,893 2,384 2,365 3,066
Totalassets 152,954 157,303 141,208 133,411 130,358 131,754 121,347 113,644 102,908 94,682 84,912
Long-termdebt 27,684 30,675 22,442 12,857 15,122 13,328 11,489 12,969 9,156 8,223 8,120
Operatingcashflow 22,201 21,056 18,767 19,569 18,710 17,414 15,396 14,298 16,385 16,571 14,972
Commonstock
information
Dividendspaidpershare $3.54 3.32 3.15 2.95 2.76 2.59 2.40 2.25 2.11 1.93 1.795
Shareholders’equityper
share 22.44 22.43 26.02 25.82 25.06 26.25 23.33 20.95 20.66 18.37 15.35
Marketpricepershare
(year-endclose) $127.27 139.72 115.21 102.72 105.06 92.35 69.48 65.58 61.85 64.41 58.56
Averagesharesoutstanding
(millions)
—basic 2,681.5 2,692.0 2,737.3 2,771.8 2,815.2 2,809.2 2,753.3 2,736.0 2,751.4 2,759.5 2,802.5
—diluted 2,728.7 2,745.3 2,788.9 2,812.9 2,863.9 2,877.0 2,812.6 2,775.3 2,788.8 2,789.1 2,835.6
Employees(thousands) 135.1 134.0 126.4 127.1 126.5 128.1 127.6 117.9 114.0 115.5 118.7
(1) AttributabletoJohnson&Johnson
* PertheadoptionofASU2017-07prioryearamountsontheConsolidatedStatementofEarningshavebeenreclassifiedtoretroactivelyapply
classificationoftheservicecostcomponentandtheothercomponentsofnetperiodicbenefitcost
N/M=NotMeaningful
14 • Johnson&Johnson2018AnnualReportItem 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF
OPERATIONS AND FINANCIAL CONDITION
Organization and Business Segments
DescriptionoftheCompanyandBusinessSegments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately135,100employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.The
Consumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty,over-the-counter
pharmaceutical,women’shealthandwoundcaremarkets.Theseproductsaremarketedtothegeneralpublicandsold
bothtoretailoutletsanddistributorsthroughouttheworld.ThePharmaceuticalsegmentisfocusedonsixtherapeutic
areas,includingimmunology,infectiousdiseases,neuroscience,oncology,pulmonaryhypertension,andcardiovascular
andmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealth
careprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroadrangeofproductsusedinthe
orthopaedic,surgery,interventionalsolutions(cardiovascularandneurovascular),diabetescare(divestedinthefiscal
fourthquarterof2018)andvisionfieldswhicharedistributedtowholesalers,hospitalsandretailers,andusedprincipally
intheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Consumer,PharmaceuticalandMedicalDevicesbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithcompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotectingtheunderlyingintellectual
propertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareasofitsbusiness.The
competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,thedevelopmentand
maintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvessignificantexpendituresforadvertising
andpromotion.
Johnson&Johnson2018AnnualReport • 15Management’sObjectives
With“OurCredo”asthefoundation,theCompany’spurposeistoblendheart,scienceandingenuitytoprofoundly
changethetrajectoryofhealthforhumanity.TheCompanyiscommittedtobringingitsfullbreadthanddepthtoensure
healthforpeopletodayandforfuturegenerations.Unitedaroundthiscommonambition,theCompanyispoisedtofulfillits
purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes.
TheCompanyisbroadlybasedinhumanhealthcare,andiscommittedtocreatingvaluebydevelopingaccessible,high
quality,innovativeproductsandservices.Newproductsintroducedwithinthepastfiveyearsaccountedforapproximately
25%of2018sales.In2018,$10.8billionwasinvestedinresearchanddevelopmentand$0.9billionspenton
acquisitions,reflectingmanagement’scommitmenttocreatelife-enhancinginnovationsandtocreatevaluethrough
partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity.
AcriticaldriveroftheCompany’ssuccess,isthe135,100diverseemployeesthatworkacrossmorethan260operating
companies,whicharelocatedinmorethan60countries.Employeesareempoweredandinspiredtoleadwiththe
Company’sOurCredoandpurposeasguides.ThisallowseveryemployeetousetheCompany’sreachandsizeto
advancetheCompany’spurpose,andtoalsoleadwithagilityandurgency.Leveragingtheextensiveresourcesacrossthe
enterprise,enablestheCompanytoinnovateandexecutewithexcellence.ThisensurestheCompanycanremainfocused
onaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact,ultimatelydeliveringvaluetoits
patients,consumersandhealthcareprofessionals,employees,communitiesandshareholders.
10.8
snoilliB
nI
$
snoilliB
nI
$
sralloD
nI
Research & Acquisi(cid:2)ons (net of cash Dividends Paid Per
Development acquired) Share
10.6
9.1 3.54 3.32 3.15 35.2
4.5 0.9
2018 2017 2016 2018 2017 2016 2018 2017 2016
Results of Operations
AnalysisofConsolidatedSales
In2018,worldwidesalesincreased6.7%to$81.6billion,comparedtoanincreasesof6.3%and2.6%in2017and
2016,respectively.Thesesaleschangesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2018 2017 2016
Volume 8.5% 8.0% 3.2%
Price (2.2) (2.0) 0.7
Currency 0.4 0.3 (1.3)
Total 6.7% 6.3% 2.6%
In2018,thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasapositiveimpactof0.8%.In
2017,acquisitionsanddivestitureshadapositiveimpactof3.6%ontheworldwidesalesgrowth.In2016,acquisitions
anddivestitureshadanegativeimpactof1.1%ontheworldwidesalesgrowthandcompetitiveproductstothe
Company’sHepatitisCproducts,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),hadanegativeimpactof
0.8%ontheworldwidesalesgrowth.OperationsinVenezuelanegativelyimpactedtheworldwidesalesgrowth0.3%.
SalesbyU.S.companieswere$41.9billionin2018,$39.9billionin2017and$37.8billionin2016.Thisrepresents
increasesof5.1%in2018,5.4%in2017and6.0%in2016.Salesbyinternationalcompanieswere$39.7billionin2018,
$36.6billionin2017and$34.1billionin2016.Thisrepresentsanincreaseof8.5%in2018,7.4%in2017,anda
decreaseof0.9%in2016.
16 • Johnson&Johnson2018AnnualReportThefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere2.7%,5.6%and0.1%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere2.5%,2.6%and
2.4%,respectively.
In2018,salesbycompaniesinEuropeachievedgrowthof9.5%ascomparedtotheprioryear,includingoperational
growthof6.2%andapositivecurrencyimpactof3.3%.SalesbycompaniesintheWesternHemisphere(excludingthe
U.S.)achievedgrowthof1.2%ascomparedtotheprioryear,includingoperationalgrowthof8.2%andanegative
currencyimpactof7.0%.SalesbycompaniesintheAsia-Pacific,Africaregionachievedgrowthof10.5%ascomparedto
theprioryear,includingoperationalgrowthof9.4%andapositivecurrencyimpactof1.1%.
In2018,theCompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately
14.0%,11.0%and11.0%ofthetotalconsolidatedrevenues.In2017,theCompanyhadtwowholesalersdistributing
productsforallthreesegmentsthatrepresentedapproximately14.0%and10.0%ofthetotalconsolidatedrevenues.In
2016,theCompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately
13.5%and10.7%ofthetotalconsolidatedrevenues.
2018 Sales by Geographic Region (in billions) 2018 Sales by Segment (in billions)
$41.9
$27.0
$40.7
$14.8
$6.1
$18.8 $13.9
Europe Western Hemisphere Consumer Pharmaceutical
Asia-Pacific, Africa U.S. Medical Devices
Analysis of Sales by Business Segments
ConsumerSegment
Consumersegmentsalesin2018were$13.9billion,anincreaseof1.8%from2017,whichincluded2.2%operational
growthandanegativecurrencyimpactof0.4%.U.S.Consumersegmentsaleswere$5.8billion,anincreaseof3.5%.
Internationalsaleswere$8.1billion,anincreaseof0.7%,whichincluded1.4%operationalgrowthandanegative
currencyimpactof0.7%.In2018,acquisitionsanddivestitureshadanetnegativeimpactof1.0%ontheoperational
salesgrowthoftheworldwideConsumersegment.
MajorConsumerFranchiseSales:
%Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
Beauty $4,382 4,200 3,897 4.3% 7.8
OTC 4,334 4,126 3,977 5.0 3.7
BabyCare 1,858 1,916 2,001 (3.0) (4.2)
OralCare 1,555 1,531 1,568 1.6 (2.4)
Women’sHealth 1,049 1,050 1,067 (0.1) (1.6)
WoundCare/Other 675 779 797 (13.4) (2.3)
TotalConsumerSales $13,853 13,602 13,307 1.8% 2.2
Johnson&Johnson2018AnnualReport • 17TheBeautyfranchisesalesof$4.4billionincreased4.3%ascomparedtotheprioryear.Growthwasprimarilydrivenby
NEUTROGENA®,OGX®andAVEENO®productsaswellasstrengthofDR.CI:LABOandDABAO®productsoutside
theU.S.GrowthwaspartiallyoffsetbythedivestitureofNIZORAL®.
TheOver-the-Counter(OTC)franchisesalesof$4.3billionincreased5.0%ascomparedtotheprioryear.Growthwas
primarilydrivenbyshare,consumptionandmarketgrowthacrossmultiplebrandsincludingZYRTEC®,TYLENOL®and
Children’sMOTRIN®,aswellasdigestivehealthproductsandanti-smokingaids.Additionally,salesfromtherecentU.S.
acquisitionofZarbee’sInc.contributedapproximately0.9%togrowth.
TheBabyCarefranchisesaleswere$1.9billionin2018,adecreaseof3.0%comparedtotheprioryear,primarilydueto
JOHNSON’s®sharedeclineandincreasedtradepromotionsduetotheJOHNSON’s®babyrelaunchandthenegative
impactofcurrency.ThiswaspartiallyoffsetbystronggrowthofAVEENO®babydrivenbygeographicexpansion.
TheOralCarefranchisesalesof$1.6billionincreased1.6%ascomparedtotheprioryear,primarilydrivenbystrong
marketingcampaignsandnewproductlaunches.
TheWomen’sHealthfranchisesaleswere$1.0billionin2018,adecreaseof0.1%ascomparedtotheprioryear.Growth
inLatinAmericawasoffsetbythenegativeimpactofcurrency.
TheWoundCare/Otherfranchisesaleswere$0.7billionin2018,adecreaseof13.4%ascomparedtotheprioryear,
primarilyduetothedivestitureofCOMPEED®.
Consumersegmentsalesin2017were$13.6billion,anincreaseof2.2%from2016,whichincluded1.3%operational
growthandapositivecurrencyimpactof0.9%.U.S.Consumersegmentsaleswere$5.6billion,anincreaseof2.7%.
Internationalsaleswere$8.0billion,anincreaseof1.9%,whichincluded0.4%operationalgrowthandapositivecurrency
impactof1.5%.In2017,acquisitionsanddivestitureshadanetpositiveimpactof1.8%ontheoperationalsalesgrowth
oftheworldwideConsumersegment.
18 • Johnson&Johnson2018AnnualReportPharmaceutical Segment
Pharmaceuticalsegmentsalesin2018were$40.7billion,anincreaseof12.4%from2017,whichincludedoperational
growthof11.8%andapositivecurrencyimpactof0.6%.U.S.saleswere$23.3billion,anincreaseof8.4%.International
saleswere$17.4billion,anincreaseof18.0%,whichincluded16.5%operationalgrowthandapositivecurrencyimpact
of1.5%.In2018,acquisitionsanddivestitureshadanetpositiveimpactof3.4%ontheoperationalsalesgrowthofthe
worldwidePharmaceuticalsegment.
MajorPharmaceutical TherapeuticAreaSales:*
%Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
TotalImmunology $13,120 12,244 11,968 7.2% 2.3
REMICADE® 5,326 6,315 6,966 (15.7) (9.3)
SIMPONI®/SIMPONIARIA® 2,084 1,833 1,745 13.7 5.0
STELARA® 5,156 4,011 3,232 28.5 24.1
TREMFYA® 544 63 — ** **
OtherImmunology 10 22 25 (54.5) (12.0)
TotalInfectiousDiseases 3,304 3,154 3,208 4.8 (1.7)
EDURANT®/rilpivirine 816 714 573 14.3 24.6
PREZISTA®/PREZCOBIX®/REZOLSTA®/SYMTUZA® 1,955 1,821 1,851 7.4 (1.6)
OtherInfectiousDiseases 533 619 784 (13.9) (21.0)
TotalNeuroscience 6,077 5,986 6,085 1.5 (1.6)
CONCERTA®/methylphenidate 663 791 863 (16.2) (8.3)
INVEGASUSTENNA®/XEPLION®/INVEGATRINZA®/
TREVICTA® 2,928 2,569 2,214 14.0 16.0
RISPERDALCONSTA® 737 805 893 (8.4) (9.9)
OtherNeuroscience 1,749 1,821 2,115 (4.0) (13.9)
TotalOncology 9,844 7,258 5,807 35.6 25.0
DARZALEX® 2,025 1,242 572 63.0 **
IMBRUVICA® 2,615 1,893 1,251 38.1 51.3
VELCADE® 1,116 1,114 1,224 0.2 (9.0)
ZYTIGA®/abirateroneacetate 3,498 2,505 2,260 39.6 10.8
OtherOncology 590 504 500 17.1 0.8
PulmonaryHypertension 2,573 1,327 — 93.9 ***
OPSUMIT® 1,215 573 — ** ***
TRACLEER® 546 403 — 35.5 ***
UPTRAVI® 663 263 — ** ***
Other 149 88 — 69.3 ***
Cardiovascular/Metabolism/Other 5,816 6,287 6,396 (7.5) (1.7)
XARELTO® 2,477 2,500 2,288 (0.9) 9.3
INVOKANA®/INVOKAMET® 881 1,111 1,407 (20.7) (21.0)
PROCRIT®/EPREX® 988 972 1,105 1.6 (12.0)
Other 1,470 1,704 1,596 (13.7) 6.8
TotalPharmaceuticalSales $40,734 36,256 33,464 12.4% 8.3
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** Percentagegreaterthan100%ornotmeaningful
*** ProductsacquiredfromActeliononJune16,2017
Johnson&Johnson2018AnnualReport • 19Immunologyproductssaleswere$13.1billionin2018,representinganincreaseof7.2%ascomparedtotheprioryear.
GrowthwasdrivenbystronguptakeofSTELARA®(ustekinumab)inCrohn’sdisease,stronglaunchuptakeofTREMFYA®
(guselkumab),expandedindicationsofSIMPONI®/SIMPONIARIA®(golimumab),andtheU.S.immunologymarket
growth.ImmunologywasnegativelyimpactedbylowersalesofREMICADE®(infliximab)duetoincreaseddiscounts/
rebatesandbiosimilarcompetition.
ThepatentsforREMICADE®(infliximab)incertaincountriesinEuropeexpiredinFebruary2015.Biosimilarversionsof
REMICADE®havebeenintroducedincertainmarketsoutsidetheU.S.,resultinginareductioninsalesofREMICADE®in
thosemarkets.AdditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninREMICADE®salesinmarkets
outsidetheUnitedStates.IntheU.S.,abiosimilarversionofREMICADE®wasintroducedin2016,andadditional
competitorscontinuetoenterthemarket.ContinuedinfliximabbiosimilarcompetitionintheU.S.marketwillresultina
furtherreductioninU.S.salesofREMICADE®.SeeNote21totheConsolidatedFinancialStatementsforadescriptionof
legalmattersregardingtheREMICADE®patents.
Infectiousdiseaseproductssaleswere$3.3billionin2018,representinganincreaseof4.8%ascomparedtotheprior
year.SalesgrowthofPREZCOBIX®/REZOLSTA®(darunavir/cobicistat),EDURANT®/rilpivirine,andthelaunchof
SYMTUZA®andJULUCA®(dolutegravir/rilpivirine)waspartiallyoffsetbylowersalesofPREZISTA®(darunavir).
Neuroscienceproductssaleswere$6.1billion,representinganincreaseof1.5%ascomparedtotheprioryear.Strong
salesoflong-actinginjectablesINVEGATRINZA®/TREVICTA®(paliperidonepalmitate)andINVEGASUSTENNA®/
XEPLION®werepartiallyoffsetbycannibalizationofRISPERDALCONSTA®(risperidone)andgenericcompetitionfor
CONCERTA®/methylphenidate.
Oncologyproductsachievedsalesof$9.8billionin2018,representinganincreaseof35.6%ascomparedtotheprior
year.ContributorstothegrowthwerestrongsalesofDARZALEX®(daratumumab)withcontinuedmarketgrowthand
sharegain,IMBRUVICA®(ibrutinib)duetoincreasedpatientuptakegloballyandsalesofZYTIGA®(abirateroneacetate)
drivenbyLATITUDEdataandmarketgrowth.Additionally,salesfromthelaunchofERLEADA™(apalutamide)contributed
tothegrowth.AnumberofcompaniesmarketinggenericpharmaceuticalshavefiledAbbreviatedNewDrugApplications
(ANDAs)withtheFDA,orundertakensimilarregulatoryprocessesoutsideoftheU.S.,seekingtomarketgenericformsof
ZYTIGA®priortoexpirationofitsapplicablepatents.TheseANDAsincludeallegationsofnon-infringementandinvalidity
oftheapplicablepatents.InOctober2018,theCourtissuedarulinginvalidatingallassertedclaimsoftheapplicable
patent.JanssenhasappealedtheCourt’sdecision.InNovember2018,theU.S.CourtofAppealsfortheFederalCircuit
deniedJanssen’srequestforaninjunctionpendingappeal.Asaresult,severalgenericversionsofZYTIGA®haveentered
themarket,resultinginadeclineinsalesofZYTIGA®intheUnitedStates.In2018,theCompanyreportedU.S.salesof
$1.8billionforZYTIGA®.SeeNote21totheConsolidatedFinancialStatementsforadescriptionoflegalmatters
regardingZYTIGA®.
ThePulmonaryHypertensiontherapeuticareawasestablishedwiththeacquisitionofActelionLtdonJune16,2017.
Salesin2018representedafullyearascomparedtohalfayearin2017.SalesofOPSUMIT®(macitentan)and
UPTRAVI®(selexipag)werepositivelyimpactedbymarketgrowthandsharegainswhilesalesofTRACLEER®(bosetan)
werenegativelyimpactedbyincreaseduseofOPSUMIT®andgenerics.
Cardiovascular/Metabolism/Otherproductssaleswere$5.8billion,adeclineof7.5%ascomparedtotheprioryear.
LowersalesofINVOKANA®/INVOKAMET®(canagliflozin)intheU.S.wasprimarilyduetoanincreaseinpricediscounts,
higherrebatesandmarketsharedeclinedrivenbycompetitivepressure.LowersalesofXARELTO®(rivaroxaban)were
drivenbyanincreaseindiscountsandrebates,partiallyoffsetbyanincreaseinmarketshare.
20 • Johnson&Johnson2018AnnualReportDuring2018,theCompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand
additionalindicationsforexistingdrugsasfollows:
ProductName(Chemical US EU US EU
Name) Indication Approval Approval Filing Filing
DARZALEX®(daratumumab) Frontlinemultiplemyelomatransplantineligiblepatientsin
combinationwithbortezomib,melphalan,andprednisone ✓ ✓
erdafitinib Treatmentoflocallyadvancedormetastaticurothelialcancer ✓
ERLEADA™(apalutamide) Treatmentofnon-metastaticcastration-resistantprostate
cancer ✓ ✓
esketamine Antidepressantfortreatment-resistantdepressioninadults ✓ ✓
IMBRUVICA®(ibrutinib) TreatmentofWaldenstrom’smacroglobulinemiausedin
combinationwithrituximab ✓ ✓
TreatmentforpreviouslyuntreatedChronicLymphocytic
Leukemiaincombinationwithobinutuzumab ✓ ✓
INVOKANA®(canagliflozin) Reducetheriskofdeathintype2diabeteswithestablished,
orriskfor,cardiovasculardisease.(CANVAS/CANVAS-R) ✓ ✓
JULUCA®(rilpivirineand Single-tablet,once-daily,two-drugregimenforthetreatment
dolutegravir) ofHIV-1infection ✓
OPSUMIT®(macitentan) Treatmentofadultswithinoperablechronicthromboembolic
pulmonaryhypertensiontoimproveexercisecapacityand
pulmonaryvascularresistance ✓ ✓
STELARA®(ustekinumab) Treatmentofadultswithmoderatelytoseverelyactive
ulcerativecolitis ✓ ✓
SYMTUZA®(darunavir/
cobicistat/emtricitabine/tenofovir Acompletedarunavir-basedsingle-tabletregimenforthe
alafenamide) treatmentofHIV-1infection ✓
TREMFYA®(guselkumab) Patientcontrolledinjectorforthetreatmentofadultslivingwith
moderatetosevereplaquepsoriasis ✓ ✓
XARELTO®(rivaroxaban) Treatmenttoreducetheriskofmajorcardiovasculareventsin
peoplewithchroniccoronaryorperipheralarterydisease ✓
Forthepreventionofvenousthromboembolismformedicallyill
patients ✓
ZYTIGA®(abirateroneacetate) TreatmentofHormoneNaïveMetastaticProstateCancer ✓
Pharmaceuticalsegmentsalesin2017were$36.3billion,anincreaseof8.3%from2016,whichincludedoperational
growthof8.0%andapositivecurrencyimpactof0.3%.U.S.saleswere$21.5billion,anincreaseof6.7%.International
saleswere$14.8billion,anincreaseof10.8%,whichincluded10.1%operationalgrowthandapositivecurrencyimpact
of0.7%.In2017,acquisitionsanddivestitureshadanetpositiveimpactof3.8%ontheoperationalsalesgrowthofthe
worldwidePharmaceuticalsegment.Adjustmentstopreviousreserveestimates,ascomparedtotheprioryear,negatively
impactedthereportedPharmaceuticalsegmentoperationalgrowthbyapproximately1.8%,primarilyintheImmunology
andCardiovascular/Metabolism/Othertherapeuticareas.
MedicalDevicesSegment
TheMedicalDevicessegmentsalesin2018were$27.0billion,anincreaseof1.5%from2017,whichincludedan
operationalincreaseof1.1%andapositivecurrencyimpactof0.4%.U.S.saleswere$12.8billion,anincreaseof0.1%
ascomparedtotheprioryear.Internationalsaleswere$14.2billion,anincreaseof2.8%ascomparedtotheprioryear,
withanoperationalincreaseof1.9%andapositivecurrencyimpactof0.9%.In2018,acquisitionsanddivestitureshada
netnegativeimpactof1.5%ontheworldwideoperationalsalesgrowthoftheMedicalDevicessegmentascomparedto
2017.
Johnson&Johnson2018AnnualReport • 21MajorMedicalDevicesFranchiseSales:*
%Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
Surgery $9,901 9,559 9,296 3.6% 2.8
Advanced 4,002 3,756 3,517 6.5 6.8
General 4,557 4,463 4,362 2.1 2.3
Specialty 1,342 1,340 1,417 0.1 (5.4)
Orthopaedics 8,885 9,058 9,128 (1.9) (0.8)
Hips 1,418 1,394 1,361 1.7 2.4
Knees 1,502 1,523 1,524 (1.4) (0.1)
Trauma 2,699 2,616 2,569 3.2 1.8
Spine&Other 3,266 3,525 3,674 (7.3) (4.1)
Vision 4,553 4,063 2,785 12.1 45.9
ContactLenses/Other 3,302 3,036 2,785 8.8 9.0
Surgical 1,251 1,027 — 21.8 **
InterventionalSolutions(1) 2,646 2,296 2,055 15.2 11.7
DiabetesCare 1,009 1,615 1,789 (37.5) (9.7)
Diagnostics(2) — 1 66 *** ***
TotalMedicalDevicesSales $26,994 26,592 25,119 1.5% 5.9
(1) PreviouslyreferredtoasCardiovascular
(2) OnJune30,2014,theCompanydivestedtheOrtho-ClinicalDiagnosticsbusiness(theDiagnosticsFranchise)andamounts
representtransitionalserviceagreementthatconcludedin2017.
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** ProductsacquiredfromAbbottMedicalOptics(AMO)onFebruary27,2017
*** Percentagegreaterthan100%ornotmeaningful
TheSurgeryfranchisesaleswere$9.9billionin2018,anincreaseof3.6%from2017.GrowthinAdvancedSurgerywas
primarilydrivenbyendocutter,biosurgeryandenergyproducts.GrowthinGeneralSurgerywasprimarilydrivenbywound
careproducts.GrowthinSpecialtySurgerywasprimarilydrivenbyAdvancedSterilizationProducts.
TheOrthopaedicsfranchisesaleswere$8.9billionin2018,adecreaseof1.9%from2017.ThedeclineinSpine&Other
wasprimarilyduetotheCodmanNeurosurgerydivestitureandsharelossinSpinepartiallyoffsetbynewproduct
launches.ThedeclineinkneeswasprimarilyduetocompetitivepressureintheU.S.partiallyoffsetbygrowthinAsia
Pacific.Growthinhipsandtraumawasduetocontinueduptakeofnewproducts.
TheVisionfranchiseachievedsalesof$4.6billionin2018,anincreaseof12.1%from2017.Growthwasprimarilydriven
bystrengthoftheastigmatismanddailydisposablelensesintheOASYS®contactlensescategory.Surgicalgrowthwas
drivenbycataractperformanceprimarilyoutsidetheU.S.
TheInterventionalSolutionsfranchise(includestheCerenovusbusinesspreviouslyincludedinSpineandOtherin
Orthopaedics)saleswere$2.6billion,anincreaseof15.2%from2017.Stronggrowthintheelectrophysiologybusiness
wasdrivenbyAtrialFibrillationproceduregrowthandcontinueduptakeoftheTHERMOCOOLSMARTTOUCH®Contact
ForceSensingCatheter.
TheDiabetesCarefranchisesaleswere$1.0billion,adecreaseof37.5%from2017.Thedeclinewasprimarilydueto
divestitureofitsLifeScanbusinessinthefiscalfourthquarterof2018andtheCompany’sdecisiontoexittheAnimas
insulinpumpbusinessinthefiscalfourthquarterof2017.
TheMedicalDevicessegmentsalesin2017were$26.6billion,anincreaseof5.9%from2016,whichincludedan
operationalincreaseof5.7%andapositivecurrencyimpactof0.2%.U.S.saleswere$12.8billion,anincreaseof4.5%
ascomparedtotheprioryear.Internationalsaleswere$13.8billion,anincreaseof7.1%ascomparedtotheprioryear,
withanoperationalincreaseof6.7%andapositivecurrencyimpactof0.4%.In2017,acquisitionsanddivestitureshada
netpositiveimpactof4.2%ontheworldwideoperationalsalesgrowthoftheMedicalDevicessegmentascomparedto
2016.
22 • Johnson&Johnson2018AnnualReportAnalysis of Consolidated Earnings Before Provision for Taxes on Income
Consolidatedearningsbeforeprovisionfortaxesonincomewas$18.0billion,$17.7billionand$19.8billionforthefiscal
yearsended2018,2017and2016,respectively.Asapercenttosales,consolidatedearningsbeforeprovisionfortaxes
onincomewas22.1%,23.1%,and27.5%in2018,2017and2016,respectively.
Earnings Before Provision for Taxes
$19.8
$18.0 $17.7
27.5%
22.1% 23.1%
2018 2017
Period Ending
Income Before Tax
)snoilliB(
$
2016
Percent to sales
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:Costofproductssoldandselling,
marketingandadministrativeexpensesasapercenttosaleswereasfollows:*
%ofSales 2018 2017 2016
Costofproductssold* 33.2% 33.3 30.3
Percentpointincrease/(decrease)overtheprioryear (0.1) 3.0 (0.3)
Selling,marketingandadministrativeexpenses* 27.6% 28.1 27.9
Percentpointincrease/(decrease)overtheprioryear (0.5) 0.2 (2.2)
* Prioryearsamountswerereclassifiedtoconformtocurrentyearpresentation(adoptionofASU2017-07)
In2018,costofproductssoldasapercenttosalesdecreasedto33.2%from33.3%ascomparedtothesameperioda
yearagoprimarilyduetolowerinventorystep-upcostsrelatedtotheActelionacquisitionandfavorableproductand
segmentmixdrivenbyahigherpercentageofsalesfromthePharmaceuticalsegment.Thiswasmostlyoffsetbyhigher
amortizationexpenseprimarilyrelatedtotheActelionacquisitiononJune16,2017.Intangibleassetamortizationexpense
of$4.4billionwasincludedincostofproductssoldfor2018ascomparedto$3.0billionin2017.Therewasadecrease
inthepercenttosalesofselling,marketingandadministrativeexpensesin2018ascomparedtotheprioryear,primarily
duetolowercostsrelativetosalesgrowthinthePharmaceuticalbusinessandfavorablesegmentmix.
In2017,costofproductssoldasapercenttosalesincreasedto33.3%from30.3%ascomparedtothesameperioda
yearago.Theunfavorableincreasewasprimarilydrivenby$2.3billionofhigheramortizationexpenseandchargesfor
inventorystep-uprelatedtotherecentacquisitions,primarilyActelion.Intangibleassetamortizationexpenseof$3.0billion
wasincludedincostofproductssoldfor2017ascomparedto$1.2billionin2016.Therewasanincreaseinthepercent
tosalesofselling,marketingandadministrativeexpensesin2017ascomparedtotheprioryear,primarilydueto
investmentsinnewproductlaunchespartiallyoffsetbyfavorablemix.
Johnson&Johnson2018AnnualReport • 23ResearchandDevelopmentExpense:Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:*
2018 2017 2016
(DollarsinMillions) Amount %ofSales** Amount %ofSales** Amount %ofSales**
Consumer $565 4.1% 586 4.3 585 4.4
Pharmaceutical 8,446 20.7 8,392 23.1 7,001 20.9
MedicalDevices 1,764 6.5 1,616 6.1 1,557 6.2
Totalresearchanddevelopmentexpense $10,775 13.2% 10,594 13.9 9,143 12.7
Percentincrease/(decrease)overtheprior
year 1.7% 15.9 1.6
* Prioryearsamountswerereclassifiedtoconformtocurrentyearpresentation(adoptionofASU2017-07)
** Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,upfrontpaymentsandmilestones,improvingexisting
products,aswellasensuringproductefficacyandregulatorycompliancepriortolaunch.TheCompanyremains
committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproducts.In
2018,worldwidecostsofresearchanddevelopmentactivitiesincreasedby1.7%comparedto2017butdecreasedasa
percentofsales.ThedecreaseasapercentofsalesinthePharmaceuticalsegmentwasattributabletolowercosts
relativetosalesgrowth.TheincreaseddollarspendintheMedicalDevicesandPharmaceuticalsegmentswasfor
investmentspendingtoadvancethepipeline.In2017,worldwidecostsofresearchanddevelopmentactivitiesincreased
by15.9%comparedto2016.TheincreaseasapercentofsaleswasprimarilyinthePharmaceuticalsegmentdueto
generalportfolioprogressionaswellascollaborativeagreementsenteredintowithIdorsiaLtd.andLegendBiotech.
ResearchfacilitiesarelocatedintheU.S.,Belgium,Brazil,China,France,Germany,India,Israel,theNetherlands,Poland,
Singapore,Sweden,SwitzerlandandtheUnitedKingdomwithadditionalR&Dsupportinover30othercountries.
In-ProcessResearchandDevelopment(IPR&D):In2018,theCompanyrecordedanIPR&Dchargeof$1.1billion.
Ofthe$1.1billion,apartialimpairmentchargeof$0.8billionrelatedtothedevelopmentprogramofAL-8176,an
investigationaldrugforthetreatmentofRespiratorySyncytialVirus(RSV)andhumanmetapneumovirus(hMPV)acquired
withthe2014acquisitionofAliosBiopharmaInc.Theimpairmentchargewascalculatedbasedonupdatedcashflow
projectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephase2bclinicaltrial
suspension,adecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivities.The
Companycontinuestoevaluateinformationwithrespecttothedevelopmentprogramandwillmonitortheremaining
$0.9billionintangibleassetforfurtherimpairment.Inaddition,animpairmentchargeof$0.3billionwasrecordedforthe
discontinuationofthedevelopmentprojectforananti-thrombinantibodyassociatedwiththe2015acquisitionofXO1
Limited.
In2017,theCompanyrecordedanIPR&Dchargeof$0.4billionprimarilyforthediscontinuationofcertaindevelopment
projectsrelatedtoNovirawhichwasacquiredin2015.Theproductdevelopmentwascanceledduetosafetyconcerns.In
2016,theCompanyrecordedanIPR&Dchargeof$29millionforthediscontinuationofadevelopmentprogramrelatedto
Crucell.
Other(Income)Expense,Net:Other(income)expense,netistheaccountwheretheCompanyrecordsgainsand
lossesrelatedtothesaleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&Johnson
Innovation—JJDC,Inc.(JJDC),unrealizedgainsandlossesoninvestments,gainsandlossesondivestitures,certain
transactionalcurrencygainsandlosses,acquisition-relatedcosts,litigationaccrualsandsettlements,aswellasroyalty
income.
Thechangeinother(income)expense,netforthefiscalyear2018wasanunfavorablechangeof$1.4billionprimarilydue
tolitigationexpenseof$2.0billionin2018ascomparedto$1.3billionin2017.Additionally,2018includedunrealized
lossesonsecuritiesof$0.2billionandlowerrealizedgainsof$0.4billionrelatedtoinvestmentsinequitysecuritiesas
comparedtotheprioryear.Thiswaspartiallyoffsetbyareversalofacontingentliabilityof$0.2billionandlowercostsof
$0.1billionrelatedtotheActelionandAMOacquisitionsin2018ascomparedto2017.Thefiscalyearof2017included
againof$0.2billionrelatedtomonetizationoffutureroyaltyreceivablesoffsetbyanassetimpairmentchargeof
$0.2billionprimarilyrelatedtotheinsulinpumpbusiness.Divestituregainswereapproximately$1.2billionin2018and
includedtheLifeScanbusiness,NIZORAL®,RoC®andcertainnon-strategicPharmaceuticalproducts.Divestituregains
wereapproximately$1.3billionin2017andprimarilyincludedtheCodmanNeurosurgeryandCOMPEED®divestitures.
Additionally,restructuringrelatedexpensein2018was$0.3billionascomparedto$0.4billion2017.
24 • Johnson&Johnson2018AnnualReportThechangeinother(income)expense,netforthefiscalyear2017wasafavorablechangeof$0.3billionduetohigher
gainsof$0.7billiononthesaleofassets/businesses,primarilytheCodmanNeurosurgeryandCOMPEED®divestitures,a
gainof$0.2billionrelatedtomonetizationoffutureroyaltyreceivablesandahighergainof$0.3billionrelatedtothesale
ofcertaininvestmentsinequitysecuritiesascomparedtotheprioryear.Thiswaspartiallyoffsetbyhigherlitigation
expenseof$0.4billion,$0.3billionofacquisitioncostsrelatedtoActelionandAMO,anassetimpairmentchargeof
$0.2billionprimarilyrelatedtotheinsulinpumpbusinessandahigherrestructuringrelatedchargeof$0.2billionas
comparedtothefiscalyear2016.
Interest(Income)Expense:Interestincomewashigherin2018ascomparedto2017duetoahigheraverageinterest
rateandabenefitfromnetinvestmenthedgingpartiallyoffsetbyaloweraveragecash,cashequivalentsandmarketable
securitiesbalanceduringtheperiod.Cash,cashequivalentsandmarketablesecuritiestotaled$19.7billionattheendof
2018,andaveraged$19.0billionascomparedtothecash,cashequivalentsandmarketablesecuritiestotalof
$18.3billionand$30.1billionaveragecashbalancein2017.Thedecreaseintheaveragebalanceofcash,cash
equivalentsandmarketablesecuritieswasduetotheuseofcashforgeneralcorporatepurposes,primarilytheActelion
acquisitionfor$29.6billion,netofcashacquiredlateinthefiscalsecondquarterof2017.
Interestexpensein2018washigherascomparedto2017duetoahigheraveragedebtbalance.Theaveragedebt
balancewas$32.5billionin2018versus$30.9billionin2017.Thetotaldebtbalanceattheendof2018was
$30.5billionascomparedto$34.6billionattheendof2017.
Interestincomein2017increasedslightlyascomparedto2016duetohigheraverageinterestratespartiallyoffsetby
lowercash,cashequivalentsandmarketablesecuritiesbalancesduringtheperiod.Cash,cashequivalentsand
marketablesecuritiestotaled$18.3billionattheendof2017,andaveraged$30.1billionascomparedtothe
$40.1billionaveragecashbalancein2016.Thedecreaseinthebalanceofcash,cashequivalentsandmarketable
securitieswasduetotheuseofcashforgeneralcorporatepurposesincludingacquisitions,primarilytheActelion
acquisitionfor$29.6billion,netofcashacquired.
Interestexpensein2017washigherascomparedto2016.Theaveragedebtbalancewas$30.9billionin2017versus
$23.5billionin2016.Thetotaldebtbalanceattheendof2017was$34.6billionascomparedto$27.1billionattheend
of2016.Thehigherdebtbalanceofapproximately$7.5billionwasprimarilyduetoincreasedborrowings.TheCompany
increasedborrowingsinFebruaryandNovemberof2017,capitalizingonfavorabletermsinthecapitalmarkets.The
proceedsoftheborrowingswereusedforgeneralcorporatepurposes,includingthecompletionofthestockrepurchase
program.
IncomeBeforeTaxbySegment
Incomebeforetaxbysegmentofbusinesswereasfollows:
Percentof
IncomeBeforeTax SegmentSales SegmentSales
(DollarsinMillions) 2018 2017 2018 2017 2018 2017
Consumer $2,320 2,524 13,853 13,602 16.7% 18.6
Pharmaceutical 12,568 11,083 40,734 36,256 30.9 30.6
MedicalDevices 4,397 5,392 26,994 26,592 16.3 20.3
Total(1) 19,285 18,999 81,581 76,450 23.6 24.9
Less:Expensesnotallocatedtosegments(2) 1,286 1,326
Earningsbeforeprovisionfortaxesonincome $17,999 17,673 81,581 76,450 22.1% 23.1
(1) SeeNote18totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
ConsumerSegment:In2018,theConsumersegmentincomebeforetaxasapercenttosaleswas16.7%,versus
18.6%in2017.Thedecreaseintheincomebeforetaxasapercentofsalesin2018ascomparedto2017wasprimarily
attributabletohigherlitigationexpenseof$0.3billionin2018partiallyoffsetbyslowerincreasesinexpensesrelativeto
theincreaseinsales.Divestituregainsforthefiscalyearof2018,whichincludedthedivestituresofNIZORAL®andRoC®
werecomparabletofiscalyearof2017.Againof$0.3billionwasrecognizedfromthedivestitureofNIZORAL®.
In2017,theConsumersegmentincomebeforetaxasapercenttosaleswas18.6%,versus18.3%in2016.Theincrease
intheincomebeforetaxasapercentofsalesin2017ascomparedto2016wasattributabletohighergainson
Johnson&Johnson2018AnnualReport • 25divestitures,primarilythedivestitureofCOMPEED®in2017.Thiswaspartiallyoffsetbyhigherselling,marketingand
administrativeexpensesascomparedtotheprioryearduetoincreasedadvertisingandpromotionalspendingandslightly
higheramortizationexpensein2017relatedtoacquisitions.Additionally,thefiscalyear2016wasnegativelyimpactedby
operationsinVenezuela.
PharmaceuticalSegment:In2018,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas30.9%
versus30.6%in2017.Theincreaseintheincomebeforetaxasapercentofsaleswasprimarilyduetolowerinventory
step-upcostsrelatedtoActelionof$0.6billion,favorableproductmixandslowerincreasesinexpensesrelativetothe
increaseinsales,acontingentliabilityreversalof$0.2billionandhigherdivestituregainsof$0.2billionfromdivestituresof
certainnon-strategicPharmaceuticalproducts.Thiswaspartiallyoffsetbyhigheramortizationexpenseof$1.3billion
primarilyrelatedtotheActelionacquisition,ahigherIPR&Dchargeof$0.7billionandanunrealizedlossonsecuritiesof
$0.2billionascomparedtotheprioryear.Additionally,2017includedagainof$0.2billionrelatedtomonetizationof
futureroyaltyreceivablesandahighergainof$0.3billionrelatedtothesaleofcertaininvestmentsinequitysecurities.
In2017,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas30.6%versus38.3%in2016.The
decreaseintheincomebeforetaxasapercentofsaleswasprimarilydueto$2.3billionofhigheramortizationexpense
andothercostsrelatedtotheActelionacquisition,higherresearchanddevelopmentexpense,ahigherIPR&Dchargeof
$0.4billionrelatedtoNoviraandlowergainsondivestituresascomparedtotheprioryear.Additionally,thefiscalyear
2016includedapositiveadjustmentof$0.5billiontopreviousreserveestimates.Thiswaspartiallyoffsetbyagainof
$0.2billionrelatedtomonetizationoffutureroyaltyreceivables,ahighergainof$0.2billionrelatedtothesaleofcertain
investmentsinequitysecuritiesandfavorableproductmixin2017.
MedicalDevicesSegment:In2018,theMedicalDevicessegmentincomebeforetaxasapercenttosaleswas16.3%
versus20.3%in2017.Thedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduehigherlitigation
expenseof$1.7billionin2018ascomparedto$1.1billionin2017andhigherinvestmentsinthebusinessin2018.
Additionally,2018hadlowerdivestituregainsofapproximately$0.3billionascomparedtodivestituregainsin2017.In
2018theCompanyrecordedagainof$0.5billionrelatedtotheLifeScandivestiture.Thiswaspartiallyoffsetbylower
restructuringexpenseof$0.2billionin2018ascomparedto2017.Additionally,2017includedanassetimpairment
chargeof$0.2billionprimarilyrelatedtotheinsulinpumpbusiness.
In2017,theMedicalDevicessegmentincomebeforetaxasapercenttosaleswas20.3%versus22.2%in2016.The
decreaseintheincomebeforetaxasapercenttosaleswasprimarilydueto$0.3billionofhigheramortizationexpense
andotheracquisitioncostsrelatedtoAMO,$0.3billionofhigherlitigation,anassetimpairmentchargeof$0.2billion
primarilyrelatedtotheinsulinpumpbusiness,$0.1billionofhigherrestructuringandinvestmentsinnewproductlaunches
ascomparedtothefiscalyear2016.Thiswaspartiallyoffsetby$0.8billionhighergainsin2017relatedtodivestitures,
primarilythedivestitureofCodmanNeurosurgery.
Restructuring:Inthefirstquarterof2016,theCompanyannouncedrestructuringactionsinitsMedicalDevices
segment.TheCompanyhasachievedapproximately$0.7billionofannualizedpre-taxcostsavingin2018andisontrack
toachievetheannualizedpre-taxcostsavingsof$0.8billionto$1.0billionasoutlinedintherestructuringactions.The
savingswillprovidetheCompanywithaddedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesand
innovativesolutionsforcustomersandpatients.In2018,theCompanyrecordedapre-taxchargeof$462million,of
which$46millionisincludedincostofproductssoldand$227millionisincludedinother(income)expense.Total
projectcostsofapproximately$2.5billionhavebeenrecordedsincetherestructuringwasannounced.Thisrestructuring
programwascompletedinthefiscalfourthquarterof2018.
Inthesecondquarterof2018,theCompanyannouncedplanstoimplementactionsacrossitsglobalsupplychainthatare
intendedtoenabletheCompanytofocusresourcesandincreaseinvestmentsincriticalcapabilities,technologiesand
solutionsnecessarytomanufactureandsupplyitsproductportfolioofthefuture,enhanceagilityanddrivegrowth.The
Companyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategiccollaborations,andbolsteringits
initiativestoreducecomplexity,improvingcost-competitiveness,enhancingcapabilitiesandoptimizingits
network.Discussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevantconsultation
requirementsbeforetheyarefinalized.Intotal,theCompanyexpectstheseactionstogenerateapproximately$0.6to
$0.8billioninannualpre-taxcostsavingsthatwillbesubstantiallydeliveredby2022.TheCompanyexpectstorecord
pre-taxrestructuringchargesofapproximately$1.9to$2.3billion.TheCompanyestimatesthatapproximately70%ofthe
cumulativepre-taxcostswillresultincashoutlays.In2018,theCompanyrecordedapre-taxchargeof$238million,of
which$59millionisincludedincostofproductssoldand$117millionisincludedinother(income)expense.
SeeNote22totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtotherestructuringprograms.
26 • Johnson&Johnson2018AnnualReportProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas15.0%in2018,92.6%in2017and
16.5%in2016.The2018effectivetaxratedecreasedby77.6%ascomparedto2017.The2017effectivetaxratewas
primarilydrivenbyaprovisionaltaxchargeofapproximately$13.0billionasaresultoftheTaxCutsandJobsAct(TCJA)
recordedinthefourthquarterof2017andtheimpactofaBelgianstatutorytaxratechangewhichincreasedthe2017
effectiverateby3.4%.TheCompanyalsoreceivedabenefitin2018fromalowerU.S.statutorytaxratevs.2017aswell
asfavorableadjustmentstothe2017provisionalTCJAtaxchargepartiallyoffsetbyunfavorableincometaxmixandthe
U.S.taxonglobalintangiblelow-taxedincome(GILTI).
The2017effectivetaxrateincreasedby76.1%ascomparedto2016,primarilydrivenbytheenactmentoftheTaxCuts
andJobsAct(TCJA)intheUnitedStatesinDecember2017.TheenactmentoftheTCJAresultedinaprovisionaltax
chargeinthefourthquarterof2017,ofapproximately$13.0billionorapproximately73.3percentagepointincreasetothe
effectivetaxrate.SeeNote8totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtotheTCJA.
Theremainderoftheincreaseinthetaxratefor2017wasrelatedtotheremeasurementoftheCompany’sdeferredtax
assetsinBelgium,asaresultofchangesintheBelgianstatutorycorporatetaxrate,enactedinDecember2017,offsetby
ataxbenefitfortheclosureoftheCompany’sAnimasinsulinpumpbusiness.
ThegovernmentinSwitzerlandiscurrentlyconsideringtaxreformlegislation,whichcouldhaveamaterialimpactonthe
Company’seffectivetaxrateifenactedintolaw.
SeeNote8totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtotheTCJAandincometaxes.
Liquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$18.1billionattheendof2018ascomparedto$17.8billionattheendof2017.The
primarysourcesandusesofcashthatcontributedtothe$0.3billionincreasewereapproximately$22.2billionofcash
generatedfromoperatingactivities.Thiswaspartiallyoffsetby$3.2billionnetcashusedbyinvestingactivities,
$18.5billionnetcashusedbyfinancingactivitiesand$0.2billionduetotheeffectonexchangeratechangesoncash
andcashequivalents.Inaddition,theCompanyhad$1.6billioninmarketablesecuritiesattheendof2018and
$0.5billionattheendof2017.SeeNote1totheConsolidatedFinancialStatementsforadditionaldetailsoncash,cash
equivalentsandmarketablesecurities.
Cashflowfromoperationsof$22.2billionwastheresultof$15.3billionofnetearningsand$9.2billionofnon-cash
expensesandotheradjustmentsfordepreciationandamortization,stock-basedcompensationandassetswrite-downs,
offsetby$2.3billionfromnetgainsonsaleofassets/businesses,deferredtaxprovisionandaccountsreceivable
allowances,$3.9billionrelatedtoanincreaseinaccountsreceivable,inventoriesandothercurrentandnon-currentassets
andadecreaseinothercurrentandnon-currentliabilities.Additionalsourcesofoperatingcashflowof$4.0billion
resultedfromanincreaseinaccountspayableandaccruedliabilities.Thedecreaseincurrentandnon-currentliabilitiesis
primarilyduetothe2018taxpaymentrelatedtoTCJA.
Investingactivitiesuseof$3.2billionwasforadditionstoproperty,plantandequipmentof$3.7billion,thenetpurchase
ofinvestmentsprimarilymarketablesecuritiesof$1.3billion,acquisitions,netofcashacquiredof$0.9billion(primarilythe
acquisitionsofZarbee’s)andotherusesof$0.5billion.Thiswaspartiallyoffsetby$3.2billionofproceedsfromthe
disposalofassets/businesses(primarilythedivestitureofLifeScan).
Financingactivitiesuseof$18.5billionwasprimarilyfordividendstoshareholdersof$9.5billion,$5.9billionforthe
repurchaseofcommonstock,$3.9billionforthenetretirementofshortandlong-termdebtand$0.2billionofother
financing.Financingactivitiesalsoincludedsourcesof$1.0billionofproceedsfromstockoptionsexercised/employee
withholdingtaxonstockawards,net.
OnDecember17,2018,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.Therepurchase
programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.Anysharesacquiredwillbe
availableforgeneralcorporatepurposes.TheCompanyintendstofinancethesharerepurchaseprogramthroughavailable
cash.AsofDecember30,2018,$0.9billionhasbeenrepurchasedundertheprogram.
AsofDecember30,2018,theCompany’snotespayableandlong-termdebtwasinexcessofcash,cashequivalentsand
marketablesecurities.AsofDecember30,2018,thenetdebtpositionwas$10.8billionascomparedtotheprioryearof
$16.3billion.Therewasadecreaseinthenetdebtpositionduetoretirementofdebt.Thedebtbalanceattheendof
Johnson&Johnson2018AnnualReport • 272018was$30.5billionascomparedto$34.6billionin2017.Additionallytherewasahighercash,cashequivalentsand
marketablesecuritiesbalanceattheendof2018.In2018,theCompanycontinuedtohaveaccesstoliquiditythroughthe
commercialpapermarket.Additionally,asaresultoftheTCJA,theCompanyhasaccesstoitscashoutsidetheU.S.ata
significantlyreducedcost.TheCompanyanticipatesthatoperatingcashflows,theabilitytoraisefundsfromexternal
sources,borrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswill
continuetoprovidesufficientresourcestofundoperatingneedsforthenexttwelvemonths.TheCompanymonitorsthe
globalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable.
TheCompanyfiledanewshelfregistrationonFebruary27,2017whichwillenableittoissuedebtsecuritiesonatimely
basis.Foradditionaldetailsonborrowings,seeNote7totheConsolidatedFinancialStatements.
FinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
fromtheDecember30,2018marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$57million.Conversely,a10%depreciationoftheU.S.DollarfromtheDecember30,2018marketrateswoulddecrease
theunrealizedvalueoftheCompany’sforwardcontractsby$69million.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$226million.Ineitherscenario,atmaturity,thegainor
lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhaveno
impactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditrating.Thecounter-parties
tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counter-party.Managementbelievestheriskoflossisremote.Duringthefiscalsecondquarterof2017,theCompany
enteredintocreditsupportagreements(CSA)withcertainderivativecounterpartiesestablishingcollateralthresholds
basedonrespectivecreditratingsandnettingagreements.
TheCompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate
risk.Thefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrates,whilefloating
ratesecuritiesmayproducelessincomethanpredictedifinterestratesfall.A1%(100basispoints)changeinspreadon
theCompany’sinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash
equivalentsandcurrentmarketablesecuritiesbyapproximately$8million.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2018,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember12,2019.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementarenotmaterial.
Totalborrowingsattheendof2018and2017were$30.5billionand$34.6billion,respectively.Thedecreasein
borrowingswasduetotheretirementofdebtin2018.In2018,netdebt(cashandcurrentmarketablesecurities,netof
debt)was$10.8billioncomparedtonetdebtof$16.3billionin2017.Totaldebtrepresented33.8%oftotalcapital
(shareholders’equityandtotaldebt)in2018and36.5%oftotalcapitalin2017.Shareholders’equitypershareattheend
of2018was$22.44comparedto$22.43atyear-end2017.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
ContractualObligationsandCommitments
TheCompany’scontractualobligationsareprimarilyfortherecentlyenactedtaxlegislation,leases,debtandunfunded
retirementplans.Therearenoothersignificantobligations.Tosatisfytheseobligations,theCompanywillusecashfrom
28 • Johnson&Johnson2018AnnualReportoperations.ThefollowingtablesummarizestheCompany’scontractualobligationsandtheiraggregatematuritiesasof
December30,2018(seeNotes7,8,10and16totheConsolidatedFinancialStatementsforfurtherdetails):
Tax Intereston Unfunded
Legislation Debt Debt Retirement Operating
(DollarsinMillions) (TCJA) Obligations Obligations Plans Leases Total
2019 $— 2,636 949 92 223 3,900
2020 531 1,098 886 95 188 2,798
2021 812 1,796 841 101 154 3,704
2022 812 2,134 796 108 116 3,966
2023 1,522 1,553 764 115 76 4,030
After2023 4,565 21,103 8,850 697 139 35,354
Total $8,242 30,320 13,086 1,208 896 53,752
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.Forotherretirementplanandpost-employment
medicalbenefitinformation,seeNote10totheConsolidatedFinancialStatements.Thetabledoesnotincludeactivity
relatedtobusinesscombinations.
Dividends
TheCompanyincreaseditsdividendin2018forthe56thconsecutiveyear.Cashdividendspaidwere$3.54persharein
2018comparedwithdividendsof$3.32persharein2017,and$3.15persharein2016.
Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockbasedawards.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa
contractwiththecustomeraresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.The
Company’sglobalpaymenttermsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,
tradepromotions,coupons,productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand
recordedasareductioninsales.SeeNote1totheConsolidatedFinancialStatementsfortheAccountingStandards
Updaterelatedtorevenuewhichwasadoptedin2018.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
terms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof
wholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
Johnson&Johnson2018AnnualReport • 29tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsfor
certainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualnettradesalesduringthefiscalreportingyears2018,2017and2016.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsofcertain
products,whichareincludedinsalestocustomers.Forallyearspresented,profit-sharepaymentswerelessthan2.0%of
thetotalrevenuesandareincludedinsalestocustomers.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativesellingprice.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover
theperformanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
Belowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedDecember30,2018andDecember31,
2017.
ConsumerSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2018
Accruedrebates(1) $186 836 (751) 271
Accruedreturns 68 98 (109) 57
Accruedpromotions 481 2,233 (2,217) 497
Subtotal $735 3,167 (3,077) 825
Reservefordoubtfulaccounts 31 10 (9) 32
Reserveforcashdiscounts 23 204 (204) 23
Total $789 3,381 (3,290) 880
2017
Accruedrebates(1) $136 638 (588) 186
Accruedreturns 65 128 (125) 68
Accruedpromotions 358 2,148 (2,025) 481
Subtotal $559 2,914 (2,738) 735
Reservefordoubtfulaccounts 24 10 (3) 31
Reserveforcashdiscounts 25 205 (207) 23
Total $608 3,129 (2,948) 789
(1) Includesreserveforcustomerrebatesof$57millionatDecember30,2018and$48millionatDecember31,2017,recordedasa
contraasset.
30 • Johnson&Johnson2018AnnualReportPharmaceutical Segment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits(2) Period
2018
Accruedrebates(1) $4,862 22,644 (19,996) 7,510
Accruedreturns 362 385 (311) 436
Accruedpromotions 35 46 (68) 13
Subtotal $5,259 23,075 (20,375) 7,959
Reservefordoubtfulaccounts 77 37 (67) 47
Reserveforcashdiscounts 55 860 (862) 53
Total $5,391 23,972 (21,304) 8,059
2017
Accruedrebates(1) $3,420 16,447 (15,005) 4,862
Accruedreturns 334 256 (228) 362
Accruedpromotions — 69 (34) 35
Subtotal $3,754 16,772 (15,267) 5,259
Reservefordoubtfulaccounts 38 40 (1) 77
Reserveforcashdiscounts 58 714 (717) 55
Total $3,850 17,526 (15,985) 5,391
(1) Includesreserveforcustomerrebatesof$89millionatDecember30,2018and$90millionatDecember31,2017,recordedasa
contraasset.
(2) Includesadjustments
MedicalDevicesSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2018
Accruedrebates(1) $1,620 6,344 (6,746) 1,218
Accruedreturns 152 362 (400) 114
Accruedpromotions 83 116 (157) 42
Subtotal $1,855 6,822 (7,303) 1,374
Reservefordoubtfulaccounts 183 29 (43) 169
Reserveforcashdiscounts 15 372 (387) —
Total $2,053 7,223 (7,733) 1,543
2017
Accruedrebates(1) $1,500 6,407 (6,287) 1,620
Accruedreturns 127 729 (704) 152
Accruedpromotions 32 135 (84) 83
Subtotal $1,659 7,271 (7,075) 1,855
Reservefordoubtfulaccounts 190 27 (34) 183
Reserveforcashdiscounts 16 389 (390) 15
Total $1,865 7,687 (7,499) 2,053
(1) Includesreserveforcustomerrebatesof$632millionatDecember30,2018and$501millionatDecember31,2017,recordedasa
contraasset.
Johnson&Johnson2018AnnualReport • 31IncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesin
taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAP,which
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximately$0.7billion
undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingencies,includinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
SeeNotes1and21totheConsolidatedFinancialStatementsforfurtherinformationregardingproductliabilityandlegal
proceedings.
Long-LivedandIntangibleAssets:TheCompanyassesseschangesineconomicconditionsandmakesassumptions
regardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’sproperty,plantandequipment,goodwill
andintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,itmayormaynotbenecessaryforthe
Companytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,mortalityrates,expectedsalaryincreases,healthcare
costtrendratesandattritionrates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsontheserates
andtheeffectaratechangetothehealthcarecosttrendwouldhaveontheCompany’sresultsofoperations.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.Basedonthetypeofequityinstrument,thefairvalueisestimatedonthedate
ofgrantusingeithertheBlack-ScholesoptionvaluationmodeloracombinationofboththeBlack-Scholesoption
valuationmodelandMonteCarlovaluationmodel,andisexpensedinthefinancialstatementsovertheserviceperiod.The
inputassumptionsusedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandexpected
dividendyield.Forperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe
dateofgrant.Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon
thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheaward,discountedfordividends,whicharenot
paidontheperformanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalof
eachperformanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.SeeNote17to
theConsolidatedFinancialStatementsforadditionalinformation.
NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofDecember30,2018.
32 • Johnson&Johnson2018AnnualReportEconomicandMarketFactors
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2008-2018,intheU.S.,the
weightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
TheCompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallenges.The
Companycontinuestomonitorthesesituationsandtakeappropriateactions.Inflationratescontinuetohaveaneffecton
worldwideeconomiesand,consequently,onthewaycompaniesoperate.TheCompanyhasaccountedforoperationsin
Argentina(beginninginthefiscalthirdquarterof2018)andVenezuelaashighlyinflationary,asthepriorthree-year
cumulativeinflationratesurpassed100%.ThisdidnothaveamaterialimpacttotheCompany’sresultsintheperiod.In
thefaceofincreasingcosts,theCompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms,
productivityimprovementsandperiodicpriceincreases.
InJune2016,theUnitedKingdom(U.K.)heldareferenduminwhichvotersapprovedanexitfromtheEuropeanUnion
(E.U.),commonlyreferredtoas“Brexit”andinMarch2017theU.K.formallystartedtheprocessfortheU.K.toleavethe
E.U.Giventhelackofcomparableprecedent,itisunclearwhatfinancial,trade,regulatoryandlegalimplicationsthe
withdrawaloftheU.K.fromtheE.U.willhave.Brexitcreatesglobalpoliticalandeconomicuncertainty,whichmaycause,
amongotherconsequences,volatilityinexchangeratesandinterestrates,additionalcostcontainmentbythird-party
payorsandchangesinregulations.However,theCompanycurrentlydoesnotbelievethattheseandotherrelatedeffects
willhaveamaterialimpactontheCompany’sconsolidatedfinancialpositionoroperatingresults.AsofDecember30,
2018,thebusinessoftheCompany’sU.K.subsidiariesrepresentedlessthan3%ofboththeCompany’sconsolidated
assetsandfiscaltwelvemonthsrevenues,respectively.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2018wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$390millionandnetincomebyapproximately$100million.
Governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlaws,whichmayincludeincreasingor
decreasingexistingstatutorytaxrates.Achangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe
Company’sdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis
enacted.ThischangewouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidatedStatementof
Earnings.TheCompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.Changestothe
statutorytaxratemayoccuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter
andyearinwhichthelawchangeisenacted.OnSeptember28,2018theSwissParliamentapprovedtheFederalActon
TaxReformandAHVFinancing(SwissTaxReform).However,areferendumhasbeencalledand,asaresult,apublicvote
ontheSwissTaxReformwilltakeplaceonMay19th,2019.IftheSwissTaxReformpasses,thenthemeasuresare
expectedtocomeintoforceineitherJanuary2020orJanuary2021.Priortoapprovalinthereferendumandits
subsequentcantonalimplementation,theproposedSwissTaxReformisnotenactedandthereforetheCompanyhasnot
reflectedanyofthepotentialimpactsinitsfiscalresults.TheCompanyiscurrentlyassessingtheimpactoftheproposed
SwissTaxReform,andwhenenacted,thelawmayhaveamaterialimpactontheCompany’soperatingresults.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotionsandreimbursementofhealthcare
products.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoinghealth
careinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpacttheCompany’s
businesses.
TheCompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrights.Firmshavefiled
AbbreviatedNewDrugApplicationsorBiosimilarBiologicalProductApplicationswiththeFDAorotherwisechallenged
thecoverageand/orvalidityoftheCompany’spatents,seekingtomarketgenericorbiosimilarformsofmanyofthe
Company’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Intheevent
theCompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuits,genericorbiosimilar
versionsoftheproductsatissuewillbeintroducedtothemarket,resultinginthepotentialforsubstantialmarketshareand
Johnson&Johnson2018AnnualReport • 33revenuelossesforthoseproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociatedintangible
asset.Thereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue
followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace.Forfurtherinformation,seethe
discussionon“REMICADE®RelatedCases”and“LitigationAgainstFilersofAbbreviatedNewDrugApplications”in
Note21totheConsolidatedFinancialStatements.
LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.TheCompanyhasaccruedforcertain
litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther
developmentsinaccordancewithAccountingStandardsCodification(ASC)450-20-25.Fortheseandotherlitigation
andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossible,theCompanyisunableto
estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Amountsaccruedforlegalcontingencies
oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand
assumptions.Theabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactors,includingwhether
damagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnot
commencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificant
factsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote21totheConsolidatedFinancialStatementsforfurtherinformationregardinglegalproceedings.
CommonStock
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary15,
2019,therewere142,029recordholdersofCommonStockoftheCompany.
34 • Johnson&Johnson2018AnnualReportItem 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
Theinformationcalledforbythisitemisincorporatedhereinbyreferenceto“Item7.Management’sDiscussionand
AnalysisofResultsofOperationsandFinancialCondition-LiquidityandCapitalResources-FinancingandMarketRisk”
ofthisReport;andNote1“SummaryofSignificantAccountingPolicies-FinancialInstruments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
IndextoAuditedConsolidatedFinancialStatements
36 ConsolidatedBalanceSheets
37 ConsolidatedStatementsofEarnings
38 ConsolidatedStatementsofComprehensiveIncome
39 ConsolidatedStatementsofEquity
40 ConsolidatedStatementsofCashFlows
41 NotestoConsolidatedFinancialStatements
98 ReportofIndependentRegisteredPublicAccountingFirm
100 Management’sReportonInternalControlOverFinancialReporting
Johnson&Johnson2018AnnualReport • 35JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AtDecember30,2018andDecember31,2017
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2018 2017
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $18,107 17,824
Marketablesecurities(Notes1and2) 1,580 472
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$248(2017,$291) 14,098 13,490
Inventories(Notes1and3) 8,599 8,765
Prepaidexpensesandotherreceivables 2,699 2,537
Assetsheldforsale(Note20) 950 —
Totalcurrentassets 46,033 43,088
Property,plantandequipment,net(Notes1and4) 17,035 17,005
Intangibleassets,net(Notes1and5) 47,611 53,228
Goodwill(Notes1and5) 30,453 31,906
Deferredtaxesonincome(Note8) 7,640 7,105
Otherassets 4,182 4,971
Totalassets $152,954 157,303
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $2,796 3,906
Accountspayable 7,537 7,310
Accruedliabilities 7,601 7,304
Accruedrebates,returnsandpromotions 9,380 7,210
Accruedcompensationandemployeerelatedobligations 3,098 2,953
Accruedtaxesonincome(Note8) 818 1,854
Totalcurrentliabilities 31,230 30,537
Long-termdebt(Note7) 27,684 30,675
Deferredtaxesonincome(Note8) 7,506 8,368
Employeerelatedobligations(Notes9and10) 9,951 10,074
Long-termtaxespayable(Note8) 8,242 8,472
Otherliabilities 8,589 9,017
Totalliabilities 93,202 97,143
Shareholders’equity
Preferredstock—withoutparvalue(authorizedandunissued2,000,000shares) — —
Commonstock—parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(loss)(Note13) (15,222) (13,199)
Retainedearnings 106,216 101,793
94,114 91,714
Less:commonstockheldintreasury,atcost(Note12)(457,519,000sharesand437,318,000shares) 34,362 31,554
Totalshareholders’equity 59,752 60,160
Totalliabilitiesandshareholders’equity $152,954 157,303
SeeNotestoConsolidatedFinancialStatements
36 • Johnson&Johnson2018AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)*
2018 2017 2016
Salestocustomers $81,581 76,450 71,890
Costofproductssold 27,091 25,439 21,789
Grossprofit 54,490 51,011 50,101
Selling,marketingandadministrativeexpenses 22,540 21,520 20,067
Researchanddevelopmentexpense 10,775 10,594 9,143
In-processresearchanddevelopment 1,126 408 29
Interestincome (611) (385) (368)
Interestexpense,netofportioncapitalized(Note4) 1,005 934 726
Other(income)expense,net 1,405 (42) 210
Restructuring(Note22) 251 309 491
Earningsbeforeprovisionfortaxesonincome 17,999 17,673 19,803
Provisionfortaxesonincome(Note8) 2,702 16,373 3,263
Netearnings $15,297 1,300 16,540
Netearningspershare(Notes1and15)
Basic $5.70 0.48 6.04
Diluted $5.61 0.47 5.93
Averagesharesoutstanding(Notes1and15)
Basic 2,681.5 2,692.0 2,737.3
Diluted 2,728.7 2,745.3 2,788.9
*Prioryearsamountswerereclassifiedtoconformtocurrentyearpresentation(adoptionofASU2017-07)
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2018AnnualReport • 37JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(DollarsinMillions)(Note1)
2018 2017 2016
Netearnings $15,297 1,300 16,540
Othercomprehensiveincome(loss),netoftax
Foreigncurrencytranslation (1,518) 1,696 (612)
Securities:(1)
Unrealizedholdinggain(loss)arisingduringperiod (1) 159 (52)
Reclassificationstoearnings 1 (338) (141)
Netchange — (179) (193)
Employeebenefitplans:
Priorservicecredit(cost),netofamortization (44) 2 21
Gain(loss),netofamortization (56) 29 (862)
Effectofexchangerates 92 (201) 159
Netchange (8) (170) (682)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod (73) (4) (359)
Reclassificationstoearnings (192) 359 110
Netchange (265) 355 (249)
Othercomprehensiveincome(loss) (1,791) 1,702 (1,736)
Comprehensiveincome $13,506 3,002 14,804
(1) 2018includestheimpactfromadoptionofASU2016-01.ForfurtherdetailsseeNote1totheConsolidatedFinancialStatements
Thetaxeffectsinothercomprehensiveincomeforthefiscalyearsended2018,2017and2016respectively:Foreign
CurrencyTranslation$236millionin2018duetotheenactmentoftheU.S.TaxCutsandJobsAct;Securities:$0million,
$96millionand$104million,EmployeeBenefitPlans:$4million,$83millionand$346million,Derivatives&Hedges:
$70million,$191millionand$134million.
SeeNotestoConsolidatedFinancialStatements
38 • Johnson&Johnson2018AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(DollarsinMillions)(Note1)
Accumulated Common
Other Stock Treasury
Retained Comprehensive Issued Stock
Total Earnings Income Amount Amount
Balance,January3,2016 $71,150 103,879 (13,165) 3,120 (22,684)
Netearnings 16,540 16,540
Cashdividendspaid($3.15pershare) (8,621) (8,621)
Employeecompensationandstockoptionplans 2,130 (1,181) 3,311
Repurchaseofcommonstock (8,979) (8,979)
Other (66) (66)
Othercomprehensiveincome(loss),netoftax (1,736) (1,736)
Balance,January1,2017 70,418 110,551 (14,901) 3,120 (28,352)
Netearnings 1,300 1,300
Cashdividendspaid($3.32pershare) (8,943) (8,943)
Employeecompensationandstockoptionplans 2,077 (1,079) 3,156
Repurchaseofcommonstock (6,358) (6,358)
Other (36) (36)
Othercomprehensiveincome(loss),netoftax 1,702 1,702
Balance,December31,2017 60,160 101,793 (13,199) 3,120 (31,554)
Cumulativeadjustment (486) (254)(1) (232)
Netearnings 15,297 15,297
Cashdividendspaid($3.54pershare) (9,494) (9,494)
Employeecompensationandstockoptionplans 1,949 (1,111) 3,060
Repurchaseofcommonstock (5,868) (5,868)
Other (15) (15)
Othercomprehensiveincome(loss),netoftax (1,791) (1,791)
Balance,December30,2018 $59,752 106,216 (15,222) 3,120 (34,362)
(1) SeeNote1toConsolidatedFinancialStatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearnings.
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2018AnnualReport • 39JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DollarsinMillions)(Note1)
2018 2017 2016
Cashflowsfromoperatingactivities
Netearnings $15,297 1,300 16,540
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 6,929 5,642 3,754
Stockbasedcompensation 978 962 878
Assetwrite-downs 1,258 795 283
Gainonsaleofassets/businesses (1,217) (1,307) (563)
Deferredtaxprovision (1,016) 2,406 (341)
Accountsreceivableallowances (31) 17 (11)
Changesinassetsandliabilities,netofeffectsfromacquisitionsanddivestitures:
Increaseinaccountsreceivable (1,185) (633) (1,065)
(Increase)/Decreaseininventories (644) 581 (249)
Increaseinaccountspayableandaccruedliabilities 3,951 2,725 656
Increaseinothercurrentandnon-currentassets (275) (411) (529)
(Decrease)/Increaseinothercurrentandnon-currentliabilities (1,844) 8,979 (586)
Netcashflowsfromoperatingactivities 22,201 21,056 18,767
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (3,670) (3,279) (3,226)
Proceedsfromthedisposalofassets/businesses,net 3,203 1,832 1,267
Acquisitions,netofcashacquired(Note20) (899) (35,151) (4,509)
Purchasesofinvestments (5,626) (6,153) (33,950)
Salesofinvestments 4,289 28,117 35,780
Other(primarilyintangibles) (464) (234) (123)
Netcashusedbyinvestingactivities (3,167) (14,868) (4,761)
Cashflowsfromfinancingactivities
Dividendstoshareholders (9,494) (8,943) (8,621)
Repurchaseofcommonstock (5,868) (6,358) (8,979)
Proceedsfromshort-termdebt 80 869 111
Retirementofshort-termdebt (2,479) (1,330) (2,017)
Proceedsfromlong-termdebt,netofissuancecosts 5 8,992 12,004
Retirementoflong-termdebt (1,555) (1,777) (2,223)
Proceedsfromtheexerciseofstockoptions/employeewithholdingtaxonstockawards,net 949 1,062 1,189
Other (148) (188) (15)
Netcashusedbyfinancingactivities (18,510) (7,673) (8,551)
Effectofexchangeratechangesoncashandcashequivalents (241) 337 (215)
Increase/(Decrease)incashandcashequivalents 283 (1,148) 5,240
Cashandcashequivalents,beginningofyear(Note1) 17,824 18,972 13,732
Cashandcashequivalents,endofyear(Note1) $18,107 17,824 18,972
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $1,049 960 730
Interest,netofamountcapitalized 963 866 628
Incometaxes 4,570 3,312 2,843
Supplementalscheduleofnon-cashinvestingandfinancingactivities
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds/employee
withholdingtaxonstockawards $2,095 2,062 2,043
Conversionofdebt 6 16 35
Acquisitions
Fairvalueofassetsacquired $1,047 36,937 4,586
Fairvalueofliabilitiesassumedandnoncontrollinginterests (148) (1,786) (77)
Netcashpaidforacquisitions $899 35,151 4,509
SeeNotestoConsolidatedFinancialStatements
40 • Johnson&Johnson2018AnnualReportNOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately135,100employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.The
Consumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty,over-the-counter
pharmaceutical,women’shealthandwoundcaremarkets.Theseproductsaremarketedtothegeneralpublicandsold
bothtoretailoutletsanddistributorsthroughouttheworld.ThePharmaceuticalsegmentisfocusedonsixtherapeutic
areas,includingimmunology,infectiousdiseases,neuroscience,oncology,pulmonaryhypertension,andcardiovascular
andmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealth
careprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroadrangeofproductsusedinthe
orthopaedic,surgery,interventionalsolutions(cardiovascularandneurovascular),diabetescare(divestedinthefiscal
fourthquarterof2018)andvisionfields,whicharedistributedtowholesalers,hospitalsandretailers,andusedprincipally
intheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
NewAccountingStandards
RecentlyAdoptedAccountingStandards
ASU2014-09:RevenuefromContractswithCustomers
OnJanuary1,2018,theCompanyadoptedthenewaccountingstandard,ASC606,RevenuefromContractswith
Customersandalltherelatedamendments(newrevenuestandard)toallcontractsusingthemodifiedretrospective
method.Thecumulativeeffectofinitiallyapplyingthenewrevenuestandardwasrecognizedasanadjustmenttothe
openingbalanceofretainedearnings.Thecomparativeinformationhasnotbeenrestatedandcontinuestobereported
undertheaccountingstandardsineffectforthoseperiods.Theadoptionofthenewrevenuestandardhasnothada
materialimpacttoeitherreportedSalestocustomersorNetearnings.Additionally,theCompanywillcontinueto
recognizerevenuefromproductsalesasgoodsareshippedordeliveredtothecustomer,ascontrolofgoodstransfersat
thesametime.
Inaccordancewiththenewrevenuestandardrequirements,thedisclosureoftheimpactofadoptionontheCompany’s
ConsolidatedStatementofEarningsandBalanceSheetwasasfollows:
StatementofEarnings—ForthefiscalyearendedDecember30,2018
Balancewithoutadoption
(Dollarsinmillions) AsReported Effectofchange ofASC606
Salestocustomers $81,581 (35) 81,546
Netearnings 15,297 (28) 15,269
BalanceSheet–AsofDecember30,2018
Balancewithoutadoption
AsReported Effectofchange ofASC606
Assets 152,954 23 152,977
Liabilities 93,202 4 93,206
Equity $59,752 19 59,771
TheCompanymadeacumulativeeffectadjustmenttothe2018openingbalanceofretainedearningsuponadoptionof
ASU2014-09,whichdecreasedbeginningretainedearningsby$47million.
Johnson&Johnson2018AnnualReport • 41AspartoftheadoptionofASC606seeNote18totheConsolidatedFinancialStatementsforfurtherdisaggregationof
revenue.
ASU2016-01:FinancialInstruments:RecognitionandMeasurementofFinancialAssetsandFinancialLiabilities
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2018onamodifiedretrospectivebasis.The
amendmentsinthisupdatesupersedetheguidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesinto
differentcategories(thatis,tradingoravailable-for-sale)andrequireequitysecuritiestobemeasuredatfairvaluewith
changesinthefairvaluerecognizedthroughnetearnings.Thestandardamendsfinancialreportingbyprovidingrelevant
informationaboutanentity’sequityinvestmentsandreducingthenumberofitemsthatarerecognizedinother
comprehensiveincome.
TheCompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofASU
2016-01thatincreasedretainedearningsby$232millionnetoftaxanddecreasedaccumulatedothercomprehensive
incomeforpreviouslyunrealizedgainsfromequityinvestments.ForadditionaldetailsseeNote6totheConsolidated
FinancialStatements.
ASU2016-16:IncomeTaxes:Intra-EntityTransfersofAssetsOtherThanInventory
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2018.Thisupdateremovesthecurrent
exceptioninU.S.GAAPprohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelated
totransferofassets,otherthaninventory,withintheconsolidatedentity.Thecurrentexceptiontodefertherecognitionof
anytaximpactonthetransferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffected.
AsdiscussedfurtherinNote8totheConsolidatedFinancialStatements,inthefourthfiscalquarterof2018theCompany
electedanaccountingpolicytotreatthetaxonglobalintangiblelow-taxedincome(GILTI)underthedeferredtax
accountingmodel.Asaresult,theCompanyisrequiredtorecordanadditionaldeferredtaxliabilityrelatedtothebasis
differenceoftheseintra-entityassettransfers.TheCompanyrecordednetadjustmentsincludinganincreasetodeferred
taxassetsofapproximately$2.0billion,anincreasetodeferredtaxliabilitiesofapproximately$1.7billion,relatedtothe
GILTIaccountingpolicyelectioninthefourthfiscalquarterof2018,adecreasetoOtherAssetsofapproximately
$0.7billionandadecreasetoretainedearningsofapproximately$0.4billion.Theadoptionofthisstandarddidnothavea
materialimpactontheCompany’sconsolidatedfinancialstatements.
ASU2017-01:ClarifyingtheDefinitionofaBusiness
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2018.Thisupdatenarrowsthedefinitionofa
businessbyprovidingascreentodeterminewhenanintegratedsetofassetsandactivitiesisnotabusiness.Thescreen
specifiesthatanintegratedsetofassetsandactivitiesisnotabusinessifsubstantiallyallofthefairvalueofthegross
assetsacquiredordisposedofisconcentratedinasingleoragroupofsimilaridentifiableassets.Thisupdatewasapplied
prospectively.TheadoptionofthisstandarddidnothaveamaterialimpactontheCompany’sconsolidatedfinancial
statements.
ASU2017-07:ImprovingthePresentationofNetPeriodicPensionCostandNetPeriodicPostretirementBenefitCost
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2018.Thisupdaterequiresthatanemployer
disaggregatetheservicecostcomponentfromtheothercomponentsofnetperiodicbenefitcost(NPBC).Inaddition,only
theservicecostcomponentwillbeeligibleforcapitalization.Theamendmentsinthisupdatearerequiredtobeapplied
retrospectivelyforthepresentationoftheservicecostcomponentandtheothercomponentsofNPBCinthe
ConsolidatedStatementofEarningsandprospectively,onandaftertheadoptiondate,forthecapitalizationoftheservice
costcomponentofNPBCinassets.Asrequiredbythetransitionprovisionsofthisupdate,thefollowingtableshowsthe
impactoftheadoptionontherespectivelineitemsintheConsolidatedStatementofEarningsfor2018andthe
reclassificationstothe2017and2016fiscalyearConsolidatedStatementofEarningstoretroactivelyapplyclassification
oftheservicecostcomponentandtheothercomponentsofNPBC:
Increase(Decrease)
toNetExpense
(DollarsInmillions) 2018 2017 2016
Costofproductssold $ 51 85 104
Selling,marketingandadministrativeexpenses 55 100 122
Researchanddevelopmentexpense 21 40 48
Other(income)expense,net (127) (225) (274)
Earningsbeforeprovisionfortaxesonincome $ — — —
42 • Johnson&Johnson2018AnnualReportThefollowingtablesummarizesthecumulativeeffectadjustmentsmadetothe2018openingbalanceofretainedearnings
uponadoptionofthenewaccountingstandardsmentionedabove:
CumulativeEffect
AdjustmentIncrease
(Decrease)to
(DollarsinMillions) RetainedEarnings
ASU2014-09—RevenuefromContractswithCustomers $(47)
ASU2016-01—FinancialInstruments 232
ASU2016-16—IncomeTaxes:Intra-EntityTransfers (439)
Total $(254)
ASU2017-12:TargetedImprovementstoAccountingforHedgingActivities
TheCompanyelectedtoearlyadoptthisstandardasofthebeginningofthefiscalsecondquarterof2018.Thisupdate
makesmorefinancialandnonfinancialhedgingstrategieseligibleforhedgeaccounting.Italsoamendsthepresentation
anddisclosurerequirementsandchangeshowcompaniesassesseffectiveness.Theadoptionofthisstandarddidnot
haveamaterialimpactontheCompany’sconsolidatedfinancialstatements.ForadditionalrequireddisclosuresseeNote
6totheConsolidatedFinancialStatements.
RecentlyIssuedAccountingStandards
NotAdoptedasofDecember30,2018
ASU2018-18:CollaborativeArrangements
ThisupdateclarifiestheinteractionbetweenASC808,CollaborativeArrangementsandASC606,Revenuefrom
ContractswithCustomers.Theupdateclarifiesthatcertaintransactionsbetweenparticipantsinacollaborative
arrangementshouldbeaccountedforunderASC606whenthecounterpartyisacustomer.Inaddition,theupdate
precludesanentityfrompresentingconsiderationfromatransactioninacollaborativearrangementasrevenueifthe
counterpartyisnotacustomerforthattransaction.ThisupdatewillbeeffectivefortheCompanyforfiscalyearsbeginning
afterDecember15,2019,andinterimperiodswithinthosefiscalyears.ASU2018-18shouldbeappliedretrospectivelyto
thedateofinitialapplicationofASC606andearlyadoptionispermitted.TheCompanyiscurrentlyassessingtheimpact
ofthisupdateontheCompany’sconsolidatedfinancialstatementsandrelateddisclosures.
ASU2018-16:DerivativesandHedging(TopicASC815)
ThisupdateaddstheOvernightIndexSwap(OIS)ratebasedontheSecuredOvernightFinancingRate(SOFR)asan
eligiblebenchmarkinterestratepermittedintheapplicationofhedgeaccounting.Thisupdatewillbeeffectiveforthe
CompanyforfiscalyearsbeginningafterDecember15,2018andinterimperiodswithinthosefiscalyears.Earlyadoption
ispermittedifanentityhasadoptedASU2017-12.TheCompanyiscurrentlyassessingtheimpactofthisupdateonthe
Company’sconsolidatedfinancialstatementsandrelateddisclosures.
ASU2018-02:ReclassificationofCertainTaxEffectsfromAccumulatedOtherComprehensiveIncome
Thisupdateallowsareclassificationfromaccumulatedothercomprehensiveincometoretainedearningsforstrandedtax
effectsresultingfromtheTaxCutsandJobActenactedinDecember2017.ThisupdatewillbeeffectivefortheCompany
forfiscalyearsbeginningafterDecember15,2018andinterimperiodswithinthosefiscalyears.TheCompanydoesnot
expectthisstandardtohaveamaterialimpactontheCompany’sconsolidatedfinancialstatements.
ASU2016-13:FinancialInstruments—CreditLosses
Thisupdateintroducesthecurrentexpectedcreditloss(CECL)model,whichwillrequireanentitytomeasurecredit
lossesforcertainfinancialinstrumentsandfinancialassets,includingtradereceivables.Underthisupdate,oninitial
recognitionandateachreportingperiod,anentitywillberequiredtorecognizeanallowancethatreflectstheentity’s
currentestimateofcreditlossesexpectedtobeincurredoverthelifeofthefinancialinstrument.Thisupdatewillbe
effectivefortheCompanyforfiscalyearsbeginningafterDecember15,2019andinterimperiodswithinthosefiscalyears.
Earlyadoptionispermitted.TheCompanyiscurrentlyassessingtheimpactofthisupdateontheCompany’sconsolidated
financialstatementsandrelateddisclosures.
ASU2016-02:Leases
Thisupdaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand
disclosingkeyinformationaboutleasingarrangements.Thisupdaterequirestherecognitionofleaseassetsandlease
liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccounting
Johnson&Johnson2018AnnualReport • 43principles.ThisupdatewillbeeffectivefortheCompanyforallannualperiodsbeginningafterDecember15,2018,
includinginterimperiodswithinthosefiscalyears.TheCompanywillapplythenewstandardatitsadoptiondaterather
thanattheearliestcomparativeperiodpresentedinthefinancialstatements.TheCompany’soperatingleaseswillresultin
therecognitionofadditionalassetsandthecorrespondingliabilitiesonitsConsolidatedBalanceSheets.Theadoptionof
thisstandardwillnothaveamaterialimpactontheCompany’sconsolidatedfinancialstatements.
CashEquivalents
TheCompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase
ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof
purchaseascurrentmarketablesecurities.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercial
institutionsthathaveatleastaninvestmentgradecreditrating.TheCompanyinvestsitscashprimarilyingovernment
securitiesandobligations,corporatedebtsecurities,moneymarketfundsandreverserepurchaseagreements(RRAs).
RRAsarecollateralizedbydepositsintheformofGovernmentSecuritiesandObligationsforanamountnotlessthan
102%oftheirvalue.TheCompanydoesnotrecordanassetorliabilityastheCompanyisnotpermittedtosellor
repledgetheassociatedcollateral.TheCompanyhasapolicythatthecollateralhasatleastanA(orequivalent)credit
rating.TheCompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis
maintainedat102%ofthevalueoftheRRAsonadailybasis.RRAswithstatedmaturitiesofgreaterthanthreemonths
fromthedateofpurchaseareclassifiedasmarketablesecurities.
Investments
Investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare
reportedinearnings.Investmentsclassifiedasavailable-for-salearecarriedatestimatedfairvaluewithunrealizedgains
andlossesrecordedasacomponentofaccumulatedothercomprehensiveincome.Available-for-salesecuritiesavailable
forcurrentoperationsareclassifiedascurrentassetsotherwise,theyareclassifiedaslongterm.Managementdetermines
theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandre-evaluatessuch
determinationateachbalancesheetdate.TheCompanyreviewsitsinvestmentsinequitysecuritiesforimpairmentand
adjuststheseinvestmentstofairvaluethroughearnings,asrequired.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 20-30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
Revenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer
aresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.TheCompany’sglobalpayment
termsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin
sales.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
44 • Johnson&Johnson2018AnnualReportterms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof
wholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsfor
certainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualnettradesalesduringthefiscalreportingyears2018,2017and2016.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsforcertain
products,whichareincludedinsalestocustomers.Forallyearspresented,profit-sharepaymentswerelessthan2.0%of
thetotalrevenuesandareincludedinsalestocustomers.
ShippingandHandling
Shippingandhandlingcostsincurredwere$1,090million,$1,042millionand$974millionin2018,2017and2016,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan0.5%ofsalestocustomersforallperiodspresented.
Inventories
Inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompletedtheannualimpairmenttestfor2018inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted.Purchasedin-process
researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,
atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset,orabandoned,atwhichpoint
theintangibleassetwillbewrittenofforpartiallyimpaired.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
Johnson&Johnson2018AnnualReport • 45TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:(1)
minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and(4)
managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially
determinedestimateswhereapplicable.Theaccrualsareadjustedperiodicallyasadditionalinformationbecomes
available.TheCompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts
areprobableandcanbereasonablyestimated.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,
theCompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.
Asaresultofcostandavailabilityfactors,effectiveNovember1,2005,theCompanyceasedpurchasingthird-party
productliabilityinsurance.TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.In
additiontoaccrualsintheselfinsuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesare
probableandamountscanbereasonablyestimated.
ResearchandDevelopment
ResearchanddevelopmentexpensesareexpensedasincurredinaccordancewithASC730,Researchand
Development.Upfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment
collaborationsareexpensedasincurreduptothepointofregulatoryapproval.Paymentsmadetothirdpartiessubsequent
toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproduct.Amounts
capitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulatedamortization.
TheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare
generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract
developmentservicesisnotcentraltotheCompany’soperations.Ingeneral,theincomestatementpresentationforthese
collaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct&profitsharepaymentsreceived Salestocustomers
Royalties/milestonespaidtocollaborativepartner(post- Costofproductssold
regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartner
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
46 • Johnson&Johnson2018AnnualReportTheCompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding
XARELTO®,co-developedwithBayerHealthCareAGandIMBRUVICA®,developedincollaborationandco-marketed
withPharmacyclicsLLC,anAbbViecompany.
TheCompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingDARZALEX®,licensed
fromGenmabA/S.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.6billion,$2.5billionand$2.4billionin2018,2017and2016,respectively.
IncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesintaxlawsand
ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
Inthefourthfiscalquarterof2018,theCompanyhaselectedtoaccountfortheGILTItaxunderthedeferredmethod.The
deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasGILTI
isincurred.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximately$0.7billion
undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.
SeeNote8forfurtherinformationregardingincometaxes.
NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,withholdingtaxes,
depreciation,amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresults
mayormaynotdifferfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
andthereforeincludesadditionalshippingdays,aswasthecasein2015,andwillbethecaseagainin2020.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
Johnson&Johnson2018AnnualReport • 472. Cash, Cash Equivalents and Current Marketable Securities
Attheendof2018and2017,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
2018
Cash& Current
Carrying Estimated Cash Marketable
(DollarsinMillions) Amount FairValue Equivalents Securities
Cash $2,619 2,619 2,619 —
U.S.Reverserepurchaseagreements 3,009 3,009 3,009 —
OtherReverserepurchaseagreements 443 443 443 —
Moneymarketfunds 3,397 3,397 3,397 —
Timedeposits(1) 485 485 485 —
Subtotal $9,953 9,953 9,953 —
Gov’tSecurities $9,474 9,474 8,144 1,330
Corporatedebtsecurities 260 260 10 250
Subtotalavailableforsale(2) $9,734 9,734 8,154 1,580
Totalcash,cashequivalentsandcurrentmarketablesecurities $18,107 1,580
In2018,thecarryingamountwasthesameastheestimatedfairvalue.
In2017,thecarryingamountwasthesameastheestimatedfairvalue.
2017
Estimated Cash& Current
Carrying Fair Cash Marketable
(DollarsinMillions) Amount Value Equivalents Securities
Cash $2,929 2,929 2,929 —
OtherSovereignSecurities(1) 279 279 219 60
U.S.Reverserepurchaseagreements 4,025 4,025 4,025 —
Corporatedebtsecurities(1) 289 289 244 45
Moneymarketfunds 4,288 4,288 4,288 —
Timedeposits(1) 1,176 1,176 1,175 1
Subtotal $12,986 12,986 12,880 106
Gov’tSecurities $4,864 4,864 4,833 31
OtherSovereignSecurities 186 186 80 106
Corporatedebtsecurities 260 260 31 229
Subtotalavailableforsale(2) $5,310 5,310 4,944 366
Totalcash,cashequivalentsandcurrentmarketablesecurities $17,824 472
(1) Heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings.
(2) Availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother
comprehensiveincome.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
48 • Johnson&Johnson2018AnnualReportThecontractualmaturitiesoftheavailableforsaledebtsecuritiesatDecember30,2018areasfollows:
Cost Fair
(DollarsinMillions) Basis Value
Duewithinoneyear $9,670 9,670
Dueafteroneyearthroughfiveyears 64 64
Dueafterfiveyearsthroughtenyears — —
Totaldebtsecurities $9,734 9,734
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastaninvestmentgradecreditrating.
3. Inventories
Attheendof2018and2017,inventorieswerecomprisedof:
(DollarsinMillions) 2018 2017
Rawmaterialsandsupplies $1,114 1,140
Goodsinprocess 2,109 2,317
Finishedgoods 5,376 5,308
Totalinventories $8,599(1) 8,765
(1) NetofassetsheldforsaleontheConsolidatedBalanceSheetforapproximately$0.2billionrelatedtothedivestitureofthe
AdvancedSterilizationProductsbusinessand$0.3billionrelatedtothestrategiccollaborationwithJabilInc.,bothofwhichwere
pendingasofDecember30,2018.
4. Property, Plant and Equipment
Attheendof2018and2017,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2018 2017
Landandlandimprovements $807 829
Buildingsandbuildingequipment 11,176 11,240
Machineryandequipment 25,992 25,949
Constructioninprogress 3,876 3,448
Totalproperty,plantandequipment,gross $41,851 41,466
Lessaccumulateddepreciation 24,816 24,461
Totalproperty,plantandequipment,net $17,035(1) 17,005
(1) NetofassetsheldforsaleontheConsolidatedBalanceSheetforapproximately$0.1billionrelatedtothedivestitureofthe
AdvancedSterilizationProductsbusinessand$0.1billionrelatedtothestrategiccollaborationwithJabilInc.,bothofwhichwere
pendingasofDecember30,2018.
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedin2018,2017and2016was$86million,$94millionand$102million,respectively.
Depreciationexpense,includingtheamortizationofcapitalizedinterestin2018,2017and2016was$2.6billion,
$2.6billionand$2.5billion,respectively.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
Johnson&Johnson2018AnnualReport • 495. Intangible Assets and Goodwill
Attheendof2018and2017,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2018 2017
Intangibleassetswithdefinitelives:
Patentsandtrademarks—gross $35,194 36,427
Lessaccumulatedamortization 9,784 7,223
Patentsandtrademarks—net $25,410 29,204
Customerrelationshipsandotherintangibles—gross $21,334 20,204
Lessaccumulatedamortization 8,323 7,463
Customerrelationshipsandotherintangibles—net $13,011 12,741
Intangibleassetswithindefinitelives:
Trademarks $6,937 7,082
Purchasedin-processresearchanddevelopment(1) 2,253 4,201
Totalintangibleassetswithindefinitelives $9,190 11,283
Totalintangibleassets—net $47,611 53,228
(1) Thedecreasewasprimarilyattributabletothewrite-downof$1.1billionrelatedtotheassetsacquiredintheacquisitionsofAlios
BiopharmaInc.(Alios)andXO1Limited(XO1).Ofthe$1.1billion,theCompanyrecordedapartialimpairmentchargeof$0.8billion
relatedtothedevelopmentprogramofAL-8176,aninvestigationaldrugforthetreatmentofRespiratorySyncytialVirus(RSV)and
humanmetapneumovirus(hMPV)acquiredwiththe2014acquisitionofAlios.Theimpairmentchargewascalculatedbasedon
updatedcashflowprojectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephase2b
clinicaltrialsuspension,adecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivities.In
addition,animpairmentchargeof$0.3billionwasrecordedforthediscontinuationofthedevelopmentprojectforananti-thrombin
antibodyassociatedwiththe2015acquisitionofXO1.Additionally,$0.8billionofIPR&DrelatedtoERLEADA™wasreclassifiedto
definitelivedintangibleassetsuponcommercialization.
GoodwillasofDecember30,2018andDecember31,2017,asallocatedbysegmentofbusiness,wasasfollows:
(DollarsinMillions) Consumer Pharmaceutical MedicalDevices Total
GoodwillatJanuary1,2017 $8,263 2,840 11,702 22,805
Goodwill,relatedtoacquisitions(1) 102 6,161 2,200 8,463
Goodwill,relatedtodivestitures (74) (1) (102) (177)
Currencytranslation/other 584 109 122 815
GoodwillatDecember31,2017 $8,875 9,109 13,922 31,906
Goodwill,relatedtoacquisitions 168 51 184 403
Goodwill,relatedtodivestitures — — (1,348)(2) (1,348)
Currencytranslation/other (373) (97) (38) (508)
GoodwillatDecember30,2018 $8,670 9,063 12,720 30,453
(1) Goodwillof$6.2billionrelatedtotheActelionacquisitionacquiredinthefiscalsecondquarterof2017,withinthePharmaceutical
segmentand$1.7billionrelatedtotheAMOacquisitionacquiredinthefiscalfirstquarterof2017,withintheMedicalDevices
segment.
(2) Goodwillof$1.0billionisrelatedtothedivestitureoftheLifeScanbusiness.Goodwillof$0.3billionisrelatedtothedivestitureof
theAdvancedSterilizationProductsbusiness,whichwaspendingandclassifiedasassetsheldforsaleontheConsolidatedBalance
SheetasofDecember30,2018.
Theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible
assetsare11yearsand22years,respectively.Theamortizationexpenseofamortizableassetsincludedincostof
productssoldwas$4.4billion,$3.0billionand$1.2billionbeforetax,forthefiscalyearsendedDecember30,2018,
December31,2017andJanuary1,2017,respectively.Theestimatedamortizationexpenseforthefivesucceedingyears
approximates$4.3billionbeforetax,peryear.Intangibleassetwrite-downsareincludedinOther(income)expense,net.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures.
50 • Johnson&Johnson2018AnnualReport6. Fair Value Measurements
TheCompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarily
relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthird-partypurchasesofmaterials
denominatedinaforeigncurrency.TheCompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.Bothtypesofderivativesaredesignatedascashflowhedges.
Additionally,theCompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate
borrowings.Thesederivativesaredesignatedasfairvaluehedges.TheCompanyusescrosscurrencyinterestrateswaps
andforwardforeignexchangecontractsdesignatedasnetinvestmenthedges.Additionally,theCompanyusesforward
foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilities.Theseforwardforeign
exchangecontractsarenotdesignatedashedgesandtherefore,changesinthefairvaluesofthesederivativesare
recognizedinearnings,therebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities.
TheCompanyearlyadoptedASU2017-12:TargetedImprovementstoAccountingforHedgeActivitieseffectiveasofthe
beginningoffiscalsecondquarterof2018.
TheCompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposes,orthatcontaincredit
riskrelatedcontingentfeatures.Duringthefiscalsecondquarterof2017,theCompanyenteredintocreditsupport
agreements(CSA)withcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecredit
ratingsandnettingagreements.AsofDecember30,2018,thetotalamountofcollateralpaidunderthecreditsupport
agreements(CSA)amountedto$182millionnet.Onanongoingbasis,theCompanymonitorscounter-partycredit
ratings.TheCompanyconsiderscreditnon-performancerisktobelow,becausetheCompanyprimarilyentersinto
agreementswithcommercialinstitutionsthathaveatleastaninvestmentgradecreditrating.Refertothetableon
significantfinancialassetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswith
thesecommercialinstitutions.AsofDecember30,2018,theCompanyhadnotionalamountsoutstandingforforward
foreignexchangecontracts,crosscurrencyinterestrateswapsandinterestrateswapsof$41.1billion,$7.3billion,and
$0.5billionrespectively.AsofDecember31,2017,theCompanyhadnotionalamountsoutstandingforforwardforeign
exchangecontracts,crosscurrencyinterestrateswapsandinterestrateswapsof$34.5billion,$2.3billion,and
$1.1billionrespectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Foreignexchangecontractsdesignatedascashflowhedgesareaccountedforunder
theforwardmethodandallgains/lossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen
thehedgeditemimpactsearnings.Changesinthefairvalueofthesederivativesarerecordedinaccumulatedother
comprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,andarethenreclassifiedtoearningsinthesame
accountasthehedgedtransaction.
Gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin
interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccur.Gainsandlossesonnetinvestment
hedgeareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincome.The
portionexcludedfromeffectivenesstestingisrecordedthroughinterest(income)expenseusingthespotmethod.Onan
ongoingbasis,theCompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof
hedgeditems.Ifandwhenaderivativeisnolongerexpectedtobehighlyeffective,hedgeaccountingisdiscontinued.
Duringthefiscalsecondquarterof2016,theCompanydesignateditsEurodenominatednotesissuedinMay2016with
duedatesrangingfrom2022to2035asanetinvestmenthedgeoftheCompany’sinvestmentsincertainofits
internationalsubsidiariesthatusetheEuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychanges
inexchangerates.
AsofDecember30,2018,thebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive
incomewas$195millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill
bereclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthat
period.ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excluding
interestratecontracts,netinvestmenthedgesandequitycollarcontracts.Theamountultimatelyrealizedinearningsmay
differasforeignexchangerateschange.Realizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat
maturityofthederivative.
Johnson&Johnson2018AnnualReport • 51ThefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedDecember30,
2018andDecember31,2017:
December30,2018 December31,2017
Costof Interest Other Costof Interest Other
Products R&D (Income) (Income) Products R&D (Income) (Income)
(DollarsinMillions) Sales Sold Expense Expense Expense Sales Sold Expense Expense Expense
Theeffectsoffairvalue,netinvestment
andcashflowhedging:
Gain(Loss)onfairvaluehedging
relationship:
Interestrateswapscontracts:
Hedgeditems $ — — — 5 — — — — 5 —
Derivativesdesignatedashedging
instruments — — — (5) — — — — (5) —
Gain(Loss)onnetinvestment
hedgingrelationship:
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)recognizedin
incomeonderivativeamount
excludedfromeffectivenesstesting — — — 56 — — — — — —
Amountofgainor(loss)recognizedin
AOCI — — — 56 — — — — — —
Gain(Loss)oncashflowhedging
relationship:
Forwardforeignexchange
contracts:
Amountofgainor(loss)reclassified
fromAOCIintoincome(1) 47 200 (220) — (24) (31) (159) (165) — (87)
Amountofgainor(loss)recognizedin
AOCI(1) (32) (17) (193) — (4) 49 96 (199) — (60)
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)reclassified
fromAOCIintoincome — — — 133 — — — — 83 —
Amountofgainor(loss)recognizedin
AOCI $ — — — 117 — — — — 110 —
(1) Includesequitycollarcontracts.TheequitycollarcontractsexpiredinDecemberof2017.
ForthefiscalyearsendedDecember30,2018andDecember31,2017,thefollowingamountswererecordedonthe
ConsolidatedBalanceSheet
CumulativeAmountofFairValue
LineitemintheConsolidatedBalance HedgingAdjustment
Sheetinwhichthehedgeditemis IncludedintheCarrying
included CarryingAmountoftheHedgedLiability AmountoftheHedgedLiability
(DollarsinMillions) December30,2018 December31,2017 December30,2018 December31,2017
CurrentPortionofLong-termDebt $494 597 5 2
Long-termDebt — 496 — 3
Thefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsended
December30,2018andDecember31,2017:
LocationofGain/(Loss) Gain/(Loss)
RecognizedinIncomeon RecognizedIn
(DollarsinMillions) Derivative IncomeonDerivative
DerivativesNotDesignatedasHedgingInstruments December30,2018 December31,2017
ForeignExchangeContracts Other(income)expense (68) (5)
52 • Johnson&Johnson2018AnnualReportThefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedDecember30,2018and
December31,2017:
Gain/(Loss)
Gain/(Loss) LocationofGainor(Loss)Reclassified ReclassifiedFrom
RecognizedIn fromAccumulatedOtherComprehensive AccumulatedOCI
AccumulatedOCI IncomeIntoIncome IntoIncome
(DollarsinMillions) 2018 2017 2018 2017
Debt $218 (597) Other(income)expense — —
CrossCurrencyinterestrateswaps $150 — Other(income)expense — —
TheCompanyadoptedASU2016-01:FinancialInstruments:RecognitionandMeasurementofFinancialAssetsand
FinancialLiabilitiesasofthebeginningofthefiscalyear2018.ThisASUamendspriorguidancetoclassifyequity
investmentswithreadilydeterminablemarketvaluesintodifferentcategories(thatis,tradingoravailable-for-sale)and
requireequityinvestmentstobemeasuredatfairvaluewithchangesinfairvaluerecognizedthroughnetearnings.The
CompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofASU
2016-01whichincreasedretainedearningsby$232million,netoftax,anddecreasedaccumulatedothercomprehensive
incomeforpreviouslynetunrealizedgainsfromequityinvestments.
TheCompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily
determinablefairvalues.TheCompanyhaselectedtomeasureequityinvestmentsthatdonothavereadilydeterminable
fairvaluesatcostminusimpairment,ifany,plusorminuschangesresultingfromobservablepricechangesinorderly
transactionsfortheidenticalorasimilarinvestmentofthesameissuer.
ThefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsasofDecember30,2018:
ChangesinFairValue
December31,2017 December30,2018
ReflectedinNet Sales/ NonCurrentOther
(DollarsinMillions) CarryingValue Income(1) Purchases/Other(2) CarryingValue Assets
EquityInvestmentswithreadily
determinablevalue $751 (247) 7 511 511
EquityInvestmentswithoutreadily
determinablevalue $510 13 158 681 681
(1) RecordedinOtherIncome/Expense
(2) Otherincludesimpactofcurrency
Forequityinvestmentswithoutreadilydeterminablemarketvalues,$54millionofthechangesinfairvaluereflectedinnet
incomeweretheresultofimpairments.Therewere$67millionofchangesinfairvaluereflectedinnetincomedueto
changesinobservableprices.
ForthefiscalyearsendedDecember31,2017,changesinfairvaluereflectedwithinothercomprehensiveincomedueto
previouslyunrealizedgainsonequityinvestmentswithreadilydeterminablefairvaluesnetoftaxwasanetgainof
$232million.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.The
authoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.,forwardforeignexchangecontracts,interestratecontracts)isthe
aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand
subsequentlyconvertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethat
fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor
maturity,orthatthechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsor
financialposition.TheCompanyalsoholdsequityinvestmentswhichareclassifiedasLevel1anddebtsecuritieswhich
areclassifiedasLevel2.TheCompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire
revisedvaluationsunderthisstandardthatarerecognizedatfairvalue.
Johnson&Johnson2018AnnualReport • 53Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1—Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2—Significantotherobservableinputs.
Level3—Significantunobservableinputs.
TheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofDecember30,2018and
December31,2017wereasfollows:
2018 2017
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ — 501 — 501 418
Interestratecontracts(2)(4) — 161 — 161 7
Total — 662 — 662 425
Liabilities:
Forwardforeignexchangecontracts — 548 — 548 402
Interestratecontracts(3)(4) — 292 — 292 165
Total — 840 — 840 567
Derivativesnotdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts — 32 — 32 38
Liabilities:
Forwardforeignexchangecontracts — 32 — 32 38
AvailableForSaleOtherInvestments:
Equityinvestments(5) 511 — — 511 751
Debtsecurities(6) $ — 9,734 — 9,734 5,310
GrosstoNetDerivativeReconciliation 2018 2017
(DollarsinMillions)
TotalGrossAssets $694 463
CreditSupportAgreement(CSA) (423) (76)
TotalNetAsset 271 387
TotalGrossLiabilities 872 605
CreditSupportAgreement(CSA) (605) (238)
TotalNetLiabilities $267 367
(1) 2017assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofequityinvestmentsof$751million,whichareclassifiedas
Level1.
(2) Includes$6millionand$7millionofnon-currentassetsforthefiscalyearsendingDecember30,2018andDecember31,2017,
respectively.
(3) Includes$3millionand$9millionofnon-currentliabilitiesforthefiscalyearsendingDecember30,2018andDecember31,2017,
respectively.
(4) Includescrosscurrencyinterestrateswapsandinterestrateswaps.
(5) Classifiedasnon-currentotherassets.Thecarryingamountoftheequityinvestmentswere$511millionand$751millionasof
December30,2018andDecember31,2017,respectively.
(6) Classifiedascashequivalentsandcurrentmarketablesecurities.
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
54 • Johnson&Johnson2018AnnualReport7. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2018 Rate% 2017 Rate%
5.15%Debenturesdue2018 $ — 900 5.18
1.65%Notesdue2018 — 597 1.70
4.75%Notesdue2019(1BEuro1.14)(2)/(1BEuro1.1947)(3) 1,139(2) 5.83 1,192(3) 5.83
1.875%Notesdue2019 494 1.93 496 1.93
0.89%Notesdue2019 300 1.32 300 1.75
1.125%Notesdue2019 699 1.13 699 1.13
3%ZeroCouponConvertibleSubordinatedDebenturesdue2020 51 3.00 60 3.00
2.95%Debenturesdue2020 548 3.15 547 3.15
1.950%Notesdue2020 499 1.99 499 1.99
3.55%Notesdue2021 449 3.67 448 3.67
2.45%Notesdue2021 349 2.48 349 2.48
1.65%Notesdue2021 998 1.65 998 1.65
0.250%Notesdue2022(1BEuro1.14)(2)/(1BEuro1.1947)(3) 1,137(2) 0.26 1,191(3) 0.26
2.25%Notesdue2022 996 2.31 995 2.31
6.73%Debenturesdue2023 250 6.73 250 6.73
3.375%Notesdue2023 805 3.17 806 3.17
2.05%Notesdue2023 498 2.09 498 2.09
0.650%Notesdue2024(750MMEuro1.14)(2)/(750MMEuro1.1947)(3) 851(2) 0.68 891(3) 0.68
5.50%Notesdue2024(500MMGBP1.2636)(2)/(500MMGBP1.3444)(3) 627(2) 6.75 666(3) 6.75
2.625%Notesdue2025 748 2.63 747 2.63
2.45%Notesdue2026 1,992 2.47 1,990 2.47
2.95%Notesdue2027 996 2.96 995 2.96
1.150%Notesdue2028(750MMEuro1.14)(2)/(750MMEuro1.1947)(3) 847(2) 1.21 887(3) 1.21
2.900%Notesdue2028 1,493 2.91 1,492 2.91
6.95%Notesdue2029 297 7.14 296 7.14
4.95%Debenturesdue2033 498 4.95 498 4.95
4.375%Notesdue2033 856 4.24 856 4.24
1.650%Notesdue2035(1.5BEuro1.14)(2)/(1.5BEuro1.1947)(3) 1,693(2) 1.68 1,774(3) 1.68
3.55%Notesdue2036 988 3.59 987 3.59
5.95%Notesdue2037 991 5.99 991 5.99
3.625%Notesdue2037 1,486 3.64 1,486 3.64
5.85%Debenturesdue2038 696 5.85 696 5.85
3.400%Notesdue2038 990 3.42 990 3.42
4.50%Debenturesdue2040 538 4.63 538 4.63
4.85%Notesdue2041 297 4.89 296 4.89
4.50%Notesdue2043 495 4.52 495 4.52
3.70%Notesdue2046 1,972 3.74 1,971 3.74
3.75%Notesdue2047 991 3.76 990 3.76
3.500%Notesdue2048 742 3.52 742 3.52
Other 24 – 75 –
Subtotal 30,320(4) 3.19%(1) 32,174(4) 3.19(1)
Lesscurrentportion 2,636 1,499
Totallong-termdebt $27,684 30,675
Johnson&Johnson2018AnnualReport • 55(1) Weightedaverageeffectiverate.
(2) TranslationrateatDecember30,2018.
(3) TranslationrateatDecember31,2017.
(4) Theexcessofthefairvalueoverthecarryingvalueofdebtwas$0.3billionin2018and$2.0billionin2017.
Fairvalueofthelong-termdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerpricesand
significantotherobservableinputs.(Level2)
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2018,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember12,2019.Interestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementsarenotmaterial.
Throughout2018,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$2.8billionattheendof2018,ofwhich
$2.6billionisthecurrentportionofthelongtermdebt,andtheremainderprincipallyrepresentslocalborrowingby
internationalsubsidiaries.
Throughout2017,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$3.9billionattheendof2017,ofwhich
$2.3billionwasborrowedundertheCommercialPaperProgram,$1.5billionisthecurrentportionofthelong-termdebt,
andtheremainderprincipallyrepresentslocalborrowingbyinternationalsubsidiaries.
Aggregatematuritiesoflong-termobligationscommencingin2019are:
(DollarsinMillions)
2019 2020 2021 2022 2023 After2023
$2,636 1,098 1,796 2,134 1,553 21,103
8. Income Taxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2018 2017 2016
Currentlypayable:
U.S.taxes $1,081 11,969 1,896
U.S.taxesoninternationaloperations 203 126 49
Internationaltaxes 2,434 1,872 1,659
Totalcurrentlypayable 3,718 13,967 3,604
Deferred:
U.S.taxes (148) (1,956) 294
U.S.taxesoninternationaloperations 1,358
Internationaltaxes (2,226) 4,362 (635)
Totaldeferred (1,016) 2,406 (341)
Provisionfortaxesonincome $2,702 16,373 3,263
56 • Johnson&Johnson2018AnnualReportAcomparisonofincometaxexpenseattheU.S.statutoryrateof21%in2018and35%in2017and2016,tothe
Company’seffectivetaxrateisasfollows:
(DollarsinMillions) 2018 2017 2016
U.S. $5,575 4,865 7,457
International 12,424 12,808 12,346
Earningsbeforetaxesonincome: $17,999 17,673 19,803
Taxrates:
U.S.statutoryrate 21.0% 35.0 35.0
Internationaloperations(1) (3.7) (12.8) (17.2)
Researchandorphandrugtaxcredits (1.0) (0.4) (0.4)
U.S.stateandlocal 0.8 0.6 (0.1)
U.S.manufacturingdeduction — (0.8) (0.6)
U.S.taxoninternationalincome(2) 1.4 0.7 1.3
Taxbenefitsonshare-basedcompensation (1.5) (2.1) (1.8)
U.S.taxbenefitonasset/businessdisposals 0.5 (0.8) —
Allother (0.6) (0.1) 0.3
TCJAandrelatedimpacts(3) (1.9)(3) 73.3(4) —
EffectiveRate 15.0% 92.6 16.5
(1) ForallperiodspresentedtheCompanyhassubsidiariesoperatinginPuertoRicoundervarioustaxincentives.International
operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheU.S.,particularlyIreland,
SwitzerlandandPuertoRico,whichisafavorableimpactontheeffectivetaxrateascomparedwiththeU.S.statutoryrate.The2017
amountalsoincludestaxcostrelatedtotherevaluationofdeferredtaxbalancesrelatedtothechangeintheBelgianstatutorytaxrate
increasingthetaxprovisionbyapproximately3.4%.
(2) IncludestheimpactoftheGILTItax,theForeign-DerivedIntangibleIncomedeductionandotherforeignincomethatistaxableunder
theU.S.taxcode.
(3) Representsimpactofadjustmentstothe2017TCJAprovisionaltaxcharge.Thisalsoincludesanettaxbenefitfromthereductionof
adeferredtaxliabilityrelatedtoforeignwithholdingtaxesoriginallyaccruedaspartoftheprovisionalcharge.Thisbenefitreducedthe
Company’seffectivetaxratebyapproximately11%.Furtherdescriptionisincludedbelow.
(4) IncludesU.S.stateandlocaltaxesprovisionallyrecordedaspartTCJAprovisionalchargewhichwasapproximately0.6%ofthetotal
effectivetaxrate.
OnDecember22,2017,theUnitedStatesenactedintolawnewU.S.taxlegislation,theTaxCutsandJobsAct(TCJA).
Thislawincludedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcode,includingareductionofthe
statutorycorporatetaxratefrom35%to21%,effectiveonJanuary1,2018.Thislegislationalsoeliminatedorreduced
certaincorporateincometaxdeductionsaswellasintroducednewprovisionsthattaxedcertainforeignincomenot
previouslytaxedbytheUnitedStates.TheTCJAalsoincludedaprovisionforataxonallpreviouslyundistributedearnings
ofU.S.companieslocatedinforeignjurisdictions.Undistributedearningsintheformofcashandcashequivalentswere
taxedatarateof15.5%andallotherearningsaretaxedatarateof8.0%.Thistaxispayableover8yearsandwillnot
accrueinterestandthesepaymentsbeganin2018andwillcontinuethrough2025.Theremainingbalanceattheendof
thefiscalyear2018wasapproximately$8.2billion.
InDecember2017,theSECprovidedregulatoryguidanceforaccountingoftheimpactsoftheTCJA,referredtoasSAB
118.UndertheguidanceinSAB118,theincometaxeffects,whichtheaccountingunderASC740isincomplete,are
reportedasaprovisionalamountbasedonareasonableestimate.Thereasonableestimateissubjecttoadjustmentduring
a“measurementperiod”,nottoexceedoneyear,untiltheaccountingiscomplete.Theestimateisalsosubjecttothe
finalizationofmanagement’sanalysisrelatedtocertainmatters,suchasdevelopinginterpretationsoftheprovisionofthe
TCJA,changestocertainestimatesandamountsrelatedtotheearningsandprofitsofcertainsubsidiariesandthefilingof
taxreturns.
Inthefourthquarterof2017,theCompanyrecordedaprovisionaltaxcostofapproximately$13.0billionwhichconsisted
primarilyofthefollowingcomponents:
• a$10.1billionchargeonpreviouslyundistributedforeignearningsasofDecember31,2017
Johnson&Johnson2018AnnualReport • 57• a$4.5billiondeferredtaxliabilityforforeignlocalandwithholdingtaxes,offsetbya$1.1billiondeferredtaxassetfor
U.S.foreigntaxcredits,forrepatriationofsubstantiallyallthoseearnings
• a$0.6billiontaxbenefitrelatingtotheremeasurementofU.S.deferredtaxassetsandliabilitiesandtheimpactofthe
TCJAonunrecognizedtaxbenefits
• a$0.1billionchargeforU.S.stateandlocaltaxesontherepatriationoftheseforeignearnings
Duringthefourthquarterof2018,theCompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpact
ofTCJA.TheCompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately
$0.2billion.Theserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplying
interpretativeguidanceissuedbytheU.S.DepartmentofTreasurytothefactsandcircumstancesthatexistedasofthe
TCJAenactmentdate.Thischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland
withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofDecember31,2017thatwerenot
providedforintheprovisionalchargeinthefourthquarterof2017.
TheTCJAalsoincludesprovisionsforataxonglobalintangiblelow-taxedincome(GILTI).GILTIisdescribedasthe
excessofaU.S.shareholder’stotalnetforeignincomeoveradeemedreturnontangibleassets,asprovidedbytheTCJA.
InJanuary2018,theFASBissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe
taxeffectsofGILTIintheperiodthetaxliabilityisgenerated(i.e.,“periodcost”)orprovidefordeferredtaxassetsand
liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofGILTIinclusioninfutureyears
uponreversal(i.e.,“deferredmethod”).Throughthethirdfiscalquarterof2018,theCompanyhadprovisionallyelectedto
treatGILTIasaperiodexpense.Uponfurtheranalysisofthisnewtaxprovision,theCompanyhaselectedtoaccountfor
GILTIunderthedeferredmethod.Thedeferredtaxamountsrecordedarebasedontheevaluationoftemporary
differencesthatareexpectedtoreverseasGILTIisincurred.Asaresultofthiselection,theCompanyrecordedadeferred
taxcostrelatedtoGILTIofapproximately$1.4billioninthefourthfiscalquarterof2018relatedtofactsand
circumstancesthatexistedonthedateofTCJAenactment.
AsaresultoftheGILTIdeferredtaxchargeandtheotheradjustmentstotheprovisionalamount,theCompanyrecordeda
totalof$1.6billionofadjustmentstothe2017provisionalchargeincreasingtheCompany’sannualeffectivetaxrateby
approximately9%.
During2018,theCompanyreorganizedtheownershipstructureofcertainforeignsubsidiarieswhichresultedina
reductionofcertainforeignwithholdingtaxesthatithadrecognizedaspartoftheprovisionalTCJAtaxchargeinthefourth
quarterof2017.Followingthecompletionofthisrestructuringinthefourthquarter2018,andasaresultofclarificationby
Swisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxtorepatriationofcertainearnings,theCompany
reversedadeferredtaxliabilityof$2.8billionandarelateddeferredtaxassetof$0.9billionforU.S.foreigntaxcredits,for
anetdeferredtaxbenefitof$1.9billion.AsthisrestructuringoccurredaftertheTCJAenactmentdate,thebenefitisnot
consideredanadjustmenttotheprovisionalamountrecordedin2017underSAB118.ThisbenefitwiththeSAB118
adjustmentshasbeenreflectedas“TCJAandrelatedimpacts”ontheCompany’seffectivetaxratereconciliation.
AsdescribedinNote1totheConsolidatedFinancialStatements,in2018theCompanyadoptedASU2016-16:Income
Taxes:Intra-EntityTransfersofAssetsOtherThanInventory.Thisstandardrequiresentitiestorecognizedeferredtaxassets
andliabilitiesrelatedtotransferofassets,otherthaninventory,withintheconsolidatedentity.Atthebeginningoffiscal
2018,theCompanyrecordedanetadjustmenttodeferredtaxassetsofapproximately$2.0billion.Inthefourthquarterof
2018,asaresultoftheelectiontorecordGILTIonthedeferredmethod,theCompanyrecordedaGILTIdeferredtax
liabilityof$1.7billionrelatedtotheadoptionprovisionsofASU2016-16asanadjustmenttoretainedearnings.
The2018effectivetaxratedecreasedby77.6%comparedto2017.The2017effectivetaxratewasprimarilydrivenbythe
approximately$13billionprovisionaltaxchargerecordedinthefourthquarterof2017andtheimpactofaBelgianstatutory
taxratechangewhichincreasedthe2017effectiverateby3.4%.Additionaldriversofthe2018annualeffectivetaxwere:
• thereductionoftheU.S.statutorycorporatetaxrateincludingtheeffectsoftaxelectionswhichresultedinthe
accelerationofcertaindeductionsintothe2017taxreturn.Theimpactoftheseaccelerateddeductionsdecreasedthe
annualeffectivetaxratebyapproximately1.7%
• theimpactoftheadjustmentstothe2017provisionalTCJAcharge,includingbothSAB118adjustmentsandthe
internalrestructuring,decreasedtheeffectivetaxratebyapproximately1.9%
• GILTItaxwhichincreasedtheannualeffectivetaxratebyapproximately1.6%,whichexcludestheimpactoftheSAB
118adjustmentfortheadoptionofthedeferredmethodforGILTI
• taxbenefitsreceivedfromstock-basedcompensationduringfiscal2018and2017,reducedtheeffectivetaxrateby
1.5%and2.0%,respectively
58 • Johnson&Johnson2018AnnualReport• inthefourthquarterof2018,theCompanycompletedthedivestitureofitsLifeScanbusiness(Note20),which
increasedtheCompanyannualeffectivetaxratebyapproximately0.8%
• moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto2017
The2017effectivetaxrateincreasedby76.1%ascomparedto2016,primarilydrivenbytheenactmentoftheTCJAin
theU.S.inDecember2017.TheenactmentoftheTCJAresultedinaprovisionaltaxchargeinthefourthquarterof2017,
ofapproximately$13.0billionorapproximately73.3percentagepointincreasetotheeffectivetaxrate.
Theremainderoftheincreaseinthetaxratefor2017wasrelatedtotheremeasurementoftheCompany’sdeferredtax
assetsinBelgium,asaresultofchangesintheBelgianstatutorycorporatetaxrateenactedinDecember2017,offsetby
ataxbenefitfortheclosureoftheCompany’sAnimasinsulinpumpbusiness.
Temporarydifferencesandcarryforwardsfor2018and2017wereasfollows:
2018 2017
DeferredTax DeferredTax
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $2,398 2,259
Stockbasedcompensation 639 507
Depreciation&amortization 1,784 (9)
Non-deductibleintangibles (5,967) (6,506)
InternationalR&Dcapitalizedfortax 1,282 1,307
Reserves&liabilities 1,647 1,718
Incomereportedfortaxpurposes 1,104 1,316
Netoperatinglosscarryforwardinternational 786 762
Undistributedforeignearnings 693 (2,240) 1,101 (4,457)
Globalintangiblelow-taxedincome (2,971)
Miscellaneousinternational 603 (93) 755 (194)
MiscellaneousU.S. 469 177
Totaldeferredincometaxes $11,405 (11,271) 9,902 (11,166)
TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenetlosses.TheCompanybelievesthatitis
morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets.
Thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2018 2017 2016
Beginningofyear $3,151 3,041 3,080
Increasesrelatedtocurrentyeartaxpositions 242 332 348
Increasesrelatedtopriorperiodtaxpositions 145 232 11
Decreasesrelatedtopriorperiodtaxpositions (137) (416)(1) (338)
Settlements (40) (2) (37)
Lapseofstatuteoflimitations (35) (36) (23)
Endofyear $3,326 3,151 3,041
(1) In2017,$347millionofthisdecreaseisrelatedtotheTCJA
Theunrecognizedtaxbenefitsof$3.3billionatDecember30,2018,ifrecognized,wouldaffecttheCompany’sannual
effectivetaxrate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits
inprogresswithanumberoftaxauthorities.TheIRShascompleteditsauditforthetaxyearsthrough2009andis
currentlyauditingthetaxyears2010-2012.TheCompanycurrentlyexpectscompletionofthisauditduring2019.Final
conclusionofthetaxauditmayresultinanoutcomethatisdifferentthantheCompany’sestimatesandmayresultina
materialimpactontheCompany’scurrentandfutureoperatingresultsorcashflowsintheperiodthattheauditis
concluded.InothermajorjurisdictionswheretheCompanyconductsbusiness,theyearsthatremainopentotaxauditgo
Johnson&Johnson2018AnnualReport • 59backtotheyear2006.TheCompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsome
jurisdictionsoverthenexttwelvemonths.However,theCompanyisnotabletoprovideareasonablyreliableestimateof
thetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities.
Interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompany
recognizedaftertaxinterestexpenseof$53million,$60millionand$7millionin2018,2017and2016,respectively.The
totalamountofaccruedinterestwas$503millionand$436millionin2018and2017,respectively.
9. Employee Related Obligations
Attheendof2018and2017,employeerelatedobligationsrecordedontheConsolidatedBalanceSheetswere:
(DollarsinMillions) 2018 2017
Pensionbenefits $5,327 5,343
Postretirementbenefits 2,283 2,331
Postemploymentbenefits 2,330 2,250
Deferredcompensation 410 475
Totalemployeeobligations 10,350 10,399
Lesscurrentbenefitspayable 399 325
Employeerelatedobligations—non-current $9,951 10,074
Prepaidemployeerelatedobligationsof$475millionand$526millionfor2018and2017,respectively,areincludedin
OtherassetsontheConsolidatedBalanceSheets.
10. Pensions and Other Benefit Plans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
RetirementplanbenefitsforemployeeshiredbeforeJanuary1,2015areprimarilybasedontheemployee’scompensation
duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofservice.In2014,theCompanyannounced
thattheU.S.DefinedBenefitPlanwasamendedtoadoptanewbenefitformula,effectiveforemployeeshiredonorafter
January1,2015.Thebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof
service.
Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrustees,annuitiesarepurchasedundergroup
contracts,orreservesareprovided.
TheCompanydoesnottypicallyfundretireehealthcarebenefitsinadvance,butmaydosoatitsdiscretion.TheCompany
alsohastherighttomodifytheseplansinthefuture.
In2018and2017theCompanyusedDecember31,2018andDecember31,2017,respectively,asthemeasurement
dateforallU.S.andinternationalretirementandotherbenefitplans.
60 • Johnson&Johnson2018AnnualReportNetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2018,2017and
2016includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2018 2017 2016 2018 2017 2016
Servicecost $1,283 1,080 949 269 247 224
Interestcost 996 927 927 148 159 158
Expectedreturnonplanassets (2,212) (2,041) (1,962) (7) (6) (6)
Amortizationofpriorservicecost(credit) 3 2 1 (31) (30) (34)
Recognizedactuariallosses 852 609 496 123 138 135
Curtailmentsandsettlements 1 17 11 — — —
Netperiodicbenefitcost $923 594 422 502 508 477
In2018,aspertheadoptionofASU2017-07,theservicecostcomponentofnetperiodicbenefitcostwaspresentedin
thesamelineitemsontheConsolidatedStatementofEarningswhereotheremployeecompensationcostsarereported.
AllothercomponentsofnetperiodicbenefitcostarepresentedaspartofOther(income)expense,netonthe
ConsolidatedStatementofEarnings.
AmountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearfortheCompany’sdefinedbenefit
retirementplansandotherpost-retirementplans:
(DollarsinMillions)
Amortizationofnettransitionobligation $ —
Amortizationofnetactuariallosses 656
Amortizationofpriorservicecredit 27
UnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheaccumulatedpostretirementbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridor
areamortizedovertheaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceofplan
participantsatthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedover
theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
Thefollowingtablerepresentstheweighted-averageactuarialassumptions:
RetirementPlans OtherBenefitPlans
WorldwideBenefitPlans 2018 2017 2016 2018 2017 2016
NetPeriodicBenefitCost
Servicecostdiscountrate 3.20% 3.59 3.98 3.85 4.63 4.77
Interestcostdiscountrate 3.60% 3.98 4.24 3.62 3.94 4.10
Rateofincreaseincompensationlevels 3.98% 4.01 4.02 4.29 4.31 4.32
Expectedlong-termrateofreturnonplanassets 8.46% 8.43 8.55
BenefitObligation
Discountrate 3.76% 3.30 3.78 4.40 3.78 4.42
Rateofincreaseincompensationlevels 3.97% 3.99 4.02 4.29 4.30 4.29
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.Inthefiscalyear
2016,theCompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage
discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplans’liabilitycashflows,which
managementhasconcludedisamorepreciseestimate.Priortothischangeinmethodology,theCompanymeasured
Johnson&Johnson2018AnnualReport • 61serviceandinterestcostsutilizingasingleweighted-averagediscountratederivedfromtheyieldcurveusedtomeasure
theplanobligations.TheCompanyhasaccountedforthischangeasachangeinaccountingestimateand,accordingly,
hasaccountedforitonaprospectivebasis.Thischangedoesnotimpactthebenefitobligationanddidnothavea
materialimpacttothe2016fullyearresults.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthCarePlans 2018 2017
Healthcarecosttrendrateassumedfornextyear 6.12% 6.33%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.55% 4.55%
Yeartheratereachestheultimatetrendrate 2038 2038
Aone-percentage-pointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect:
One-Percentage- One-Percentage-
(DollarsinMillions) PointIncrease PointDecrease
HealthCarePlans
Totalinterestandservicecost $28 (22)
Post-retirementbenefitobligation $340 (280)
62 • Johnson&Johnson2018AnnualReportThefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyear-end
2018and2017fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2018 2017 2018 2017
ChangeinBenefitObligation
Projectedbenefitobligation—beginningofyear $33,221 28,116 4,582 4,605
Servicecost 1,283 1,080 269 247
Interestcost 996 927 148 159
Planparticipantcontributions 66 60 — —
Amendments 26 (7) — (17)
Actuarial(gains)losses (2,326) 2,996 (119) (166)
Divestitures&acquisitions (29) 201 — 88
Curtailments,settlements&restructuring (21) (35) — 2
Benefitspaidfromplan (1,018) (1,050) (383) (351)
Effectofexchangerates (528) 933 (17) 15
Projectedbenefitobligation—endofyear $31,670 33,221 4,480 4,582
ChangeinPlanAssets
Planassetsatfairvalue—beginningofyear $28,404 23,633 281 75
Actualreturnonplanassets (1,269) 4,274 — 12
Companycontributions 1,140 664 282 545
Planparticipantcontributions 66 60 — —
Settlements (13) (32) — —
Divestitures&acquisitions (17) 173 — —
Benefitspaidfromplanassets (1,018) (1,050) (383) (351)
Effectofexchangerates (475) 682 — —
Planassetsatfairvalue—endofyear $26,818 28,404 180 281
Fundedstatus—endofyear $(4,852) (4,817) (4,300) (4,301)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $475 526 — —
Currentliabilities (98) (92) (281) (228)
Non-currentliabilities (5,229) (5,251) (4,019) (4,073)
Totalrecognizedintheconsolidatedbalancesheet—endofyear $(4,852) (4,817) (4,300) (4,301)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $8,323 8,140 1,263 1,500
Priorservicecost(credit) 2 (25) (106) (137)
Unrecognizednettransitionobligation — — — —
Totalbeforetaxeffects $8,325 8,115 1,157 1,363
AccumulatedBenefitObligations—endofyear $28,533 29,793
Johnson&Johnson2018AnnualReport • 63OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2018 2017 2018 2017
AmountsRecognizedinNetPeriodicBenefitCostandOtherComprehensive
Income
Netperiodicbenefitcost $923 594 502 508
Netactuarial(gain)loss 1,153 740 (111) (169)
Amortizationofnetactuarialloss (852) (609) (123) (138)
Priorservicecost(credit) 26 (7) – (17)
Amortizationofpriorservice(cost)credit (3) (2) 31 30
Effectofexchangerates (114) 256 (3) 3
Totalloss/(income)recognizedinothercomprehensiveincome,beforetax $210 378 (206) (291)
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $1,133 972 296 217
TheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2018,theCompanycontributed$679millionand$461milliontoitsU.S.andinternationalpensionplans,respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember31,2018andDecember31,2017,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2018 2017 2018 2017 2018 2017 2018 2017
PlanAssets $17,725 18,681 — — 9,093 9,723 — —
ProjectedBenefitObligation 18,609 19,652 2,176 2,257 10,467 10,863 418 449
AccumulatedBenefitObligation 16,851 17,654 1,793 1,849 9,510 9,893 379 397
Over(Under)FundedStatus
ProjectedBenefitObligation $(884) (971) (2,176) (2,257) (1,374) (1,140) (418) (449)
AccumulatedBenefitObligation 874 1,027 (1,793) (1,849) (417) (170) (379) (397)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$7.5billion,$8.8billionand$4.3billion,respectively,attheendof2018,and
$3.8billion,$4.6billionand$0.7billion,respectively,attheendof2017.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2019 2020 2021 2022 2023 2024-2028
Projectedfuturebenefitpayments
Retirementplans $1,062 1,104 1,182 1,257 1,332 7,679
Otherbenefitplans $375 397 411 428 413 2,273
Thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplans.Theseamounts
donotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthefuture.
2024-
(DollarsinMillions) 2019 2020 2021 2022 2023 2028
Projectedfuturecontributions $92 95 101 108 115 697
Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
64 • Johnson&Johnson2018AnnualReportconsidersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
durationofliabilities;andotherrelevantfactorsincluding:diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
TheCompany’sretirementplanassetallocationattheendof2018and2017andtargetallocationsfor2019areas
follows:
Percentof Target
PlanAssets Allocation
2018 2017 2019
WorldwideRetirementPlans
Equitysecurities 71% 76% 70%
Debtsecurities 29 24 30
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestmentfunds—Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamount
heldondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNetAsset
Value(NAV)providedbytheadministratorofthefund.TheNAVisbasedonthevalueoftheunderlyingassetsowned
bythefund,minusitsliabilities,andthendividedbythenumberofsharesoutstanding.TheNAVisaquotedpriceina
marketthatisnotactiveandclassifiedasLevel2.
• Governmentandagencysecurities—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket
onwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
usingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
• Equitysecurities—Equitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallcommonstockisclassifiedwithinLevel1ofthevaluationhierarchy.
Johnson&Johnson2018AnnualReport • 65• Commingledfunds—TheseinvestmentvehiclesarevaluedusingtheNAVprovidedbythefundadministrator.TheNAV
isbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthendividedbythenumberof
sharesoutstanding.AssetsintheLevel2categoryhaveaquotedmarketprice.
• Insurancecontracts—Theinstrumentsareissuedbyinsurancecompanies.Thefairvalueisbasedonnegotiatedvalue
andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe
issuer.Theunderlyinginvestmentsaregovernment,asset-backedandfixedincomesecurities.Ingeneral,insurance
contractsareclassifiedasLevel3astherearenoquotedpricesnorotherobservableinputsforpricing.
• Otherassets—Otherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestments,aswellas
commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebt.Otherassetsthatareexchange
listedandactivelytradedareclassifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.
ThefollowingtablesetsforththeRetirementPlans’investmentsmeasuredatfairvalueasofDecember31,2018and
December31,2017:
QuotedPrices Significant
inActive Other Significant Investments
Marketsfor Observable Unobservable Measuredat
IdenticalAssets Inputs Inputs(a) NetAsset
(Level1) (Level2) (Level3) Value TotalAssets
(DollarsinMillions) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017
Short-terminvestmentfunds $122 429 529 427 — — — — 651 856
Governmentandagencysecurities — — 3,595 3,094 — — — — 3,595 3,094
Debtinstruments — — 3,105 2,013 — — — — 3,105 2,013
Equitysecurities 11,298 13,848 4 — — — — — 11,302 13,848
Commingledfunds — — 2,304 1,780 133 57 5,201 6,158 7,638 7,995
Insurancecontracts — — — — 193 199 — — 193 199
Otherassets — — 33 121 — — 301 278 334 399
Investmentsatfairvalue $11,420 14,277 9,570 7,435 326 256 5,502 6,436 26,818 28,404
(a) TheactivityfortheLevel3assetsisnotsignificantforallyearspresented.
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$72millionand
$81millionandU.S.short-terminvestmentfunds(Level2)of$108millionand$200millionatDecember31,2018and
December31,2017,respectively.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$876million(3.3%oftotalplan
assets)atDecember31,2018and$938million(3.3%oftotalplanassets)atDecember31,2017.
11. Savings Plan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$242million,$214millionand
$191millionin2018,2017and2016,respectively.
66 • Johnson&Johnson2018AnnualReport12. Capital and Treasury Stock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatJanuary3,2016 364,681 $22,684
Employeecompensationandstockoptionplans (30,839) (3,311)
Repurchaseofcommonstock 79,490 8,979
BalanceatJanuary1,2017 413,332 28,352
Employeecompensationandstockoptionplans (25,508) (3,156)
Repurchaseofcommonstock 49,494 6,358
BalanceatDecember31,2017 437,318 31,554
Employeecompensationandstockoptionplans (22,082) (3,060)
Repurchaseofcommonstock 42,283 5,868
BalanceatDecember30,2018 457,519 $34,362
Aggregatesharesofcommonstockissuedwereapproximately3,119,843,000sharesattheendof2018,2017and
2016.
Cashdividendspaidwere$3.54persharein2018,comparedwithdividendsof$3.32persharein2017,and$3.15per
sharein2016.
OnDecember17,2018,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.Therepurchase
programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.Anysharesacquiredwillbe
availableforgeneralcorporatepurposes.TheCompanyintendstofinancethesharerepurchaseprogramthroughavailable
cash.AsofDecember30,2018,$0.9billionhasbeenrepurchasedundertheprogram.
OnOctober13,2015,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$10.0billionoftheCompany’ssharesofcommonstock.Thisshare
repurchaseprogramwascompletedasofJuly2,2017.
13. Accumulated Other Comprehensive Income (Loss)
Componentsofothercomprehensiveincome(loss)consistofthefollowing:
Total
Gain/(Loss) Accumulated
Foreign Gain/(Loss) Employee On Other
Currency On Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income(Loss)
January3,2016 $(8,435) 604 (5,298) (36) (13,165)
Net2016changes (612) (193) (682) (249) (1,736)
January1,2017 (9,047) 411 (5,980) (285) (14,901)
Net2017changes 1,696 (179) (170) 355 1,702
December31,2017 (7,351) 232 (6,150) 70 (13,199)
Cumulativeadjustmenttoretainedearnings (232)(1) (232)
Net2018changes (1,518) — (8) (265) (1,791)
December30,2018 $(8,869) — (6,158) (195) (15,222)
(1) SeeNote1toConsolidatedFinancialStatementsforadditionaldetailsontheadoptionofASU2016-01
Amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
Johnson&Johnson2018AnnualReport • 67DetailsonreclassificationsoutofAccumulatedOtherComprehensiveIncome:
Gain/(Loss)OnSecurities—reclassificationsreleasedtoOther(income)expense,net.
EmployeeBenefitPlans—reclassificationsareincludedinnetperiodicbenefitcost.SeeNote10foradditional
details.
Gain/(Loss)OnDerivatives&Hedges—reclassificationstoearningsarerecordedinthesameaccountasthe
hedgedtransaction.SeeNote6foradditionaldetails.
14. International Currency Translation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.Beginninginthefiscalthirdquarterof2018,
theCompanyaccountedforoperationsinArgentinaashighlyinflationary.ForthemajorityoftheCompany’ssubsidiaries
thelocalcurrencyisthefunctionalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.Thisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand
liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalrates,exceptforthoselocatedinhighlyinflationary
economies.Thetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperating
results.
Arollforwardofthechangesduring2018,2017and2016forforeigncurrencytranslationadjustmentsisincludedin
Note13.
NetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$265million,$216million
and$289millionin2018,2017and2016,respectively.
15. Earnings Per Share
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
December30,2018,December31,2017andJanuary1,2017:
(InMillionsExceptPerShareAmounts) 2018 2017 2016
Basicnetearningspershare $5.70 0.48 6.04
Averagesharesoutstanding—basic 2,681.5 2,692.0 2,737.3
Potentialsharesexercisableunderstockoptionplans 139.0 139.7 142.4
Less:sharesrepurchasedundertreasurystockmethod (92.5) (87.3) (92.1)
Convertibledebtshares 0.7 0.9 1.3
Adjustedaveragesharesoutstanding—diluted 2,728.7 2,745.3 2,788.9
Dilutednetearningspershare $5.61 0.47 5.93
Thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated
reductionininterestexpenseof$1millionafter-taxfor2018and2017,and$2millionfor2016.
Thedilutednetearningspersharecalculationfor2018,2017and2016includedallsharesrelatedtostockoptions,as
theexercisepriceofalloptionswaslessthantheaveragemarketvalueoftheCompany’sstock.
16. Rental Expense and Lease Commitments
Rentalsofspace,vehicles,manufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases
wereapproximately$332million,$372millionand$330millionin2018,2017and2016,respectively.
68 • Johnson&Johnson2018AnnualReportTheapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnon-cancelable
leasetermsinexcessofoneyearatDecember30,2018are:
(DollarsinMillions)
After
2019 2020 2021 2022 2023 2023 Total
$223 188 154 116 76 139 896
Commitmentsundercapitalleasesarenotsignificant.
17. Common Stock, Stock Option Plans and Stock Compensation Agreements
AtDecember30,2018,theCompanyhad2stock-basedcompensationplans.Thesharesoutstandingareforcontracts
undertheCompany’s2005Long-TermIncentivePlanandthe2012Long-TermIncentivePlan.The2005Long-Term
IncentivePlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthe
2012Long-TermIncentivePlan.Underthe2012Long-TermIncentivePlan,theCompanymayissueupto650million
sharesofcommonstock,plusanysharescanceled,expired,forfeited,ornotissuedfromthe2005Long-TermIncentive
PlansubsequenttoApril26,2012.Sharesavailableforfuturegrantsunderthe2012Long-TermIncentivePlanwere
351millionattheendof2018.
Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$978million,$962millionand
$878millionfor2018,2017and2016,respectively.Thetotalincometaxbenefitrecognizedintheincomestatementfor
share-basedcompensationcostswas$192million,$275millionand$256millionfor2018,2017and2016,
respectively.Anadditionaltaxbenefitof$353millionwasrecognizedin2016duetotheadoptionofanewaccounting
standardforthereportingofadditionaltaxbenefitsonshare-basedcompensation.Thetotalunrecognizedcompensation
costwas$827million,$798millionand$749millionfor2018,2017and2016,respectively.Theweightedaverage
periodforthiscosttoberecognizedwas1.73years,1.76yearsand1.09yearsfor2018,2017,and2016,respectively.
Share-basedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiods.
TheCompanysettlesemployeebenefitequityissuanceswithtreasuryshares.Treasurysharesarereplenishedthroughout
theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.
ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.For2018,2017and2016grants,expectedvolatilityrepresentsa
blendedrateof10-yearweeklyhistoricaloverallvolatilityrate,anda5-weekaverageimpliedvolatilityratebasedon
at-the-moneytradedJohnson&Johnsonoptionswithalifeof2years.Forallgrants,historicaldataisusedtodetermine
theexpectedlifeoftheoption.Therisk-freeratewasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$17.98,$13.38and$10.01,in2018,2017and2016,respectively.The
fairvaluewasestimatedbasedontheweightedaverageassumptionsof:
2018 2017 2016
Risk-freerate 2.77% 2.25% 1.51%
Expectedvolatility 15.77% 15.30% 15.76%
Expectedlife(inyears) 7.0 7.0 7.0
Expecteddividendyield 2.70% 2.90% 3.10%
Johnson&Johnson2018AnnualReport • 69AsummaryofoptionactivityunderthePlanasofDecember30,2018,December31,2017andJanuary1,2017,and
changesduringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatJanuary3,2016 116,517 $76.41 $3,065
Optionsgranted 22,491 101.87
Optionsexercised (22,547) 65.66
Optionscanceled/forfeited (3,006) 92.83
SharesatJanuary1,2017 113,455 83.16 3,636
Optionsgranted 19,287 115.67
Optionsexercised (18,975) 70.87
Optionscanceled/forfeited (2,461) 101.40
SharesatDecember31,2017 111,306 90.48 5,480
Optionsgranted 17,115 129.51
Optionsexercised (16,228) 75.44
Optionscanceled/forfeited (2,541) 112.90
SharesatDecember30,2018 109,652 $98.29 $3,214
Thetotalintrinsicvalueofoptionsexercisedwas$1,028million,$1,060millionand$980millionin2018,2017and
2016,respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatDecember30,2018:
(SharesinThousands) Outstanding Exercisable
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$52.13-$65.62 13,466 1.8 $62.67 13,466 $62.67
$66.07-$72.54 12,710 4.0 $72.53 12,710 $72.53
$90.44-$100.48 29,162 5.6 $95.34 28,537 $95.23
$101.87-$115.67 37,877 7.6 $108.33 111 $108.04
$115.68-$129.51 16,437 9.1 $129.51 38 $129.51
109,652 6.2 $98.29 54,862 $82.03
(1) Averagecontractualliferemaininginyears.
StockoptionsoutstandingatDecember31,2017andJanuary1,2017were111,306andanaveragelifeof6.3yearsand
113,455andanaveragelifeof6.2years,respectively.StockoptionsexercisableatDecember31,2017andJanuary1,
2017were52,421atanaveragepriceof$73.61and50,414atanaveragepriceof$65.77,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrom6monthsto3years.The
Companyalsograntsperformanceshareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockafterthe
endofathree-yearperformanceperiod.Whetheranyperformanceshareunitsvest,andtheamountthatdoesvest,istied
tothecompletionofserviceperiodsthatrangefrom6monthsto3yearsandtheachievement,overathree-yearperiod,
ofthreeequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholderreturn:operationalsales,
adjustedoperationalearningspershare,andrelativetotalshareholderreturn.Thenumberofsharesactuallyearnedatthe
endofthethree-yearperiodwillvary,basedonlyonactualperformance,from0%to200%ofthetargetnumberof
performanceshareunitsgranted.Inthefourthquarterof2017,theCompanymodifiedtherestrictedshareunitsthatare
scheduledtovestbetweenJanuary1,2018andMarch15,2018.Thismodificationguaranteedaminimumaggregate
70 • Johnson&Johnson2018AnnualReportvalue,belowthemarketvalueofthetotalexpectedpayoutamount,forallawardsexpectedtovestduringthisperiod.The
amountthatwascommittedwasnotmaterialtotheCompany’soverallfinancialposition.
AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofDecember30,2018is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatDecember31,2017 20,161 2,625
Granted 6,074 1,142
Issued (6,684) (1,151)
Canceled/forfeited/adjusted (1,091) (122)
SharesatDecember30,2018 18,460 2,494
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$119.67,$107.69and$92.45in2018,2017and2016,
respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswasdiscountedfor
dividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueofrestrictedshareunits
issuedwas$613.7million,$596.5millionand$587.7millionin2018,2017and2016,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitsgrantedwas$120.64,$114.13and$105.30in2018,
2017and2016,calculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthe
dateofgrant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Thefairvalueof
performanceshareunitsissuedwas$128.8million,$132.5millionand$127.7millionin2018,2017and2016,
respectively.
Johnson&Johnson2018AnnualReport • 7118. Segments of Business and Geographic Areas
SalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
CONSUMER
BabyCare
U.S. $422 449 488 (6.0)% (8.0)
International 1,436 1,467 1,513 (2.1) (3.0)
Worldwide 1,858 1,916 2,001 (3.0) (4.2)
Beauty
U.S. 2,403 2,335 2,135 2.9 9.4
International 1,979 1,865 1,762 6.1 5.8
Worldwide 4,382 4,200 3,897 4.3 7.8
OralCare
U.S. 637 616 648 3.4 (4.9)
International 918 915 920 0.3 (0.5)
Worldwide 1,555 1,531 1,568 1.6 (2.4)
OTC
U.S. 1,850 1,716 1,675 7.8 2.4
International 2,484 2,410 2,302 3.1 4.7
Worldwide 4,334 4,126 3,977 5.0 3.7
Women’sHealth
U.S. 13 12 19 8.3 (36.8)
International 1,036 1,038 1,048 (0.2) (1.0)
Worldwide 1,049 1,050 1,067 (0.1) (1.6)
WoundCare/Other
U.S. 436 437 455 (0.2) (4.0)
International 239 342 342 (30.1) 0.0
Worldwide 675 779 797 (13.4) (2.3)
TOTALCONSUMER
U.S. 5,761 5,565 5,420 3.5 2.7
International 8,092 8,037 7,887 0.7 1.9
Worldwide 13,853 13,602 13,307 1.8 2.2
PHARMACEUTICAL
Immunology
U.S. 9,073 8,871 8,846 2.3 0.3
International 4,047 3,373 3,122 20.0 8.0
Worldwide 13,120 12,244 11,968 7.2 2.3
REMICADE®
U.S. 3,664 4,525 4,842 (19.0) (6.5)
U.S.Exports 436 563 782 (22.6) (28.0)
International 1,226 1,227 1,342 (0.1) (8.6)
Worldwide 5,326 6,315 6,966 (15.7) (9.3)
SIMPONI/SIMPONIARIA®
U.S. 1,051 954 959 10.2 (0.5)
International 1,033 879 786 17.5 11.8
72 • Johnson&Johnson2018AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
Worldwide 2,084 1,833 1,745 13.7 5.0
STELARA®
U.S. 3,469 2,767 2,263 25.4 22.3
International 1,687 1,244 969 35.6 28.4
Worldwide 5,156 4,011 3,232 28.5 24.1
TREMFAYA®
U.S. 453 62 — * *
International 91 1 — * *
Worldwide 544 63 — * *
OTHERIMMUNOLOGY
U.S. — — — — —
International 10 22 25 (54.5) (12.0)
Worldwide 10 22 25 (54.5) (12.0)
InfectiousDiseases
U.S. 1,378 1,358 1,461 1.5 (7.0)
International 1,926 1,796 1,747 7.2 2.8
Worldwide 3,304 3,154 3,208 4.8 (1.7)
EDURANT®/rilpivirine
U.S. 58 58 52 0.0 11.5
International 758 656 521 15.5 25.9
Worldwide 816 714 573 14.3 24.6
PREZISTA®/PREZCOBIX®/REZOLSTA®/SYMTUZA®
U.S. 1,169 1,109 1,143 5.4 (3.0)
International 786 712 708 10.4 0.6
Worldwide 1,955 1,821 1,851 7.4 (1.6)
OTHERINFECTIOUSDISEASES
U.S. 151 191 266 (20.9) (28.2)
International 382 428 518 (10.7) (17.4)
Worldwide 533 619 784 (13.9) (21.0)
Neuroscience
U.S. 2,574 2,630 2,628 (2.1) 0.1
International 3,503 3,356 3,457 4.4 (2.9)
Worldwide 6,077 5,986 6,085 1.5 (1.6)
CONCERTA®/Methylphenidate
U.S. 229 384 468 (40.4) (17.9)
International 434 407 395 6.6 3.0
Worldwide 663 791 863 (16.2) (8.3)
INVEGASUSTENNA®/XEPLION®/INVEGATRINZA®/
TREVICTA®
U.S. 1,791 1,590 1,343 12.6 18.4
International 1,137 979 871 16.1 12.4
Worldwide 2,928 2,569 2,214 14.0 16.0
Johnson&Johnson2018AnnualReport • 73SalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
RISPERDALCONSTA®
U.S. 315 360 381 (12.5) (5.5)
International 422 445 512 (5.2) (13.1)
Worldwide 737 805 893 (8.4) (9.9)
OTHERNEUROSCIENCE
U.S. 239 296 436 (19.3) (32.1)
International 1,510 1,525 1,679 (1.0) (9.2)
Worldwide 1,749 1,821 2,115 (4.0) (13.9)
Oncology
U.S. 4,331 3,098 2,335 39.8 32.7
International 5,513 4,160 3,472 32.5 19.8
Worldwide 9,844 7,258 5,807 35.6 25.0
DARZALEX®
U.S. 1,203 884 471 36.1 87.7
International 822 358 101 * *
Worldwide 2,025 1,242 572 63.0 *
IMBRUVICA®
U.S. 1,129 841 613 34.2 37.2
International 1,486 1,052 638 41.3 64.9
Worldwide 2,615 1,893 1,251 38.1 51.3
VELCADE®
U.S. — — — — —
International 1,116 1,114 1,224 0.2 (9.0)
Worldwide 1,116 1,114 1,224 0.2 (9.0)
ZYTIGA®/abirateroneacetate
U.S. 1,771 1,228 1,089 44.2 12.8
International 1,727 1,277 1,171 35.2 9.1
Worldwide 3,498 2,505 2,260 39.6 10.8
OTHERONCOLOGY
U.S. 228 145 162 57.2 (10.5)
International 362 359 338 0.8 6.2
Worldwide 590 504 500 17.1 0.8
PulmonaryHypertension
U.S. 1,651 773 — * *
International 922 554 — 66.4 *
Worldwide 2,573 1,327 — 93.9 *
OPSUMIT®
U.S. 700 320 — * *
International 515 253 — * *
Worldwide 1,215 573 — * *
TRACLEER®
U.S. 268 161 — 66.5 *
International 278 242 — 14.9 *
74 • Johnson&Johnson2018AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
Worldwide 546 403 — 35.5 *
UPTRAVI®
U.S. 598 238 — * *
International 65 25 — * *
Worldwide 663 263 — * *
OTHER
U.S. 85 54 — 57.4 *
International 64 34 — 88.2 *
Worldwide 149 88 — 69.3 *
Cardiovascular/Metabolism/Other
U.S. 4,279 4,744 4,855 (9.8) (2.3)
International 1,537 1,543 1,541 (0.4) 0.1
Worldwide 5,816 6,287 6,396 (7.5) (1.7)
XARELTO®
U.S. 2,477 2,500 2,288 (0.9) 9.3
International — — — — —
Worldwide 2,477 2,500 2,288 (0.9) 9.3
INVOKANA®/INVOKAMET®
U.S. 711 944 1,273 (24.7) (25.8)
International 170 167 134 1.8 24.6
Worldwide 881 1,111 1,407 (20.7) (21.0)
PROCRIT®/EPREX®
U.S. 674 675 767 (0.1) (12.0)
International 314 297 338 5.7 (12.1)
Worldwide 988 972 1,105 1.6 (12.0)
OTHER
U.S. 417 625 527 (33.3) 18.6
International 1,053 1,079 1,069 (2.4) 0.9
Worldwide 1,470 1,704 1,596 (13.7) 6.8
TOTALPHARMACEUTICAL
U.S. 23,286 21,474 20,125 8.4 6.7
International 17,448 14,782 13,339 18.0 10.8
Worldwide 40,734 36,256 33,464 12.4 8.3
MEDICALDEVICES
DiabetesCare
U.S. 371 612 739 (39.4) (17.2)
International 638 1,003 1,050 (36.4) (4.5)
Worldwide 1,009 1,615 1,789 (37.5) (9.7)
Diagnostics
U.S. — — — — —
International — 1 66 * *
Worldwide — 1 66 * *
Johnson&Johnson2018AnnualReport • 75SalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
InterventionalSolutions
U.S. 1,283 1,148 1,031 11.8 11.3
International 1,363 1,148 1,024 18.7 12.1
Worldwide 2,646 2,296 2,055 15.2 11.7
Orthopaedics
U.S. 5,281 5,404 5,438 (2.3) (0.6)
International 3,604 3,654 3,690 (1.4) (1.0)
Worldwide 8,885 9,058 9,128 (1.9) (0.8)
HIPS
U.S. 841 827 798 1.7 3.6
International 577 567 563 1.8 0.7
Worldwide 1,418 1,394 1,361 1.7 2.4
KNEES
U.S. 911 948 943 (3.9) 0.5
International 591 575 581 2.8 (1.0)
Worldwide 1,502 1,523 1,524 (1.4) (0.1)
TRAUMA
U.S. 1,599 1,576 1,545 1.5 2.0
International 1,100 1,040 1,024 5.8 1.6
Worldwide 2,699 2,616 2,569 3.2 1.8
SPINE&OTHER
U.S. 1,930 2,053 2,152 (6.0) (4.6)
International 1,336 1,472 1,522 (9.2) (3.3)
Worldwide 3,266 3,525 3,674 (7.3) (4.1)
Surgery
U.S. 4,125 4,085 4,026 1.0 1.5
International 5,776 5,474 5,270 5.5 3.9
Worldwide 9,901 9,559 9,296 3.6 2.8
ADVANCED
U.S. 1,657 1,620 1,524 2.3 6.3
International 2,345 2,136 1,993 9.8 7.2
Worldwide 4,002 3,756 3,517 6.5 6.8
GENERAL
U.S. 1,751 1,728 1,669 1.3 3.5
International 2,806 2,735 2,693 2.6 1.6
Worldwide 4,557 4,463 4,362 2.1 2.3
SPECIALTY
U.S. 717 737 833 (2.7) (11.5)
International 625 603 584 3.6 3.3
Worldwide 1,342 1,340 1,417 0.1 (5.4)
76 • Johnson&Johnson2018AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2018 2017 2016 ’18vs.’17 ’17vs.’16
Vision
U.S. 1,777 1,575 1,032 12.8 52.6
International 2,776 2,488 1,753 11.6 41.9
Worldwide 4,553 4,063 2,785 12.1 45.9
CONTACTLENSES/OTHER
U.S. 1,237 1,122 1,032 10.2 8.7
International 2,065 1,914 1,753 7.9 9.2
Worldwide 3,302 3,036 2,785 8.8 9.0
SURGICAL
U.S. 540 453 — 19.2 *
International 711 574 — 23.9 *
Worldwide 1,251 1,027 — 21.8 *
TOTALMEDICALDEVICES
U.S. 12,837 12,824 12,266 0.1 4.5
International 14,157 13,768 12,853 2.8 7.1
Worldwide 26,994 26,592 25,119 1.5 5.9
WORLDWIDE
U.S. 41,884 39,863 37,811 5.1 5.4
International 39,697 36,587 34,079 8.5 7.4
Worldwide $81,581 76,450 71,890 6.7% 6.3
* Percentagegreaterthan100%ornotmeaningful
IncomeBeforeTax IdentifiableAssets
(DollarsinMillions) 2018(3) 2017(4) 2016(5) 2018 2017
Consumer $2,320 2,524 2,441 $25,877 25,030
Pharmaceutical 12,568 11,083 12,827 56,636 59,450
MedicalDevices 4,397 5,392 5,578 46,254 45,413
Total 19,285 18,999 20,846 128,767 129,893
Less:Expensenotallocatedtosegments(1) 1,286 1,326 1,043
Generalcorporate(2) 24,187 27,410
Worldwidetotal $17,999 17,673 19,803 $152,954 157,303
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2018 2017 2016 2018 2017 2016
Consumer $438 485 486 $688 674 608
Pharmaceutical 1,012 936 927 3,802 2,416 886
MedicalDevices 1,843 1,566 1,472 2,103 2,216 1,928
Segmentstotal 3,293 2,987 2,885 6,593 5,306 3,422
Generalcorporate 377 292 341 336 336 332
Worldwidetotal $3,670 3,279 3,226 $6,929 5,642 3,754
Johnson&Johnson2018AnnualReport • 77SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2018 2017 2016 2018 2017
UnitedStates $41,884 39,863 37,811 $37,117 38,556
Europe 18,753 17,126 15,770 51,433 56,677
WesternHemisphereexcludingU.S. 6,113 6,041 5,734 2,752 2,990
Asia-Pacific,Africa 14,831 13,420 12,575 2,733 2,773
Segmentstotal 81,581 76,450 71,890 94,035 100,996
Generalcorporate 1,064 1,143
Othernonlong-livedassets 57,855 55,164
Worldwidetotal $81,581 76,450 71,890 $152,954 157,303
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.In2018,theCompanyhadthreewholesalersdistributingproductsforallthreesegments
thatrepresentedapproximately14.0%,11.0%and11.0%ofthetotalconsolidatedrevenues.In2017,theCompanyhad
twowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately14.0%and10.0%ofthetotal
consolidatedrevenues.In2016,theCompanyhadtwowholesalersdistributingproductsforallthreesegmentsthat
representedapproximately13.5%and10.7%ofthetotalconsolidatedrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
(2) Generalcorporateincludescash,cashequivalentsandmarketablesecurities.
(3) TheConsumersegmentincludesagainof$0.3billionfromthedivestitureofNIZORAL®andlitigationexpenseof$0.3billion.The
Pharmaceuticalsegmentincludesanin-processresearchanddevelopmentchargeof$1.1billionrelatedtotheAliosandXO1
assetsandthecorrespondingXO1contingentliabilityreversalof$0.2billion,Actelionacquisitionrelatedcostsof$0.2billion,
unrealizedlossonsecuritiesof$0.2billionandagainof$0.2billionfromthedivestitureofcertainnon-strategicPharmaceutical
products.TheMedicalDevicessegmentincludesnetlitigationexpenseof$1.7billion,arestructuringrelatedchargeof$0.6billion,
AMOacquisitionrelatedcostsof$0.1billionandagainof$0.5billionfromthedivestitureoftheLifeScanbusinessinthefiscal
fourthquarter.
(4) ThePharmaceuticalsegmentincludes$0.8billionforActelionacquisitionrelatedcosts,anin-processresearchanddevelopment
expenseof$0.4billionandlitigationexpenseof$0.1billion.TheMedicalDevicessegmentincludeslitigationexpenseof$1.1billion,
arestructuringrelatedchargeof$0.8billion,anassetimpairmentof$0.2billionprimarilyrelatedtotheinsulinpumpbusinessand
$0.1billionforAMOacquisitionrelatedcosts.TheMedicalDevicessegmentincludesagainof$0.7billionfromthedivestitureof
CodmanNeurosurgery.TheConsumersegmentincludesagainof$0.5billionfromthedivestitureofCOMPEED®.
(5) Includesnetlitigationexpenseof$0.8billionandarestructuringrelatedchargeof$0.7billionintheMedicalDevicessegment.The
Pharmaceuticalsegmentincludesapositiveadjustmentof$0.5billiontopreviousreserveestimatesandgainsfromthedivestitures
ofthecontrolledsubstancerawmaterialandactivepharmaceuticalingredient(API)businessandcertainanestheticproductsin
Europe.
(6) Long-livedassetsincludeproperty,plantandequipment,netfor2018,and2017of$17,035and$17,005,respectively,and
intangibleassetsandgoodwill,netfor2018and2017of$78,064and$85,134,respectively.
78 • Johnson&Johnson2018AnnualReport19. Selected Quarterly Financial Data (unaudited)
Selectedunauditedquarterlyfinancialdatafortheyears2018and2017aresummarizedbelow:
2018 2017
(DollarsinMillionsExceptPerShare First Second Third Fourth First Second Third Fourth
Data) Quarter(1) Quarter(2) Quarter(3) Quarter(4) Quarter(5) Quarter(6) Quarter(7) Quarter(8)
Segmentsalestocustomers
Consumer $3,398 3,504 3,415 3,536 3,228 3,478 3,356 3,540
Pharmaceutical 9,844 10,354 10,346 10,190 8,245 8,635 9,695 9,681
MedicalDevices 6,767 6,972 6,587 6,668 6,293 6,726 6,599 6,974
Totalsales 20,009 20,830 20,348 20,394 17,766 18,839 19,650 20,195
Grossprofit 13,395 13,903 13,759 13,433 12,357 12,993 12,725 12,936
Earningsbeforeprovisionfortaxeson
income 5,481 4,973 4,423 3,122 5,575 4,748 4,790 2,560
Netearnings(loss) 4,367 3,954 3,934 3,042 4,422 3,827 3,764 (10,713)
Basicnetearnings(loss)pershare $1.63 1.47 1.47 1.14 1.63 1.42 1.40 (3.99)
Dilutednetearnings(loss)pershare $1.60 1.45 1.44 1.12 1.61 1.40 1.37 (3.99)
(1) Thefirstquarterof2018includesanActelionacquisitionrelatedcostof$92millionafter-tax($96millionbefore-tax)anda
restructuringrelatedchargeof$81millionafter-tax($107millionbefore-tax).
(2) Thesecondquarterof2018includesalitigationexpenseof$609millionafter-tax($703millionbefore-tax)andarestructuring
relatedchargeof$152millionafter-tax($176millionbefore-tax).
(3) Thethirdquarterof2018includesanin-processresearchanddevelopmentexpenseof$859millionafter-tax($1,126million
before-tax)relatedtotheAliosandXO1assetsandthecorrespondingXO1contingentliabilityreversalof$184millionafterand
beforetax,arestructuringrelatedchargeof$162millionafter-tax($190millionbefore-tax)anda$265millionbenefitafter-taxfrom
theimpactoftaxlegislation.
(4) Thefourthquarterof2018includesalitigationexpenseof$1,113millionafter-tax($1,288millionbefore-tax),arestructuringrelated
chargeof$190millionafter-tax($227millionbefore-tax)anda$137millionbenefitafter-taxfromtheimpactoftaxlegislation.
(5) Thefirstquarterof2017includesarestructuringchargeof$121millionafter-tax($161millionbefore-tax)andanAMOacquisition
relatedcostof$251millionafter-tax($38millionbefore-tax).
(6) Thesecondquarterof2017includesalitigationexpenseof$352millionafter-tax($493millionbefore-tax),Actelionacquisition
relatedcostsof$199millionafter-tax($213millionbefore-tax)arestructuringchargeof$101millionafter-tax($128million
before-tax)andanassetimpairmentchargeof$125millionafter-tax($182millionbefore-tax).
(7) Thethirdquarterof2017includesalitigationexpenseof$97millionafter-tax($118millionbefore-tax),Actelionacquisitionrelated
costsof$255millionafter-tax($367millionbefore-tax)andarestructuringchargeof$136millionafter-tax($187millionbefore-tax).
(8) Thefourthquarterof2017includesalitigationexpenseof$506millionafter-tax($645millionbefore-tax),Actelionacquisitionrelated
costsof$313millionafter-tax($217millionbefore-tax),arestructuringchargeof$237millionafter-tax($284millionbefore-tax),an
in-processresearchanddevelopmentexpenseof$266millionafter-tax($408millionbefore-tax)andanafter-taxbenefitof
$116millionrelatedtotheinsulinpumpbusiness.Additionally,thefourthquarterof2017includesaprovisionalchargeof
$13.6billionforrecentlyenactedtaxlegislation.
Johnson&Johnson2018AnnualReport • 7920. Business Combinations and Divestitures
Certainbusinesseswereacquiredfor$0.9billionincashand$0.1billionofliabilitiesassumedduring2018.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2018acquisitionsprimarilyincluded:Zarbee’s,Inc.,aprivatelyheldcompanythatisaleaderinnaturally-based
consumerhealthcareproducts;MedicalEnterprisesDistributionLLC,aprivatelyheldhealthcaretechnologyfirmfocused
onsurgicalprocedureinnovation;BeneVirBiopharm,Inc.(BeneVir),aprivately-held,biopharmaceuticalcompany
specializinginthedevelopmentofoncolyticimmunotherapiesandOrthotaxy,aprivately-helddeveloperofsoftware-
enabledsurgerytechnologies,includingadifferentiatedrobotic-assistedsurgerysolution.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$1.0billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
OnOctober23,2018,theCompanyenteredintoanagreementtoacquireCi:zHoldingsCo.,Ltd.,aJapanesecompany
focusedonthemarketing,developmentanddistributionofabroadrangeofdermocosmetic,cosmeticandskincare
productsforatotalpurchasepriceofapproximately¥230billion,whichequatestoapproximately$2.1billion,usingthe
exchangerateof109.06JapaneseYentoeachU.S.DollaronJanuary16,2019.Theacquisitionwascompletedon
January17,2019,throughaseriesoftransactionsthatincludedanall-cashtenderoffertoacquirethepubliclyheldshares
notalreadyheldbytheCompanyfor¥5,900pershare.Uponcompletionofthetenderofferandtherelatedtransactions,
theCompanyacquired89%oftheoutstandingshares.TheCompanyplanstoacquiretheremainingsharesthatwerenot
tenderedinthetenderofferthroughashareconsolidationunderJapaneselawduringthefirsthalfof2019andtake
appropriateactionstodelistfromtheTokyoStockExchange.Theacquisitionwillincludetherangeofbrandscomprising
DR.CI:LABO,LABOLABOandGENOMERlineofskincareproducts.TheCompanyexpectstotreatthistransactionasa
businesscombinationandwillincludeitintheConsumersegment.
OnFebruary13,2019,theCompanyenteredintoadefinitiveagreementtoacquireAurisHealth,Inc.forapproximately
$3.4billionincash.Additionalcontingentpaymentsofupto$2.35billion,intheaggregate,maybepayableupon
reachingcertainpredeterminedmilestones.AurisHealthisaprivatelyhelddeveloperofrobotictechnologies,initially
focusedinlungcancer,withanFDA-clearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeutic
procedures.Theclosingissubjecttoantitrustclearanceandothercustomaryclosingconditions.Thetransactionis
expectedtoclosebytheendofthesecondquarterof2019.TheCompanyexpectstotreatthistransactionasabusiness
combinationandwillincludeitintheMedicalDevicessegment.
During2017certainbusinesseswereacquiredfor$35.2billionincashand$1.8billionofliabilitiesassumed.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2017acquisitionsprimarilyincluded:ActelionLtd,anestablishedleadingfranchiseofdifferentiated,innovative
productsforpulmonaryarterialhypertension(PAH);AbbottMedicalOptics(AMO),awholly-ownedsubsidiaryofAbbott
Laboratories,whichincludedophthalmicproductsrelatedto:cataractsurgery,laserrefractivesurgeryandconsumereye
health;NeuraviLimited,aprivately-heldmedicaldevicecompanythatdevelopsandmarketsmedicaldevicesfor
neurointerventionaltherapy;TearScienceInc.,amanufacturerofproductsdedicatedtotreatingmeibomiangland
dysfunction;Sightbox,Inc.,aprivately-heldcompanythatdevelopedasubscriptionvisioncareservicethatconnects
consumerswitheyecareprofessionalsandasupplyofcontactlenses;ToraxMedical,Inc.,aprivately-heldmedicaldevice
companythatmanufacturesandmarketstheLINX™RefluxManagementSystemforthesurgicaltreatmentof
gastroesophagealrefluxdiseaseandMegadyneMedicalProducts,Inc.,aprivately-heldmedicaldevicecompanythat
develops,manufacturesandmarketselectrosurgicaltools.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$34.4billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately
$1.1billionhasbeenidentifiedasthevalueofIPR&D,primarilyassociatedwiththeacquisitionofActelionLtd.Thevalue
oftheIPR&Dwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskintheprojects.
During2017,theCompanycompletedtheacquisitionofActelionLtdthroughanallcashtenderofferinSwitzerlandfor
$280pershare,amountingto$29.6billion,netofcashacquired.Aspartofthetransaction,immediatelypriortothe
completionoftheacquisition,Actelionspunoutitsdrugdiscoveryoperationsandearly-stageclinicaldevelopmentassets
intoanewlycreatedSwissbiopharmaceuticalcompany,IdorsiaLtd.ThesharesofIdorsiaarelistedontheSIXSwiss
Exchange(SIX).In2017theCompanyheld9.9%ofthesharesofIdorsiaandhadrightstoanadditional22.1%ofIdorsia
equitythroughaconvertibleloanwithaprincipalamountofapproximately$0.5billion.AsaresultofIdorsiaraising
80 • Johnson&Johnson2018AnnualReportadditionalcapitalinJuly2018,theCompanycurrentlyholds9.0%ofthesharesofIdorsiaandhasrightstoanadditional
20.8%ofIdorsiaequitythroughaconvertibleloanwithaprincipalamountofapproximately$0.5billion.Theconvertible
loanmaybeconvertedintoIdorsiasharesasfollows:(i)uptoanaggregateshareholdingof16%ofIdorsiasharesasa
resultofcertainshareholdersholdingmorethan20%oftheissuedIdorsiashares,and(ii)uptothebalanceofthe
remainingamountwithin20businessdaysofthematuritydateoftheconvertibleloan,whichhasa10yearterm,orif
Idorsiaundergoesachangeofcontroltransaction.TheinvestmentinIdorsiawasrecordedasacostmethodinvestmentin
OtherassetsintheCompany’sconsolidatedBalanceSheet.TheCompanyalsoexercisedtheoptionacquiredon
ACT-132577,aproductwithinIdorsiabeingdevelopedforresistanthypertensioncurrentlyinphase2ofclinical
development.TheCompanyhasalsoenteredintoanagreementtoprovideIdorsiawithaSwissfrancdenominatedcredit
facilityofapproximately$250million.AsofDecember30,2018,Idorsiahasnotmadeanydraw-downsunderthecredit
facility.ActelionhasenteredintoatransitionalservicesagreementwithIdorsia.Actelionhasestablishedaleading
franchiseofdifferentiated,innovativeproductsforpulmonaryarterialhypertension(PAH)thatarehighlycomplementaryto
theexistingportfoliooftheCompany.TheadditionofActelion’sspecialtyin-marketmedicinesandlate-stageproductsis
consistentwiththeCompany’seffortstogrowinattractiveandcomplementarytherapeuticareasandservepatientswith
seriousillnessesandsignificantunmetmedicalneed.
Duringthefiscalsecondquarterof2018,theCompanyfinalizedthepurchasepriceallocationtotheindividualassets
acquiredandliabilitiesassumedusingtheacquisitionmethod.Thefollowingtablepresentstheamountsrecognizedfor
assetsacquiredandliabilitiesassumedasoftheacquisitiondatewithadjustmentsmadethroughthesecondquarterof
2018:
(DollarsinMillions)
Cash&Cashequivalents $469
Inventory(1) 759
AccountsReceivable 485
Othercurrentassets 93
Property,plantandequipment 104
Goodwill 6,161
Intangibleassets 25,010
DeferredTaxes 99
Othernon-currentassets 19
TotalAssetsAcquired 33,199
Currentliabilities 956
DeferredTaxes 1,776
Othernon-currentliabilities 413
TotalLiabilitiesAssumed 3,145
NetAssetsAcquired $30,054
(1) Includesadjustmentof$642milliontowrite-uptheacquiredinventorytoitsestimatedfairvalue.
Theadjustmentsmadesincethedateofacquisitionwere$0.2billiontothedeferredtaxesand$0.4billiontothecurrent
liabilitieswiththeoffsettogoodwill.TheassetsacquiredarerecordedinthePharmaceuticalsegment.Theacquisitionof
Actelionresultedinapproximately$6.2billionofgoodwill.Thegoodwillisprimarilyattributabletosynergiesexpectedto
arisefromtheacquisition.Thegoodwillisnotexpectedtobedeductiblefortaxpurposes.
Johnson&Johnson2018AnnualReport • 81Thepurchasepriceallocationtotheidentifiableintangibleassetsisasfollows:
(DollarsinMillions)
Intangibleassetswithdefinitelives:
Patentsandtrademarks* $24,230
Totalamortizableintangibles 24,230
In-processresearchanddevelopment 780
Totalintangibleassets $25,010
* Includes$0.4billionrelatedtoVALCHLOR®,oneoftheacquiredproducts,whichwasdivestedinthefiscalsecondquarterof2018.
Thepatentsandtrademarksacquiredarecomprisedofdevelopedtechnologywithaweightedaveragelifeof9yearsand
wasprimarilybasedonthepatentlifeofthemarketedproducts.Theintangibleassetswithdefiniteliveswereassigned
assetlivesrangingfrom4to10years.Thein-processresearchanddevelopmentintangibleassetswerevaluedfor
technologyprogramsforunapprovedproducts.
ThevalueoftheIPR&Dwascalculatedusingprobabilityadjustedcashflowprojectionsdiscountedfortheriskinherentin
suchprojects.Thediscountrateappliedwas9%.
Theacquisitionwasaccountedforusingtheacquisitionmethodand,accordingly,theresultsofoperationsofActelion
werereportedintheCompany’sfinancialstatementsbeginningonJune16,2017,thedateofacquisition.Fortheyear
endedDecember31,2017,totalsalesandanetlossforActelionfromthedateofacquisitionwere$1.4billionand
$1.4billion,respectively.
ThefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendedDecember31,2017andJanuary1,
2017,asifActelionhadbeenacquiredasofJanuary4,2016.Theproformaresultsincludetheeffectofcertainpurchase
accountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseontheacquiredtangible
andintangibleassets.However,proformaresultsdonotincludeanyanticipatedcostsavingsorothereffectsofthe
plannedintegrationofActelion.Accordingly,suchamountsarenotnecessarilyindicativeoftheresultsiftheacquisition
hadoccurredonthedatesindicatedorwhichmayoccurinthefuture.
UnauditedProformaConsolidatedResults
(DollarsinMillionsExceptPerShareData) 2017 2016
NetSales $77,681 74,339
NetEarnings 1,509 13,916
DilutedNetEarningsperCommonShare 0.55 4.99
TheCompanyrecordedActelionacquisitionrelatedcostsbeforetaxofapproximately$0.2billionand$0.8billionin2018
and2017,respectively,whichwasrecordedinOther(income)/expenseandCostofproductssold.
During2017,theCompanyacquiredAbbottMedicalOptics(AMO),awholly-ownedsubsidiaryofAbbottLaboratories,for
$4.3billion,netofcashacquired.Theacquisitionincludedophthalmicproductsrelatedto:cataractsurgery,laser
refractivesurgeryandconsumereyehealth.Thenetpurchasepricewasprimarilyrecordedasamortizableintangible
assetsfor$2.3billionandgoodwillfor$1.7billion.Theweightedaveragelifeoftotalamortizableintangibles,themajority
beingcustomerrelationships,isapproximately14.4years.Thegoodwillisprimarilyattributabletosynergiesexpectedto
arisefromthebusinessacquisitionandisnotdeductiblefortaxpurposes.Theintangibleassetsandgoodwillamountsare
basedonthefinalpurchasepriceallocation.TheassetsacquiredwererecordedintheMedicalDevicessegment.
Certainbusinesseswereacquiredfor$4.5billionincashand$0.1billionofliabilitiesassumedduring2016.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2016acquisitionsprimarilyincluded:VogueInternationalLLC,aprivately-heldcompanyfocusedonthemarketing,
developmentanddistributionofsalon-influencedandnatureinspiredhaircareandotherpersonalproducts;NeuWave
Medical,Inc.,aprivately-heldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue
microwaveablationsystems;NeoStrataCompany,Inc.,agloballeaderindermocosmetics;andtheglobalrightsforthe
commercializationofRHINOCORT®allergysprayoutsidetheUnitedStates.
82 • Johnson&Johnson2018AnnualReportTheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$4.1billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
ThenetpurchasepriceforVogueInternationalLLCof$3.3billionwasprimarilyrecordedasamortizableintangibleassets
for$2.3billionandgoodwillfor$1.1billion.Theweightedaveragelifeforthe$2.3billionoftotalamortizableintangiblesis
approximately22years.Thetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfrom10to22years,
withthemajoritybeing22years.Thegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness
acquisitionandisexpectedtobedeductiblefortaxpurposes.TheassetsacquiredwererecordedintheConsumer
segment.
In2012,theCompanycompletedtheacquisitionofSynthes,Inc.forapurchasepriceof$20.2billionincashandstock.
InconnectionwiththeacquisitionofSynthes,Inc.theCompanyenteredintotwoacceleratedsharerepurchase(ASR)
agreements.In2013,theCompanysettledtheremainingliabilitiesundertheASRagreements.WhiletheCompany
believesthatthetransactionsundereachASRagreementandaseriesofrelatedinternaltransactionswereconsummated
inataxefficientmannerinaccordancewithapplicablelaw,itispossiblethattheInternalRevenueServicecouldassert
oneormorecontrarypositionstochallengethetransactionsfromataxperspective.Ifchallenged,anamountuptothe
totalpurchasepricefortheSynthessharescouldbetreatedassubjecttoapplicableU.S.taxatapproximatelythe
statutoryratetotheCompany,plusinterest.
WiththeexceptionoftheActelionLtdacquisition,supplementalproformainformationfor2018,2017and2016in
accordancewithU.S.GAAPstandardsrelatedtobusinesscombinations,andgoodwillandotherintangibleassets,isnot
provided,astheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectontheCompany’sresultsof
operations,cashflowsorfinancialposition.
During2018,theCompanydivestedtheLifeScanIncbusinessforapproximately$2.1billionandretainedcertainnet
liabilities.Otherdivestituresin2018included:NIZORAL®,RoC®andcertainnon-strategicPharmaceuticalproducts.In
2018,thepre-taxgainsonthedivestitureswereapproximately$1.2billion.Additionally,in2018,theCompanyaccepted
thebindingofferfromFortiveCorporationtoacquireitsAdvancedSterilizationProducts(ASP)businessforapproximately
$2.7billion,subjecttocustomaryadjustments.Thetransactionisexpectedtoclosein2019.AsofDecember30,2018,
theassetsheldforsaleontheConsolidatedBalanceSheetwere$0.2billionofinventory,$0.1billionofproperty,plant
andequipmentand$0.3billionofgoodwill.TheCompanywillretaincertainnetreceivablesofapproximately$0.1billion
associatedwiththeASPbusiness.
In2018,theCompanyacceptedabindingoffertoformastrategiccollaborationwithJabilInc.,oneoftheworld’sleading
manufacturingservicesprovidersforhealthcareproductsandtechnologyproducts.TheCompanyisexpandinga12-year
relationshipwithJabiltoproducearangeofproductswithintheEthiconEndo-SurgeryandDePuySynthesbusinesses.
Thistransactionincludesthetransferofemployeesandmanufacturingsites.AsofDecember30,2018,theassetsheldfor
saleontheConsolidatedBalanceSheetwere$0.3billionofinventoryand$0.1billionofproperty,plantandequipment,
net.ForadditionaldetailsontheglobalsupplychainrestructuringseeNote22totheConsolidatedFinancialStatements.
During2017,theCompanydivestituresprimarilyincluded:theCodmanNeurosurgerybusiness,toIntegraLifeSciences
HoldingsCorporationandthedivestitureofCOMPEED®toHRAPharma.In2017,thepre-taxgainsonthedivestitures
wereapproximately$1.3billion.
During2016,theCompanydivestituresincluded:thecontrolledsubstancerawmaterialandactivepharmaceutical
ingredient(API)business;certainanestheticproductsinEurope;andcertainnon-strategicConsumerbrands.In2016,the
pre-taxgainsonthedivestitureswereapproximately$0.6billion.
21. Legal Proceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercial,supplierindemnificationandothermatters;governmentalinvestigations;andotherlegal
proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.AsofDecember30,2018,theCompany
hasdeterminedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.
TheCompanyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsas
mightbewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Forthese
andotherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,the
Companyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Amountsaccrued
Johnson&Johnson2018AnnualReport • 83forlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrely
heavilyonestimatesandassumptions.Theabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvarious
factors,includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegal
discoveryhasnotcommencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;
therearesignificantfactsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
PRODUCTLIABILITY
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving
multipleproducts.Claimantsinthesecasesseeksubstantialcompensatoryand,whereavailable,punitivedamages.While
theCompanybelievesithassubstantialdefenses,itisnotfeasibletopredicttheultimateoutcomeoflitigation.The
CompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithASC450-20basedon
currentlyavailableinformation,whichinsomecasesmaybelimited.TheCompanyaccruesanestimateofthelegal
defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimated.Forcertain
ofthesematters,theCompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlements,
damagesandotherlosses.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,theCompanydoes
notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.Productliabilityaccruals
canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworld,eachindifferentlitigationenvironments
andwithdifferentfactpatterns.Changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes
available.
Themostsignificantofthesecasesinclude:theDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacing
System;thePINNACLE®AcetabularCupSystem;pelvicmeshes;RISPERDAL®;XARELTO®;bodypowderscontaining
talc,primarilyJOHNSONS®BabyPowder;INVOKANA®;andETHICONPHYSIOMESH®FlexibleCompositeMesh.Asof
December30,2018,intheUnitedStatestherewereapproximately1,800plaintiffswithdirectclaimsinpendinglawsuits
regardinginjuriesallegedlyduetotheDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacingSystem;
10,500withrespecttothePINNACLE®AcetabularCupSystem;34,800withrespecttopelvicmeshes;13,400with
respecttoRISPERDAL®;25,600withrespecttoXARELTO®;13,000withrespecttobodypowderscontainingtalc;
1,050withrespecttoINVOKANA®;and2,100withrespecttoETHICONPHYSIOMESH®FlexibleCompositeMesh.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystemusedinhipreplacementsurgery.Claimsforpersonalinjuryhavebeen
madeagainstDePuyandJohnson&Johnson.Thenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits
aresettledordismissedandadditionallawsuitsarefiled.CasesfiledinfederalcourtsintheUnitedStateshavebeen
organizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofOhio.Litigationhas
alsobeenfiledincountriesoutsideoftheUnitedStates,primarilyintheUnitedKingdom,Canada,Australia,Ireland,
GermanyandItaly.InNovember2013,DePuyreachedanagreementwithaCourt-appointedcommitteeoflawyers
representingASRHipSystemplaintiffstoestablishaprogramtosettleclaimswitheligibleASRHippatientsintheUnited
StateswhohadsurgerytoreplacetheirASRHips,knownasrevisionsurgery,asofAugust31,2013.DePuyreached
additionalagreementsinFebruary2015andMarch2017,whichfurtherextendedthesettlementprogramtoincludeASR
HippatientswhohadrevisionsurgeriesafterAugust31,2013andpriortoFebruary15,2017.Thissettlementprogram
hasresolvedmorethan10,000claims,thereforebringingtoresolutionsignificantASRHiplitigationactivityintheUnited
States.However,lawsuitsintheUnitedStatesremain,andthesettlementprogramdoesnotaddresslitigationoutsideof
theUnitedStates.InAustralia,aclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofASRHip
patientsinthatcountry.InCanada,theCompanyhasreachedagreementstosettletwopendingclassactionswhichhave
beenapprovedbytheQuébecSuperiorCourtandtheSupremeCourtofBritishColumbia.TheBritishColumbiaorderis
currentlythesubjectofanappeal.TheCompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcosts
associatedwiththisrecallonaworldwidebasis.TheCompanyhasestablishedaccrualsforthecostsassociatedwiththe
UnitedStatessettlementprogramandDePuyASR™Hip-relatedproductliabilitylitigation.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyOrthopaedics,Inc.andJohnson&Johnson(collectively,
DePuy)relatingtothePINNACLE®AcetabularCupSystemusedinhipreplacementsurgery.Thenumberofpending
productliabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwithrespecttopotential
84 • Johnson&Johnson2018AnnualReportcostsandtheanticipatednumberofcases.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasa
multi-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofTexas.Litigationhasalsobeenfiledin
somestatecourtsandincountriesoutsideoftheUnitedStates.Severaladverseverdictshavebeenrenderedagainst
DePuy,oneofwhichwasreversedonappealandremandedforretrial,thesecondremainsunderappealandthethirdis
pendingdecisiononpost-trialmotionsinthedistrictcourt.TheCompanyhasestablishedanaccrualforproductliability
litigationassociatedwiththePINNACLE®AcetabularCupSystem.TheCompanyisnegotiatingsettlementsofthese
casesandtherelatedcostsarereflectedintheCompany’saccruals.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andJohnson&JohnsonarisingoutofEthicon’s
pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.TheCompanycontinuesto
receiveinformationwithrespecttopotentialcostsandadditionalcases.CasesfiledinfederalcourtsintheUnitedStates
havebeenorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheSouthernDistrictofWest
Virginia.TheCompanyhassettledorotherwiseresolvedamajorityoftheUnitedStatescasesandthecostsassociated
withthesesettlementsarereflectedintheCompany’saccruals.Inaddition,classactionsandindividualpersonalinjury
casesorclaimshavebeencommencedinvariouscountriesoutsideoftheUnitedStates,includingclaimsandcasesinthe
UnitedKingdom,theNetherlandsandBelgium,andclassactionsinIsrael,AustraliaandCanada,seekingdamagesfor
allegedinjuryresultingfromEthicon’spelvicmeshdevices.InAustralia,atrialofclassactionissueshasbeencompleted
andthepartiesareawaitingadecision.TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation
associatedwithEthicon’spelvicmeshproducts.
FollowingaJune2016worldwidemarketwithdrawalofETHICONPHYSIOMESH®FlexibleCompositeMesh,claimsfor
personalinjuryhavebeenmadeagainstEthicon,Inc.andJohnson&Johnsonallegingpersonalinjuryarisingoutoftheuse
ofthisherniameshdevice.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-district
litigation(MDL)intheUnitedStatesDistrictCourtfortheNorthernDistrictofGeorgia.Amulticountylitigation(MCL)has
alsobeenformedinNewJerseystatecourtandassignedtoAtlanticCountyforcasespendinginNewJersey.Product
liabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsand
theanticipatednumberofcases.TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation
associatedwithETHICONPHYSIOMESH®FlexibleCompositeMesh.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andJohnson&Johnsonarisingoutofthe
useofRISPERDAL®,indicatedforthetreatmentofschizophrenia,acutemanicormixedepisodesassociatedwithbipolarI
disorderandirritabilityassociatedwithautism,andrelatedcompounds.Lawsuitshavebeenprimarilyfiledinstatecourtsin
Pennsylvania,California,andMissouri.OtheractionsarependinginvariouscourtsintheUnitedStatesandCanada.
Productliabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotential
costsandtheanticipatednumberofcases.TheCompanyhassettledorotherwiseresolvedmanyoftheUnitedStates
casesandthecostsassociatedwiththesesettlementsarereflectedintheCompany’saccruals.
ClaimsforpersonalinjuryarisingoutoftheuseofXARELTO®,anoralanticoagulant,havebeenmadeagainstJanssen
Pharmaceuticals,Inc.(JPI);Johnson&Johnson;andJPI’scollaborationpartnerforXARELTO®BayerAGandcertainofits
affiliates.Thenumberofpendingproductliabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceive
informationwithrespecttopotentialcostsandtheanticipatednumberofcases.CasesfiledinfederalcourtsintheUnited
Stateshavebeenorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheEasternDistrictof
Louisiana.Inaddition,caseshavebeenfiledinstatecourtsacrosstheUnitedStates.Manyofthesecaseshavebeen
consolidatedintoastatemasstortlitigationinPhiladelphia,Pennsylvania;andtherearecoordinatedproceedingsin
Delaware,CaliforniaandMissouri.ClassactionlawsuitsalsohavebeenfiledinCanada.TheCompanyhasestablishedan
accrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithXARELTO®.
PersonalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstJohnson&JohnsonConsumerInc.and
Johnson&Johnsonarisingoutoftheuseofbodypowderscontainingtalc,primarilyJOHNSONS®BabyPowder.The
numberofpendingproductliabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwith
respecttopotentialcostsandtheanticipatednumberofcases.Lawsuitshavebeenprimarilyfiledinstatecourtsin
Missouri,NewJerseyandCalifornia.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-
districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofNewJersey.TheCompanyhassuccessfullydefended
anumberofthesecasesbuttherehavebeenverdictsagainsttheCompany,includingaverdictinJuly2018of
$4.7billion.TheCompanybelievesthatithasstronggroundsonappealtooverturntheseverdicts.TheCompanyhas
establishedanaccrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithbodypowders
containingtalc.
InFebruary2018,asecuritiesclassactionlawsuitwasfiledagainstJohnson&Johnsonandcertainnamedofficersinthe
UnitedStatesDistrictCourtfortheDistrictofNewJersey,allegingthatJohnson&Johnsonviolatedthefederalsecurities
Johnson&Johnson2018AnnualReport • 85lawsbyfailingtoadequatelydisclosetheallegedasbestoscontaminationinbodypowderscontainingtalc,primarily
JOHNSON’S®BabyPowder,andthatpurchasersofJohnson&Johnson’ssharessufferedlossesasaresult.Plaintiffsare
seekingdamages.InOctober2018,ashareholderderivativelawsuitwasfiledagainstJohnson&Johnsonasthenominal
defendantanditscurrentdirectorsasdefendantsintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,alleging
abreachoffiduciarydutiesrelatedtotheallegedasbestoscontaminationinbodypowderscontainingtalc,primarily
JOHNSON’S®BabyPowder,andthatJohnson&Johnsonhassuffereddamagesasaresultofthosealleged
breaches.PlaintiffisseekingdamagesandanorderfortheCompanytoreformitsinternalpoliciesandprocedures.In
January2019,twoERISAclassactionlawsuitswerefiledbyparticipantsintheJohnson&JohnsonSavingsPlanagainst
Johnson&Johnson,itsPensionandBenefitsCommittee,andcertainnamedofficersintheUnitedStatesDistrictCourtfor
theDistrictofNewJersey,allegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingJohnson&Johnson
stockasaJohnson&JohnsonSavingsPlaninvestmentoptionwhenitwasimprudenttodosobecauseoffailuresto
discloseallegedasbestoscontaminationinbodypowderscontainingtalc,primarilyJOHNSON’S®BabyPowder.Plaintiffs
areseekingdamagesandinjunctiverelief.Eachofthesematterswillbeadjudicatedinconjunctionwiththemulti-district
litigationreferencedinthepriorparagraph.Inaddition,theCompanyhasreceivedpreliminaryinquiriesandsubpoenasto
producedocumentsregardingthesemattersfromSenatorMurray,amemberoftheSenateCommitteeonHealth,
Education,LaborandPensions,theDepartmentofJusticeandtheSecuritiesandExchangeCommission.TheCompanyis
cooperatingwiththesegovernmentinquiriesandwillbeproducingdocumentsinresponse.
ClaimsforpersonalinjuryhavebeenmadeagainstanumberofJohnson&Johnsoncompanies,includingJanssen
Pharmaceuticals,Inc.andJohnson&Johnson,arisingoutoftheuseofINVOKANA®,aprescriptionmedicationindicated
toimproveglycemiccontrolinadultswithType2diabetes.LawsuitsfiledinfederalcourtsintheUnitedStateshavebeen
organizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofNewJersey.Caseshavealso
beenfiledinstatecourtsinPennsylvania,CaliforniaandNewJersey.ClassactionlawsuitshavebeenfiledinCanada.
Productliabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotential
costsandtheanticipatednumberofcases.TheCompanyhassettledorotherwiseresolvedmanyofthecasesandclaims
intheUnitedStatesandthecostsassociatedwiththesesettlementsarereflectedintheCompany’saccruals.
INTELLECTUALPROPERTY
CertainsubsidiariesofJohnson&Johnsonaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedto
patent,trademarkandotherintellectualpropertymattersarisingoutoftheirbusinesses.Manyofthesemattersinvolve
challengestothecoverageand/orvalidityofthepatentsonvariousproductsandallegationsthatcertainoftheCompany’s
productsinfringethepatentsofthirdparties.Althoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto
thesechallengesandallegationswithrespecttoallsignificantpatents,therecanbenoassuranceastotheoutcomeof
thesematters.Alossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts,
resultinlossofsalesduetolossofmarketexclusivity,requirethepaymentofpastdamagesandfutureroyalties,andmay
resultinanon-cashimpairmentchargeforanyassociatedintangibleasset.Themostsignificantofthesemattersare
describedbelow.
MedicalDevices
InJune2009,RembrandtVisionTechnologies,L.P.(Rembrandt)filedapatentinfringementlawsuitagainstJohnson&
JohnsonVisionCare,Inc.(JJVCI)intheUnitedStatesDistrictCourtfortheEasternDistrictofTexasallegingthatJJVCI’s
manufactureandsaleofitsACUVUE®ADVANCEandACUVUEOASYS®HydrogelContactLensesinfringed
Rembrandt’sUnitedStatesPatentNo.5,712,327andseekingmonetaryrelief.ThecasewastransferredtotheUnited
StatesDistrictCourtfortheMiddleDistrictofFlorida,whereatrialinMay2012resultedinaverdictofnon-infringement
thatwassubsequentlyupheldonappeal.InJuly2014,Rembrandtsoughtanewtrialbasedonallegednewevidence,
whichthedistrictcourtdenied.InApril2016,theCourtofAppealsoverturnedthatrulingandremandedthecasetothe
districtcourtforanewtrial.AnewtrialwasheldinAugust2017,andthejuryreturnedaverdictofnon-infringementin
favorofJJVCI.RembrandthasappealedtheverdicttotheUnitedStatesCourtofAppealsfortheFederalCircuit(CAFC).
InFebruary2019,theCAFCaffirmedthejudgmentinfavorofJJVCI.
InMarch2013,MedinolLtd.(Medinol)filedapatentinfringementlawsuitagainstCordisCorporation(Cordis)and
Johnson&JohnsonintheUnitedStatesDistrictCourtfortheSouthernDistrictofNewYorkallegingthatCordis’ssalesof
theCYPHER™andCYPHERSELECT™stentsmadeintheUnitedStatessince2005willfullyinfringedfourofMedinol’s
patentsdirectedtothegeometryofarticulatedstents.Medinolisseekingdamagesandattorneys’fees.Although
Johnson&JohnsonhassincesoldCordis,ithasretainedliabilityforthiscase.AftertrialinJanuary2014,thedistrictcourt
dismissedthecase,findingMedinolunreasonablydelayedbringingitsclaims(thelachesdefense).InSeptember2014,
86 • Johnson&Johnson2018AnnualReportthedistrictcourtdeniedamotionbyMedinoltovacatethejudgmentandgrantitanewtrial.Medinolappealedthe
decisiontotheUnitedStatesCourtofAppealsfortheFederalCircuit.InMarch2017,theUnitedStatesSupremeCourt
heldthatthelachesdefenseisnotavailableinpatentcases.InApril2018,theUnitedStatesCourtofAppealsforthe
FederalCircuitremandedthecasebacktothedistrictcourttoreconsiderMedinol’smotionforanewtrial,andbriefingin
thedistrictcourtwascompletedinJune2018.
InNovember2016,MedIdea,L.L.C.(MedIdea)filedapatentinfringementlawsuitagainstDePuyOrthopaedics,Inc.inthe
UnitedStatesDistrictCourtfortheNorthernDistrictofIllinoisalleginginfringementbytheATTUNE®KneeSystem.In
April2017,MedIdeafiledanamendedcomplaintaddingDePuySynthesProducts,Inc.andDePuySynthesSales,Inc.as
nameddefendants.MedIdeaallegesinfringementofUnitedStatesPatentNos.6,558,426(’426);8,273,132(’132);
8,721,730(’730)and9,492,280(’280)relatingtoposteriorstabilizedkneesystems.Specifically,MedIdeaallegesthatthe
SOFCAMTMContactfeatureoftheATTUNE®posteriorstabilizedkneeproductsinfringesthepatents-in-suit.MedIdeais
seekingmonetarydamagesandinjunctiverelief.InJune2017,thecasewastransferredtotheUnitedStatesDistrictCourtfor
theDistrictofMassachusetts.AclaimconstructionhearingwasheldinOctober2018,andaclaimconstructionorderwas
issuedinNovember2018.InDecember2018,MedIdeastipulatedtonon-infringementofthe’132,’730and’280patents,
basedonthedistrictcourt’sclaimconstructionandreservingitsrighttoappealthatconstruction,leavingonlythe’426patent
atissuebeforethedistrictcourt.InJanuary2019,thedistrictcourtstayedthecasependingadecisionintheInterPartes
Reviewproceedingonthe’426patent(seebelow).InDecember2017,DePuySynthesProducts,Inc.filedaPetitionforInter
PartesReviewwiththeUnitedStatesPatentandTrademarkOffice(USPTO),seekingtoinvalidatethetwoclaimsofthe
’426patentassertedinthedistrictcourtlitigation,andinJune2018,theUSPTOinstitutedreviewofthoseclaims.Ahearing
trialisscheduledforMarch2019,andadecisionintheproceedingisduebyJune2019.
InDecember2016,EthiconEndo-Surgery,Inc.andEthiconEndo-Surgery,LLC(nowknownasEthiconLLC)sued
Covidien,Inc.intheUnitedStatesDistrictCourtfortheDistrictofMassachusettsseekingadeclarationthatUnitedStates
PatentNos.6,585,735(the’735patent);7,118,587;7,473,253;8,070,748and8,241,284(the’284patent),areeither
invalidornotinfringedbyEthicon’sENSEAL®X1LargeJawTissueSealerproduct.InApril2017,CovidienLP,Covidien
SalesLLC,andCovidienAG(collectively,Covidien)answeredandcounterclaimed,denyingtheallegations,asserting
willfulinfringementofthe’735patent,the’284patentandUnitedStatesPatentNos.8,323,310(the’310patent);
9,084,608;9,241,759(the’759patent)and9,113,882,andseekingdamagesandaninjunction.Covidienfiledamotion
forpreliminaryinjunction,whichwasdeniedinOctober2017.Thepartieshaveenteredjointstipulationssuchthatonlythe
’735patent,the’310patentandthe’759patentremainindispute.TrialisscheduledtobegininSeptember2019.
InNovember2017,BoardofRegents,TheUniversityofTexasSystemandTissuegen,Inc.(collectively,UT)filedalawsuit
intheUnitedStatesDistrictCourtfortheWesternDistrictofTexasagainstEthicon,Inc.andEthiconUS,LLCallegingthe
manufactureandsaleofVICRYL®PlusAntibacterialSutures,MONOCRYL®PlusAntibacterialSutures,PDS®Plus
AntibacterialSutures,STRATAFIX®POS®AntibacterialSuturesandSTRATAFIX®MONOCRYL®PlusAntibacterial
Suturesinfringeplaintiffs’UnitedStatesPatentNos.6,596,296and7,033,603directedtoimplantablepolymerdrug
releasingbiodegradablefiberscontainingatherapeuticagent.UTisseekingdamagesandaninjunction.InDecember
2018,EthiconfiledpetitionswiththeUSPTO,seekingInterPartesReview(IPR)ofbothassertedpatents.Thosepetitions
havebeenstayedbytheUSPTOpendingadecisionbytheU.S.CourtofAppealsfortheFederalCircuitinanunrelated
case.
Pharmaceutical
InApril2016,MorphoSysAG,aGermanbiotechcompany,filedapatentinfringementlawsuitagainstJanssenBiotech,
Inc.(JBI),GenmabU.S.Inc.andGenmabA/S(collectively,Genmab)intheUnitedStatesDistrictCourtfortheDistrictof
Delaware.MorphoSysallegedthatJBI’smanufactureandsaleofDARZALEX®(daratumumab)willfullyinfringed
MorphoSys’UnitedStatesPatentNos.8,263,746,9,200,061and9,785,590.MorphoSyssoughtmoneydamages.JBI
licensespatentsandthecommercialrightstoDARZALEX®fromGenmab.InJanuary2019,thedistrictcourtgranted
summaryjudgmentinJBIandGenmab’sfavor,invalidatingtheassertedclaimsofthepatents-in-suit,andthepartiesfileda
jointstipulationofdismissaloftheaction.
InAugust2016,SandozLtdandHexalAG(collectively,Sandoz)filedalawsuitintheEnglishHighCourtagainstG.D.
SearleLLC,aPfizercompany(Searle)andJanssenSciencesIrelandUC(JSI)allegingthatSearle’ssupplementary
protectioncertificateSPC/GB07/038(SPC),whichisexclusivelylicensedtoJSI,isinvalidandshouldberevoked.
Janssen-CilagLimitedsellsPREZISTA®(darunavir)intheUnitedKingdompursuanttothislicense.InOctober2016,
SearleandJSIcounterclaimedagainstSandozforthreatenedinfringementoftheSPCbasedonstatementsofitsplansto
launchgenericdarunavirintheUnitedKingdom.Sandozadmittedthatitsgenericdarunavirproductwouldinfringethe
Johnson&Johnson2018AnnualReport • 87SPCifitisfoundvalid.SearleandJSIareseekinganorderenjoiningSandozfrommarketingitsgenericdarunavirbefore
theexpirationoftheSPC.FollowingatrialinApril2017,thecourtenteredadecisionholdingthattheSPCisvalidand
grantingafinalinjunction.Sandozhasappealedthecourt’sdecisionandtheinjunctionisstayedpendingtheappeal.In
January2018,thecourtreferredtheissueonappealtotheCourtofJusticefortheEuropeanUnion(CJEU)andstayedthe
proceedingspendingtheCJEU’srulingontheissue.
InApril2018,AcertaPharmaB.V.,AstraZenecaUKLtdandAstraZenecaPharmaceuticalsLPfiledapatentinfringement
lawsuitintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstPharmacylicsLLCandAbbvieInc.
(collectively,Abbvie),allegingthatthemanufactureandsaleofIMBRUVICA®infringesU.S.PatentNo.7,459,554.
JanssenBiotech,Inc.,whichcommercializesIMBRUVICA®jointlywithAbbvie,intervenedintheactioninNovember2018.
AtrialisscheduledtobegininJanuary2021.
REMICADE®RelatedCases
InAugust2014,CelltrionHealthcareCo.Ltd.andCelltrionInc.(collectively,Celltrion)filedanapplicationwiththeUnited
StatesFoodandDrugAdministration(FDA)forapprovaltomakeandsellitsowninfliximabbiosimilar.InMarch2015,
JanssenBiotech,Inc.(JBI)filedalawsuitintheUnitedStatesDistrictCourtfortheDistrictofMassachusettsagainst
CelltrionandHospiraHealthcareCorporation(Hospira),whichhasexclusivemarketingrightsforCelltrion’sinfliximab
biosimilarintheUnitedStates,seeking,amongotherthings,adeclaratoryjudgmentthattheirbiosimilarproductinfringesor
potentiallyinfringesseveralJBIpatents,includingUnitedStatesPatentNo.6,284,471relatingtoREMICADE®(infliximab)
(the’471patent)andUnitedStatesPatentNo.7,598,083(the’083patent)directedtothecellculturemediausedtomake
Celltrion’sbiosimilar.InAugust2016,thedistrictcourtgrantedbothCelltrion’sandHospira’smotionsforsummary
judgmentofinvalidityofthe’471patent.JBIappealedthosedecisionstotheUnitedStatesCourtofAppealsfortheFederal
Circuit.InJanuary2018,theFederalCircuitdismissedtheappealasmootbasedonitsaffirmanceofadecisionbythe
USPTO’sPatentTrialandAppealBoardaffirminginvalidityofthe’471patent.
InJune2016,JBIfiledtwoadditionalpatentinfringementlawsuitsassertingthe’083patent,oneagainstCelltrionand
HospiraintheUnitedStatesDistrictCourtfortheDistrictofMassachusettsandtheotheragainstHyCloneLaboratories,
Inc.,themanufacturerofthecellculturemediathatCelltrionusestomakeitsbiosimilarproduct,intheUnitedStates
DistrictCourtfortheDistrictofUtah.OnJuly30,2018thedistrictcourtgrantedCelltrion’smotionforsummaryjudgment
ofnon-infringementandenteredanorderdismissingthe’083lawsuitagainstCelltrionandHospira.JBIappealedtothe
UnitedStatesCourtofAppealsfortheFederalCircuit.ThelitigationagainstHyCloneinUtahisstayedpendingthe
outcomeoftheMassachusettsactions.
TheFDAapprovedthefirstinfliximabbiosimilarforsaleintheUnitedStatesin2016,andanumberofsuchproductshave
beenlaunched.
LitigationAgainstFilersofAbbreviatedNewDrugApplications(ANDAs)
ThefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledAbbreviatedNewDrugApplications
(ANDAs)withtheFDAorundertakensimilarregulatoryprocessesoutsideoftheUnitedStates,seekingtomarketgeneric
formsofproductssoldbyvarioussubsidiariesofJohnson&Johnsonpriortoexpirationoftheapplicablepatentscovering
thoseproducts.TheseANDAstypicallyincludeallegationsofnon-infringementandinvalidityoftheapplicablepatents.In
theeventthesubsidiariesarenotsuccessfulinanaction,ortheautomaticstatutorystayoftheANDAsexpiresbeforethe
UnitedStatesDistrictCourtrulingsareobtained,thethird-partycompaniesinvolvedwouldhavetheability,uponapproval
oftheFDA,tointroducegenericversionsoftheirproductstothemarket,resultinginthepotentialforsubstantialmarket
shareandrevenuelossesfortheapplicableproducts,andwhichmayresultinanon-cashimpairmentchargeinany
associatedintangibleasset.Inaddition,fromtimetotime,subsidiariesmaysettlethesetypesofactionsandsuch
settlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationof
therelevantpatents.TheInterPartesReview(IPR)processwiththeUnitedStatesPatentandTrademarkOffice(USPTO),
createdunderthe2011AmericaInventsAct,isalsobeingusedattimesbygenericcompaniesinconjunctionwithANDAs
andlawsuits,tochallengetheapplicablepatents.
ZYTIGA®
InJuly2015,JanssenBiotech,Inc.,JanssenOncology,Inc.andJanssenResearch&Development,LLC(collectively,
Janssen)andBTGInternationalLtd.(BTG)initiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyagainstanumberofgenericcompanies(andcertainoftheiraffiliatesand/orsuppliers)whofiled
ANDAsseekingapprovaltomarketagenericversionofZYTIGA®250mgbeforetheexpirationofUnitedStatesPatent
No.8,822,438(the’438patent).ThegenericcompaniesincludeAmnealPharmaceuticals,LLCand
88 • Johnson&Johnson2018AnnualReportAmnealPharmaceuticalsofNewYork,LLC(collectively,Amneal);ApotexInc.andApotexCorp.(collectively,Apotex);
CitronPharmaLLC(Citron);Dr.Reddy’sLaboratories,Ltd.andDr.Reddy’sLaboratories,Inc.(collectively,Dr.Reddy’s);
MylanPharmaceuticalsInc.andMylanInc.(collectively,Mylan);ParPharmaceuticals,Inc.andParPharmaceutical
Companies,Inc.(collectively,Par);SunPharmaceuticalIndustriesLtd.andSunPharmaceuticalsIndustries,Inc.
(collectively,Sun);TevaPharmaceuticalsUSA,Inc.(Teva);WockhardtBioA.G.;WockhardtUSALLCandWockhardt
Ltd.(collectively,Wockhardt);West-WardPharmaceuticalCorp.(West-Ward)andHikmaPharmaceuticals,LLC(Hikma).
JanssenandBTGalsoinitiatedpatentinfringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstAmerigenPharmaceuticalsLimited(Amerigen)inMay2016,andGlenmarkPharmaceuticals,Inc.(Glenmark)in
June2016,eachofwhomfiledanANDAseekingapprovaltomarketitsgenericversionofZYTIGA®beforetheexpirationof
the’438patent.TheselawsuitshavebeenconsolidatedwiththelawsuitfiledinJuly2015.
InAugust2015,JanssenandBTGfiledanadditionaljurisdictionalprotectivelawsuitagainsttheMylandefendantsinthe
UnitedStatesDistrictCourtfortheNorthernDistrictofWestVirginia,whichhasbeenstayed.
InAugust2017,JanssenandBTGinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofNewJerseyagainstTeva,whofiledanANDAseekingapprovaltomarketagenericversionofZYTIGA®500mgbefore
theexpirationofthe’438patent.ThislawsuithasbeenconsolidatedwiththelawsuitfiledinJuly2015.
InFebruary2018,JanssenandBTGfiledapatentinfringementlawsuitagainstMSNPharmaceuticals,Inc.andMSN
LaboratoriesPrivateLimited(collectively,MSN)inUnitedStatesDistrictCourtfortheDistrictofNewJerseybasedonits
ANDAseekingapprovalforagenericversionofZYTIGA®priortotheexpirationofthe’438patent.
InNovember2018,JanssenandBTGinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyagainstQiluPharmaceuticalCo.,Ltd.andQiluPharma,Inc.(collectively,Qilu),whofiledanANDA
seekingapprovaltomarketagenericversionofZYTIGA®beforetheexpirationofthe’438patent.
InDecember2017,JanssenandBTGenteredintoasettlementagreementwithGlenmark.InJanuary2018,Janssen
dismisseditslawsuitagainstSunafteritwithdrewitsANDA.InApril2018,JanssenandBTGenteredintoasettlement
agreementwithApotex.
InOctober2018,theUnitedStatesDistrictCourtfortheDistrictofNewJerseyissuedarulinginvalidatingallasserted
claimsofthe’438patent.Thecourtheldthatthepatentclaimswouldbeinfringedifthepatentwerevalid.Janssen
appealedthecourt’sdecision.
InNovember2018,theUnitedStatesCourtofAppealsfortheFederalCircuitdeniedJanssen’srequestforaninjunction
pendingappeal.Asaresult,severalgenericversionsofZYTIGA®haveenteredthemarket.Janssenhasappealedthe
decisionoftheUnitedStatesDistrictCourtfortheDistrictofNewJersey,andtheoralargumentontheappealis
scheduledforMarch2019.
ThelawsuitsagainstMSNandQiluremainpendinginthedistrictcourts.Ineachoftheselawsuits,Janssenisseekingan
orderenjoiningthedefendantsfrommarketingtheirgenericversionsofZYTIGA®beforetheexpirationofthe’438patent.
SeveralgenericcompaniesincludingAmerigen,ArgentumPharmaceuticalsLLC(Argentum),Mylan,Wockhardt,Actavis,
Amneal,Dr.Reddy’s,Sun,Teva,West-WardandHikmafiledPetitionsforInterPartesReview(IPR)withtheUSPTO,
seekingtoinvalidatethe’438patent.InJanuary2018,theUSPTOissueddecisionsfindingthe’438patentclaims
unpatentable,andJanssenrequestedrehearing.InDecember2018,theUSPTOdeniedJanssen’srequestforrehearingof
theIPRdecisions.Janssenfiledanappeal,whichwasconsolidatedwiththeabove-mentionedappealofthedecisionof
theUnitedStatesDistrictCourtfortheDistrictofNewJersey.
InOctober2017,JanssenInc.andJanssenOncology,Inc.(collectively,Janssen)initiatedtwoNoticesofApplication
underSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstTevaCanadaLimited(Teva)and
theMinisterofHealthinCanadainresponsetoTeva’sfilingAbbreviatedNewDrugSubmissions(ANDS)andseeking
approvaltomarketgenericversionsofZYTIGA®250mgandZYTIGA®500mgbeforetheexpirationofCanadianPatent
No.2,661,422.InJune2018,thepartiesenteredintoasettlementagreement.
InNovember2017,JansseninitiatedaNoticeofApplicationunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexInc.(Apotex)andtheMinisterofHealthinCanadainresponsetoApotex’sfiling
ofanAbbreviatedNewDrugSubmission(ANDS)seekingapprovaltomarketagenericversionofZYTIGA®beforethe
expirationofCanadianPatentNo.2,661,422.ThefederalcourtofCanadascheduledtheFinalHearingforApril2019.
JanssenisseekinganorderprohibitingtheMinisterofHealthfromissuingaNoticeofCompliancewithrespectto
Apotex’sANDSbeforetheexpirationofJanssen’spatent.
Johnson&Johnson2018AnnualReport • 89InJanuary2019,JansseninitiatedaNoticeofApplicationunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexandtheMinisterofHealthinCanadainresponsetoApotex’sfilingofan
AbbreviatedNewDrugSubmission(ANDS)seekingapprovaltomarketafilm-coatedgenericversionofZYTIGA®before
theexpirationofCanadianPatentNo.2,661,422.JanssenisseekinganorderprohibitingtheMinisterofHealthfrom
issuingaNoticeofCompliancewithrespecttoApotex’sANDSbeforetheexpirationofJanssen’spatent.
XARELTO®
BeginninginOctober2015,JanssenPharmaceuticals,Inc.(JPI)andBayerPharmaAGandBayerIntellectualProperty
GmbH(collectively,Bayer)filedpatentinfringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelaware
againstanumberofgenericcompanieswhofiledANDAsseekingapprovaltomarketgenericversionsofXARELTO®
beforeexpirationofBayer’sUnitedStatesPatentNos.7,157,456,7,585,860and7,592,339relatingtoXARELTO®.JPIis
theexclusivesublicenseeoftheassertedpatents.Thefollowinggenericcompaniesarenameddefendants:Aurobindo
PharmaLimitedandAurobindoPharmaUSA,Inc.(collectively,Aurobindo);BreckenridgePharmaceutical,Inc.
(Breckenridge);InvaGenPharmaceuticalsInc.(InvaGen);MicroLabsUSAInc.andMicroLabsLtd(collectively,Micro);
MylanPharmaceuticalsInc.(Mylan);PrinstonPharmaceuticals,Inc.;SigmapharmLaboratories,LLC(Sigmapharm);Torrent
Pharmaceuticals,LimitedandTorrentPharmaInc.(collectively,Torrent).TrialconcludedinApril2018.InJuly2018the
districtcourtenteredjudgmentagainstMylanandSigmapharm,holdingthattheassertedcompoundpatentisvalidand
infringed.InSeptember2018,thedistrictcourtenteredjudgmentagainsttheremainingdefendants.Noneofthe
defendantsappealedthejudgment.
BeginninginApril2017,JPIandBayerIntellectualPropertyGmbHandBayerAG(collectively,BayerAG)filedpatent
infringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstanumberofgeneric
companieswhofiledANDAsseekingapprovaltomarketgenericversionsofXARELTO®beforeexpirationofBayerAG’s
UnitedStatesPatentNo.9,539,218(’218)relatingtoXARELTO®.JPIistheexclusivesublicenseeoftheassertedpatent.
Thefollowinggenericcompaniesarenameddefendants:AlembicPharmaceuticalsLimited,AlembicGlobalHoldingSA
andAlembicPharmaceuticals,Inc.(Alembic);Aurobindo;Breckenridge;InvaGen;LupinLimitedandLupin
Pharmaceuticals,Inc.(collectively,Lupin);Micro;Mylan;Sigmapharm;TaroPharmaceuticalIndustriesLtd.andTaro
PharmaceuticalsU.S.A.,Inc.(collectively,Taro)andTorrent.Lupincounterclaimedfordeclaratoryjudgmentof
noninfringementandinvalidityofUnitedStatesPatentNo.9,415,053,butLupindismisseditscounterclaimsafteritwas
providedacovenantnottosueonthatpatent.Aurobindo,Taro,Torrent,Micro,Breckenridge,InvaGen,Sigmapharm,
LupinandAlembichaveagreedtohavetheircasesstayedandtobeboundbytheoutcomeofanyfinaljudgment
renderedagainstanyoftheotherdefendants.The’218caseshavebeenconsolidatedfordiscoveryandtrial,andare
currentlysetfortrialinApril2019.
InDecember2018,JPIandBayerAGfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofDelawareagainstTevaPharmaceuticalsUSA,Inc.andTevaPharmaceuticalIndustriesLtd.(collectively,Teva)whofiled
anANDAseekingapprovaltomarketagenericversionofXARELTO®beforeexpirationofBayerAG’s’218patent.
Ineachoftheselawsuits,JPIisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof
XARELTO®beforetheexpirationoftherelevantpatents.
InMay2018,MylanfiledaPetitionforInterPartesReviewwiththeUSPTO,seekingtoinvalidatethe’218patent.In
December2018,theUSPTOissuedadecisiondenyinginstitutionofMylan’sPetitionforInterPartesReview.
PREZISTA®
InMay2018,JanssenProducts,L.P.andJanssenSciencesIrelandUC(collectively,Janssen)initiatedapatent
infringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstDr.ReddysLaboratories,Inc.,
Dr.ReddysLaboratories,Ltd.,LaurusLabs,Ltd.andPharmaq,Inc.(collectively,DRL)whofiledanANDAseekingapproval
tomarketgenericversionsofPREZISTA®beforetheexpirationofUnitedStatesPatentNos.8,518,987;7,126,015;and
7,595,408.TrialisscheduledtobegininMay2020.
InDecember2018,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstAmnealPharmaceuticals,LLC,AmnealPharmaceuticalsCompanyGmbH,AmnealPharmaceuticalsof
NewYork,LLC,AmnealPharmaceuticalsPvtLtd.,andRaksPharmaPvt.Ltd.(collectively,Amneal),whofiledanANDA
seekingapprovaltomarketgenericversionsofPREZISTA®beforetheexpirationofUnitedStatesPatentNos.8,518,987;
7,126,015;and7,595,408.
Ineachoftheselawsuits,Janssenisseekinganorderenjoiningthedefendantsfrommarketingitsgenericversionsof
PREZISTA®beforetheexpirationoftherelevantpatents.
90 • Johnson&Johnson2018AnnualReportINVOKANA®/INVOKAMET®
BeginninginJuly2017,JanssenPharmaceuticals,Inc.,JanssenResearch&Development,LLC,CilagGmbHInternational
andJanssenPharmaceuticaNV(collectively,Janssen)andMitsubishiTanabePharmaCorporation(MTPC)filedpatent
infringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,theUnitedStatesDistrictCourtfor
theDistrictofColoradoandtheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstanumberofgeneric
companieswhofiledANDAsseekingapprovaltomarketgenericversionsofINVOKANA®and/orINVOKAMET®before
expirationofMTPC’sUnitedStatesPatentNos.7,943,582and/or8,513,202relatingtoINVOKANA®andINVOKAMET®.
Janssenistheexclusivelicenseeoftheassertedpatents.Thefollowinggenericcompaniesarenameddefendants:Apotex
Inc.andApotexCorp.(Apotex);AurobindoPharmaUSAInc.(Aurobindo);MacleodsPharmaceuticalsLtd.andMacleods
PharmaUSA,Inc.;InvaGenPharmaceuticals,Inc.(InvaGen);PrinstonPharmaceuticalsInc.;Dr.Reddy’sLaboratories,Inc.
andDr.Reddy’sLaboratoriesLtd;HeteroUSA,Inc.,HeteroLabsLimitedUnit-VandHeteroLabsLimited;MSN
LaboratoriesPrivateLtd.andMSNPharmaceuticals,Inc.;LaurusLabsLtd.;IndocoRemediesLtd.;ZydusPharmaceuticals
(USA)Inc.(Zydus);Sandoz,Inc.(Sandoz);TevaPharmaceuticalsUSA,Inc.;andLupinLtd.andLupinPharmaceuticals,
Inc.
BeginninginJuly2017,JanssenandMTPCfiledpatentinfringementlawsuitsintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyandtheUnitedStatesDistrictCourtfortheDistrictofColoradoagainstSandozandInvaGen,who
filedANDAsseekingapprovaltomarketgenericversionsofINVOKANA®and/orINVOKAMET®beforeexpirationof
MTPC’sUnitedStatesPatentNo.7,943,788(the’788patent)relatingtoINVOKANA®andINVOKAMET®andagainst
Zydus,whofiledANDAsseekingapprovaltomarketgenericversionsofINVOKANA®andINVOKAMET®beforeexpiration
ofthe’788patent,MTPC’sUnitedStatesPatentNo.8,222,219relatingtoINVOKANA®andINVOKAMET®andMTPC’s
UnitedStatesPatentNo.8,785,403relatingtoINVOKAMET®,andagainstAurobindo,whofiledanANDAseeking
approvaltomarketagenericversionofINVOKANA®beforeexpirationofthe’788patentandthe’219patentrelatingto
INVOKANA®.
Janssenistheexclusivelicenseeoftheassertedpatents.InOctober2017,theColoradolawsuitsagainstSandozwere
dismissed.InDecember2017,theDelawarelawsuitsagainstApotexandTevaweredismissed.
InApril2018,JanssenandMTPCfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstPrinston,whofiledanANDAseekingapprovaltomarketagenericversionofINVOKANA®before
expirationofthe’788patentrelatingtoINVOKANA®.
Ineachoftheselawsuits,JanssenandMTPCareseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric
versionsofINVOKANA®and/orINVOKAMET®beforetheexpirationoftherelevantpatents.
OPSUMIT®
InJanuary2018,ActelionPharmaceuticalsLtd(Actelion)initiatedapatentinfringementlawsuitintheUnitedStates
DistrictCourtfortheDistrictofNewJerseyagainstZydusPharmaceuticals(USA)Inc.(Zydus)andAmneal
PharmaceuticalsLLC(Amneal),eachofwhomfiledanANDAseekingapprovaltomarketagenericversionofOPSUMIT®
beforetheexpirationofUnitedStatesPatentNo.7,094,781.Inthelawsuit,ActelionisseekinganorderenjoiningZydus
andAmnealfrommarketinggenericversionsofOPSUMIT®beforetheexpirationofthepatent.InDecember2018,the
districtcourtenteredanorderwhereinoneofthedefendants,Amneal,stipulatedtoinfringement.Trialisscheduledto
commenceinOctober2020.
INVEGASUSTENNA®
InJanuary2018,JanssenPharmaceuticaNVandJanssenPharmaceuticals,Inc.(collectively,Janssen)initiatedapatent
infringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstTevaPharmaceuticalsUSA,
Inc.(Teva),whofiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNA®beforethe
expirationofUnitedStatesPatentNo.9,439,906.Inthelawsuit,JanssenisseekinganorderenjoiningTevafrom
marketingagenericversionofINVEGASUSTENNA®beforetheexpirationofthepatent.
InFebruary2018,JanssenInc.andJanssenPharmaceuticaNV(collectively,Janssen)initiatedaNoticesofApplication
underSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstTevaCanadaLimited(Teva)and
theMinisterofHealthinresponsetoTeva’sfilingofanAbbreviatedNewDrugSubmission(ANDS)seekingapprovalto
marketagenericversionofINVEGASUSTENNA®beforetheexpirationofCanadianPatentNos.2,309,629and
2,655,335.JanssenisseekinganorderprohibitingtheMinisterofHealthfromissuingaNoticeofCompliancewith
respecttoTeva’sANDSbeforetheexpirationofthesepatents.TheFinalHearingisscheduledtobegininSeptember
2019.
Johnson&Johnson2018AnnualReport • 91IMBRUVICA®
BeginninginJanuary2018,PharmacyclicsLLC(Pharmacyclics)andJanssenBiotech,Inc.(JBI)filedpatentinfringement
lawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstanumberofgenericcompanieswhofiled
ANDAsseekingapprovaltomarketgenericversionsofIMBRUVICA®beforeexpirationofPharmacyclics’UnitedStates
PatentNos.8,008,309,7,514,444,8,697,711,8,735,403,8,957,079,9,181,257,8,754,091,8,497,277,8,925,015,
8,476,284,8,754,090,8,999,999,9,125,889,9,801,881,9,801,883,9,814,721,9,795,604,9,296,753,9,540,382,
9,713,617and/or9,725,455relatingtoIMBRUVICA®.JBIistheexclusivelicenseeoftheassertedpatents.Thefollowing
genericcompaniesarenameddefendants:CiplaLimitedandCiplaUSAInc.(Cipla);FreseniusKabiUSA,LLC,Fresenius
KabiUSA,Inc.,andFreseniusKabiOncologyLimited(FreseniusKabi);SandozInc.andLekPharmaceuticalsd.d.
(Sandoz);ShilpaMedicareLimited(Shilpa);SunPharmaGlobalFZEandSunPharmaceuticalIndustriesLimited(Sun);
TevaPharmaceuticalsUSA,Inc.(Teva);andZydusWorldwideDMCCandCadilaHealthcareLimited(Zydus).Trialis
scheduledtobegininOctober2020.
InOctober2018,PharmacyclicsandJBIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofDelawareagainstSunassertingnewlyissuedUnitedStatesPatentNo.10,004,746.
Ineachofthelawsuits,PharmacyclicsandJBIareseekinganorderenjoiningthedefendantsfrommarketinggeneric
versionsofIMBRUVICA®beforetheexpirationoftherelevantpatents.
InJanuary2019,PharmacyclicsandJBIamendedtheircomplaintsagainstFreseniusKabi,Zydus,TevaandSandozto
furtherallegeinfringementofU.S.PatentNos.10,106,548,and10,125,140.
InJanuary2019,PharmacyclicsandJBIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofDelawareagainstZydus,whofiledanANDAseekingapprovaltomarketagenericversionofIMBRUVICA®70
mgbeforetheexpirationofU.S.PatentNos.514,444,8,003,309,8,476,284,8,497,277,8,697,711,8,753,403,
8,754,090,8,754,091,8,952,015,8,957,079,9,181,257,9,296,753,9,540,382,9,713,617,9,725,455,10,106,548,
and10,125,140.
GOVERNMENTPROCEEDINGS
Likeothercompaniesinthepharmaceuticalandmedicaldevicesindustries,Johnson&Johnsonandcertainofits
subsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnitedStatesand
othercountriesinwhichtheyoperate.Asaresult,interactionwithgovernmentagenciesisongoing.Themostsignificant
litigationbroughtby,andinvestigationsconductedby,governmentagenciesarelistedbelow.Itispossiblethatcriminal
chargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation.
AverageWholesalePrice(AWP)Litigation
Johnson&Johnsonandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,werenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving
allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise
actionableconductbecause,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice
(AWP)forthedrugsatissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.The
plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof
thedrugsatissuebasedonAWP,andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissue
basedonAWP.Manyofthesecases,bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidated
forpre-trialpurposesinamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofMassachusetts,where
allclaimsagainsttheJ&JAWPDefendantswereultimatelydismissed.TheJ&JAWPDefendantsalsoprevailedinacase
broughtbytheCommonwealthofPennsylvania.OtherAWPcaseshavebeenresolvedthroughcourtorderorsettlement.
Twocasesremainpending.InacasebroughtbyIllinois,trialhasbeenscheduledforMarch2019.InNewJersey,a
putativeclassactionbaseduponAWPallegationsispendingagainstCentocor,Inc.andOrthoBiotechInc.(bothnow
JanssenBiotech,Inc.),Johnson&JohnsonandALZACorporation.
OpioidsLitigation
Beginningin2014andcontinuingtothepresent,Johnson&JohnsonandJanssenPharmaceuticals,Inc.(JPI),alongwith
otherpharmaceuticalcompanies,havebeennamedinmorethan1,600lawsuitsbroughtbycertainstateandlocal
governmentsrelatedtothemarketingofopioids,includingDURAGESIC®,NUCYNTA®andNUCYNTA®ER.Todate,
complaintsagainstpharmaceuticalcompanies,includingJohnson&JohnsonandJPI,havebeenfiledinstatecourtbythe
92 • Johnson&Johnson2018AnnualReportstateAttorneysGeneralinArkansas,Florida,Kentucky,Louisiana,Mississippi,Missouri,NewHampshire,NewJersey,New
Mexico,Ohio,OklahomaandSouthDakota.Complaintsagainstthemanufacturersalsohavebeenfiledinstateorfederalcourt
bycity,countyandlocalgovernmentagenciesinthefollowingstates:Alabama;Arkansas;California;Connecticut;Florida;
Georgia;Illinois;Kentucky;Louisiana;Maine;Maryland;Massachusetts;Mississippi;Missouri;Nevada;NewHampshire;New
Jersey;NewMexico;NewYork;NorthCarolina;Ohio;Oklahoma;Oregon;Pennsylvania;RhodeIsland;SouthCarolina;South
Dakota;Tennessee;Texas;Utah;Virginia;Washington;WestVirginiaandWisconsin.TheGovernmentofPuertoRicofiledsuit
inSuperiorCourtofSanJuan.Inaddition,theProvinceofBritishColumbiafiledsuitinCanada.Theseactionsallegeavariety
ofclaimsrelatedtoopioidsmarketingpractices,includingfalseadvertising,unfaircompetition,publicnuisance,consumerfraud
violations,deceptiveactsandpractices,falseclaimsandunjustenrichment.Thesuitsgenerallyseekpenaltiesand/orinjunctive
andmonetaryreliefand,insomeofthesuits,theplaintiffsareseekingjointandseveralliabilityamongthedefendants.These
casesareinearlystagesoflitigation.InOctober2017,Johnson&JohnsonandJPIwerebothservedwithamotionto
consolidate66pendingmattersintoafederalMultiDistrictLitigation(MDL)intheSouthernDistrictofOhio.In
December2017,theMDLwasapprovedintheNorthernDistrictofOhioandthereareover1,400casesthathavebeen
transferredtotheMDL.
Johnson&Johnson,JPIandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation
relatedtoopioidsmarketingpracticesfromthefollowingstateAttorneysGeneral:Alaska,Indiana,Montana,New
Hampshire,SouthCarolina,Tennessee,TexasandWashington.InSeptember2017,Johnson&JohnsonandJPIwere
contactedbytheTexasandColoradoAttorneyGeneral’sOfficesonbehalfofapproximately38statesregardingamulti-
stateAttorneyGeneralinvestigation.Themulti-statecoalitionservedJohnson&JohnsonandJPIwithsubpoenasaspartof
theinvestigation.Johnson&JohnsonandJPIhavealsoreceivedrequestsforinformationfromtherankingminoritymember
oftheUnitedStatesSenateCommitteeonHomelandSecurityandGovernmentalAffairsregardingthesales,marketing,
andeducationalstrategiesrelatedtothepromotionofopioidsuse.
Other
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowknownasDePuySynthes,Inc.),andJohnson&Johnson
Services,Inc.(collectivelyDePuy)receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsandtheCivilDivisionoftheUnitedStatesDepartmentofJustice(theUnitedStates)fortheproductionof
materialsrelatingtotheDePuyASR™XLHipdevice.InJuly2014,theUnitedStatesnotifiedtheUnitedStatesDistrict
CourtfortheDistrictofMassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttotheFalse
ClaimsActagainstthecompanies.InFebruary2016,thedistrictcourtgrantedthecompanies’motiontodismisswith
prejudice,unsealedthequitamcomplaint,anddeniedthequitamrelators’requestforleavetofileafurtheramended
complaint.ThequitamrelatorsappealedthecasetotheUnitedStatesCourtofAppealsfortheFirstCircuit.InJuly2017,
theFirstCircuitaffirmedthedistrictcourt’sdismissalinpart,reversedinpart,andaffirmedthedecisiontodenythe
relators’requesttofileathirdamendedcomplaint.Therelators’remainingclaimsarenowpendingbeforethedistrictcourt,
andfactdiscoveryiscurrentlyscheduledtocloseinSeptember2019.Additionally,DePuyfiledapetitionforcertiorariwith
theUnitedStatesSupremeCourt,seekingreviewoftheFirstCircuit’sdecision.TheSupremeCourtdeniedthepetitionin
April2018.
SinceOctober2013,agroupofStateAttorneysGeneralhaveissuedCivilInvestigativeDemandsrelatingtothe
development,salesandmarketingofseveralofDePuyOrthopaedics,Inc.‘shipproducts.InJuly2014,theOregon
DepartmentofJustice,whichwasinvestigatingthesemattersindependentlyoftheotherstates,announcedasettlementof
itsASR™XLHipdeviceinvestigationwiththeStateofOregon.InDecember2018,theCompany,theremainingstates
andtheDistrictofColumbiaagreedtosettlealloftheinvestigations,andonJanuary22,2019,thestatesandthe
Companyfiledconsentjudgmentsresolvingthematter.
InOctober2012,Johnson&JohnsonwascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-state
AttorneyGeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby
Johnson&Johnson’ssubsidiary,Ethicon,Inc.(Ethicon).Johnson&JohnsonandEthiconhavesinceenteredintoaseries
oftollingagreementswiththe47statesandtheDistrictofColumbiaparticipatinginthemulti-stateinvestigationandhave
respondedtoCivilInvestigativeDemandsservedbycertainoftheparticipatingstates.Thestatesareseekingmonetary
andinjunctiverelief.InMay2016,CaliforniaandWashingtonfiledcivilcomplaintsagainstJohnson&Johnson,Ethiconand
EthiconUS,LLCallegingviolationsoftheirconsumerprotectionstatutes.Similarcomplaintswerefiledagainstthe
companiesbyKentuckyinAugust2016andbyMississippiinOctober2017.Johnson&JohnsonandEthiconhave
enteredintoanewtollingagreementwiththeremaining43statesandtheDistrictofColumbia.
InDecember2012,Therakos,Inc.(Therakos),formerlyasubsidiaryofJohnson&JohnsonandpartoftheOrtho-Clinical
Diagnostics,Inc.(OCD)franchise,receivedaletterfromthecivildivisionoftheUnitedStatesAttorney’sOfficeforthe
Johnson&Johnson2018AnnualReport • 93EasternDistrictofPennsylvaniainformingTherakosthattheUnitedStatesAttorney’sOfficewasinvestigatingthesales
andmarketingofUvadex®(methoxsalen)andtheUvarXts®andCellex®Systemsduringtheperiod2000tothepresent.
TheUnitedStatesAttorney’sOfficerequestedthatOCDandJohnson&Johnsonpreservedocumentsthatcouldrelateto
theinvestigation.TherakoswassubsequentlyacquiredbyanaffiliateofGoresCapitalPartnersIII,L.P.inJanuary2013,
andOCDwasdivestedinJune2014.FollowingthedivestitureofOCD,Johnson&JohnsonretainsOCD’sportionofany
liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleofTherakos.InMarch2014and
March2016,theUnitedStatesAttorney’sOfficerequestedthatJohnson&Johnsonproducecertaindocuments,and
Johnson&Johnsoniscooperatingwiththoserequests.
InJune2014,theMississippiAttorneyGeneralfiledacomplaintinChanceryCourtofTheFirstJudicialDistrictofHinds
County,MississippiagainstJohnson&JohnsonandJohnson&JohnsonConsumerCompanies,Inc.(nowknownas
Johnson&JohnsonConsumerInc.)(JJCI).Thecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisks
associatedwithfemaleconsumers’useoftalccontainedinJOHNSON’S®BabyPowderandJOHNSON’S®Showerto
Shower(aproductdivestedin2012)andseeksinjunctiveandmonetaryrelief.Trialisstayedpendinginterlocutoryappeal
ofadenialofJJCI’smotionforsummaryjudgment.
InMarch2016,JanssenPharmaceuticals,Inc.(JPI)receivedaCivilInvestigativeDemandfromtheUnitedStates
Attorney’sOfficefortheSouthernDistrictofNewYorkrelatedtoJPI’scontractualrelationshipswithpharmacybenefit
managersovertheperiodfromJanuary1,2006tothepresentwithregardtocertainofJPI’spharmaceuticalproducts.The
demandwasissuedinconnectionwithaninvestigationundertheFalseClaimsAct.
InJanuary2017,JanssenPharmaceuticals,Inc.(JPI)receivedaCivilInvestigativeDemandfromtheUnitedStates
DepartmentofJusticerelatingtoallegationsconcerningthesalesandmarketingpracticesofOLYSIO®.InDecember
2017,Johnson&JohnsonandJPIwereservedwithawhistleblowerlawsuitfiledintheUnitedStatesDistrictCourtforthe
CentralDistrictofCaliforniaallegingtheoff-labelpromotionofOLYSIO®andadditionalproducts,includingNUCYNTA®,
XARELTO®,LEVAQUIN®andREMICADE®.Atthistime,thefederalandstategovernmentshavedeclinedtointervene
andthelawsuit,whichisrelatedtotheCivilInvestigativeDemand,isbeingprosecutedbyaformercompanyemployee.
TheUnitedStatesDistrictCourtfortheCentralDistrictofCaliforniadismissedtheclaiminApril2018.InMay2018,the
relatorfiledanoticeofappealtotheUnitedStatesCourtofAppealsfortheNinthCircuit.
InNovember2018,asecondwhistleblowerlawsuitwasunsealedintheUnitedStatesDistrictCourtfortheCentral
DistrictofCalifornia.Thelawsuitissubstantiallysimilartothelawsuitunderappealbutisbroughtinthenameofthe
originalrelator.Thefederalandstategovernmentshavedeclinedtointerveneinthesecondsuitatthistime.
InFebruary2017,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusettsseekingtheproductionofrecordspertainingtopaymentstoany501(c)(3)charitableorganizationthat
providesfinancialassistancetoMedicarepatients.Multiplepharmaceuticalcompanieshavepubliclyreportedreceiptof
subpoenasandongoinginquiriessimilartothisoneandtheonedescribedbelow.Thegovernmenthasrepresentedthatit
willnotbepursuingactionagainstthecompanyinthismatter.
ActelionPharmaceuticalsUS,Inc.(ActelionUS),receivedasubpoenainMay2016,withfollow-uprequestsfor
documentsfromtheUnitedStatesAttorney’sOfficefortheDistrictofMassachusetts.Thesubpoenaseekstheproduction
ofrecordspertainingtoActelionUS’paymentsto501(c)(3)charitableorganizationsthatprovidefinancialassistanceto
Medicarepatients.InDecember2018,theCompanyandtheUnitedStatesDepartmentofJusticeagreedtoasettlement
inthismatter.
InMarch2017,JanssenBiotech,Inc.receivedaCivilInvestigativeDemandfromtheUnitedStatesDepartmentofJustice
regardingaFalseClaimsActinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand
gastroenterologypracticesthatpurchasedREMICADE®orSIMPONIARIA®.
InAprilandSeptember2017,Johnson&JohnsonreceivedsubpoenasfromtheUnitedStatesAttorneyfortheDistrictof
MassachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsforDARZALEX®,
OLYSIO®,REMICADE®,SIMPONI®,STELARA®andZYTIGA®.ThesubpoenasalsoseekdocumentsrelatingtoAverage
ManufacturerPriceandBestPricereportingtotheCenterforMedicareandMedicaidServicesrelatedtothoseproducts,
aswellasrebatepaymentstostateMedicaidagencies.
InJune2017,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsseekinginformationregardingpracticespertainingtothesterilizationofDePuySynthes,Inc.spinal
implantsatthreehospitalsinBostonaswellasinteractionsofemployeesofCompanysubsidiarieswithphysiciansat
thesehospitals.Johnson&JohnsonandDePuySynthes,Inc.haveproduceddocumentsinresponsetothesubpoenaand
arefullycooperatingwiththegovernment’sinvestigation.
94 • Johnson&Johnson2018AnnualReportInJuly2018,AdvancedSterilizationProducts(ASP)receivedaCivilInvestigativeDemandfromtheUnitedStates
DepartmentofJusticeregardingaFalseClaimsActinvestigationconcerningthepricing,quality,marketingandpromotion
ofEvoTechECR,TyvekPeelPouches,orSterradCyclesure24biologicalindicators.
InJuly2018thePublicProsecutionServiceinRiodeJaneiroandrepresentativesfromtheBrazilianantitrustauthority
CADEinspectedtheofficesofmorethan30companiesincludingJohnson&JohnsondoBrasilIndústriaeComérciode
ProdutosparaSaúdeLtda.Theauthoritiesappeartobeinvestigatingallegationsofpossibleanti-competitivebehaviorand
possibleimproperpaymentsinthemedicaldeviceindustry.TheUnitedStatesDepartmentofJusticeandtheUnited
StatesSecuritiesandExchangeCommissionhavemadeadditionalpreliminaryinquiriesabouttheinspectioninBrazil,and
Johnson&JohnsondoBrasilIndústriaeComérciodeProdutosparaSaúdeLtda.iscooperatingwiththoserequests.
Fromtimetotime,theCompanyhasreceivedrequestsfromavarietyofUnitedStatesCongressionalCommitteesto
produceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsontocooperatewith
theseinquiriesbyproducingtherequestedinformation.
GENERALLITIGATION
InApril2016,aputativeclassactionwasfiledagainstJohnson&Johnson,Johnson&JohnsonSalesandLogistics
Company,LLCandMcNeilPPC,Inc.(nowknownasJohnson&JohnsonConsumer,Inc.)inNewJerseySuperiorCourt,
CamdenCountyonbehalfofpersonswhoresideinthestateofNewJerseywhopurchasedvariousMcNeil
over-the-counterproductsfromDecember2008throughthepresent.ThecomplaintallegesviolationsoftheNewJersey
ConsumerFraudAct.Followingthegrantofamotiontodismissandthefilingofanamendedcomplaint,inMay2017,the
courtdeniedamotiontodismisstheamendedcomplaint.InDecember2018,asettlementwasreachedandthematter
hasbeendismissed.
InMay2014,twopurportedclassactionswerefiledinfederalcourt,oneintheUnitedStatesDistrictCourtfortheCentral
DistrictofCaliforniaandoneintheUnitedStatesDistrictCourtfortheSouthernDistrictofIllinois,againstJohnson&
JohnsonandJohnson&JohnsonConsumerCompanies,Inc.(nowknownasJohnson&JohnsonConsumerInc.)(JJCI)
allegingviolationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalc
containedinJOHNSON’S®BabyPowderandJOHNSON’S®ShowertoShower(aproductnolongersoldbyJJCI).Both
casesseekinjunctivereliefandmonetarydamages;neitherincludesaclaimforpersonalinjuries.InOctober2016,both
casesweretransferredtotheUnitedStatesDistrictCourtfortheDistrictCourtofNewJerseyaspartofanewlycreated
federalmulti-districtlitigation.InJuly2017,thedistrictcourtgrantedJohnson&Johnson’sandJJCI’smotiontodismiss
oneofthecases.InSeptember2018,theUnitedStatesCourtofAppealsfortheThirdCircuitaffirmedthisdismissal.In
September2017,theplaintiffinthesecondcasevoluntarilydismissedtheircomplaint.InMarch2018,theplaintiffinthe
secondcaserefiledinIllinoisStateCourt.
InAugust2014,UnitedStatesCustomsandBorderProtection(USCBP)issuedaPenaltyNoticeagainstJanssenOrtho
LLC(JanssenOrtho),assessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolate(theactive
pharmaceuticalingredientinPREZISTA®)inconnectionwithitsimportationintotheUnitedStates.InOctober2014,
JanssenOrthosubmittedaPetitionforReliefinresponsetothePenaltyNotice.InMay2015,USCBPissuedan
AmendedPenaltyNoticeassessingsubstantialpenaltiesandJanssenOrthofiledaPetitionforReliefinJuly2015.
InMarchandApril2015,over30putativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts
aroundtheUnitedStatesagainstJohnson&JohnsonVisionCare,Inc.(JJVCI)andothercontactlensmanufacturers,
distributors,andretailers,allegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlenses.The
complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers
concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumers.Theplaintiffsareseekingdamagesand
injunctiverelief.AlloftheclassactioncasesweretransferredtotheUnitedStatesDistrictCourtfortheMiddleDistrictof
FloridainJune2015.TheplaintiffsfiledaconsolidatedclassactioncomplaintinNovember2015.InJune2016,the
districtcourtdeniedmotionstodismissfiledbyJJVCIandotherdefendants.Discoveryisongoing.InMarch2017,the
plaintiffsfiledamotionforclasscertification.ThedistrictcourtheldahearingonthemotionforclasscertificationinAugust
2018.InDecember2018,thedistrictcourtgrantedtheplaintiffsmotionforclasscertification.
InAugust2015,twothird-partypayorsfiledapurportedclassactionintheUnitedStatesDistrictCourtfortheEastern
DistrictofLouisianaagainstJanssenResearch&Development,LLC,JanssenOrthoLLC,JanssenPharmaceuticals,Inc.,
Ortho-McNeil-JanssenPharmaceuticals,Inc.andJohnson&Johnson(aswellascertainBayerentities),allegingthatthe
defendantsimproperlymarketedandpromotedXARELTO®assaferandmoreeffectivethanlessexpensivealternative
medicationswhilefailingtofullydiscloseitsrisks.Thecomplaintseeksdamages.
Johnson&Johnson2018AnnualReport • 95InMay2017,LonzaSalesAG(Lonza)filedaRequestforArbitrationwiththeLondonCourtofInternationalArbitration
againstJanssenResearch&Development,LLC(JanssenR&D).LonzaallegesthatJanssenR&Dbreacheda2005
agreementbetweenthepartiesbysublicensingcertainLonzatechnologyusedinthemanufactureofdaratumumab
withoutLonza’sconsent.Lonzaseeksmonetarydamages.ThearbitrationhearingwasheldinSeptember2018.Post
hearingbriefingiscomplete,andthepartiesareawaitingadecision.
InMay2017,apurportedclassactionwasfiledintheUnitedStatesDistrictCourtfortheWesternDistrictofWashingtonagainst
LifeScanInc.,Johnson&Johnson,otherdiabetesteststripmanufacturersandcertainPharmacyBenefitManagers(PBMs).The
complaintallegesthatconsumerspaidinflatedpricesforglucosemonitorteststripsasaconsequenceofundisclosedrebatesand
otherincentivespaidbymanufacturerstoPBMs.ThecomplaintincludesRICO,ERISA,andstateconsumerprotectionclaims.The
complaintseeksequitablereliefanddamages.InNovember2017,thecasewasorderedtransferredtoUnitedStatesDistrict
CourtfortheDistrictofNewJersey.TheLifeScanbusinesswasdivestedinOctober2018andJohnson&Johnsonretainedliability
thatmayresultfromtheseclaimspriortotheclosingofthedivestiture.
InSeptember2017,Pfizer,Inc.(Pfizer)filedanantitrustcomplaintagainstJohnson&JohnsonandJanssenBiotech,Inc.
(collectively,Janssen)inUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.PfizerallegesthatJanssen
hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforREMICADE®.Thecomplaintseeksdamagesand
injunctiverelief.
BeginninginSeptember2017,multiplepurportedclassactionswerefiledagainstJohnson&JohnsonandJanssen
Biotech,Inc.(collectively,Janssen)allegingthatJanssen’sREMICADE®contractingstrategiesviolatedfederalandstate
antitrustandconsumerlawsandseekingdamagesandinjunctiverelief.InNovember2017,thecaseswereconsolidated
forpre-trialpurposesinUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvaniaasInreRemicadeAntitrust
Litigation.
InJune2018,WalgreenCo.andKrogerCo,filedanantitrustcomplaintagainstJohnson&JohnsonandJanssenBiotech,
Inc.(collectively,Janssen)intheUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.Thecomplaint
allegesthatJanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforREMICADE®.Thecomplaint
seeksdamagesandinjunctiverelief.
InOctober2017,certainUnitedStatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof
pharmaceuticalandmedicaldevicescompanies,includingJohnson&Johnsonandcertainofitssubsidiaries,allegingthat
thedefendantsviolatedtheUnitedStatesAnti-TerrorismAct.Thecomplaintallegesthatthedefendantsprovidedfunding
forterroristorganizationsthroughtheirsalespracticespursuanttopharmaceuticalandmedicaldevicecontractswiththe
IraqiMinistryofHealth.
AndoverHealthcare,Inc.(Andover)filedaLanhamactcaseagainstJohnson&JohnsonConsumerInc.inApril2017inthe
UnitedStatesDistrictCourtfortheDistrictofMassachusetts.Andoverassertsthattheclaim“notmadewithnatural
rubberlatex”onCOACH®SportsWrap,BAND-AID®BrandSECURE-FLEX®WrapandBAND-AID®BrandHURT-
FREE®Wrapisfalse.Andoverseeksactualdamagesandpre-judgmentinterestthereon,disgorgementofprofits,treble
damages,attorney’sfeesandinjunctiverelief.InDecember2018,thepartiesenteredintoasettlementagreement.
InOctober2018,twoseparateputativeclassactionswerefiledagainstActelionPharmaceuticalLtd.,Actelion
PharmaceuticalsUS,Inc.,andActelionClinicalResearch,Inc.(collectively,Actelion)inUnitedStatesDistrictCourtforthe
DistrictofMarylandandUnitedStatesDistrictCourtfortheDistrictofColumbia.ThecomplaintsallegethatActelion
violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical
manufacturerswithsamplesofTRACLEER®.TRACLEER®issubjecttoaRiskEvaluationandMitigationStrategy,which
imposesrestrictionsondistributionoftheproduct.InJanuary2019,theplaintiffsdismissedtheDistrictofColumbiacase
andfiledaconsolidatedcomplaintinfederalcourtinMaryland.
InDecember2018,JanssenBiotech,Inc.,JanssenOncology,Inc,JanssenResearch&Development,LLC,andJohnson&
Johnson(collectively,Janssen)wereservedwithaquitamcomplaintfiledonbehalfoftheUnitedStates,28states,and
theDistrictofColumbia.Thecomplaint,whichwasfiledinDecember2017inUnitedStatesDistrictCourtfortheNorthern
DistrictofCalifornia,allegesthatJanssenviolatedthefederalFalseClaimsActandstatelawwhenprovidingpricing
informationforZYTIGA®tothegovernmentinconnectionwithdirectgovernmentsalesandgovernment-fundeddrug
reimbursementprograms.Atthistime,thefederalandstategovernmentshavedeclinedtointervene.
Johnson&JohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtundertheComprehensive
EnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localor
foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
96 • Johnson&Johnson2018AnnualReport22. Restructuring
Inthefirstquarterof2016,theCompanyannouncedrestructuringactionsinitsMedicalDevicessegmenttobetterserve
theneedsofpatientsandcustomersintoday’sevolvinghealthcaremarketplace.TheCompanyhasundertakenactionsto
strengthenitsgo-to-marketmodel,acceleratethepaceofinnovation,furtherprioritizekeyplatformsandgeographies,and
streamlineoperationswhilemaintaininghighqualitystandards.
In2018,theCompanyrecordedapre-taxchargeof$462million,ofwhich$46millionwasincludedincostofproducts
soldand$227millionwasincludedinother(income)expense.Totalprojectcostsof$2.5billionhavebeenrecorded
sincetherestructuringhasbeenannounced.Thisrestructuringprogramwascompletedinthefiscalfourthquarterof
2018.
OnApril17,2018,theCompanyannouncedplanstoimplementaseriesofactionsacrossitsGlobalSupplyChainthat
areintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilities,technologiesandsolutionsnecessary
tomanufactureandsupplyitsproductportfolio,enhanceagilityanddrivegrowth.TheGlobalSupplyChainactionswill
includeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexity,improvecost-
competitiveness,enhancecapabilitiesandoptimizetheSupplyChainnetwork.Foradditionaldetailsontheglobalsupply
chainrestructuringstrategiccollaborationsseeNote20totheConsolidatedFinancialStatements.In2018,theCompany
recordedapre-taxchargeof$238million,ofwhich$59millionwasincludedincostofproductssoldand$117million
wasincludedinother(income)expense.Seethefollowingtableforadditionaldetailsontherestructuringprograms.
Intotal,theCompanyexpectstheGlobalSupplyChainactionstogenerateapproximately$0.6billionto$0.8billionin
annualpre-taxcostsavingsthatwillbesubstantiallydeliveredby2022.TheCompanyexpectstorecordpre-tax
restructuringchargesofapproximately$1.9billionto$2.3billion,overthe4to5yearperiodofthisactivity.Thesecosts
areassociatedwithnetworkoptimizations,exitcostsandaccelerateddepreciationandamortization.
Thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe
fiscalyearended2018:
(DollarsinMillions) Severance AssetWrite-offs Other** Total
Reservebalance,January3,2016 $484 — 17 501
2016activity (104) — (16) (120)
Reservebalance,January1,2017 380 — 1 381
2017activity (151) — 37 (114)
Reservebalance,December31,2017 229 — 38 267
Currentyearactivity:
Charges — 132 568 700
Cashpayments (35) — (558) (593)
Settlednoncash — (132) — (132)
Reservebalance,December30,2018* $194 — 48 242
* Cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenext2yearsinaccordancewiththeCompany’splans
andlocallaws.
** Otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpenses.
AlthoughtheMedicalDevicesrestructuringprogramwascompletedin2018,theCompanyexpectsthatseverance
chargeswillcontinuebeyondthatdate.TheCompanycontinuouslyreevaluatesitsseverancereservesrelatedto
restructuringandthetimingofpaymentshasextendedduetotheplannedreleaseofassociatesregardingseverallonger-
termprojects.TheCompanybelievesthattheexistingseverancereservesaresufficienttocovertheGlobalSupplyChain
plansgiventheperiodoverwhichtheactionswilltakeplace.TheCompanywillcontinuetoassessandmakeadjustments
asnecessaryifadditionalamountsbecomeprobableandestimable.Approximately2,375individualsreceivedseparation
paymentssincetheserestructuringannouncements.
Johnson&Johnson2018AnnualReport • 97Report of Independent Registered Public
Accounting Firm
TotheBoardofDirectorsandShareholdersofJohnson&Johnson
OpinionsontheFinancialStatementsandInternalControloverFinancialReporting
WehaveauditedtheaccompanyingconsolidatedbalancesheetsofJohnson&Johnsonanditssubsidiaries(the
“Company”)asofDecember30,2018andDecember31,2017,andtherelatedconsolidatedstatementsofearnings,of
comprehensiveincome,ofequity,andofcashflowsforeachofthethreeyearsintheperiodendedDecember30,2018
includingtherelatednotes(collectivelyreferredtoasthe“consolidatedfinancialstatements”).Wealsohaveauditedthe
Company’sinternalcontroloverfinancialreportingasofDecember30,2018,basedoncriteriaestablishedinInternal
Control—IntegratedFramework(2013)issuedbytheCommitteeofSponsoringOrganizationsoftheTreadway
Commission(COSO).
Inouropinion,theconsolidatedfinancialstatementsreferredtoabovepresentfairly,inallmaterialrespects,thefinancial
positionoftheCompanyasofDecember30,2018andDecember31,2017,andtheresultsofitsoperationsanditscash
flowsforeachofthethreeyearsintheperiodendedDecember30,2018inconformitywithaccountingprinciples
generallyacceptedintheUnitedStatesofAmerica.Alsoinouropinion,theCompanymaintained,inallmaterialrespects,
effectiveinternalcontroloverfinancialreportingasofDecember30,2018,basedoncriteriaestablishedinInternal
Control—IntegratedFramework(2013)issuedbytheCOSO.
BasisforOpinions
TheCompany’smanagementisresponsiblefortheseconsolidatedfinancialstatements,formaintainingeffectiveinternal
controloverfinancialreporting,andforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting,
includedintheaccompanyingManagement’sReportonInternalControloverFinancialReporting.Ourresponsibilityisto
expressopinionsontheCompany’sconsolidatedfinancialstatementsandontheCompany’sinternalcontroloverfinancial
reportingbasedonouraudits.WeareapublicaccountingfirmregisteredwiththePublicCompanyAccountingOversight
Board(UnitedStates)(PCAOB)andarerequiredtobeindependentwithrespecttotheCompanyinaccordancewiththe
U.S.federalsecuritieslawsandtheapplicablerulesandregulationsoftheSecuritiesandExchangeCommissionandthe
PCAOB.
WeconductedourauditsinaccordancewiththestandardsofthePCAOB.Thosestandardsrequirethatweplanand
performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial
misstatement,whetherduetoerrororfraud,andwhethereffectiveinternalcontroloverfinancialreportingwasmaintained
inallmaterialrespects.
Ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial
misstatementoftheconsolidatedfinancialstatements,whetherduetoerrororfraud,andperformingproceduresthat
respondtothoserisks.Suchproceduresincludedexamining,onatestbasis,evidenceregardingtheamountsand
disclosuresintheconsolidatedfinancialstatements.Ourauditsalsoincludedevaluatingtheaccountingprinciplesused
andsignificantestimatesmadebymanagement,aswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial
statements.Ourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol
overfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtestingandevaluatingthedesignand
operatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalsoincludedperformingsuchother
proceduresasweconsiderednecessaryinthecircumstances.Webelievethatourauditsprovideareasonablebasisfor
ouropinions.
DefinitionandLimitationsofInternalControloverFinancialReporting
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
98 • Johnson&Johnson2018AnnualReportprinciples,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
/s/PricewaterhouseCoopersLLP
FlorhamPark,NewJersey
February20,2019
WehaveservedastheCompany’sauditorsinceatleast1920.Wehavenotbeenabletodeterminethespecificyearwe
beganservingasauditoroftheCompany.
Johnson&Johnson2018AnnualReport • 99Management’s Report on Internal Control
Over Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofDecember30,2018.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework(2013).”
Thesecriteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunication,
andmonitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignand
operatingeffectivenessofitsinternalcontrolsoverfinancialreporting.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
December30,2018,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofDecember30,2018hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
/s/AlexGorsky /s/JosephJ.Wolk
AlexGorsky JosephJ.Wolk
Chairman,BoardofDirectors ExecutiveVicePresident,
ChiefExecutiveOfficer ChiefFinancialOfficer
100 • Johnson&Johnson2018AnnualReportShareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingDecember31,2018,againstthecumulativetotalreturnoftheStandard&
Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthCareEquipment
Index.Thegraphsandtablesassumethat$100wasinvestedonDecember31,2013andDecember31,2008ineachof
theCompany’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexand
theStandard&Poor’sHealthCareEquipmentIndexandthatalldividendswerereinvested.
5 Year Shareholder Return
Performance J&J vs. Indices
$220
Johnson & Johnson
$200
S&P 500 Index
$180
S&P Pharmaceu(cid:2)cal Index
$160
S&P Healthcare Equipment
Index
$140
5-Year CAGR
J&J 10.1% $120
S&P 500 8.5%
S&P Pharm 9.1%
$100
S&P H/C Equip 16.6% 2013 2014 2015 2016 2017 2018
2013 2014 2015 2016 2017 2018
Johnson&Johnson $100.00 $117.34 $118.69 $136.88 $170.29 $161.54
S&P500Index $100.00 $113.68 $115.24 $129.02 $157.17 $150.27
S&PPharmaceuticalIndex $100.00 $122.22 $129.29 $127.27 $143.27 $154.86
S&PHealthcareEquipmentIndex $100.00 $126.28 $133.82 $142.50 $186.53 $216.82
10 Year Shareholder Return
Performance J&J vs. Indices
$450
Johnson & Johnson
$400
S&P 500 Index
$350
S&P Pharmaceu(cid:2)cal Index
$300
S&P Healthcare Equipment
$250
Index
10-Year CAGR $200
J&J 11.3%
$150
S&P 500 13.1%
S&P Pharm 12.9%
$100
S&P H/C Equip 15.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Johnson&Johnson $100.00 $111.28 $110.63 $121.57 $134.73 $181.37 $212.81 $215.28 $248.26 $308.85 $292.99
S&P500Index $100.00 $126.45 $145.49 $148.55 $172.31 $228.09 $259.29 $262.86 $294.28 $358.50 $342.75
S&PPharmaceuticalIndex $100.00 $118.62 $119.54 $140.77 $161.07 $217.82 $266.21 $281.62 $277.21 $312.06 $337.32
S&PHealthcareEquipmentIndex $100.00 $128.79 $125.30 $124.30 $145.76 $186.12 $235.04 $249.08 $265.23 $347.17 $403.55
Johnson&Johnson2018AnnualReport • 101Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE
Notapplicable.
Item 9A. CONTROLS AND PROCEDURES
DisclosureControlsandProcedures.AttheendoftheperiodcoveredbythisReport,theCompanyevaluatedthe
effectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures.TheCompany’sdisclosurecontrols
andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatit
filesorsubmitsundertheExchangeActisrecorded,processed,summarizedandreportedwithinthetimeperiods
specifiedintheSEC’srulesandforms.Disclosurecontrolsandproceduresinclude,withoutlimitation,controlsand
proceduresdesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatitfilesor
submitsundertheExchangeActisaccumulatedandcommunicatedtotheCompany’smanagement,includingitsprincipal
executiveandprincipalfinancialofficers,orpersonsperformingsimilarfunctions,asappropriatetoallowtimelydecisions
regardingrequireddisclosure.AlexGorsky,ChairmanandChiefExecutiveOfficer,andJosephJ.Wolk,ExecutiveVice
President,ChiefFinancialOfficer,reviewedandparticipatedinthisevaluation.Basedonthisevaluation,Messrs.Gorsky
andWolkconcludedthat,asoftheendoftheperiodcoveredbythisReport,theCompany’sdisclosurecontrolsand
procedureswereeffective
ReportsonInternalControlOverFinancialReporting.Theinformationcalledforbythisitemisincorporatedhereinby
referenceto“Management’sReportonInternalControlOverFinancialReporting”,andtheattestationregardinginternal
controlsoverfinancialreportingincludedinthe“ReportofIndependentRegisteredPublicAccountingFirm”includedin
Item8ofthisReport.
ChangesinInternalControlOverFinancialReporting.DuringthefiscalquarterendedDecember30,2018,therewereno
changesintheCompany’sinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired
underRules13a-15and15d-15undertheExchangeActthathavemateriallyaffected,orarereasonablylikelyto
materiallyaffect,theCompany’sinternalcontroloverfinancialreporting.
TheCompanyisimplementingamulti-year,enterprise-wideinitiativetointegrate,simplifyandstandardizeprocessesand
systemsforthehumanresources,informationtechnology,procurement,supplychainandfinancefunctions.Theseare
enhancementstosupportthegrowthoftheCompany’sfinancialsharedservicecapabilitiesandstandardizefinancial
systems.ThisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessintheCompany’sinternalcontrolover
financialreporting.Inresponsetothisinitiative,theCompanyhasandwillcontinuetoalignandstreamlinethedesignand
operationofitsfinancialcontrolenvironment.
Item 9B. OTHER INFORMATION
Notapplicable.
102 • Johnson&Johnson2018AnnualReportPART III
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheAuditCommitteeunder
thecaption“Item1.ElectionofDirectors—BoardCommittees”;andthematerialunderthecaptions“Item1.Electionof
Directors”and“StockOwnershipandSection16Compliance—Section16(a)BeneficialOwnershipReporting
Compliance”intheProxyStatement;andthematerialunderthecaption“ExecutiveOfficersoftheRegistrant”inPartIof
thisReport.
TheCompany’sCodeofBusinessConduct,whichcoversallemployees(includingtheChiefExecutiveOfficer,Chief
FinancialOfficerandController),meetstherequirementsoftheSECrulespromulgatedunderSection406ofthe
Sarbanes-OxleyActof2002.TheCodeofBusinessConductisavailableontheCompany’swebsiteatwww.jnj.com/
code-of-business-conduct,andcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttotheSecretary
attheCompany’sprincipalexecutiveoffices.AnysubstantiveamendmenttotheCodeofBusinessConductoranywaiver
oftheCodegrantedtotheChiefExecutiveOfficer,theChiefFinancialOfficerortheControllerwillbepostedonthe
Company’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(andretainedonthewebsiteforatleastone
year).
Inaddition,theCompanyhasadoptedaCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsand
ExecutiveOfficers.TheCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers
isavailableontheCompany’swebsiteatwww.investor.jnj.com/gov/boardconduct.cfm,andcopiesareavailableto
shareholderswithoutchargeuponwrittenrequesttotheSecretaryattheCompany’sprincipalexecutiveoffices.Any
substantiveamendmenttotheCodeoranywaiveroftheCodegrantedtoanymemberoftheBoardofDirectorsorany
executiveofficerwillbepostedontheCompany’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(and
retainedonthewebsiteforatleastoneyear).
Item 11. EXECUTIVE COMPENSATION
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors—DirectorCompensation,”and“Item2.CompensationCommitteeReport,”“Compensation
DiscussionandAnalysis”and“ExecutiveCompensationTables”intheProxyStatement.
Thematerialincorporatedhereinbyreferencetothematerialunderthecaption“CompensationCommitteeReport”inthe
ProxyStatementshallbedeemedfurnished,andnotfiled,inthisReportandshallnotbedeemedincorporatedby
referenceintoanyfilingundertheSecuritiesActof1933,asamended,ortheSecuritiesExchangeActof1934,as
amended,asaresultofthisfurnishing,excepttotheextentthattheCompanyspecificallyincorporatesitbyreference.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item1.Stock
OwnershipandSection16Compliance”intheProxyStatement;andNote17“CommonStock,StockOptionPlansand
StockCompensationAgreements”oftheNotestoConsolidatedFinancialStatementsinItem8ofthisReport.
Johnson&Johnson2018AnnualReport • 103Equity Compensation Plan Information
ThefollowingtableprovidescertaininformationasofDecember30,2018concerningthesharesoftheCompany’s
CommonStockthatmaybeissuedunderexistingequitycompensationplans.
Numberof
Securitiesto
beIssuedUpon WeightedAverage NumberofSecurities
Exerciseof ExercisePriceof RemainingAvailablefor
Outstanding Outstanding FutureIssuanceUnderEquity
PlanCategory OptionsandRights OptionsandRights CompensationPlans(2)(3)
EquityCompensationPlansApprovedbySecurity
Holders(1) 130,605,768 $82.52 351,079,202
EquityCompensationPlansNotApprovedbySecurity
Holders — — —
Total 130,605,768 $82.52 351,079,202
(1) IncludedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbytheCompany’sshareholders:
2005Long-TermIncentivePlanand2012Long-TermIncentivePlan.
(2) Thiscolumnexcludessharesreflectedunderthecolumn“NumberofSecuritiestobeIssuedUponExerciseofOutstandingOptions
andRights.”
(3) The2005Long-TermIncentivePlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewere
underthe2012Long-TermIncentivePlan.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors—DirectorIndependence”and“RelatedPersonTransactions”intheProxyStatement.
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item3.
RatificationofAppointmentofIndependentRegisteredPublicAccountingFirm”intheProxyStatement.
104 • Johnson&Johnson2018AnnualReportPART IV
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Thefollowingdocumentsarefiledaspartofthisreport:
1. FinancialStatements
ConsolidatedBalanceSheetsatendofFiscalYears2018and2017
ConsolidatedStatementsofEarningsforFiscalYears2018,2017and2016
ConsolidatedStatementsofComprehensiveIncomeforFiscalYears2018,2017and2016
ConsolidatedStatementsofEquityforFiscalYears2018,2017and2016
ConsolidatedStatementsofCashFlowsforFiscalYears2018,2017and2016
NotestoConsolidatedFinancialStatements
ReportofIndependentRegisteredPublicAccountingFirm
Allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial
statementsornotes.
2. ExhibitsRequiredtobeFiledbyItem60lofRegulationS-K
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheExhibitIndexinthisReport.
Item 16. FORM 10-K SUMMARY
RegistrantsmayvoluntarilyincludeasummaryofinformationrequiredbyForm10-KunderthisItem16.TheCompanyhas
electednottoincludesuchsummaryinformation.
Johnson&Johnson2018AnnualReport • 105SIGNATURES
PursuanttotherequirementsofSection13oftheSecuritiesExchangeActof1934,theregistranthasdulycausedthis
Reporttobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized.
Date:February20,2019
JOHNSON&JOHNSON
(Registrant)
By /s/A.Gorsky
A.Gorsky,Chairman,BoardofDirectors,
andChiefExecutiveOfficer
PursuanttotherequirementsoftheSecuritiesExchangeActof1934,thisreporthasbeensignedbelowbythefollowing
personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated.
Signature Title Date
/s/A.Gorsky Chairman,BoardofDirectors February20,2019
A.Gorsky ChiefExecutiveOfficer
(PrincipalExecutiveOfficer)
/s/J.J.Wolk ChiefFinancialOfficer February20,2019
J.J.Wolk (PrincipalFinancialOfficer)
/s/R.A.Kapusta ControllerandChiefAccountingOfficer February20,2019
R.A.Kapusta (PrincipalAccountingOfficer)
/s/M.C.Beckerle Director February20,2019
M.C.Beckerle
/s/D.S.Davis Director February20,2019
D.S.Davis
/s/I.E.L.Davis Director February20,2019
I.E.L.Davis
/s/J.A.Doudna Director February20,2019
J.A.Doudna
/s/M.B.McClellan Director February20,2019
M.B.McClellan
/s/A.M.Mulcahy Director February20,2019
A.M.Mulcahy
/s/W.D.Perez Director February20,2019
W.D.Perez
/s/C.Prince Director February20,2019
C.Prince
/s/A.E.Washington Director February20,2019
A.E.Washington
/s/R.A.Williams Director February20,2019
R.A.Williams
106 • Johnson&Johnson2018AnnualReportEXHIBIT INDEX
Reg.S-K
ExhibitTable
ItemNo. DescriptionofExhibit
3(i) RestatedCertificateofIncorporationeffectiveFebruary19,2016—IncorporatedhereinbyreferencetoExhibit3(i)ofthe
Registrant’sForm10-KAnnualReportforthefiscalyearendedJanuary3,2016.
3(ii) By-LawsoftheCompany,asamendedeffectiveJanuary26,2016—IncorporatedhereinbyreferencetoExhibit3.1the
Registrant’sForm8-KCurrentReportfiledJanuary26,2016.
4(a) UpontherequestoftheSecuritiesandExchangeCommission,theRegistrantwillfurnishacopyofallinstrumentsdefiningthe
rightsofholdersoflong-termdebtoftheRegistrant.
10(a) 2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit4oftheRegistrant’sS-8RegistrationStatement
filedwiththeCommissiononMay10,2005(fileno.333-124785).*
10(b) FormofStockOptionCertificateunderthe2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit10.1of
theRegistrant’sForm8-KCurrentReportfiledJanuary13,2012.*
10(c) 2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoAppendixAoftheRegistrant’sProxyStatementfiledwith
theCommissiononMarch15,2017.*
10(d) FormofStockOptionCertificate,RestrictedShareUnitCertificateandPerformanceShareUnitCertificateunderthe2012
Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.2,10.3and10.4oftheRegistrant’sForm10-Q
QuarterlyReportfiledMay7,2012.*
10(e) GlobalNonQualifiedStockOptionAwardAgreement,GlobalRestrictedShareUnitAwardAgreementandGlobalPerformance
ShareUnitAwardAgreementunderthe2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.1,
10.2and10.3oftheRegistrant’sForm10-QQuarterlyReportfiledMay1,2018.*
10(f) Johnson&JohnsonExecutiveIncentivePlan(asamended)—IncorporatedhereinbyreferencetoExhibit10(f)oftheRegistrant’s
Form10-KAnnualReportforthefiscalyearendedDecember31,2000.*
10(g) DomesticDeferredCompensation(CertificateofExtraCompensation)Plan—IncorporatedhereinbyreferencetoExhibit10(g)
oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2003.*
10(h) AmendmentstotheCertificateofExtraCompensationPlaneffectiveasofJanuary1,2009—Incorporatedhereinbyreferenceto
Exhibit10(j)oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2008.*
10(i) 2009CertificatesofLong-TermPerformancePlan—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm
10-QQuarterlyReportforthequarterendedSeptember27,2009.*
10(j) AmendedandRestatedDeferredFeePlanforDirectors(AmendedasofJanuary17,2012)—Incorporatedhereinbyreference
toExhibit10(k)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedJanuary1,2012.*
10(k) TheJohnson&JohnsonExecutiveIncomeDeferralPlan(AmendedandRestatedEffectiveJanuary1,2010)—Incorporated
hereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedSeptember30,2012.*
10(l) ExcessSavingsPlan(EffectiveasofJanuary1,1996)—IncorporatedhereinbyreferencetoExhibit10(j)oftheRegistrant’s
Form10-KAnnualReportforthefiscalyearendedDecember29,1996.*
10(m) AmendmentstotheJohnson&JohnsonExcessSavingsPlaneffectiveasofJanuary1,2009—Incorporatedhereinbyreference
toExhibit10(p)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedDecember28,2008.*
10(n)** ExcessBenefitPlan(SupplementalRetirementPlan)—IncorporatedhereinbyreferencetoExhibit10(h)oftheRegistrant’sForm
10-KAnnualReportforthefiscalyearendedJanuary3,1993.*
10(o) AmendmentstotheExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanieseffectiveasofJanuary1,2009—
IncorporatedhereinbyreferencetoExhibit10(r)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearended
December28,2008.*
10(p) AmendmenttotheExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanies,effectiveasofJanuary1,2015—
IncorporatedhereinbyreferencetoExhibit10(q)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearended
December28,2014.*
10(q)** ExecutiveLifePlanAgreement—IncorporatedhereinbyreferencetoExhibit10(i)oftheRegistrant’sForm10-KAnnualReport
forthefiscalyearendedJanuary3,1993.*
10(r) ExecutiveLifePlanAgreementClosureLetter—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedMarch29,2015.*
10(s) EmploymentAgreementforDr.PaulusStoffels—IncorporatedhereinbyreferencetoExhibit10.2oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedSeptember30,2012.*
10(t) SummaryofEmploymentArrangementsforSandraE.Peterson—IncorporatedhereinbyreferencetoExhibit10(t)ofthe
Registrant’sForm10-KAnnualReportfortheyearendedDecember30,2012.*
Johnson&Johnson2018AnnualReport • 10710(u) SeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies,AmendedandRestatedasofOctober1,2014—
IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterended
September28,2014.*
10(v) FirstAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReport
forthequarterendedJune28,2015.*
10(w) SecondAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10(x)oftheRegistrant’sForm10-KAnnualReportfor
thefiscalyearendedJanuary3,2016.*
21 Subsidiaries-Filedwiththisdocument.
23 ConsentofIndependentRegisteredPublicAccountingFirm—Filedwiththisdocument.
31.1 CertificationofChiefExecutiveOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
31.2 CertificationofChiefFinancialOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
32.1 CertificationofChiefExecutiveOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
32.2 CertificationofChiefFinancialOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
101 XBRL(ExtensibleBusinessReportingLanguage)ThefollowingmaterialsfromthisReportforthefiscalyearendedDecember30,
2018,formattedinExtensiveBusinessReportingLanguage(XBRL):(i)ConsolidatedBalanceSheets,(ii)Consolidated
StatementsofEarnings,(iii)ConsolidatedStatementsofComprehensiveIncome,(iv)ConsolidatedStatementsofEquity,
(v)ConsolidatedStatementsofCashFlows,and(vi)NotestotheConsolidatedFinancialStatements.
* Managementcontractorcompensatoryplan.
**Paperfiling.
AcopyofanyoftheExhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest
specifyingthedesiredexhibit(s)totheSecretaryattheprincipalexecutiveofficesoftheCompany.PursuanttoItem
601(b)(4)(iii)(A)ofRegulationS-K,theCompanyhasnotfiledasexhibitstothisForm10-Kcertainlong-termdebt
instruments,includingindentures,underwhichthetotalamountofsecuritiesauthorizeddoesnotexceed10%ofthetotal
assetsoftheCompanyanditssubsidiariesonaconsolidatedbasis.TheCompanyherebyagreestofurnishacopyofany
suchinstrumenttotheSECuponrequest.
ThefollowingExhibits,indicatedasbeingfiledwiththisdocument,areomittedfromtheprintedversionofthis2018
AnnualReport.
Exhibit21
Exhibit23
108 • Johnson&Johnson2018AnnualReportExhibit31.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,AlexGorsky,certifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedDecember30,2018(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Date:February20,2019
Johnson&Johnson2018AnnualReportExhibit31.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,JosephJ.Wolkcertifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedDecember30,2018(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Date:February20,2019
Johnson&Johnson2018AnnualReportExhibit32.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,AlexGorsky,theChiefExecutiveOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedDecember30,2018(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Dated:February20,2019
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2018AnnualReportExhibit32.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,JosephJ.Wolk,theChiefFinancialOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedDecember30,2018(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Dated:February20,2019
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2018AnnualReport[THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK]ReconciliationofNon-GAAPFinancialMeasures
TwelveMonths %Incr./
(DollarsinMillionsExceptPerShareData) 2018 2017 (Decr.)
Earningsbeforeprovisionfortaxesonincome-asreported $17,999 17,673 1.8%
Intangibleassetamortizationexpense 4,357 2,963
Litigationexpense,net 1,991 1,256
Actelionacquisitionrelatedcost 243 797
Restructuring/Other(1) 700 760
In-processresearchanddevelopment 1,126 408
Diabetesassetimpairment 4 215
AMOacquisitionrelatedcost 109 140
Contingentliabilityreversal (184) –
Unrealizedlossonsecurities 179 –
Impactoftaxlegislation 72 –
Other 102 –
Earningsbeforeprovisionfortaxesonincome-asadjusted $26,698 24,212 10.3%
NetEarnings-asreported $15,297 1,300 N/M%
Intangibleassetamortizationexpense 3,888 2,481
Litigationexpense,net 1,722 955
Actelionacquisitionrelatedcost 232 767
Restructuring/Other 585 595
In-processresearchanddevelopment 859 266
Diabetesassetimpairment 3 4
AMOacquisitionrelatedcost 89 116
Contingentliabilityreversal (184) –
Unrealizedlossonsecurities 141 –
Impactoftaxlegislation(2) (390) 13,556
Other 73 –
NetEarnings-asadjusted $22,315 20,040 11.4%
DilutedNetEarningspershare-asreported $5.61 0.47 N/M%
Intangibleassetamortizationexpense 1.42 0.90
Litigationexpense,net 0.63 0.35
Actelionacquisitionrelatedcost 0.09 0.28
Restructuring/Other 0.21 0.22
In-processresearchanddevelopment 0.32 0.10
AMOacquisitionrelatedcost 0.03 0.04
Contingentliabilityreversal (0.07) –
Unrealizedlossonsecurities 0.05 –
Impactoftaxlegislation (0.14) 4.94
Other 0.03 –
DilutedNetEarningspershare-asadjusted $8.18 7.30 12.1%
OperationalDilutedNetEarningspershare-asadjustedat2016foreigncurrencyexchange
rates 7.24
Impactofcurrencyat2017foreigncurrencyexchangerates (0.12) 0.06
OperationalDilutedNetEarningspershare-asadjustedat2017foreigncurrencyexchange
rates $8.06 7.30 10.4%
(1) Includes$105millionrecordedincostofproductssoldand$344millionrecordedinother(income)expensein2018,and
$88millionrecordedincostofproductssoldand$363millionrecordedinother(income)expensein2017.
(2) Includesforeigncurrencytranslation
N/M=NotMeaningful
Johnson&Johnson2018AnnualReportTheCompanyprovidesearningsbeforeprovisionfortaxesonincome,netearningsandnetearningspershare(diluted)on
anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestors.Amongother
things,thesemeasuresmayassistinvestorsinevaluatingtheCompany’sresultsofoperationsperiodoverperiod.In
variousperiods,thesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpense,significantcosts
associatedwithacquisitions,restructuring,litigation,andchangesinapplicablelawsandregulations(includingsignificant
accountingortaxmatters).Thesespecialitemsmaybehighlyvariable,difficulttopredict,andofasizethatsometimeshas
substantialimpactontheCompany’sreportedresultsofoperationsforaperiod.Managementusesthesemeasures
internallyforplanning,forecastingandevaluatingtheperformancesoftheCompany’sbusinesses,includingallocating
resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargets.Unlikeearningsbeforeprovision
fortaxesonincome,netearningsandnetearningspershare(diluted)preparedinaccordancewithGAAP,adjusted
earningsbeforeprovisionfortaxesonincome,adjustednetearningsandadjustednetearningspershare(diluted)maynot
becomparablewiththecalculationofsimilarmeasuresforothercompanies.Thelimitationsofusingthesenon-GAAP
financialmeasuresasperformancemeasuresarethattheyprovideaviewoftheCompany’sresultsofoperationswithout
includingalleventsduringaperiod,suchasintangibleassetamortizationexpense,theeffectsofanacquisition,
restructuring,litigation,andchangesinapplicablelawsandregulations(includingsignificantaccountingortaxmatters)and
donotprovideacomparableviewoftheCompany’sperformancetoothercompaniesinthehealthcareindustry.Investors
shouldconsidernon-GAAPfinancialmeasuresinadditionto,andnotasreplacementsfor,orsuperiorto,measuresof
financialperformancepreparedinaccordancewithGAAP.
Thetablesbelowareprovidedtoreconcilecertainnon-GAAPfinancialdisclosuresinthe2018Chairman’sLetter.
(DollarsinMillions) 2018
Netcashflowsfromoperatingactivities $22,201
Additionstoproperty,plantandequipment (3,670)
Freecashflow $18,531
OperationalGrowth Incr./
MedicalDevices 2018 2017 (Decr.)
Worldwideasreported: 1.1% 5.7
Impactofacquisitions/divestitures 1.5 (4.2)
Worldwideoperationalgrowthexcludingacquisitions/divestitures 2.6% 1.5 1.1
Operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestituresisanon-GAAPfinancialmeasure.
Investorsshouldconsidernon-GAAPfinancialmeasuresinadditionto,andnotasreplacementsfor,orsuperiorto,
measuresoffinancialperformancepreparedinaccordancewithGAAP.Duetothevariablenatureofacquisitionsand
divestitures,andtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrends,
managementbelievesthatprovidingthismeasureenhancesaninvestor’sunderstandingoftheCompany’s
performanceandmayassistintheevaluationofongoingbusinessoperationsperiodoverperiod.Thisnon-GAAP
financialmeasureispresentedtopermitinvestorstomorefullyunderstandhowmanagementassessesthe
performanceoftheCompany,includingforinternalevaluationoftheperformanceoftheCompany’sbusinessesand
planningandforecastingforfutureperiods.Theuseofthisnon-GAAPfinancialmeasureasaperformancemeasureis
limitedinthatitprovidesaviewoftheCompany’sresultsofoperationswithoutincludingalleventsduringaperiodand
maynotprovideacomparableviewoftheCompany’sperformancetothatofothercompaniesinthehealthcare
industry.
Johnson&Johnson2018AnnualReportBoard of Directors Senior Management
ALEXGORSKY ALEXGORSKY*
Chairman,BoardofDirectors ChiefExecutiveOfficer;
Chairman,ExecutiveCommittee
MARYC.BECKERLE
ChiefExecutiveOfficer,HuntsmanCancerInstitute JOAQUINDUATO*
attheUniversityofUtah; ViceChairman,ExecutiveCommittee
DistinguishedProfessorofBiology,
CollegeofScience,UniversityofUtah PAULUSSTOFFELS*
ViceChairman,ExecutiveCommittee;ChiefScientificOfficer
D.SCOTTDAVIS
FormerChairmanandChiefExecutiveOfficer, PETERM.FASOLO*
UnitedParcelService,Inc. ExecutiveVicePresident,ChiefHumanResourcesOfficer
IANE.L.DAVIS RONALDA.KAPUSTA
Chairman,Rolls-RoyceHoldingsplc; CorporateController;ChiefAccountingOfficer
FormerChairmanandWorldwideManagingDirector,
ASHLEYMcEVOY*
McKinsey&Company
ExecutiveVicePresident,WorldwideChairman,
JENNIFERA.DOUDNA MedicalDevices
ProfessorofChemistry;ProfessorofBiochemistry&
THIBAUTMONGON*
MolecularBiology;
ExecutiveVicePresident,WorldwideChairman,Consumer
LiKaShingChancellor’sProfessorinBiomedical
andHealth,UniversityofCalifornia,Berkeley
MICHELLER.RYAN
Treasurer
MARKB.McCLELLAN
Director,Duke-RobertJ.Margolis,MD,
MICHAELE.SNEED*
CenterforHealthPolicy
ExecutiveVicePresident,GlobalCorporateAffairs;
ChiefCommunicationsOfficer
ANNEM.MULCAHY
FormerChairmanandChiefExecutiveOfficer,
THOMASJ.SPELLMANIII
XeroxCorporation
CorporateSecretary;AssistantGeneralCounsel
WILLIAMD.PEREZ
JENNIFERTAUBERT*
RetiredPresidentandChiefExecutiveOfficer,
ExecutiveVicePresident,WorldwideChairman,
Wm.WrigleyJr.Company
Pharmaceuticals
CHARLESPRINCE
MICHAELH.ULLMANN*
RetiredChairmanandChiefExecutiveOfficer,
ExecutiveVicePresident,GeneralCounsel
CitigroupInc.
KATHRYNE.WENGEL*
A.EUGENEWASHINGTON
ExecutiveVicePresident,ChiefGlobalSupplyChainOfficer
DukeUniversity’sChancellorforHealthAffairs;
PresidentandChiefExecutiveOfficer, JOSEPHJ.WOLK*
DukeUniversityHealthSystem
ExecutiveVicePresident,ChiefFinancialOfficer
RONALDA.WILLIAMS
*Member,ExecutiveCommittee
FormerChairmanandChiefExecutiveOfficer,
AetnaInc.
Johnson&Johnson2018AnnualReportPRINCIPALOFFICE STOCKLISTING JOHNSON&JOHNSONONLINE
OneJohnson&JohnsonPlaza Johnson&JohnsonCommonStock
Ourwebsite:www.jnj.com
NewBrunswick,NewJersey08933 ListedonNewYorkStockExchange
(732)524-0400 StockSymbol:JNJ
http://www.jnj.com/media-center
2019ANNUALMEETINGOFSHAREHOLDERS SHAREHOLDERRELATIONSCONTACT
Thursday,April25,2019 ThomasJ.SpellmanIII
www.facebook.com/jnj
CorporateSecretary
10:00a.m.(Eastern);Doorsopentomeetingat
(732)524-2455
9:15a.m. www.twitter.com/JNJNews
www.twitter.com/JNJCares
HyattRegencyNewBrunswick INVESTORRELATIONSCONTACT
TwoAlbanyStreet
ChristopherDelOrefice
NewBrunswick,NewJersey www.youtube.com/jnj
VicePresident,InvestorRelations
Allshareholdersasoftherecorddateof (800)950-5089
February26,2019areinvitedtoattend. (732)524-2955 http://www.linkedin.com/company/
johnson-&-johnson
AformalNoticeofAnnualMeeting, InvestorRelationswebsite:
ProxyStatementandProxyhavebeen www.investor.jnj.com
TheJohnson&Johnson2018Yearin
madeavailabletoshareholders.
STOCKTRANSFERAGENTANDREGISTRAR Reviewisavailableonourwebsiteat
2018ANNUALREPORTONFORM10-KAND Questionsregardingstockholdings, https://www.jnj.com/2018-year-in-review.
2019PROXYSTATEMENT
certificatereplacement/transfer,dividends Theinformationonthesewebsitesshould
Johnson&Johnson’sAnnualReportonForm10-K andaddresschangesshouldbedirectedto notbedeemedtobepartofthisAnnual
forthefiscalyearendedDecember30,2018is ourstocktransferagentandregistrarat: Report.
includedinthisAnnualReportinitsentirety,with
ComputershareTrustCompany,N.A.
theexceptionofcertainexhibits.TheForm10-K, P.O.Box505000
completewithallofitsexhibits,isavailableonour Louisville,KY40233
websiteatwww.investor.jnj.com/sec.cfm,andthe
Overnightmail:
SEC’swebsiteatwww.sec.gov. ComputershareTrustCompany,N.A.
Shareholdersmayalsoobtaincopiesofthe 462South4thStreet,Suite1600
exhibits,our2018AnnualReporton Louisville,KY40202
Form10-Kandour2019ProxyStatement, (800)328-9033or(781)575-2718
withoutcharge,uponwrittenrequesttothe Shareholderwebsite:
OfficeoftheCorporateSecretaryatour www.computershare.com/investor
principalofficeaddress,orbycalling
(800)950-5089. DividendReinvestmentPlan
ThePlanallowsforfullorpartialdividend
ELECTRONICDELIVERYNOTIFICATION reinvestmentandadditionalweeklycash
The2019ProxyStatementandour2018Annual investmentsupto$50,000peryearin
Reportareavailableonourwebsite Johnson&JohnsonCommonStockwithout
www.investor.jnj.com/gov/ pershareorservicechargesonstock C132107
annualmeetingmaterials.cfm.Shareholderswho purchases.Ifyouareinterestedin
receivepapercopiesofourProxyStatementand participatinginthePlanandneedan
AnnualReportbymailcanelecttoreceiveinstead enrollmentformand/ormoreinformation,
ane-mailmessagewithalinktothosedocuments pleasecallthePlanadministrator,
TheJohnson&Johnson2018AnnualReport
ontheInternet.Registeredshareholdersmay ComputershareTrustCompany,N.A.at
containsmanyofthevaluabletrademarks
enrollinelectronicdeliveryat: (800)328-9033or(781)575-2718
andtradenamesownedandusedbythe
www.computershare-na.com/green.Beneficial (outsidetheU.S.)oraccessonlineat
Johnson&JohnsonFamilyofCompaniesin
shareholders(whoholdsharesofJohnson& www.computershare.com/investor.
theUnitedStatesandinternationallyto
JohnsonCommonStockthroughabank,brokeror
distinguishproductsandservicesof
otherholderofrecord)generallycanenrollfor HearingImpaired
outstandingquality.
electronicdeliveryat:enroll.icsdelivery.com/jnj. Shareholderswhohaveinquiriesregarding
©Johnson&Johnson2019
stock-relatedmatterscancommunicate
directlywithComputershareTrustCompany,
N.A.viaatelecommunicationsdevice(TDD).
Thetelephonenumberforthisserviceis
(800)952-9245or(781)575-2692
(outsidetheU.S.).We blend heart, science and ingenuity
to profoundly change the trajectory
of health for humanity.